<SEC-DOCUMENT>0001178913-23-000694.txt : 20230222
<SEC-HEADER>0001178913-23-000694.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222060349
ACCESSION NUMBER:		0001178913-23-000694
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		75
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269218
		FILM NUMBER:		23650430

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>zk2329281.htm
<DESCRIPTION>S-1/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cmmb="http://www.anchiano.com/20221231"  >
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Chemomab Therapeutics Ltd. - 1534248 - 2023</title>
</head>
<body><div style="font-size: 10pt;"><div style="font-size: 10pt;">

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:footnote id="FN20230201025135527" xml:lang="en-US">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date. </ix:footnote>
    <ix:footnote id="FN20230201025203207" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</ix:footnote>
    <ix:footnote id="FN20230201025249960" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</ix:footnote>
    <ix:footnote id="FN20230201025314607" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</ix:footnote>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20221231" id="FFact_0000000000489" >0001534248</ix:nonNumeric>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20221231" id="FFact_0000000000491" >false</ix:nonNumeric>
    <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20200501to20200510" id="Fxbrl_20230131233234992" >2023-05-31</ix:nonNumeric>
    <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20211001to20211024" id="Fxbrl_20230131233722905" >2024-10-31</ix:nonNumeric>
    <ix:nonNumeric name="dei:DocumentType" contextRef="C_20220101to20221231" id="Fxbrl_20230213103251859" >S-1/A</ix:nonNumeric>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cmmb-20221231.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20220101to20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220701to20220731">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-01-13</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200101to20201231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-16</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-23</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyUSD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtCurrencyAxis_currencyUSD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtCurrencyAxis_currencyILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyXXX">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtCurrencyAxis_currencyXXX">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200510">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-05-10</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200501to20200510">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-10</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20211024">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211024">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-10-24</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211212">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-12</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210316">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="Share">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD_Per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <ix:relationship fromRefs="FFact_0000000000373" toRefs="FN20230201025135527"/>
    <ix:relationship fromRefs="FFact_0000000000377" toRefs="FN20230201025203207"/>
    <ix:relationship fromRefs="FFact_0000000000378" toRefs="FN20230201025203207"/>
    <ix:relationship fromRefs="FFact_0000000000379" toRefs="FN20230201025249960"/>
    <ix:relationship fromRefs="FFact_0000000000380" toRefs="FN20230201025249960"/>
    <ix:relationship fromRefs="FFact_0000000000381" toRefs="FN20230201025314607"/>
    <ix:relationship fromRefs="FFact_0000000000382" toRefs="FN20230201025314607"/>
    </ix:resources>
  </ix:header></div>

<div>

<div>

<div>

<div> <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />

<div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>As
filed with the Securities and Exchange Commission on February 22, 2023</span></span></span></span></span></div>

<div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Registration
No. 333-269218</span></span></span></span></span></div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span>UNITED
STATES</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span>SECURITIES
AND EXCHANGE COMMISSION</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>WASHINGTON,
D.C. 20549</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span>Amendment
No. 2</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">to</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">FORM
<span style="-sec-ix-hidden:Fxbrl_20230213103251859">S-1</span>&#160;</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REGISTRATION
STATEMENT</span></span></div>

<div style="text-align:center;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNDER</span></span></div>

<div style="text-align:center;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">THE
SECURITIES ACT OF 1933</span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230213104107012" name="dei:EntityRegistrantName" contextRef="C_20220101to20221231">CHEMOMAB
THERAPEUTICS LTD.</ix:nonNumeric>&#160;</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Exact
name of registrant as specified in its charter)</span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:33.33%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Israel</span></span></span></span></div>
        </td>
    <td style="width:33.33%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2834</span></span></span></span></div>
        </td>
    <td style="width:33.34%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>81-3676773</span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:33.33%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(State
        or other jurisdiction of</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>incorporation
        or organization)</span></span></span></span></div> </td>
    <td style="width:33.33%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Primary
        Standard Industrial</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Classification
        Code Number)</span></span></span></span></div> </td>
    <td style="width:33.34%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(I.R.S.
        Employer</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Identification
        No.)</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Kiryat
Atidim, Building 7&#160;</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tel
Aviv, 6158002, </span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Israel&#160;</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>+972-77-331-0156&#160;</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab
Therapeutics, Inc.<br />One Kendall Square<br />Building 1400E<br />Suite 14-105<br />Cambridge, MA 02139<br />(857) 259-4622</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;margin-left:auto;margin-right:auto;border:none;page-break-after:always;text-align:center" />
</div>

<div style="text-align:center;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Copies
to:</span></span></span></span></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:25%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:25%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:24.51%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:24.51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width:25%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Brent
        D. Fassett</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Jesse
        F. Schumaker</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Wilson
        Sonsini Goodrich &amp; Rosati, P.C.</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1881
        9<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup> Street, Suite 110</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Boulder,
        CO 80023</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(303)
        256-5900</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:25%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>David
        S. Glatt</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ronen
        Bezalel<br />Jonathan M. Nathan</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Matthew
        Rudolph<br />Meitar | Law Offices<br />16 Abba Hillel Rd.<br />Ramat Gan 5250608, Israel<br />+972 (3) 610-3100</span></span></span></span></div>
        </td>
    <td style="width:24.51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ivan
        Blumenthal</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Mintz,
        Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<br />919 Third Avenue</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>New
        York, NY 10022</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(212)
        935-3000</span></span></span></span></div> </td>
    <td style="width:24.51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chaim
        Friedland<br />Ari Fried<br />Gornitzky &amp; Co.<br />Vitania Tel Aviv<br />Tower<br />20 HaHarash Street<br />Tel Aviv, 6761310,<br />Israel<br />+972-3-710-9191</span></span></span></span></div>
        </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Approximate
date of commencement of proposed sale to the public:</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
soon as practicable after the effective date of this Registration Statement.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. <span style="font-family:'Segoe UI Symbol', sans-serif">&#9744;</span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol', sans-serif">&#9744;</span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol', sans-serif">&#9744;</span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol', sans-serif">&#9744;</span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="2" rowspan="1" style="width:161px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Large accelerated filer&#160;
        &#160; &#160; &#160; &#160;&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td>
    <td colspan="2" rowspan="1" style="width:210px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accelerated filer&#160;
        &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:161px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:342px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:210px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:293px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td colspan="2" rowspan="1" style="width:161px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230218110119689" name="dei:EntityFilerCategory" contextRef="C_20220101to20221231" format="ixt-sec:entityfilercategoryen">Non-accelerated
        filer</ix:nonNumeric></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160;
        &#160; &#160; &#160; &#9746;</span></span></div> </td>
    <td colspan="2" rowspan="1" style="width:210px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Smaller reporting company&#160;&#160;&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230218110154128" name="dei:EntitySmallBusiness" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:161px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:342px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:210px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:293px;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width:161px;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:342px;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="2" rowspan="1" style="width:210px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerging growth company&#160;&#160;&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230213103758108" name="dei:EntityEmergingGrowthCompany" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span style="font-family:'Segoe UI Symbol', sans-serif"><ix:nonNumeric id="Fxbrl_20230218131330535" name="dei:EntityExTransitionPeriod" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:100%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.</span></span></div> </div>

<div>&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div> </div> </div> </div>

<div>

<div>

<div>

<!-- Field: Include-Text; File: PF\body.htm; Date: 2023%2D02%2D22T09:59:38; Size: 0x000B93C2; Options: XMLPreprocess -->
<div><br /> </div>

<div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none">The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none">Subject
to Completion, dated February 22, 2023</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none">PRELIMINARY
PROSPECTUS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"> <img src="image00003.jpg" alt="" /></div>

<div style="line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25">

<div style="text-align: center; line-height: 1.25; font-weight: bold">Chemomab Therapeutics Ltd.</div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">&#160;

<div style="line-height: 1.25"><span style="font-weight: bold">Up to 7,614,212<span style="font-weight: bold">&#160;</span>American Depositary
Shares<br /> </span></div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Warrants to Purchase 7,614,212 American Depositary
Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"> <br /> </div> </div>

<div style="line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">7,614,212 American Depositary Shares Underlying the Warrants</div> </div> &#160; </div> &#160;</div>

<div style="line-height: 1.25; font-weight: 400; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are offering up
to 7,614,212 American Depositary Shares (&#8220;ADSs&#8221;), each representing twenty (20) of our ordinary shares, no par value per share,
together with warrants (&#8220;Warrants&#8221;) to purchase 7,614,212 ADSs (&#8220;Warrant ADSs&#8221;). The ADSs and Warrants will be
sold in combination, with each Warrant to purchase one ADS accompanying each ADS. The assumed combined public offering price for each
ADS and accompanying warrant is $1.97, which is the last reported sale price of the ADSs on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
on February 16, 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Each Warrant has an
assumed exercise price of $1.97 per ADS, which is the last reported sale price of the ADSs on Nasdaq on February 16, 2023. Each Warrant
will be immediately exercisable and will have a term of five years.&#160;The ADSs and Warrants are immediately separable and will be issued
separately in this offering, but they must be purchased together in this offering.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are also registering
the Warrant ADSs. We refer to the ADSs, the Warrants, the Warrant ADSs and the ordinary shares underlying the ADSs and the Warrant ADSs
collectively as the &#8220;Securities.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The ADSs are listed
on Nasdaq under the symbol &#8220;CMMB.&#8221;&#160; On February 16, 2023, the last reported sale price of the ADSs on Nasdaq was $1.97
per ADS. There is no established public trading market for the Warrants, and we do not expect a market to develop. We do not intend to
apply for listing of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading
market, the liquidity of the Warrants will be extremely limited.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are an &#8220;emerging
growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under U.S. federal securities laws and, as such, we have
elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Investing
in the ADSs and Warrants involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 8 of this prospectus to read
about factors you should consider before buying the ADSs and Warrants.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z26c860b70cbc41b59bdb2a23a23646e1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 83.23%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: #000000 2px solid; width: 8.36%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Per ADS and Warrant</div> </td>
    <td style="width: 0.78%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: #000000 2px solid; width: 7.64%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div> </td> </tr>
  <tr>
    <td style="width: 83.23%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">Public offering price</div> </td>
    <td style="width: 8.36%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">$</div> </td>
    <td style="width: 0.78%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 7.64%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">$</div> </td> </tr>
  <tr>
    <td style="width: 83.23%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25">Underwriting discounts and commissions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td style="width: 8.36%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25">$</div> </td>
    <td style="width: 0.78%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 7.64%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25">$</div> </td> </tr>
  <tr>
    <td style="width: 83.23%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">Proceeds, before expenses, to us<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td style="width: 8.36%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">$</div> </td>
    <td style="width: 0.78%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 7.64%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">$</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z72c0afd48a0644ccb38b79c21a9f707a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>See &#8220;Underwriting&#8221; beginning on page 50 of this prospectus for a description of the compensation payable to the underwriters.</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z8ba8deef82854f528c6a70f857ba2ac8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The amount of proceeds, before expenses, to us does not give effect to the exercise of the Warrants.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold">Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The underwriters expect to deliver the ADSs and accompanying Warrants on or about&#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold">Sole Book-Running Manager</div>

<div style="line-height: 1.25">&#160;</div>

<div style="font: normal bold 14pt/1.25 Times New Roman,Times,serif; text-align: center; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); text-transform: none">Oppenheimer
&amp; Co.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Manager</div> </div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z09b6ef786b71455985353923d056baea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font: normal bold 12pt Times New Roman,Times,serif; width: 100%; vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); text-transform: none">
        <div style="text-align: center; line-height: 1.25">Aegis Capital Corp.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25">The date of this prospectus is&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
, 2023.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">TABLE OF CONTENTS</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="2" border="0" id="z5bc1b1c3240c4b9c85337bc4a8dde051" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 95.44%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Page</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">1</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#THEOFFERING">THE OFFERING</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom; text-align: center">7</td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#RISKFACTORS">RISK FACTORS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">8</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#FORWARD-LOOKINGSTATEMENTS">FORWARD-LOOKING STATEMENTS</a></div>
        </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">12</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.44%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#DATA"><span style="text-decoration: underline">MARKET, INDUSTRY AND OTHER DATA</span></a></div>
        </td>
    <td rowspan="1" style="white-space: nowrap; width: 4.56%; vertical-align: bottom; text-align: center">13<br /> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">14</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#CAPITALIZATION">CAPITALIZATION</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">15</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#DILUTION">DILUTION</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">16</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#DIVIDENDPOLICY">DIVIDEND POLICY</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">17</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#Management">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
        OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">18</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#EXECUTIVECOMPENSATION">EXECUTIVE COMPENSATION</a></div>
        </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">24</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#SECURITY">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
        AND MANAGEMENT</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">31<br /> </div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#SHARECAPITAL">DESCRIPTION OF SHARE CAPITAL</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">33</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#DESCRIPTIONOFSECURITIES">DESCRIPTION OF SECURITIES WE
        ARE OFFERING</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">37</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#MATERIALTAXCONSIDERATIONS">MATERIAL TAX CONSIDERATIONS</a></div>
        </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">45</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#UNDERWRITING">UNDERWRITING</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom; text-align: center">52</td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#LEGALMATTERS">LEGAL MATTERS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">56</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#EXPERTS">EXPERTS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom; text-align: center">56</td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#ENFORCEMENTOFCIVILLIABILI">ENFORCEMENT OF CIVIL LIABILITIES</a></div>
        </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">57</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#WHERE">WHERE YOU CAN FIND MORE INFORMATION</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">58</div> </td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25"><a href="#INCORPORATIONBYREFERENCE">INCORPORATION BY REFERENCE</a></div>
        </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom; text-align: center">58</td> </tr>
  <tr>
    <td style="width: 95.44%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#a_001">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></div> </td>
    <td style="white-space: nowrap; width: 4.56%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">F-1</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You should rely only on the information contained in this prospectus.
Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained
in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This
prospectus is an offer to sell only the Securities offered hereby, but only under circumstances and in jurisdictions where it is lawful
to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless
of its time of delivery or any sale of Securities. Our business, financial condition, results of operations and prospects may have changed
since that date.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For investors outside the United States: We have not, and the underwriters
have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus
must inform themselves about, and observe any restrictions relating to, the offering of the Securities and the distribution of this prospectus
outside the United States.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We use our trademarks and our logo in this prospectus. This prospectus
also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks
and tradenames referred to in this prospectus appear without the &#174; and &#8482; symbols, but those references are not intended to
indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will
not assert its rights, to these trademarks and tradenames.</div>

<div style="text-align: center; line-height: 1.25"> <br /> </div>

<div style="text-align: center; line-height: 1.25">ii</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"> <br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="PROSPECTUSSUMMARY"><!--Anchor--></span>PROSPECTUS SUMMARY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">This summary highlights, and is qualified in its entirety by,
the more detailed information contained in other parts of this prospectus, including any applicable free writing prospectus and the documents
incorporated by reference herein. This summary does not contain all of the information that may be important to you in making your investment
decision. You should read this entire prospectus carefully, especially the &#8220;Risk Factors&#8221; section beginning on page 8 and
our financial statements and the related notes incorporated by reference herein, before deciding to invest in our Securities. As used
in this prospectus, unless the context otherwise requires, references to &#8220;Chemomab Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221;
the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd., an Israeli company
and its consolidated subsidiaries; however, with respect to the presentation of financial results for historical periods that preceded
the Merger (as defined below), these terms refer to the financial results of the Company&#8217;s wholly owned subsidiary, Chemomab Ltd.
(the &#8220;Subsidiary&#8221;), which was the accounting acquirer in the Merger. References to the &#8220;Merger&#8221; refer to the merger
involving Anchiano Therapeutics Ltd., or Anchiano, and the Subsidiary, whereby a wholly owned subsidiary of Anchiano merged with and into
the Subsidiary, with the Subsidiary surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger on March 16, 2021,
Anchiano changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by the Subsidiary became primarily the
business conducted by the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Company Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Chemomab is a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique
and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic
and inflammatory diseases.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Chemomab has pioneered the therapeutic targeting of CCL24, a chemokine
that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. The chemokine
is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24
inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the complex interplay of both of these
inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach
is being developed for difficult to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis,
or PSC, and systemic sclerosis, or SSc, for which patients have no established disease modifying or standard of care treatment options.
We estimate that there are approximately 77 thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion
market opportunity, and approximately 170 thousand patients suffering from SSc in those same markets, representing over a $1.5 billion
market opportunity.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">CM-101, our lead clinical product candidate, is a first-in-class
humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24, also known as eotaxin-2, as a regulator
of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and
fibrosis through a novel and differentiated mechanism of action. Based on these findings, we are actively advancing CM-101 in Phase 2
clinical studies directed toward two distinct clinical indications that include patients with liver or skin, and/or lung fibrosis. We
are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting
patients in the U.S., Europe and Israel and is being expanded by adding clinical sites, an additional high dose arm (20mg/kg) as well
as an open label extension. We had earlier proposed to add both low and high dose arms to the study but the recent encouraging results
reported from our Phase 2 liver fibrosis trial in NASH patients, dosed at 5mg/kg, along the positive Phase 1b data we previously reported
in non-alcoholic fibrotic liver disease (NAFLD) patients dosed at 5mg/kg and 2,5mg/kg, are seen as providing us sufficient data on the
performance of the lower dose to drop it from the current trial, which is focusing on the 10mg/kg and 20g/kg doses. We believe this change
will facilitate timely conduct and completion of the trial. If regulators in the future do not agree that the existing low dose data are
sufficient, we always have the option to add a lower dose group as part of the Phase 3 clinical program.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are also planning to open a Phase 2 clinical trial in SSc in
the first half of 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the skin and lung and other
organs, will focus on establishing biological and clinical proof of concept in this patient population. Although our primary focus is
on these two rare indications, as we noted, an additional Phase 2 clinical study in patients with liver fibrosis due to non-alcoholic
steatohepatitis, or NASH has recently been completed.&#160; This trial provided safety and pharmacokinetic (PK) data and is informative
in determining whether the company advances the development of its current subcutaneous formulation of CM-101. Additionally, the trial
measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. We recently
reported results from this trial, which showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated
encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments.</div> &#160;</div>
</div> </div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>&#160;

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Fibrosis is the abnormal and excessive accumulation of collagen
and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and biochemical support to surrounding
cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting
tissue properties and potentially leading to organ dysfunction and failure. Fibrosis can occur in many different tissues, including lung,
liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and
inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient tissue repair; after disease or
injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can further stimulate inflammatory processes
in a fibro-inflammatory vicious cycle.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Associated with Our Business</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our business is subject to numerous risks and uncertainties that
you should consider before investing in our company. These risks are described more fully in the section titled &#8220;Risk Factors&#8221;
in this prospectus as well as in our Annual Report on Form 10-K for the year ended December 31, 2021 and our subsequent Quarterly Reports
on Form 10-Q. These risks include, but are not limited to, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have incurred significant losses since inception and anticipate that we will continue to incur increasing levels of operating
        losses over the next several&#160;years and for the foreseeable future. We are unable to predict the extent of any future losses or when
        we will become profitable, if at all.&#160;Even if we become profitable, we may not be able to sustain or increase our profitability on
        a quarterly or annual basis.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have a limited operating history and funding, which may make it difficult to evaluate our prospects and likelihood of success.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our business is highly dependent on the success of our lead product candidate, CM-101, and any other product candidates that we advance
        into clinical studies. All of our programs will require significant additional clinical development.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our&#160;central objective is to design and develop targeted treatments for inflammation and fibrosis with an initial focus on the
        antagonism of CCL24 signaling, which is known to regulate fibrotic and inflammatory processes. While several studies are currently underway,
        our approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The successful completion of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing
        applications to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial
        marketing of any product candidates. We may experience negative or inconclusive results, which may result in us deciding, or regulators
        requiring us, to conduct additional clinical studies or trials or abandon some or all of its product development programs, which could
        have a material adverse effect on our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may encounter difficulties enrolling patients in our clinical studies, including due to the continuing effects of the COVID-19
        pandemic, or other public health emergencies and related clinical development activities could be delayed or otherwise adversely affected.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our ongoing and future clinical studies may reveal significant adverse events or immunogenicity-related responses and may result
        in a safety profile that could delay or prevent regulatory approval or market acceptance of our product candidate.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
        and if we are ultimately unable to obtain regulatory approval for CM-101 or any other product candidates, our business will be substantially
        harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization
        of our product candidates may be delayed and our business will be harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
        than us.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation
        for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including
        the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for its other product candidates.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We expect to experience significant growth in the number of our employees over time and the scope of our operations, particularly
        in the areas of product candidate development, regulatory affairs and sales and marketing. We will therefore need to expand our organization,
        and we may experience difficulties in managing this growth, which could disrupt our operations.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of
        others, our competitiveness and business prospects may be materially damaged. In addition, changes in patent laws or patent jurisprudence
        could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Risks related to our operations in Israel could materially adversely impact our business, financial condition and results of operations.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our principal executive offices are located in Israel and certain of our product candidates may be manufactured at third-party facilities
        located in Europe. In addition, our business strategy includes potentially expanding internationally if any of its product candidates
        receives regulatory approval. A variety of risks associated with operating internationally could materially adversely affect our business.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Holders of ADSs are not treated as holders of our ordinary shares.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Holders of ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in
        time to be able to exercise their right to vote.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="text-align: left; line-height: 1.25">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal
        of the underlying ordinary shares.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate
        the deposit agreement, without the prior consent of the ADS holders.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in
        less favorable outcomes to the plaintiff(s) in any such action.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal
        income tax consequences to U.S. Holders of our ordinary shares.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The Warrants are speculative in nature.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -27pt; margin-left: 47.25pt; line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>There is no established market for the Warrants being offered in this offering.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -27pt; margin-left: 47.25pt; line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Holders of the Warrants will have no rights as a shareholder until they acquire our ordinary shares.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The Warrants offered by this prospectus may not have any value.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>As our Warrant holders exercise their Warrants into Warrant ADSs and underlying ordinary shares, our shareholders&#8217; ownership
        will be diluted.</div> </td> </tr>
  </table> <br />

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Recent Developments</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">FDA Clearance of our IND Application
for CM-101 in Phase 2 Trial in SSc Patients</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: normal; font-style: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">On February 21, 2023, we reported U.S. Food and Drug Administration (FDA) clearance
of our Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc). The Phase
2 ABATE trial is a multicenter, randomized, double-blind, proof-of-biology study to evaluate the SAfety, ToleraBility, and Activity of
CM-101 in Patients with SysTEmic Sclerosis. It will enroll 45 patients with clinically active dermatologic, vascular or pulmonary SSc.
The study population is expected to be roughly split between patients with diffuse SSc and patients with limited SSc. The primary outcome
measure is safety. Secondary endpoints include multiple serum-based biological markers and a variety of exploratory biological and clinical
outcomes, including the American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) score and its revisions
(rCRISS). The trial includes a 24-week double blind period during which active treatment patients will receive 10 mg/kg of CM-101 by intravenous
infusion every three weeks, followed by a 24-week open label extension, where all patients will receive a 10 mg/kg dose. The trial includes
multiple clinical assessments of the skin, vasculature and pulmonary function. It is expected to generate additional information about
disease mechanisms, provide data relevant to future patient stratification strategies and inform the selection of appropriate endpoints
for future studies. The trial is expected&#160; to begin enrolling patients in the first half of 2023.A top-line data read-out is planned
for the second half of 2024.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Report Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker
Trial in NASH Patients</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On January 3, 2023, we reported positive top-line results from
our Phase 2a liver fibrosis biomarker trial of CM-101 in NASH patients. This trial was primarily designed to assess a subcutaneous formulation
of CM-101 and to evaluate the drug&#8217;s impact on liver fibrosis biomarkers relevant to both NASH and the fibro-inflammatory conditions
that represent the focus for the company, such as PSC and SSc. The trial met its primary endpoint of safety and tolerability, and CM-101
demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments
measured at baseline and at week 20.</div> &#160;</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The randomized, placebo-controlled trial enrolled 23 NASH patients
with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received a dose of&#160;5-mg/kg of
study drug administered by subcutaneous (SC) injection once every two weeks, for a treatment period of 16 weeks. Key findings of the CM-101
Phase 2a trial included the following.</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>CM-101 appeared to be safe and well tolerated when administered subcutaneously. Most reported adverse events observed were mild,
        with one unrelated serious adverse event reported. No significant injection site reactions were reported and no anti-drug antibodies were
        detected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles as expected, and were similar
        to what the company has previously reported.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related biomarkers, including
        ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A majority of CM-101-treated patients showed improvements in multiple liver fibrosis-related biomarkers&#8212;almost 60% of CM-101
        patients were &#8220;multiple responders&#8221;, responding in at least three biomarkers at week 20, compared to no patients in the placebo
        group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>CM-101-treated patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related biomarkers than patients
        with lower levels of CCL24 at baseline. More CM-101-treated patients with higher CCL24 levels also were &#8220;multiple responders&#8221;,
        responding in three or more of the fibrosis-related biomarkers, compared to patients with lower CCL24 levels at baseline.&#160; These
        findings further add to the growing body of evidence validating the role of CCL24 in the pathophysiology of fibrotic liver disease.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness as compared
        to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>).</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>After completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of
        fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;We believe that the data from this trial provide important
insights in support of the CM-101 development program, including the favorable safety and tolerability of CM-101 in patients with serious
liver disease, confirmation of early signs of biomarker activity that are relevant for a number of fibro-inflammatory disorders, and support
for the tolerability and pharmacokinetic data needed to assess next steps in the development of our SC formulation<span style="font-style: italic">.</span></div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Results Reported for Clinical Study of CM-101
in Patients with COVID-19-Derived Lung Damage</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 9, 2022, positive clinical data from an investigator-initiated
clinical study assessing CM-101 activity and safety in hospitalized patients with severe lung injury derived from COVID-19 was presented
at the 2022 Union Conference, an international conference on lung health. Some of the mechanisms underlying lung inflammation resulting
from COVID-19 infection are similar to those seen in system sclerosis and other chronic diseases involving lung inflammation and fibrosis.
The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized COVID-19 patients with severe pneumonia,
including its impact on biomarkers related to lung inflammation that are also relevant in SSc.<span style="font-weight: bold">&#160;</span>The
open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were receiving
standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of the study and followed
for 30 days.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Administration of CM-101 to this acutely ill patient population
appeared safe and was well tolerated. CM-101 exposures and target engagement profiles were similar to what our researchers have seen in
previous clinical studies of CM-101. Importantly, rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil
activity were observed post-treatment with CM-101.<span style="font-weight: bold">&#160;</span>Overall, this study confirmed and extended
the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers associated with lung inflammation
and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.<span style="font-weight: bold">&#160;</span>Moreover,
we believe that these results add to the data suggesting that CM-101 has the potential to attenuate lung inflammation and fibrosis, further
strengthening the rationale for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence
demonstrating CM-101&#8217;s anti-fibrotic and anti-inflammatory effects in varied organs including the lung, liver and skin.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">New Executive Appointments</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On August 29, 2022, Christina Crater, MD, joined us as our Vice
President of Clinical Development. Dr. Crater has an extensive background in medical affairs and clinical trial design and execution across
a broad range of therapeutic indications, Dr. Crater has served as a medical monitor, safety physician, therapeutic expert and study director
in all phases of clinical development. Her career spans working in-house at pharmaceutical and biotechnology firms, and at major clinical
research organizations (CROs). Previously Dr. Crater was a Senior Clinical Trial Physician at Bristol-Myers Squibb, and she served in
senior clinical development roles with PRA Health Sciences and PAREXEL International. Earlier in her career, Dr. Crater worked as an internal
medicine physician. She received an MD degree from the University of Tennessee and holds a BS degree from Rhodes College.</div> &#160;</div>
</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>&#160;

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 14, 2022, Matthew Frankel, MD, MBA joined us as our
Chief Medical Officer and Vice President of Drug Development. Dr. Frankel brings a wealth of experience across all aspects of clinical
development and medical affairs, along with a strong track record in helping to bring biologic and small molecule drugs to market for
both rare and chronic diseases. Before joining us. Dr. Frankel served as Vice President, Clinical Development and Medical Affairs, Specialty
Pharma at Boehringer Ingelheim, where he developed new drugs for oncology, immunology, pulmonary, and central nervous system diseases.
Previously Dr. Frankel was Vice President &amp; Head, Immunology and Dermatology Medical Unit at Novartis, where he oversaw medical affairs
and late phase clinical development for Cosentyx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>,
Ilaris<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>, and Zortress<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>.&#160;
At the Sandoz unit of Novartis, Dr. Frankel led the medical affairs organization supporting the biopharmaceutical, biosimilar and generics
businesses for launches including Kerydin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>, Glatopa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
and Zarxio<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>. Earlier in his career, Dr. Frankel held
clinical development leadership roles across geographies and therapeutic diseases at Reata, Fibrogen, Abbott Labs, and Schering Plough.
Dr. Frankel received a BA degree from Vassar College, an MD degree from the University of California School of Medicine, Los Angeles and
an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University.&#160; He is board certified in internal medicine.
Dr. Frankel replaced interim Chief Medical Officer David Weiner, MD, who has continued in the role of Strategic Advisor to Chemomab.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 21, 2022, Mitchell L. Jones, MD, PhD, joined us as
our Vice President of Corporate Development &amp; Strategy. Dr. Jones brings more than 15 years of leadership experience in biopharmaceutical
research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer
and licensing and acquisitions.&#160;Dr. Jones formerly was Vice President Clinical Discovery and Development at Finch Therapeutics, where
he contributed to a successful IPO and helped oversee the clinical development of novel therapeutics for inflammatory bowel disease and
cancer. Previously Dr. Jones was Vice President of Translational and Clinical Development at Biora Therapeutics, formerly Progenity, developing
clinical program strategy and overseeing development of its novel drug delivery technologies. Earlier, Dr. Jones managed the successful
trade sale of the technology platform and assets of Interface Biosciences. Dr. Jones also founded Micropharma, where he served as Head
of R&amp;D, concluded major licensing agreements and managed the company&#8217;s half billion-dollar acquisition. Dr. Jones is the author
or co-author of numerous scientific abstracts, proceedings and publications and an inventor on almost 200 filed or granted patents. He
received his MD, PhD, master&#8217;s in biomedical engineering and BS degrees from McGill University in Canada.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The Repurchase Arrangement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As previously reported in&#160; our Registration Statement on Form
S-4 (File No. 333-252070), filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 13, 2021 and declared
effective by the SEC on February 10, 2021, the Subsidiary filed an application with the Israel Tax Authority for a tax ruling (the &#8220;Tax
Ruling&#8221;) in connection with the Merger, pursuant to which certain of the Subsidiary&#8217;s shareholders were entitled to defer
an immediate Israeli tax liability resulting from the exchange of shares that otherwise would have been deemed a sale. The deferral of
the aforementioned tax liability is set to lapse on March 16, 2023, which is the two-year anniversary of the closing date of the Merger.
Dr. Adi Mor, co-founder of the Subsidiary and both our Chief Scientific Officer and a Class III director, and Professor Kobi George, co-founder
of the Subsidiary (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), will be required to pay a substantial tax liability to the
Israeli Tax Authority upon the expiration date of the deferral period. In order to pay this tax liability, the Co-Founders had to sell
part of their holdings in the Company. In light of the foregoing, Chemomab elected to enter into a share purchase agreement (the &#8220;Repurchase
Arrangement&#8221;) with the Co-Founders whereby we agreed, subject to the requisite court approval required under Section 303(a) of the
Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which we received on November 14, 2022, to repurchase up to 582,023
of&#160; ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price
of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, we repurchased the entire amount of 582,023 ADSs from the
Co-Founders at a weighted average price of $2.0848 and for total consideration of approximately $1.2 million.&#160;</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We do not expect any change in our cash runway as a result of the
Repurchase Arrangement. Our current cash, cash equivalents and short-term bank deposits are expected to last through at least March 31,
2024.&#160;Based on our planned use of the net proceeds from this offering and our existing cash, cash equivalents and short-term bank
deposits, this financing will enable us to advance our clinical development programs for PSC and SSc. We are likely to need to secure
additional financing to complete those programs which are projected to have topline readouts in the second half of 2024. We continue to
manage our cash runway and believe additional capital will be available when required.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Corporate Information</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We were incorporated on September 22, 2011, under the laws of the
State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics
Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156.
Our website is: <span style="font-style: italic">www.chemomab.com.</span> The information contained on, or that can be accessed through,
our website is not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. We have
included our website address as an inactive textual reference only.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> &#160;

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>&#160;

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Implications of Being an Emerging Growth Company and a Smaller
Reporting Company</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are an &#8220;emerging growth company&#8221; as defined in the
Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until the earliest
to occur of: the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; the date we qualify as a &#8220;large
accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; the issuance, in any three-year period,
by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal year ending after the fifth anniversary
of our initial public offering. As a result of this status, we have taken advantage of reduced reporting requirements in this prospectus
and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. In particular, in this prospectus,
we have provided only two years of audited financial statements and have not included all of the executive compensation related information
that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company can
take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these
accounting standards until they would apply to private companies. We have elected to use this extended transition period to enable us
to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier
of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period
provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised
accounting standards as of public company effective dates.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To the extent that we continue to qualify as a &#8220;smaller reporting
company,&#8221; as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we cease to qualify as an emerging
growth company, we will continue to be permitted to make certain reduced disclosures in our periodic reports and other documents that
we file with the SEC. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited
financial statements in our Annual Report on Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies
have reduced disclosure obligations regarding executive compensation. We will continue to be a smaller reporting company if either (i)&#160;the
market value of our stock held by&#160;non-affiliates&#160;is less than $250&#160;million or (ii)&#160;our annual revenue is less than
$100&#160;million during the most recently completed fiscal year and the market value of our stock held by&#160;non-affiliates&#160;is
less than $700&#160;million.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>&#160;

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="THEOFFERING"><!--Anchor--></span>THE OFFERING</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z1c9a8871db23497ab4761da76991d7a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Securities offered by us</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Up to 7,614,212 ADSs,&#160;each representing twenty (20) ordinary shares, no par value
        per share, and Warrants to purchase up to 7,614,212 ADSs. The ADSs and Warrants are immediately separable and will be issued separately
        in this offering, but must be purchased together in this offering.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8fb5e2e0a1e245b69ac50c477cfbcd2c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The ADSs</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The underwriters will deliver American Depositary Shares (ADSs) representing our ordinary
        shares. Each ADS represents twenty of our ordinary shares, no par value per share.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div>
        <div style="text-align: justify; line-height: 1.25">As an ADS holder, you will not be treated as one of our shareholders and you will
        not have shareholder rights. The depositary, The Bank of New York Mellon, will be the holder of the ordinary shares underlying the ADSs.
        You will have the rights of an ADS holder or beneficial owner (as applicable) as provided in the deposit agreement among us, the depositary
        and holders and beneficial owners of ADSs from time to time. To better understand the terms of the ADSs, see &#8220;Description of Securities
        We Are Offering.&#8221; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration
        statement of which this prospectus forms a part.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div>
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">You may turn in the ADSs to the depositary to cancel the ADSs and withdraw the ordinary
        shares. The depositary will charge you fees for any cancellation and withdrawal.</div> </div> </td> </tr>
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Warrants</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Each Warrant will have an assumed exercise price of $1.97 (based
        on an assumed public offering price of $1.97 per ADS, the last reported sale price of the ADSs on Nasdaq on February 16, 2023), will be
        immediately exercisable and will expire five years from the date of issuance. To better understand the terms of the warrants, you should
        carefully read the &#8220;Description of the Offered Securities&#8221; section of this prospectus. You should also read the form of warrant,
        which is filed as an exhibit to the registration statement that includes this prospectus.</div> </div> </td> </tr>
  <tr>
    <td style="width: 38%; vertical-align: top">&#160;</td>
    <td style="width: 62%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">ADSs outstanding prior to this offering</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">11,049,812 ADSs.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zd467b9d2338a49a69202b2deaa3020da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">ADSs outstanding after this offering</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">18,664,024 ADSs.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za10f5ddb51554a64bec69fdbda283d34" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Use of proceeds</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">We estimate the net proceeds from this offering will be approximately $13.6 million,
        after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net
        proceeds from this offering for continued clinical development of our product candidates, research activities, and for other general corporate
        purposes. See &#8220;Use of Proceeds&#8221; on page 12 of this prospectus.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecd85386713f432fab645a7223506cb2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Risk factors</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">See &#8220;Risk Factors&#8221; beginning on page 8 for a discussion of factors you
        should carefully consider before deciding to invest in our securities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zd110e51816f648e4998b2fd27c39e631" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">ADS depositary</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The Bank of New York Mellon.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zd445aeb7b7584ab3b60a06e7dc2ec3d3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Nasdaq Capital Market symbol</div> </td>
    <td style="width: 62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">The ADSs are listed on Nasdaq under the symbol &#8220;CMMB.&#8221; We do not intend to
        list the Warrants on any securities exchange or nationally recognized trading system.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The number of ADSs to be outstanding after this
offering is based on 11,049,812 ADSs outstanding as of December 31, 2022, and does not account for:</div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<table cellspacing="0" cellpadding="0" id="z955be787e80a42df89bb85d44c06285e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">1,759,577 ADSs issuable upon the exercise of
        outstanding options to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div> </div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">an aggregate of 643,369 ADSs reserved for future issuance under the Chemomab Ltd. 2015 Share Incentive
        Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company upon effectiveness of the Merger, and the 2017 Equity-Based Incentive
        Plan (the &#8220;2017 Plan&#8221; and together with the 2015 Plan, the &#8220;Share Incentive Plans&#8221;), as of December 31, 2022,
        as well as any automatic increases in the number of ADSs reserved for future issuance under the 2017 Plan;</div> </div> </div> </div>
        </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at
        a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain outstanding at the consummation of this
        offering; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb99bb1b69efa4a07a7929e936288c590" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">7,614,212 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Except as otherwise indicated, all information in this prospectus
assumes no exercise of the outstanding options and warrants described above and no exercise of the Warrants issued in this offering.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="RISKFACTORS"><!--Anchor--></span>RISK FACTORS</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Investing in our Securities involve
a high degree of risk. You should carefully consider the following risk factors, in addition to the risk factors included in our Annual
Report on Form 10-K for the year ended December 31, 2021 and in subsequent Quarterly Reports on Form 10-Q, as well as all of the other
information contained in this prospectus</span>&#160;<span style="font-style: italic">and the information incorporated by reference in
this prospectus, before deciding to invest in our Securities. Our business, financial condition, results of operations or prospects could
be materially and adversely affected if any of these risks occurs, and as a result, the market price of the ADSs could decline and you
could lose all or part of your investment. Our actual results could differ materially and adversely from those anticipated in any forward-looking
statements in this prospectus as a result of certain factors, including those set forth below. See &#8220;Forward-Looking Statements.&#8221;</span></div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to This Offering</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">You may experience future dilution as a result
of future equity offerings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In order to raise additional capital, we expect to offer in the
future additional ADSs or other securities convertible into or exchangeable for the ADSs. We cannot assure you that we will be able to
sell ADSs or other securities in any other offering at a price per share that is equal to or greater than the price per ADS paid by investors
in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders.
The price per ADS at which we sell additional ADSs or other securities convertible into or exchangeable for the ADSs in future transactions
may be higher or lower than the price per ADS in this offering.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have broad discretion to determine how to
use the funds raised in this offering, and may use them in ways that may not enhance our operating results or the price of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our management will have broad discretion over the use of proceeds
from this offering, and we could spend the proceeds from this offering in ways the ADS holders may not agree with or that do not yield
a favorable return, if at all. We intend to use the net proceeds from this offering for continued clinical development of our product
candidates,&#160;research activities, and for other general corporate purposes. However, our use of these proceeds may differ substantially
from our current plans. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may
fail to achieve expected financial results, which could cause the ADS price to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The trading price of the ADSs has been highly
volatile, and purchasers of the ADSs could incur substantial losses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The trading price of the ADSs has been highly volatile, particularly
over the last year. For example, on January 11, 2022, the closing price of theADSs was $6.98 per ADS and on December 7, 2022, it was $1.90
per ADS. This volatility may affect the price at which you are able to sell ADSs, and the sale of the ADSs in this offering could adversely
affect the price of the ADSs. Our ADS price is likely to continue to be volatile and subject to significant price and volume fluctuations
in response to market and economic factors that are beyond our control. As a result, you may not be able to sell the ADSs at or above
the price at which you purchase them. In addition, while the stock market in general has experienced high volatility, biotechnology companies
in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to operating performance.
Broad market and industry factors may negatively affect the market price of the ADSs, regardless of our actual operating performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have not paid dividends in the past and
do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have never paid dividends and do not anticipate paying dividends
in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects
and other factors our board of directors may deem relevant. If we do not pay dividends, the ADSs may be less valuable because a return
on your investment will only occur if our ADS price appreciates and you sell your ADS thereafter. In addition, the Companies Law imposes
restrictions on our ability to declare and pay dividends. See &#8220;Description of Share Capital &#8212; Dividend and Liquidation Rights&#8221;
for additional information. The payment of dividends may be subject to Israeli withholding taxes. See &#8220;Material Tax Considerations
&#8212;Israeli Taxation&#8221; for additional information.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to continue to meet all applicable
Nasdaq requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the liquidity and market price of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The ADSs are currently listed on Nasdaq, which has qualitative
and quantitative listing criteria. If we are unable to meet any of the Nasdaq listing requirements in the future, including, for example,
if the closing bid price for the ADSs falls below $1.00 per share for 30 consecutive trading days, Nasdaq could determine to delist the
ADSs, which could adversely affect the market liquidity of the ADSs and the market price of the ADSs could decrease. Such delisting could
also adversely affect our ability to obtain financing for the continuation of our operations and could result in the loss of confidence
by investors, customers and employees.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Holders of ADSs are not treated as holders
of our ordinary shares.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Holders of ADSs are not treated as holders of our ordinary shares,
unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations.
The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of
our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">You may not have the same voting rights as
the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your right to vote.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Except as described in the deposit agreement, holders of the ADSs
will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. If we request the depositary to solicit
your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send
or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct
the depositary how to vote. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct
the depositary to vote the ordinary shares underlying their ADSs. For instructions to be valid, they must reach the depositary by a date
set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our articles
of association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed
by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and,
in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Otherwise, ADS holders will not be able to exercise their right
to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far
enough in advance to withdraw those ordinary shares. In any event, the depositary will not exercise any discretion in voting deposited
securities and it will only vote or attempt to vote as instructed. In addition, the depositary and its agents are not responsible for
failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to
exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you requested.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Holders of ADSs may be subject to limitations
on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">ADSs are transferable on the books of the depositary. However,
the depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books
are closed or at any time if the depositary or we think it advisable to do so. These limitations on transfer may have a material adverse
effect on the value of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are entitled to amend the deposit agreement
and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent
of the ADS holders.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are entitled to amend the deposit agreement and to change the
rights of the ADS holders under the terms of such agreement without the prior consent of the ADS holders. We and the depositary may agree
to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary. Amendments may reflect, among
other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship
with the depositary. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of
the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders,
it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time
an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound by the ADRs
and the deposit agreement as amended. If we make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate
the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying
ordinary shares, but they will have no right to any compensation whatsoever.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">ADSs holders may not be entitled to a jury
trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in
any such action.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The deposit agreement governing the ADSs representing our ordinary
shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury
trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the deposit agreement.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If this jury trial waiver provision is not permitted by applicable
law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial
demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that
case in accordance with the applicable state and federal law. We believe that a contractual pre-dispute jury trial waiver provision is
generally enforceable, including under the laws of the State of New York, which governs the deposit agreement. In determining whether
to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently
and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If any holders or beneficial owners of ADSs bring a claim against
us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities
laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting
and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement,
it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures
and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s)
in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue
of the hearing.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">No condition, stipulation or provision of the deposit agreement
or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision
of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We presently anticipate that we will be classified
as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We would be classified as a passive foreign investment company,
or PFIC, for any taxable year if, after the application of certain look-through rules, either: (i) 75% or more of our gross income for
such year is &#8220;passive income&#8221; (as defined in the relevant provisions of the Internal Revenue Code of 1986, as amended, or
the Code), or (ii) 50% or more of the value of our assets (generally determined on the basis of a quarterly average) during such year
is attributable to assets that produce or are held for the production of passive income. Passive income generally includes, among other
things, rents, dividends, interest, royalties, gains from the disposition of passive assets, and gains from commodities and securities
transactions. For purposes of this test, we will be treated as owning a proportionate share of the assets and earning a proportionate
share of the income of any other corporation of which we own, directly or indirectly, at least 25% (by value) of the stock. Based on the
nature, composition and value of our income, operations and assets currently and in the future, we presently anticipate that we will be
a PFIC for United States federal income tax purposes for the current taxable year and in the foreseeable future. See &#8220;<span style="font-style: italic">Certain
Material U.S. Federal Income Tax Consequences &#8212; Passive Foreign Investment Company Consequences</span>.&#8221;</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">The Warrants are speculative in nature.</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Except as otherwise set forth therein, the Warrants offered in
this offering do not confer any rights of ADS ownership on their holders, such as voting rights, but rather merely represent the right
to acquire ADSs at a fixed price. Specifically with respect to the Warrants, commencing on the date of issuance, holders of the Warrants
may exercise their right to acquire ADSs and pay an assumed exercise price of $1.97 per ADS, which is the assumed offering price of the
ADSs in this offering, prior to five years from the date of issuance, after which date any unexercised Warrants will expire and have no
further value. There can be no assurance that the market price of the ADSs will continue to equal or exceed the exercise price of the
Warrants offered by this prospectus. In the event that our ADS price does not exceed the exercise price of such Warrants during the period
when such Warrants are exercisable, the Warrants may not have any value.</div> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">There is no established market for the Warrants being offered in
this offering.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There is no established trading market for the Warrants offered
in this offering. We do not intend to apply for listing of the Warrants on any securities exchange or other nationally recognized trading
system. Without an active market, the liquidity of the Warrants will be limited.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%11%%%-->

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Holders of the Warrants will have no rights as a shareholder until
they acquire our ordinary shares.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-indent: 36pt; line-height: 1.25">Until you acquire the ordinary shares underlying the Warrant ADSs, you will have no
rights with respect to the ordinary shares underlying the Warrant ADSs underlying the Warrants. Upon exercise of your Warrants and subsequent
delivery of the ordinary shares by the Company&#8217;s depositary, you will be entitled to exercise the rights of an ordinary shareholder
only as to matters for which the record date occurs after the exercise date.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">The Warrants offered by this prospectus may not have any value.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The Warrants offered by this prospectus will be exercisable for five years from the
date of issuance. There can be no assurance that the market price of the ADSs will ever exceed the exercise price of the Warrants. In
the event that our ADS price does not exceed the exercise price of the Warrants during the term of the Warrants, the Warrants may not
have any value.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">As our Warrant holders exercise their Warrants into Warrant ADSs
and underlying ordinary shares, our shareholders&#8217; ownership will be diluted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The exercise of some or all of our Warrants will result in the issuance of ADSs and
ordinary shares that dilute the ownership interests of existing shareholders. Any sales of ADSs or ordinary shares underlying the Warrants
could adversely affect prevailing market prices of the ADSs and ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%12%%%-->

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="FORWARD-LOOKINGSTATEMENTS"><!--Anchor--></span>FORWARD-LOOKING
STATEMENTS</div>

<div style="text-align: center; line-height: 1.25">&#160;<span style="font-weight: bold">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
AND INDUSTRY DATA</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus and the information incorporated by reference in
this prospectus contain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;) that involve substantial risks and uncertainties. Although our forward-looking
statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known
by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes
may differ materially from results and outcomes discussed in the forward-looking statements. These forward-looking statements speak only
as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled
&#8220;Risk Factors&#8221; and elsewhere in this prospectus.&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">All statements other than present and historical facts and conditions
contained in this prospectus, and the information incorporated by reference in this prospectus, including statements regarding our future
results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking
statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would,&#8221; or the negative of these
and similar expressions identify forward-looking statements.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We cannot assure you that the forward-looking statements in this
prospectus and the information incorporated by reference in this prospectus will prove to be accurate. Furthermore, if our forward-looking
statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our
objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You should read this prospectus and the information incorporated
by reference in this prospectus completely and with the understanding that our actual future results may be materially different from
what we expect. We qualify all of our forward-looking statements by these cautionary statements.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus and the information incorporated by reference in
this prospectus may contain market data and industry forecasts that were obtained from industry publications. These data involve a number
of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position,
market opportunity and market size information included in this prospectus and the information incorporated by reference in this prospectus
is generally reliable, we have not independently verified any third-party information and cannot guarantee its accuracy and completeness.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">

<div style="text-align: center; line-height: 1.25; font-weight: bold">MARKET, INDUSTRY AND OTHER <span id="DATA"><!--Anchor--></span>DATA</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus contains estimates, projections and other information
concerning our industry and our business. We obtained the industry, market and similar data set forth in this prospectus from our internal
estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties. We do not
expressly refer to the sources from which this information is derived. Information that is based on estimates, forecasts, projections,
market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially
from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable,
we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified
by any third party. You are cautioned not to give undue weight to any such information, projections and estimates. The sources listed
below are not a part of this prospectus and are not incorporated by reference in this prospectus.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 14.4pt; line-height: 1.25">The sources and citations of industry, market and other data, as well as published
studies, contained in this prospectus are listed below:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfaea339cbc204c4fb9ae070f8a5ae11e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">1.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Ablin, J. N., M. Entin-Meer, V. Aloush, S. Oren, O. Elkayam, J. George, and I. Barshack. 2010. 'Protective effect of eotaxin-2 inhibition
        in adjuvant-induced arthritis', Clin Exp Immunol, 161: 276-83.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd52b216972fc4f8a81e360dd6c2beaba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">2.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Bhattacharyya, S., J. Wei, and J. Varga. 2011. 'Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities',
        Nat Rev Rheumatol, 8: 42-54.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9eac5fefd1b042a7b1aee0b10a15a26e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">3.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Bocchino, V., G. Bertorelli, C. P. Bertrand, P. D. Ponath, W. Newman, C. Franco, A. Marruchella, S. Merlini, M. Del Donno, X. Zhuo,
        and D. Olivieri. 2002. 'Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis', Allergy, 57: 17-22.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z27f1ffeca4f24486a5946e65389f82f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">4.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Henderson, N. C., F. Rieder, and T. A. Wynn. 2020. 'Fibrosis: from mechanisms to medicines', Nature, 587: 555-66.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5e29d05e3c9e435f982e348baa6027b7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">5.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Jimenez, S. A., E. Hitraya, and J. Varga. 1996. 'Pathogenesis of scleroderma. Collagen', Rheum Dis Clin North Am, 22: 647-74.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z16b41944ab684f0f984b5f9437079ed0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">6.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Jose, P. J., D. A. Griffiths-Johnson, P. D. Collins, D. T. Walsh, R. Moqbel, N. F. Totty, O. Truong, J. J. Hsuan, and T. J. Williams.
        1994. 'Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation', J Exp Med,
        179: 881-7.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd42361138aab4364839e0e33e96e5e0c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">7.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Karlsen, T. H., T. Folseraas, D. Thorburn, and M. Vesterhus. 2017. 'Primary sclerosing cholangitis - a comprehensive review', J Hepatol,
        67: 1298-323.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf423b5b1ba7949ebafd7c400e305de12" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">8.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Kitaura, M., T. Nakajima, T. Imai, S. Harada, C. Combadiere, H. L. Tiffany, P. M. Murphy, and O. Yoshie. 1996. 'Molecular cloning
        of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor
        3', J Biol Chem, 271: 7725-30.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf23c9baf67a54eb0b282c1655c8f0197" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">9.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Kohan, M., I. Puxeddu, R. Reich, F. Levi-Schaffer, and N. Berkman. 2010. 'Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential
        profibrogenic effects on human lung fibroblasts', Ann Allergy Asthma Immunol, 104: 66-72.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z44ea1ebb788941d29d6a2933a9fd3361" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">10.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Mor, A. , Afek, A. , Entin-Meer, M. , Keren, G. and George, J. 2013. 'Anti eotaxin-2 antibodies attenuate the initiation and progression
        of experimental atherosclerosis.', World Journal of Cardiovascular Diseases, 3: 339-46.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf486c48d6a714864a487cbcbe6d2a018" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">11.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Mor, A., M. Segal Salto, A. Katav, N. Barashi, V. Edelshtein, M. Manetti, Y. Levi, J. George, and M. Matucci-Cerinic. 2019. 'Blockade
        of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis', Ann Rheum Dis, 78: 1260-68.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z350f85a25331486eac937f45ed9243e5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">12.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Ponath, P. D., S. Qin, D. J. Ringler, I. Clark-Lewis, J. Wang, N. Kassam, H. Smith, X. Shi, J. A. Gonzalo, W. Newman, J. C. Gutierrez-Ramos,
        and C. R. Mackay. 1996. 'Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties
        suggest a mechanism for the selective recruitment of eosinophils', J Clin Invest, 97: 604-12.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb3cdef72d15c4814b549ddacfbe37a0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">13.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Segal-Salto, M., N. Barashi, A. Katav, V. Edelshtein, A. Aharon, S. Hashmueli, J. George, Y. Maor, M. Pinzani, D. Haberman, A. Hall,
        S. Friedman, and A. Mor. 2020. 'A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models
        of liver damage', JHEP Rep, 2: 100064.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc4ffeb70fe344dbdb835e0b3978f01ee" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">14.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Wynn, T. A. 2008. 'Cellular and molecular mechanisms of fibrosis', J Pathol, 214: 199-210.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="USEOFPROCEEDS"><!--Anchor--></span>USE OF PROCEEDS</div>

<div style="line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We estimate that the net proceeds
from this offering will be approximately $13.6 million, assuming a public offering price of $1.97 per ADS and accompanying Warrant, which
was the last reported sale price per share of the ADSs on Nasdaq on February 16, 2023, after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We currently expect to use the net proceeds from this offering
for continued clinical development of our product candidates,&#160;research activities, and for other general corporate purposes. We have
not determined the amount of net proceeds to be used specifically for the foregoing purposes. This expected use of the net proceeds from
this offering represents our intentions based upon our current plans and business conditions. Amounts and timing of our actual expenditures
will depend upon a number of factors, including our sales, marketing and commercialization efforts, regulatory approval and demand for
our product candidates, operating costs, among other factors. Accordingly, our management will have flexibility in applying the net proceeds
from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base
our decisions on how to use the proceeds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pending use of the net proceeds, we intend to invest any proceeds
in a variety of capital preservation instruments, including short-term deposits and interest-bearing instruments.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Based on our planned use of the net proceeds from this offering
and our existing cash, cash equivalents and short-term bank deposits, we estimate that this financing will enable us to advance our clinical
development programs for PSC and SSc. We are likely to need to secure additional financing to complete those programs which are projected
to have topline readouts in the second half of 2024. We continue to manage our cash runway and believe additional capital will be available
when required. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources
sooner than we currently expect. In any event, we will require additional funding to complete the clinical development of, and commercialize,
our future therapeutic candidates. We may satisfy our future cash needs through the sale of equity securities, debt financings, working
capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances
or a combination of one or more of these sources.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="CAPITALIZATION"><!--Anchor--></span>CAPITALIZATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth our cash, cash equivalents and short-term
bank deposits, and our capitalization as of December 31, 2022:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36623668ffbb45f58556c1cd72a016ed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.01%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 96%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">on an actual basis; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1a9c91deebe64741b4a0cabdac73a0a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.01%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 96%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">on an as adjusted basis to give effect to the sale of 7,614,212 ADSs in this offering,
        at an assumed public offering price of $1.97 per ADS and accompanying Warrant, and after deducting the estimated underwriting discounts
        and commissions and estimated offering expenses payable by us.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The pro forma as-adjusted information below is illustrative only
and our capitalization following the completion of this offering is subject to various adjustments. See &#8220;Underwriting&#8221; below
in this prospectus. You should read this table together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; included elsewhere in this prospectus for the fiscal year ended December 31, 2022, and our financial
statements and the related notes incorporated by reference into this prospectus.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z5d3119cf72994c539ba354ed9db3419e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="6" style="width: 22.01%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">As of December 31 , 2022</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="6" style="border-bottom: #000000 2px solid; width: 22.01%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(in thousands)(unaudited)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: #000000 2px solid; width: 10%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Actual</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: #000000 2px solid; width: 10%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">As Adjusted</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="6" style="width: 22.01%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Cash and cash equivalents and short-term bank deposits</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 4px double; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">$</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 4px double; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">39,970</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 4px double; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 4px double; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">53,530</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top">
        <div style="line-height: 1.25">Shareholders&#8217; equity</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Ordinary Shares, no par value - Authorized: 650,000,000 ordinary shares as of December 31, 2022</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">&#8212;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Issued and outstanding: 232,636,700 ordinary shares issued and outstanding actual;&#160; 373,280,480 ordinary
        shares issued and outstanding as adjusted</div> </div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Additional paid-in capital</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">101,260</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">114,820</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top">
        <div style="line-height: 1.25">Treasury stock at cost</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(1,218</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(1,218)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Accumulated deficit</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 2px solid; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 2px solid; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">(63,819</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 2px solid; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: #000000 2px solid; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">(63,819)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top">
        <div style="line-height: 1.25">Total shareholders&#8217; equity</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">36,223</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">49,783</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25"><span style="font-weight: bold">Total liabilities and shareholders&#8217; equity</span>&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">$</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">43,063</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">$</div> </td>
    <td style="white-space: nowrap; width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25">56,623</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The information above is based on 11,049,812 ADSs outstanding
as of December 31, 2022, and does not account for the following:</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd97a9b97289348a6a044d714465805b4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,759,577 ADSs issuable upon the exercise of outstanding options
        to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div> </div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">an aggregate of 643,369 ADSs reserved for
        future issuance under our Share Incentive Plans, as of December 31,2022, as well as any automatic increases in the number of ADSs reserved
        for future issuance under the 2017 Plan;</div> </div> </div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at
        a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain outstanding at the consummation of this
        offering; and</div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">7,614,212 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25">Except as otherwise indicated,
all information in this prospectus assumes no exercise of the outstanding options and warrants described above and no exercise of the
Warrants issued in this offering.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="DILUTION"><!--Anchor--></span>DILUTION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">If you invest in our Securities in this offering, your ownership interest may be diluted
to the extent of the difference between the public offering price per ADS and accompanying Warrant and the as adjusted net tangible book
value per ADS after this offering. Net tangible book value per ADS is calculated by subtracting our total liabilities from our total tangible
assets, which is total assets, and dividing this amount by the number of ADSs outstanding. Our net tangible book value as of December
31, 2022 was approximately $36.2 million, or $3.28 per ADS.</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">After giving effect to the sale of 7,614,212 ADSs and accompanying Warrants in this
offering at an assumed public offering price of $1.97 per ADS and accompanying Warrant, and after deducting commissions and other estimated
offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2022 would have been approximately $49.8&#160;
million, or $2.67&#160; per ADS. This amount represents an immediate dilution in the net tangible book value of $0.61 per ADS to our existing
shareholders and an immediate increase in net tangible book value of $0.70 per ADS to new investors purchasing ADSs in this offering.
The following table illustrates this per ADS dilution:</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z21923cae9ed04c119582ed23f143e0d2" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">Assumed offering price per ADS and accompanying Warrant</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25">1.97</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Net tangible book value per ADS as of December 31, 2022</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.28</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Net dilution&#160; in net tangible book value per ADS attributable to existing shareholders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(0.61</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">As adjusted net tangible book value per ADS after this offering</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2.67</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Net increase in net tangible book value per ADS to new investors in this offering</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">0.70</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height: 1.25"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The table above assumes for illustrative
purposes that an aggregate of&#160;7,614,212 ADSs are sold at a price of $1.97 per ADS and accompanying Warrant and for aggregate gross
proceeds of approximately $15.0 million.</div> </div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The information above is based on 11,049,812 ADSs outstanding
as of&#160;December 31, 2022, and does not account for the following:</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb2953b850af1476594650f5f6bcc172b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,759,577 ADSs issuable upon the exercise of outstanding options
        to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div> </div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">an aggregate of 643,369&#160; ADSs reserved for future issuance under our Share Incentive Plans, as of
        &#160;December 31,2022, as well as any automatic increases in the number of ADSs reserved for future issuance under the 2017 Plan;</div>
        </div> </div> </div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at
        a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain outstanding at the consummation of this
        offering; and</div> </td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">&#160;</td>
    <td style="width: 96.4%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 0.57%; vertical-align: top">&#160;</td>
    <td style="width: 3.02%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#9679;</div> </td>
    <td style="width: 96.4%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">7,614,212 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-indent: 36pt; line-height: 1.25">To the extent that additional ADSs are issued pursuant to the foregoing, investors purchasing&#160;
ADSs in this offering will experience further dilution. In addition, we may offer other securities in other offerings due to market conditions
or strategic considerations. To the extent we issue such securities, you may experience further dilution.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="DIVIDENDPOLICY"><!--Anchor--></span>DIVIDEND POLICY</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have never declared nor paid any cash dividends on the ADSs
or our ordinary shares. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future.
Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject to applicable laws,
and will depend on a number of factors, including our financial condition, results of operations, capital requirements, contractual restrictions,
general business conditions, and other factors that our Board of Directors may deem relevant. In addition, the Companies Law imposes restrictions
on our ability to declare and pay dividends. See &#8220;Description of Share Capital &#8212; Dividend and Liquidation Rights&#8221; for
additional information. The payment of dividends may be subject to Israeli withholding taxes. See &#8220;Material Tax Considerations &#8212;Israeli
Taxation&#8221; for additional information.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="Management"><!--Anchor--></span>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</div> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic">You should read the following discussion and
analysis of our financial condition and results of operations together with our consolidated financial statements. Some of the information
contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing,
includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221; and Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form&#160;10-K filed on March 30, 2022 for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25">We are a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique
and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we developed CM-101, a monoclonal antibody designed
to bind and block CCL24 activity. We believe CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic
and inflammatory diseases.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25">

<div style="text-indent: 35.25pt; line-height: 1.25">We have pioneered the therapeutic targeting of CCL24, a chemokine that promotes various
types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. The chemokine is expressed in
various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product
candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the complex interplay of both of these inflammatory and
fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed
for difficult to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis (PSC) and systemic
sclerosis (SSc) for which patients have no established disease-modifying treatment options. We estimate that there are approximately 77
thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170
thousand patients suffering from SSc in those same markets, representing over a $1.5 billion market opportunity.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25">

<div style="text-indent: 35.25pt; line-height: 1.25">CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal
antibody that attenuates the basic function of the soluble chemokine CCL24, also known as eotaxin-2, as a regulator of major inflammatory
and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a
novel and differentiated mechanism of action. Based on these findings, we are actively advancing CM-101 in Phase 2 clinical studies directed
toward two distinct clinical indications that include patients with liver or skin, and/or lung fibrosis. We are currently conducting a
Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the U.S.,
Europe and Israel and is being expanded by adding clinical sites, an additional high dose arm (20mg/kg) as well as an open label extension.
We had earlier proposed to add both low and high dose arms to the study but the recent encouraging results reported from our Phase 2 liver
fibrosis trial in NASH patients, dosed at 5mg/kg, along with the positive Phase 1b data we previously reported in non-alcoholic fibrotic
liver disease (NAFLD) patients dosed at 5mg/kg and 2.5mg/kg, are seen as providing us sufficient data on the performance of the lower
dose to drop it from the current trial, which is focusing on the 10mg/kg and 20g/kg doses. We believe this change will facilitate timely
conduct and completion of the trial. If regulators in the future do not agree that the existing low dose data is sufficient, we always
have the option to add a lower dose group as part of the Phase 3 clinical program.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25">We are also planning to open a Phase 2 clinical trial in SSc
in the first half of 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the skin and lung and other
organs, will focus on establishing biological and clinical proof of concept in this patient population. Although our primary focus is
on these two rare indications, as we noted, an additional Phase 2 clinical study in patients with liver fibrosis due to non-alcoholic
steatohepatitis (NASH) has recently been completed.&#160; This trial provided safety and pharmacokinetic (PK) data and was informative
in determining whether we will advance the development of our current subcutaneous formulation of CM-101. Additionally, the trial measured
a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. We recently reported
results from this trial, which showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated
encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Components of Operating Results</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Revenues</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">To date, we have not generated any revenue from product sales and
do not expect to generate any revenue from product sales in the near future. If development efforts for our product candidates are successful
and result in our receipt of necessary regulatory approvals, or if our development efforts otherwise lead to any commercialized products
or additional license agreements with third parties, then we may generate revenue in the future from product sales.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Research and Development Expenses, net</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Research and development expenses consist primarily of costs incurred
in connection with the development of our product candidates. These expenses include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd7cb0eb4f1c241deb3a1665632479538" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>expenses incurred under agreements with clinical research organizations and contract manufacturing organizations, as well as investigative
        sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6c5d5ce660684c35977dccb022799182" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z98e5fbb77236415a9ef481af367fc9d8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>employee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for employees engaged
        in research and development functions, as well as external costs, such as fees paid to outside consultants engaged in such activities;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3b1327732f784322a8c6424daade21f0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>license maintenance fees and milestone fees incurred in connection with various license agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z91c598977c2e4d17bb2610957694c6f5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>costs related to compliance with regulatory requirements; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z54d35686cc4449afaf8d0c2915d86458" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>depreciation and other expenses.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We recognize external development costs based on an evaluation
of the progress to completion of specific tasks using information provided to us by our service providers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We do not allocate employee costs or facility expenses, including
depreciation or other indirect costs, to specific programs because these resources are deployed across multiple programs and, as such,
the related costs are not separately classified. We use internal resources primarily to oversee our research, as well as for managing
our preclinical development, process development, manufacturing and clinical development activities. Our employees work across multiple
programs; therefore, we do not track the related expenses by program.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Research and development activities are fundamental to our business.
Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical
development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research
and development expenses will increase substantially over the next several years as we continue to advance the development of our product
candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we
have entered into license agreements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">General and Administrative Expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">General and administrative expenses consist primarily of salaries
and related benefits, share-based compensation expenses for personnel in executive and administrative functions, insurance and professional
fees for legal, consulting, accounting and audit services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We anticipate that our general and administrative expenses will
increase in the future due to increased headcount and professional fees to support our continued research activities and development of
our product candidates. We also anticipate that we will continue to incur accounting, audit, legal, regulatory, compliance, director and
officer insurance costs, as well as investor and public relations expenses associated with being a public company. Additionally, once
we believe that regulatory approval of a product candidate appears likely, we will begin to incur a material increase in payroll and related
expenses as a result of preparation for commercial operations, particularly in respect of sales and marketing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financing Expenses, Net</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Financing expenses, net consist primarily of income or expenses
related to revaluation of foreign currencies and interest income on our bank deposits.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Results of Operations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">The following table summarizes our results of operations for the
years ended December 31, 2022 and 2021:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zd92efa2b64dc4dc9b4b3d7b225aac638" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Year ended December 31,</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">2021</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Operating Expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-style: italic">(in thousands</span>)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="text-align: justify; text-indent: -8.65pt; margin-left: 17.3pt; line-height: 1.25">Research and development&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">16,977</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,334</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; text-indent: -8.65pt; margin-left: 17.3pt; line-height: 1.25">General and administrative&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">11,556</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">6,033</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="text-align: justify; text-indent: -8.65pt; margin-left: 25.9pt; line-height: 1.25">Total operating expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">28,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12,367</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25">Financing (income) expense, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(353</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">111</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Loss before taxes</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">28,180</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">12,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="text-align: justify; line-height: 1.25">Taxes on income (benefit)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(534</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="text-align: justify; line-height: 1.25">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27,646</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Our results of operations have varied in the past and can be expected
to vary in the future due to numerous factors. We believe that period-to-period comparisons of our operating results are not necessarily
meaningful and should not be relied upon as indications of future performance.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br /> <br />

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Year ended December&#160;31, 2022 Compared
to the Year Ended December&#160;31, 2021</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Research and development expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Research and development expenses increased by approximately $10.7
million, or 168%, to approximately $17.0 million for the year ended December&#160;31, 2022 compared to approximately $6.3 million for
the year ended December&#160;31, 2021. The increase resulted primarily from an increase in headcount and payments to consultants and subcontractors
for clinical and pre-clinical activities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">General and administrative expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">General and administrative expenses increased by approximately
$5.6 million, or 92%, to approximately $11.6 million for the year ended December&#160;31, 2022 compared to approximately $6.0 million
for the year ended December&#160;31, 2021. This increase was primarily due to increase in headcount and professional fees and insurance
expense and share-based compensation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic">Financing (income) expense, net</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Financing expenses, net, increased by approximately $464 thousand,
or 418%, to net income of $353 thousand for the year ended December&#160;31, 2022 compared to a net loss of $111 thousand for the year
ended December&#160;31, 2021. Financing expense, net for the year ended December&#160;31, 2022 was primarily related to foreign currency
exchange rate differences, offset by interest income on deposits. Financing income, net for 2021 was primarily related to interest income
on deposits, offset by foreign currency exchange rate differences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic">Taxes on Income</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Taxes on income, net, for the year ended December 31, 2022 were
$534 thousand. The tax benefit is related&#160;to a tax return of Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company,
derived by carryback of net operating losses. Chemomab Therapeutics Inc. received $351 thousand in December 2022 on account of previous
years and expects to receive the remainder $183 thousand in 2023.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Cash Flows</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">The following table summarizes our cash flows for the years ended
December 31, 2022 and 2021:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z9b42424c2abb4c4cab356a55f0d53768" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Year ended<br /> December
        31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Increase/(decrease)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">2021</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">$ <br />
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td rowspan="1" class="cftcurrcell" colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">%</div> </div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-style: italic">(in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Net cash used in operating activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(20,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(12,374</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(7,996</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">65</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="text-align: justify; line-height: 1.25">Net cash provided by (used in) investing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">19,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(45,186</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">64,719</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(143</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Net cash provided by (used in) financing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(808</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">61,074</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(61,882</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(101</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%; padding-bottom: 4px">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Net increase (decrease) in cash, cash equivalents and restricted
        cash</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold">(1,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold">3,514</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold">(5,159</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold">(147</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold">)%</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Operating activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Net cash used in operating activities for the year ended December
31, 2022 was approximately $20.4 million and included net loss of $27.6 million, partially offset by net cash used by changes in operating
assets and liabilities of approximately $4.0 million and non-cash charges of $3.3 million, which mainly included share-based compensation
expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Net cash used in operating activities for the years ended December 31, 2021 was approximately
$12.4 million and included net loss of $12.5 million, partially offset by net cash provided by changes in operating assets and liabilities
of $1.9 million and non-cash charges of $2.0 million, which mainly included share-based compensation expenses.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="text-align: justify; line-height: 1.25; font-style: italic">Investing activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Net cash provided by investing activities for the year ended December
31, 2022 was approximately $19.5 million, which was primarily related to investment in short-term deposits offset by purchasing of fixed
assets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Net cash used in investing activities for the year ended December 31, 2021 was $45.2
million, which was primarily related to purchase of fixed assets and investment in bank deposits.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Financing activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Net cash used in financing activities for the year ended December 31, 2022 was approximately
$0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.1 million of proceeds from the exercise of stock options
offset by the repurchase of shares in the amount of $1.2 million.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Net cash provided by financing activities for the year ended December 31, 2021 was $61.1
million, consisting of $58.7 million of proceeds from the sale of ADSs, primarily from the Private Placement (as defined and described
below) and issuances under the Sales Agreement with Cantor, and $2.4 million of cash acquired in the Merger.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Funding Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We expect our expenses to increase substantially as we advance
the clinical trials of our product candidate. In addition, we expect to continue to incur additional costs associated with operating as
a public company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We believe that our existing cash, cash equivalents and bank deposits
will enable us to fund our operating expenses and capital expenditure requirements at least through March 31, 2024. We have based these
estimates on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. If we receive regulatory
approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing and distribution.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Until such time, if ever, that we generate product revenue sufficient to achieve profitability,
we expect to finance our cash needs through the sales of our securities and through other outside funding sources. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government
and other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements,
then we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or
grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
when needed, then we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Liquidity and Capital Resources</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">In connection with the Merger, on March 15, 2021, we entered into
Securities Purchase Agreements with certain investors, pursuant to which we agreed to sell approximately $45.5 million of the ADSs in
a private placement transaction (the Private Placement). The Private Placement closed on March 22, 2021, at which time we sold 2,619,270
ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants expire five years from
the date of issuance, and, if exercised in full, will provide proceeds of approximately $4.5 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">On April 30, 2021, we entered into the Sales Agreement with Cantor
Fitzgerald &amp; Co. (Cantor). Pursuant to the Sales Agreement, we may offer and sell, from time to time,&#160; ADSs having an aggregate
offering price of up to $75 million through Cantor (the ATM Facility). Sales of&#160; ADSs, if any, under the Sales Agreement will be
issued and sold pursuant to our Registration Statement on Form S-3 which was declared effective on May 17, 2021 and will be made in sales
deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act.&#160; Pursuant
to the Sales Agreement, Cantor has agreed to act as sales agent on a best efforts basis and use commercially reasonable efforts to sell
on our behalf all of the ADSs we requested to be sold in accordance with the Sales Agreement, consistent with Cantor&#8217;s normal trading
and sales practices, on mutually agreed terms.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">On April 25, 2022, we filed a prospectus supplement with the SEC
for the issuance and sale of up to $18,125,000 of ADSs in connection with the reactivation of the ATM Facility and pursuant to General
Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities we are able to offer and sell under
such registration statement during any twelve month period to one-third of our unaffiliated public float.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">During the year ended December 31, 2022, we sold 130,505 ADSs at
an average price of USD 2.11 per ADS, through the ATM facility, resulting in gross proceeds of $275,000.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman, serif">As shown in the accompanying consolidated financial
statements, we have incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at December&#160;31,
2022 of approximately $64 million. We have financed operations to date primarily through public and private placements of equity securities.
We anticipate that we will continue to incur net losses for the foreseeable future. We believe that our existing cash, cash equivalents
and bank deposits will be sufficient to fund our projected cash needs only through March 31, 2024.&#160;To meet future capital needs we
would need to raise additional capital through equity or debt financing or other strategic transactions.&#160;However, any such financing
may not be available to us on favorable terms or at all.&#160;Our failure to obtain sufficient funds on commercially acceptable terms
when needed would have a material adverse effect on our business, results of operations and financial condition.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Current Outlook</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We estimate that our current cash resources will allow us to execute
our business plans at least through March 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Developing drugs, conducting preclinical and clinical trials, obtaining
commercial manufacturing capabilities and commercializing products is expensive, and we will need to raise substantial additional funds
to achieve our strategic objectives. We will require significant additional financing in the future to fund our operations, including
if and when we progress into clinical trials of our product candidates, obtain regulatory approval for one or more of our product candidates,
obtain commercial manufacturing capabilities and commercialize one or more of our product candidates. Our future capital requirements
will depend on many factors, including, but not limited to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze776023c09bb45a1918511b18f5d5e02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the progress and costs of our preclinical and clinical trials and other research and development activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze5091b7bf0c947ec98449c256b3639e0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the scope, prioritization and number of our preclinical and clinical trials and other research and development programs;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z259dd71c3e904bafb4895a98aba64b28" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements
        with respect to our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za43ac61d50cf4f50b6b7f9eb9d145caa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of development and expansion of our operational infrastructure;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1fd50fcdfdd34da0a8f792fd5b791854" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs and timing of obtaining regulatory approval for one or more of our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze4c7b85b6a36494892b1885d88156eef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability, or that of our collaborators, to achieve development milestones, marketing approval and other events or developments
        under potential future licensing agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z52d7cf97a848463388b79b8a33b5dac6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd2a47b55b9794237a0a47c7abfb35270" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs and timing of securing manufacturing arrangements for clinical or commercial production;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcaff1cb637a844c596353fe15ebc7656" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities
        ourselves;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z48808ebcef7841fc86917d24c6facb0c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z91162632a6e0411e9d43cfeafc73ef63" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the magnitude of our general and administrative expenses; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z87b327d2ac9f41759ada4f2c8f5db733" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>any additional costs that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Until we can generate significant recurring revenues, we expect to satisfy our future
cash needs through capital raising or by out-licensing and/or co-developing applications of one or more of our product candidates. We
cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be
required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to, one
or more of our product candidates and make the necessary change to our operations to reduce the level of our expenditures in line with
available resources.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We are a development-stage company and it is not possible for us
to predict with any degree of accuracy the outcome of our research and development efforts. As such, it is not possible for us to predict
with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a
material effect on our net loss, liquidity or capital resources, or that would cause financial information to not necessarily be indicative
of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments
and events are described in this item.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Critical Accounting Estimates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">Our financial statements are prepared in accordance with generally
accepted accounting principles in the United States (GAAP). The preparation of our financial statements and related disclosures in accordance
with GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses,
and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known
trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate
our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">While our significant accounting policies are described in more
detail in Note 2 to our consolidated financial statements, we believe that the following accounting estimates are those that include a
higher degree of judgment or complexity and are reasonably likely to have a material impact on our financial condition or results of operations
and are therefore considered critical accounting estimates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Share-Based Compensation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We apply Accounting Standard Codification (ASC) 718-10, &#8220;Share-Based
Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees
and directors, including employee options under our option plans based on estimated fair values.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">ASC 718-10 requires that we estimate the fair value of equity-based
payment awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense over the requisite
service periods in our statements of comprehensive loss. We recognize share-based award forfeitures as they occur, rather than estimate
by applying a forfeiture rate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">In June 2018, the Financial Accounting Standards Board (FASB) issued
Accounting Standards Update (ASU) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting&#8221;, which simplifies the accounting for nonemployee share-based payment transactions by aligning the measurement
and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope
of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for
goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to
non-employees. We adopted these amendments on January 1, 2019.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">We recognize compensation expenses for the fair value of non-employee
awards over the requisite service period of each award.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">We estimate the fair value of options granted as equity awards using a Black-Scholes
options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected
volatility and the expected option term (the time from the grant date until the options are exercised or expire). We determine the fair
value per share of the underlying stock by taking into consideration our most recent sales of stock, as well as additional factors that
we deem relevant. Our board determined the fair value of ordinary shares based on valuations performed using the Option Pricing Method
subject to relevant facts and circumstances. We have historically been a private company and lack company-specific historical and implied
volatility information of our stock. Expected volatility is estimated based on volatility of similar companies in the biotechnology sector.
Historically, we have&#160;not paid dividends and have no foreseeable plans to issue dividends. The risk-free interest rate is based on
the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees
and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination
of each of the inputs can affect the fair value of the options granted and our results of operations.</div> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Quantitative and Qualitative Disclosures about Market Risks</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Foreign Currency Exchange Risk</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">Our functional currency is the U.S. Dollar. We are exposed to foreign exchange rate
risk. We are located in Israel, where part of our general and administrative expenses costs is incurred in New Israeli Shekels. During
each of the years ended December 31, 2022 and 2021, we recognized foreign currency transaction loss of $609 thousand and $176 thousand,
respectively. These foreign currency transaction gains and losses were recorded in financial expenses. We believe that a 10% change in
the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact on our financial position or results
of operations.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">

<div style="text-indent: 18pt; line-height: 1.25">As we continue to grow our business, our results of operations and cash flows will be
subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our results of operations. To
date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="EXECUTIVECOMPENSATION"><!--Anchor--></span>EXECUTIVE COMPENSATION</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Summary Compensation Table</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The table and summary below outline the compensation granted to individuals who served
in the role of chief executive officer during the previous fiscal year and our three most highly compensated executive officers with respect
to the year ended December 31, 2022. For purposes of the table and the summary below, &#8220;compensation&#8221; includes base salary,
bonuses, equity-based compensation, retirement or termination payments, benefits and perquisites such as car, phone and social benefits
and any undertaking to provide such compensation.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zfda7b0c3d2934420b68cd782a35e5077" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25">Name and Principal Position</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 9%">
        <div style="text-align: center; line-height: 1.25">Year</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">Salary (1) ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">Bonus (2) ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">Option<br /> Awards (3) ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">All Other</div>
        <div style="text-align: center; line-height: 1.25">Compensation (4) ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">Total ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25">Dale Pfost</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">2021</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">182,557</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">300,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">22,868</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">505,425</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25"><span style="font-style: italic">Chief Executive Officer and Chairman</span> (5)</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 9%">
        <div style="text-align: center; line-height: 1.25">2022</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">600,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">300,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,500,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">75,160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,475,160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25">Adi Mor</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 9%">
        <div style="text-align: center; line-height: 1.25">2021</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">248,547</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">167,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">8,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">64,453</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">488,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25"><span style="font-style: italic">Chief Scientific Officer, Director and Previous Chief Executive Officer
        </span>(6)</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%; text-align: center">
        <div style="line-height: 1.25">2022</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">298,470</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">120,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">16,926</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">435,396</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 9%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25">Donald Marvin</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">2021</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">88,276</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">102,390</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">11,590</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">202,256</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25"><span style="font-style: italic">Chief Financial Officer, Executive Vice President and Chief Operating
        Officer</span> (7)</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 9%">
        <div style="text-align: center; line-height: 1.25">2022</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">460,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">207,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">660,252</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">60,397</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,387,649</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25">Sigal Fattal</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 9%">
        <div style="text-align: center; line-height: 1.25">2021</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">127,050</div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">122,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">616,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">8,952</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">874,002</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25"><span style="font-style: italic">Previous Interim Chief Financial Officer</span> (8)</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 9%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(1) Salary includes gross base salary.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">(2) Bonuses disclosed under row &#8220;2021&#8221; relate to bonuses accrued in 2021
and paid in 2021 and 2022. Bonuses disclosed under &#8220;2022&#8221; represent target bonuses for 2022 (the information&#160;is not final
and based on certain estimates due to the fact that the Company has not yet determined actual bonuses for 2022).</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">(3) Represents the equity-based compensation expenses recorded in our consolidated
financial statements for the years ended December 31, 2021 and 2022, based on the options&#8217; fair value on the grant date, calculated
in accordance with applicable accounting guidance for equity-based compensation. For a discussion of the assumptions used in reaching
this valuation, see Note 8C to our consolidated financial statements filed with our Annual Report on Form 10-K for the year ended December
31, 2021 incorporated by reference in this prospectus.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(4) Represents payments by us of social benefits on behalf of the officer. Such benefits
may include, to the extent applicable, payments, contributions and/or allocations for risk insurance (e.g., life, or work disability insurance),
payments for social security, vacation, medical insurance and benefits, and other benefits and perquisites consistent with our policies.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(5) Dr. Dale Pfost&#8217;s terms of compensation were approved by the Company&#8217;s
shareholders on October 25, 2021, which includes an annual base salary of $600,000. Dr. Pfost&#8217;s compensation data set forth in the
above table is pro-rated to reflect time served as the Company&#8217;s chief executive officer in 2021.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(6) In addition to her current positions of Chief Scientific Officer and a member
of our Board, Dr. Adi Mor previously served as our Chief Executive Officer, and resigned from such role concurrent with the commencement
of Dr. Dale Pfost&#8217;s service as our Chief Executive Officer on October 25, 2021.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(7) Mr. Donald Marvin&#8217;s employment with the Company commenced on November 4,
2021, which include an annual base salary of $460,000. The compensation data set forth in the above table is pro-rated to reflect time
served as the Company&#8217;s Chief Financial Officer, Executive Vice President and Chief Operating Officer in 2021.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(8)&#160; Ms. Sigal Fattal previously served as our interim Chief Financial Officer,
and resigned from such role concurrent with the commencement of Mr. Marvin&#8217;s service as our Chief Financial Officer on November
8, 2021.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Outstanding Equity Awards at Fiscal Year-End</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-indent: 36pt; line-height: 1.25">The table below outlines the options to purchase ADSs held by our named executive officers
outstanding as of December 31, 2022.</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" border="0" id="ze22ff4c43c954e9991db22f922713830" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 52%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="12" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option awards</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25; font-weight: bold">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of securities<br /> underlying<br /> unexercised options<br />
        (#) exercisable</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of<br /> securities<br /> underlying<br /> unexercised options<br />
        (#)<br /> unexercsiable</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option<br /> exercise<br /> price ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option expiration<br /> date</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Dale Pfost,&#160;<span style="font-style: italic">Chief Executive Officer and Chairman of the Board</span></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">133,977</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">325,376</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;</div> </div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">10.05</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">October 25, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Adi Mor,&#160;<span style="font-style: italic">Chief Scientific Officer, Director and Previous Chief Executive
        Officer</span></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">131,698</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1.49</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">March 15, 2028</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Donald Marvin,&#160;<span style="font-style: italic">Chief Financial Officer, Executive Vice President
        and Chief Operating Officer</span>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">53,320</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">143,555</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;</div> </div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">9.77</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">November 8, 2031</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(1) The options granted to Dr. Pfost vest and become exercisable over a period of
four (4) years with one quarter (1/4) of the options vesting on October 25, 2022, the first anniversary of the grant date, and the remainder
in equal amounts over the ensuing 36 monthly periods, subject to Dr. Pfost&#8217;s continued service.</div>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25">(2) The options granted to Mr. Marvin vest and become exercisable over a period of
four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022, the first anniversary of the grant date, and the remainder
in equal amounts over the ensuing 36 monthly periods, subject to Mr. Marvin&#8217;s continued service.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Employment Agreements</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-style: italic">Employment Agreement with Dr. Dale Pfost, our Chief Executive Officer</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On September 1,&#160;2021, the Company&#8217;s board of directors
approved the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company, and on October 25, 2021, the shareholders of the
Company approved the terms of employment of Dr. Pfost, pursuant to an Executive Employment Agreement entered into between Dr. Pfost and
Chemomab Therapeutics Inc., the Company&#8217;s wholly owned subsidiary. In accordance with terms of Dr. Pfost&#8217;s employment agreement,
Dr. Pfost receives: (i) an annual base salary of $600,000 (the &#8220;Base Salary&#8221;); (ii) an initial target annual cash incentive
bonus of 50% of the Base Salary and an additional potential bonus of 10% of the Base Salary based on Dr. Pfost&#8217;s achievement of
certain predetermined goals, which shall be determined at the discretion of the Company&#8217;s board of directors; (iii) options to purchase&#160;459,353
ADSs of the Company (the &#8221;Options&#8221;), constituting 3.5% of the outstanding and issued ADSs of the Company (on a fully diluted
basis) which will vest over a period of four (4) years with one quarter (1/4) of the Options vesting on the first anniversary of the grant
date and the remainder in equal amounts over the ensuing 36 monthly periods, unless such options have been cancelled in accordance with
the terms and conditions of the 2015 Plan (as defined below); (iv) a one-time signing bonus in an amount of $80,000; (v) a one-time bonus
in an amount of $80,000 upon the establishment of a new office in the United State and Dr. Pfost&#8217;s domiciling in the location of
the new office, which will be payable within 15 days of such domiciling; (vi) 25 days of paid time off (&#8220;PTO&#8221;) per year, capped
at 50 days of accrued PTO; and (vii) certain severance benefits payable in the event that the Company terminates Dr. Pfost&#8217;s employment
without Cause (as defined in the employment agreement), provided that the total amount of the cash portion of severance benefits will
not exceed two hundred percent (200%) of Dr. Pfost&#8217;s annual base salary at the rate in effect on the date of termination.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Additionally, in the event of termination of Dr. Pfost&#8217;s
employment without Cause (as defined therein) as the result of a merger or sale of all or substantially all of the Company&#8217;s capital
stock or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will
immediately vest and become exercisable. Furthermore, in the event of termination of Dr. Pfost&#8217;s employment without Cause, other
than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e. a change in control
of the Company) or if Dr. Pfost terminates his employment for Good Reason (as defined in the employment agreement): (a) any time-based
Options then outstanding and due to vest on the twelve (12) month anniversary of Dr. Pfost&#8217;s employment commencement date will accelerate
and become exercisable if Dr. Pfost has been employed by the Company at such time for six (6) months or more but less than twelve (12)
months; and (b) all time-based Options then outstanding will accelerate and become exercisable if Dr. Pfost has been employed by the Company
at such time for twelve (12) months or longer.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The foregoing description of Dr. Pfost&#8217;s employment agreement
is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is filed as Exhibit 10.9 hereto.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><span style="font-style: italic">Employment Agreement with Dr. Adi Mor, our Chief Scientific Officer (and
former Chief Executive Officer</span>)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Dr. Adi Mor provides services to the Company pursuant to the terms
of a consulting agreement among Dr. Mor, an Israeli company co-owned by Dr. Mor, and the Subsidiary, dated April 18, 2022 (the &#8220;Consulting
Agreement&#8221;).&#160; Pursuant to the terms of the Consulting Agreement, Dr. Mor is entitled to a gross monthly payment, an annual
performance bonus, subject to her meeting certain performance milestones, as to be determined by our board of directors on an annual basis,
and certain other benefits.&#160; Dr. Mor&#8217;s current monthly payment and annual performance bonus target were set and approved by
the Company&#8217;s shareholders as described below.&#160; In addition, Dr. Mor is entitled to other benefits that are provided for by
Israeli law or that are customary for senior executives in Israel, including reimbursement for reasonable expenses incurred in connection
with her services and payment for variable and fixed costs of a car. The Consulting Agreement is terminable by either party upon 60 days
prior written notice, and contains customary provisions regarding noncompetition, confidentiality of information, and assignment of inventions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As required under Israeli law, the terms of Dr. Mor&#8217;s Consulting
Agreement with the Subsidiary were approved by the board of directors and presented to the shareholders for approval.&#160; At the annual
meeting of our shareholders that took place on June 7, 2022, our shareholders approved for following terms of employment for Dr. Mor:
(a) an increase to her base gross monthly salary from 67,500 NIS (approximately $21,090) (plus social benefits) to 74,250 NIS (approximately
$23,200), (plus social benefits) which represents an increase of 6,750 NIS (approximately $2,110), effective as of March 7, 2022; (b)
an increase in her 2021 gross annual bonus from $100,000 to $110,250, an increase of approximately 10%; and (c) an increase in her annual
gross target bonus opportunity from $100,000 to 45% of Dr. Mor&#8217;s annual gross payment, effective as of January 1, 2022.&#160; In
lieu of the monthly salary payment of 74,250 NIS (plus social benefits), as approved by the shareholders, Dr. Mor receives the equivalent
amount in the form of a monthly payment equal to 98,730 NIS under the Consulting Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The foregoing description of the Consulting Agreement is qualified
in its entirety by reference to the full text of the consulting agreement, a copy of which is filed as Exhibit 10.11 hereto.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Employment Agreement with Mr. Donald Marvin, our Chief Financial Officer, Executive
Vice President and Chief Operating Officer</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 8, 2021, Chemomab Therapeutics Inc. entered into an
Executive Employment Agreement with Mr. Donald Marvin. In accordance with his employment agreement, Mr. Marvin receives an annual base
salary of $460,000, and is a part of the Company&#8217;s bonus program with a yearly bonus potential of 45% of his base annual base salary,
which bonus will be based on the achievement of mutually agreeable objectives to be determined by Mr. Marvin and the Chief Executive Officer
of the Company. Additionally, in accordance with his employment agreement, Mr. Marvin received (i) 1.5% of the outstanding equity of the
Company, which exercise price is based on the average of the ADS market value over the 30 calendar days preceding November 8, 2021, and
vesting over four years, (ii) an additional 0.5% of the outstanding equity of the Company for the achievement of strategic goals as agreed
upon with the Compensation Committee and approved by the Board of Directors, (iii) a $25,000 signing bonus, and (iv) a 12-month initial
severance package, which will increase by one month every two years that Mr. Marvin is employed by the Company, provided however that
such amount does not exceed 18 months.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Additionally, in the event of termination of Mr. Marvin&#8217;s
employment without Cause as the result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets,
(i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will immediately vest
and become exercisable. Furthermore, in the event of termination of Mr. Marvin&#8217;s employment without Cause, other than as a result
of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e. a change in control of the Company)
or if Mr. Marvin terminates his employment for Good Reason (as defined in the employment agreement): (a) any time-based Options then outstanding
and due to vest on the twelve (12) month anniversary of Mr. Marvin&#8217;s employment commencement date will accelerate and become exercisable
if Mr. Marvin has been employed by the Company at such time for six (6) months or more but less than twelve (12) months; and (b) all time-based
Options due to vest on or before December 31 of the year in which termination occurs then outstanding will accelerate and become exercisable
if Mr. Marvin has been employed by the Company at such time for twelve (12) months or longer.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The foregoing description of Mr. Marvin&#8217;s employment agreement
is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is filed as Exhibit 10.10 hereto.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Director Compensation Table</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25">The table below outlines compensation earned
by our non-executive directors for the fiscal year ended December 31, 2022, including fees earned in cash and options awarded for services
provided as a director:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z09e12782d0a945048115124afde5eb5b" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Fees earned or paid<br /> in cash ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option<br /> awards ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 64%">
        <div style="line-height: 1.25">Nissim Darvish</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">47,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">76,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">(1)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">123,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%">
        <div style="line-height: 1.25">Jill Quigley</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">23,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">(2)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">38,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 64%">
        <div style="line-height: 1.25">Alan Moses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">43,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">76,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">(3)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">119,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 64%">
        <div style="line-height: 1.25">Claude Nicaise</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">47,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">76,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">(4)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">123,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 64%">
        <div style="line-height: 1.25">Neil Cohen</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">47,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">76,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">(5)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">123,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(1) (i) 11,884 of the options granted to Dr. Darvish vest and become exercisable in
equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 options vest and become exercisable on
March 16, 2023, subject to Dr. Darvish&#8217;s continued service. Additional 10,123 options have fully vested.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(2) The options granted to Ms. Quigley vest and become exercisable&#160;in equal monthly
installments over a 36 month period commencing on June 16, 2022, subject to Ms. Quigley&#8217;s continued service.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(3)&#160; (i) 11,884 of the options granted to Dr. Moses vest and become in equal
monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the options granted to Dr. Moses vest and
become exercisable on March 16, 2023, subject to Dr. Moses&#8217; continued service.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(4) (i) 11,884 of the options granted to Dr. Nicaise vest and become in equal monthly
installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the options granted to Dr. Nicaise vest and become
exercisable on March 16, 2023, subject to Dr. Nicaise's continued service.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">(5) (i) 11,884 of the options granted to Mr. Cohen vest and become exercisable in
equal monthly installments over a 36 month period commencing on March 16, 2021, (ii) 6,820 options vest and become exercisable on March
16, 2023, and (iii) 688 options vest and become exercisable over a period of three (3) years with one quarter (1/4) of the options vesting
on July 16, 2021, the first anniversary of the grant date, and the remainder in equal amounts over the ensuing 24 monthly periods commencing
on October 16, 2021, subject to Mr. Cohen&#8217;s continued service.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Director Compensation</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25">We have adopted a Compensation Policy regarding
the terms of office and employment of its &#8220;office holders&#8221; (as defined in the Israeli Companies Law, 5759-1999), including
cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. Chemomab
compensates its directors and senior management team in accordance with the recommendation of its compensation committee and, generally,
subject to the approval of our Board and shareholders. That compensation will generally need to be consistent with the terms of our Compensation
Policy, which will require periodic approval, in accordance with the requirements of the Companies Law.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25">In addition to the Compensation Policy, on
March 15, 2021, our shareholders approved certain actual compensation terms applicable to our current and future directors (the &#8220;Director
Compensation Package&#8221;), pursuant to which (and among other terms) (i) our non-employee directors are entitled to receive an annual
option grant of up to 0.05% of the Company&#8217;s share capital on a fully diluted basis, (ii) the chairman of our Board is entitled
to receive an annual option grant of up to 0.2% of the Company&#8217;s share capital on a fully diluted basis and (iii) our non-employee
directors are entitled to receive an annual cash fee of $35,000. The Director Compensation Policy implements terms for actual equity compensation
that will be granted to directors on a regular basis and determines the annual cash fee that may be paid to non-employee directors. In
accordance with the Companies Law, equity grants to our directors that are within the limitations of the Director Compensation Package
require the approval of our compensation committee and Board, but not our shareholders, while any contemplated compensation made in excess
of the Director Compensation Package will require the approval of our shareholders. Furthermore, any such compensation, including the
annual cash fee payable to our non-employee directors, must be limited to the framework of the Director Compensation Package.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Outstanding Equity Awards at Fiscal Year End</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The table below outlines options to purchase ADSs held by our non-employee
directors outstanding as of December 31, 2022.</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" border="0" id="zfebb1e8cdf164dd8a9f721583dd454d3" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="12" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option awards</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25; font-weight: bold">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of ADSs<br /> underlying<br /> unexercised options<br />
        (#) exercisable</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of<br /> ADSs<br /> underlying<br /> unexercised options<br />
        (#)<br /> unexercsiable</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option<br /> exercise<br /> price ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Option expiration<br /> date</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Nissim Darvish</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">10,123</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">0.80</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">October 27, 2026</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%">
        <div style="line-height: 1.25">Nissim Darvish</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,932</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,952</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27.26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Nissim Darvish</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,820</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Alan Moses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,932</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,952</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27.26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Alan Moses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,820</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Claude Nicaise</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,932</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,952</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27.26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Claude Nicaise</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,820</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Neil Cohen</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">515</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">173</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13.20</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">July 16, 2030</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Neil Cohen</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,932</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,952</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27.26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="text-align: center; line-height: 1.25">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Neil Cohen</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,820</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 12%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Jill Quigley</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,273</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">11,367</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%">
        <div style="text-align: center; line-height: 1.25">June 16, 2032</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Equity Incentive Plans</div>

<div style="line-height: 1.25">&#160;

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We maintain (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;),
(ii) the 2017 Plan and (iii) the 2015 Plan, which was assumed by our company from the Subsidiary upon the effectiveness of the Merger.
At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company (formerly known as Anchiano
Therapeutics Ltd.) as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.
As of December 31, 2022, a total of 1,422,153 of ADSs were reserved for issuance under the 2015 Plan, of which 172,276 ADSs had been issued
pursuant to previous exercises options, and 1,173,037 ADSs&#160;were issuable under outstanding options. Of such outstanding options,
options to purchase 620,036 ADSs had vested and were exercisable as of that date, with a weighted average exercise price of $5.96 per
ADS.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of December 31, 2022, a total of&#160;625,581 of ADSs were reserved
for issuance under the 2017 Plan, of which&#160;586,540 ADSs&#160;were issuable under outstanding options. Of such outstanding options,
options to purchase 21,377 ADSs had vested and were exercisable as of that date, with a weighted average exercise price of $6.98 per ADS.
No ADSs had been issued pursuant to previous exercises options.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">2011 Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On December 19, 2011, our board of directors adopted the 2011 Plan
to allocate options to purchase our ordinary shares to our directors, officers, employees and consultants, and those of our affiliated
companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by our board of directors or a
committee that was designated by our board of directors for such purpose (the &#8220;Administrator&#8221;).</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the 2011 Plan, we may grant options to purchase ordinary
shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through a trustee, which was approved by the
Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;), and granted under the
tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The holding period under this tax track
is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102
of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102 Earned Income Options through a trustee, granted under the tax
track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this tax track is
12 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102 of
the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding period),
or the Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall be subject
to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Options pursuant to the first three tax tracks (under Section 102
of the ITO) can be granted to our employees and directors and the grant of Options under Section 3(i) can be granted to our consultants
and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO is a person who holds, directly or
indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of the company&#8217;s issued capital or 10%
of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting power, or the right
to purchase such rights; (iii) the right to receive at least 10% of the company&#8217;s profits; or (iv) the right to appoint a company&#8217;s
director). Grantees who are not Israeli residents may be granted options that are subject to the applicable tax laws in their respective
jurisdictions.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We determine, in our sole discretion, under which of the first
three tax tracks above the Options are granted and we notify the Grantee in a grant letter, as to the elected tax track. As mentioned
above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The number of ordinary shares authorized to be issued under the
2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued as a result of a distribution
of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), or issuance
of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of ordinary shares and the number of ordinary
shares shall be rounded up to the closest number of ordinary shares.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise determined by the Administrator, the exercise
price of an Option granted under the 2011 Plan will be the average of the market price of the Company&#8217;s ordinary shares during the
22 business days prior to the date on which our board of directors authorized the grant of Options; provided, however, that such exercise
price cannot be lower than the market price at the close of the trading day at which it was granted by our board of directors. The exercise
price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the decision to grant him/her
Options under the 2011 Plan.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise determined by the Administrator, the Options granted
under the 2011 Plan will become vested and may be exercised in 16 equal portions of 6.25% of the total number of Options, at the end of
each quarter following the day the Options were granted. Unless otherwise determined by our board of directors, the Options may be exercised
for ten years following the date of grant, unless terminated earlier, and as long as the Grantee is employed by the Company (or by an
affiliated company), or provides service to the Company (or an affiliated company).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Administrator may, in its absolute discretion, accelerate the
time at which Options granted under the 2011 Plan or any portion of which will vest.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise determined by the Administrator, in the event
that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the Grantee may exercise that portion
of the Options that had vested as of the date of such termination until the end of the specified term in the grant letter or the 2011
Plan. The portion of the Options that had not vested at such date, will be forfeited and can be re-granted according to the terms of the
2011 Plan.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">2015 Plan</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In November 2015, the Subsidiary&#8217;s board of directors adopted,
and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the grant of options, restricted shares, restricted
share units and other share-based awards to the Subsidiary&#8217;s (following the Merger, the Company&#8217;s) and its subsidiaries&#8217;
and affiliates&#8217; directors, employees, officers, consultants, advisors, and any other person whose services are considered valuable
to Chemomab or its affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service providers, to
increase their efforts on Chemomab&#8217;s behalf or on behalf of its subsidiaries or affiliates, and to promote the success of its business.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The 2015 Plan is administered by Chemomab&#8217;s board of directors
or by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees of awards and the terms
of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary in the administration
of the 2015 Plan. The 2015 Plan enables Chemomab to issue awards under various tax regimes, including, without limitation, pursuant to
Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422 of the United
States Internal Revenue Code of 1986, as amended, or the Code.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The 2015 Plan provides that options granted to Chemomab&#8217;s
employees, directors and officers who are not controlling shareholders and who are considered Israeli residents are intended to qualify
for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance. Chemomab&#8217;s Israeli
non-employee service providers and controlling shareholders may only be granted options under Section 3(i) of the Ordinance, which does
not provide for similar tax benefits.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Options granted under the 2015 Plan to U.S. residents may qualify
as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified. The exercise price for
&#8220;incentive stock options&#8221; must not be less than the fair market value on the date on which an option is granted, or 110% of
the fair market value if the option holder holds more than 10% of Chemomab&#8217;s share capital.&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Options and other awards granted under the 2015 Plan generally
vest over four years commencing on the date of grant, such that 25% vests on the first anniversary of the date of grant and an additional
6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided that the participant remains
continuously employed or engaged by Chemomab.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Options, other than certain incentive share options, that are not
exercised within ten years from the grant date expire, unless otherwise determined by Chemomab&#8217;s board of directors or its designated
committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted to a person holding more
than 10% of Chemomab&#8217;s voting power will expire within five years from the date of the grant. In the event of the death of a grantee
while employed by or performing service for Chemomab or its subsidiary or within three months after the date of the employee&#8217;s termination,
or the termination of a grantee&#8217;s employment or services for reasons of disability, the grantee, or in the case of death, his or
her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year from the date
of disability or death. If Chemomab terminates a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested and
unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated for
any other reason, the grantee may generally exercise his or her vested options or other award within three months of the date of termination.
Any expired or unvested options return to the pool and become available for reissuance. From time to time, Chemomab may consider issuing
options with slightly different terms or accelerating, extending or otherwise modifying options in accordance with applicable law and
regulation and the terms of the 2015 Plan.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event of a merger or consolidation of Chemomab, or a sale
of all, or substantially all, of Chemomab&#8217;s shares or assets or other transaction having a similar effect on Chemomab, then without
the consent of the option holder, Chemomab&#8217;s board of directors or its designated committee, as applicable, may, but is not required,
to (i) cause any outstanding award to be assumed or an equivalent award to be substituted by such successor corporation, or (ii) in case
the successor corporation does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to
all or part of the shares or (b) cancel the options and pay in cash an amount determined by the board of directors or the committee as
fair in the circumstances. Notwithstanding the foregoing, Chemomab&#8217;s board of directors or its designated committee may upon such
event amend, modify or terminate the terms of any award, including conferring the right to purchase any other security or asset that the
board of directors or the committee shall deem, in good faith, appropriate.&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The 2015 plan was assumed by our company from the Subsidiary upon
the effectiveness of the Merger.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">2017 Plan</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On February 22, 2017, our board of directors adopted the 2017 Plan
to allocate a variety of share-based awards to our directors, officers, employees, consultants, advisors and service providers, and those
of our affiliates (companies that control us, are controlled by us or are under common control with us) (the &#8220;Participants&#8221;).
The 2017 Plan is currently administered by our board of directors, and may be administered by a committee designated by our board of directors
for such purpose.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the 2017 Plan, we may grant options to purchase ordinary
shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on our ordinary shares, all of which are referred
to as Awards. We may grant Awards under the same four tracks as described above with respect to the 2011 Plan, subject to the same conditions
as apply for the 2011 Plan. In addition, we may grant incentive stock options and nonqualified stock options to Participants who are residents
of the United States, and we may grant awards to Participants who are residents of other countries that comply with the laws of those
jurisdictions.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The number of ordinary shares authorized to be issued under the
2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued as a result of a distribution
of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), issuance of
rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of ordinary shares and the number of ordinary
shares shall be rounded down to the closest number of ordinary shares.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="SECURITY"><!--Anchor--></span>SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-indent: 36pt; line-height: 1.25">The following table sets forth information, as of February 16, 2023, regarding beneficial
ownership of our ordinary shares represented by ADSs:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z34fbbb47a476482499fba2f48d25dfc1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 92%; vertical-align: top">
        <div style="line-height: 1.25">each person who is known by us to own beneficially more than 5% of our ordinary shares;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 92%; vertical-align: top">
        <div style="line-height: 1.25">each director;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 92%; vertical-align: top">
        <div style="line-height: 1.25">each executive officer; and</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 92%; vertical-align: top">
        <div style="line-height: 1.25">all of our directors and executive officers collectively.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The percentages of ordinary shares beneficially owned are reported
on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC,
a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote
or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the
security.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise noted, the address of each director and current
and former executive officer of Chemomab is Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z6707c25bebb1443495fd8ff773635d20" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">NAME OF BENEFICIAL OWNER</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Beneficial</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Ownership (ADSs)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25"> </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Percentage of</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">ADSs Beneficially</div>
        <div style="text-align: center; line-height: 1.25"><span style="font-weight: bold">Owned</span>&#8224;</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-style: italic">5% and Greater Shareholders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">OrbiMed Israel (1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,270,091</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">20.5</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">The Centillion Fund(2)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">661,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.0</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Rivendell Investments 2017-9(3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,131,563</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">10.2</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Kobi George(4)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">747,445</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.7</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Apeiron Group(5)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">770,388</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-style: italic">Directors and Executive Officers</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Dale Pfost (6)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">165,187</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1.4</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Donald Marvin (7)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">71,726</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Adi Mor (8)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">747,445</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.7</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Neil Cohen (9)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,702</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Nissim Darvish (10)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">26,395</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Alan Moses (11)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,072</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Claude Nicaise (12)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,072</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Jill Quigley (13)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,788</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Matthew Frankel</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold">All current executive officers and directors as a group (9 persons)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,070,387</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">9.29</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#8224; Percentage ownership based on 11,049,812 ADSs outstanding as of February 16, 2023</div> </div>

<div style="line-height: 1.25">* Less than one percent (1%)</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z55ad4b7d02eb4b6bafd14ad7ecb0a0f2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Pursuant to a Schedule 13D/A filed with the SEC by OrbiMed Israel BioFund GP Limited Partnership (&#8220;OrbiMed BioFund&#8221;)
        and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;, and together with OrbiMed BioFund, &#8220;OrbiMed Israel&#8221;) on January 5, 2023,
        such amount consists of (i) 2,241,274 ADSs and (ii) 28,817 ADSs issuable upon the exercise of warrants to purchase ADSs. OrbiMed GP, a
        company that acts as general partner of certain limited partnerships, is the general partner of OrbiMed BioFund, which is the general
        partner of OrbiMed Israel Partners Limited Partnership, which is the entity that holds the foregoing securities.&#160;The address of OrbiMed
        Israel is 89 Medinat HaYehudim St., Build E, 11th Floor, Herzliya 46766 Israel.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z8997ed908a5a49a38a0cdb626e53d303" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zfb4a0913d3314a22a4b5fe894819854a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9 LLC, or Rivendell, as reported
        by Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs, representing 461,080 Ordinary Shares, issuable upon
        the exercise of warrants. Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of Rivendell and has sole voting
        and investment power over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z52ef97affa464850b5e6f587ef77b462" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="text-align: left; line-height: 1.25">Consists of (i) 257,247 ADSs owned directly by Dr. George, (ii) 324,775 ADSs owned by
        Dr. Adi Mor (Dr. George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs issued directly to Dr. George, issuable upon the
        exercise of options, and (iv) 131,698 options to purchase 131,698 ADSs, issued to Dr. Mor, (Dr. George&#8217;s spouse), as reported by
        Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="za471fecf856442c5acd9c3b6ec76842f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The Apeiron Group consists of (i) Apeiron SICAV Ltd. - Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight
        Capital Fund II, LP, of which owns 288,170 ADSs and 28,817 ADSs issuable upon the exercise of warrants and (iii) Apeiron Investment Group
        Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian Angermayer may be deemed to
        share voting and investment power with respect to the ADSs held by the Apeiron Group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3a166701e0124dd8a3031321dd7c0b57" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Includes 2,500 ADSs and 162,687 ADSs issuable upon the exercise
        of options within 60 days of the date hereof as reported by Dr. Dale Pfost on Form 4 filed with the SEC on March 15, 2022.</div> </div>
        </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z921913f3da9249539ec66c2b492b1c4a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Includes 2,000 ADSs and 69,726 ADSs issuable upon the exercise of options within 60 days of the date hereof
        as reported by Mr. Donald Marvin on Form 4 filed with the SEC on June 21, 2022.</div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="za7bd3358ff104282aad2e05c3845293f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(8)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Consists of (i) 324,775 ADSs owned directly by Dr. Mor, (ii) 257,247 ADSs owned by Dr. George, (Dr. Mor&#8217;s
        spouse), (iii) 131,698 ADSs issued to Dr. Mor, issuable upon the exercise of options within 60 days of the date hereof, and (iv) 33,725
        options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise of options within 60 days of
        the date hereof, as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5ba88b0517f346a4957d943bea98f3b0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(9)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Includes 10,000 ADSs, and 15,702 ADSs issuable upon the exercise of options within 60 days of the date
        hereof, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on November 11, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z517831aa110c46f49d2e8fd7bd917ad0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(10)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Includes 1,200 ADSs, and 25,195 ADSs issuable upon the exercise of options within 60 days of the date hereof,
        as reported by Dr. Nissim Darvish on Form 4 filed with the SEC on March 14, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeef8def7eac9435d8b9c46fa51e3f9db" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(11)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Represents 15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported
        by Dr. Alan Moses on Form 4 filed with the SEC on March 9, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8200a781a4754323842675adb2b34ec0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(12)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Represents&#160;15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof, as
        reported by Dr. Claude Nicaise on Form 4 filed with the SEC on March 9, 2022.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z959c0e89227c4dafb9c46e40ad3b3bab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(13)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">Represents&#160;3,788 ADSs issuable upon the exercise of options within 60 days of the date hereof, as
        reported by Ms. Jill Quigley on Form 4 filed with the SEC on June 16, 2022.</div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">DESCRIPTION OF <span id="SHARECAPITAL"><!--Anchor--></span>SHARE
CAPITAL</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following descriptions of our share capital and provisions
of our amended and restated articles of association are summaries and are qualified by reference to our amended and restated articles
of association, a copy of which is filed as Exhibit 3.1 hereto.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Registration Number and Purposes of the Company</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are registered with the Israeli Registrar of Companies. Our
registration number is 51-4672625.&#160;Our affairs are governed by our amended and restated articles of association, applicable Israeli
law and the Companies Law. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful act
or activity.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Voting Rights</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">All ordinary shares have identical voting and other rights in all
respects.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Transfer of Shares</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our fully paid ordinary shares are issued in registered form and
may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules&#160;of Nasdaq. The ownership or voting of our ordinary shares by non-residents of Israel is not
restricted in any way by our amended and restated articles of association or the laws of the State of Israel, except for ownership by
nationals of some countries that are, have been, or will be, in a state of war with Israel.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Election of Directors</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under our amended and restated articles of association, our board
of directors must consist of not less than three (3)&#160;but no more than eleven (11) directors. Pursuant to our amended and restated
articles of association, each of our directors will be appointed by a simple majority vote of holders of our ordinary shares, participating
and voting at an annual general meeting of our shareholders, provided that (i)&#160;in the event of a contested election, the method of
calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be
determined by our board of directors in its discretion, and (ii)&#160;in the event that our board of directors does not or is unable to
make a determination on such matter, then the directors will be elected by a majority of the voting power represented at the general meeting
in person or by proxy and voting on the election of directors, provided that if the number of such nominees exceeds the number of directors
to be elected, then as among such nominees the election shall be by a plurality of the votes cast. In addition, our directors are divided
into three classes, one class being elected each year at the annual general meeting of our shareholders, and shall serve on our board
of directors until the third annual general meeting following such election or re-election or until they are removed by a vote of 65%
of the total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance
with the Companies Law and our amended and restated articles of association. In addition, our amended and restated articles of association
provide that vacancies on our board of directors may be filled by a vote of a simple majority of directors then in office. Any director
so appointed will hold office until the next annual general meeting of our shareholders for the election of the class of directors in
respect of which the vacancy was created, or in the case of a vacancy due to the number of directors being less than the maximum number
of directors stated in our amended and restated articles of association, until the next annual general meeting of our shareholders for
the election of the class of directors to which such director was assigned by our board of directors.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Dividend and Liquidation Rights</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may declare a dividend to be paid to the holders of our ordinary
shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of
directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide
otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide
that dividend distributions may be determined by our board of directors.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the Companies Law, the distribution amount is limited
to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited
financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of
the period to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet
such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend
if our board of directors and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will
prevent us from satisfying our existing and foreseeable obligations as they become due.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event of our liquidation, after satisfaction of liabilities
to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as
well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of
a class of shares with preferential rights that may be authorized in the future.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Exchange Controls</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There are currently no Israeli currency control restrictions on
remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or other payments to non-residents
of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a state of war with Israel.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Shareholder Meetings</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under Israeli law, we are required to hold an annual general meeting
of our shareholders once every calendar year and no later than 15 months after the date of the previous annual general meeting. All meetings
other than the annual general meeting of shareholders are referred to in our amended and restated articles of association as special general
meetings. Our board of directors may call special general meetings of our shareholders whenever it sees fit, at such time and place, within
or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene
a special general meeting of our shareholders upon the written request of (i)&#160;any two or more of our directors, (ii)&#160;one-quarter
or more of the serving members of our board of directors or (iii)&#160;one or more shareholders holding, in the aggregate, either (a)&#160;5%
or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b)&#160;5% or more of our outstanding voting
power.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under Israeli law, one or more shareholders holding at least 1%
of the voting rights at the general meeting of the shareholders may request that the board of directors include a matter in the agenda
of a general meeting of the shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect to the
submission of shareholder proposals for general meetings.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to the provisions of the Companies Law and the regulations
promulgated thereunder, shareholders entitled to participate and vote at general meetings of shareholders are the shareholders of record
on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40
days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be
passed at a general meeting of shareholders:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="zb26e087711bf418cada5b0bc566da711" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">amendments to our amended and restated articles of association;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z04da4c947a0e44f1ac3e2952dcc79833" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">appointment, terms of service or and termination of service of our auditors;</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf0856c811083471b91a10c4fc648ddbb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">appointment of directors, including external directors (if applicable);</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1dd7ed268c644d1db584ee1f525cd9c1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">approval of certain related party transactions;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5bfbbe2194a247fe9122796e88b13758" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">increases or reductions of our authorized share capital;</div> </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97fb93b9333a413a9b3192a11a3a36bf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a merger; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za1aefc4bae4f434b8a119d926c05595e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the exercise of our board of directors&#8217; powers by a general meeting, if our
        board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law requires that a notice of any annual general
meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting
includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested
or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting. Under the Companies Law,
shareholders are not permitted to take action by way of written consent in lieu of a meeting.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Quorum</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to our amended and restated articles of association, holders
of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general
meeting of shareholders. The quorum required for our general meetings of shareholders consists of at least two shareholders present in
person or by proxy who hold or represent between them at least 33&#8531;% of the total outstanding voting rights, provided, however, that
with respect to any general meeting that was convened pursuant to a resolution adopted by the board of directors and which at the time
of such general meeting we qualify as a &#8220;foreign private issuer,&#8221; the requisite quorum shall consist of two or more shareholders
present in person or by proxy who hold or represent between them at least 25% of the total outstanding voting rights. The requisite quorum
shall be present within half an hour of the time fixed for the commencement of the general meeting. A general meeting adjourned for lack
of a quorum shall be adjourned either to the same day in the next week, at the same time and place, to such day and at such time and place
as indicated in the notice to such meeting, or to such day and at such time and place as the chairperson of the meeting shall determine.
At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a quorum, unless a meeting was called
pursuant to a request by our shareholders, in which case the quorum required is one or more shareholders, present in person or by proxy
and holding the number of shares required to call the meeting as described above.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Vote Requirements</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our amended and restated articles of association provide that all
resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our amended and restated
articles of association. Under the Companies Law, certain actions require the approval of a special majority, including: (i)&#160;an extraordinary
transaction with a controlling shareholder or in which the controlling shareholder has a personal interest, (ii)&#160;the terms of employment
or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are
not extraordinary) and (iii)&#160;certain compensation-related matters described above under &#8220;Management&#8212;Compensation Committee&#8212;Compensation
Policy under the Companies Law.&#8221; Under our amended and restated articles of association, the alteration of the rights, privileges,
preferences or obligations of any class of our shares (to the extent there are classes other than ordinary shares) requires the approval
of a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents
relevant to such class), in addition to a majority of all classes of shares voting together as a single class at a shareholder meeting.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under our amended and restated articles of association, the approval
of the holders of at least 65% of the total voting power of our shareholders is generally required to remove any of our directors from
office, to amend the provision requiring the approval of at least 65% of the total voting power of our shareholders to remove any of our
directors from office, or certain other provisions regarding our staggered board, shareholder proposals, the size of our board and plurality
voting in contested elections. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up,
or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section&#160;350 of the Companies Law, which requires
the approval of holders holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Access to Corporate Records</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, all shareholders generally have the right
to review minutes of our general meetings, our shareholder register (including with respect to material shareholders), our articles of
association, our financial statements, other documents as provided in the Companies Law and any document we are required by law to file
publicly with the Israeli Registrar of Companies or the Israeli Securities Authority. Any shareholder who specifies the purpose of its
request may request to review any document in our possession that relates to any action or transaction with a related party which requires
shareholder approval under the Companies Law. We may deny a request to review a document if we determine that the request was not made
in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise impair our
interests.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Acquisitions under Israeli Law</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Full Tender Offer</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A person wishing to acquire shares of a public Israeli company
who would, as a result, hold over 90% of the target company&#8217;s voting rights or the target company&#8217;s issued and outstanding
share capital (or of a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders
for the purchase of all of the issued and outstanding shares of the company (or the applicable class). In general, if (a)&#160;the shareholders
who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or the applicable class) and
the shareholders who accept the offer constitute a majority of the offerees that do not have a personal interest in the acceptance of
the tender offer or (b)&#160;the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share
capital of the company (or of the applicable class), all of the shares that the acquirer offered to purchase will be transferred to the
acquirer by operation of law. A shareholder who had its shares so transferred may petition an Israeli court within six months from the
date of acceptance of the full tender offer, regardless of whether such shareholder agreed to the offer, to determine whether the tender
offer was for less than fair value and whether the fair value should be paid as determined by the court. However, an offeror may provide
in the offer that a shareholder who accepted the offer will not be entitled to petition the court for appraisal rights as described in
the preceding sentence, as long as the offeror and the company disclosed the information required by law in connection with the full tender
offer. If the full tender offer was not accepted, the acquirer may not acquire shares of the company that will increase its holdings to
more than 90% of the company&#8217;s voting rights or the company&#8217;s issued and outstanding share capital (or of the applicable class)
from shareholders who accepted the tender offer. Shares purchased in contradiction to the full tender offer rules&#160;under the Companies
Law will have no rights and will become dormant shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Special Tender Offer</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law provides that, subject to certain exceptions,
an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a result of the acquisition,
the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already
another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares
of an Israeli public company must be made by means of a special tender offer if, as a result of the acquisition, the purchaser would become
a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45%
of the voting rights in the company. These requirements do not apply if (i)&#160;the acquisition occurs in the context of a private placement
by the company that received shareholder approval as a private placement whose purpose is to give the purchaser 25% or more of the voting
rights in the company, if there is no person who holds 25% or more of the voting rights in the company or as a private placement whose
purpose is to give the purchaser 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in
the company, (ii)&#160;the acquisition was from a shareholder holding 25% or more of the voting rights in the company and resulted in
the purchaser becoming a holder of 25% or more of the voting rights in the company, or (iii)&#160;the acquisition was from a shareholder
holding more than 45% of the voting rights in the company and resulted in the purchaser becoming a holder of more than 45% of the voting
rights in the company. in general, a special tender offer must be extended to all shareholders of a company. A special tender offer may
be consummated only if (i)&#160;at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by
the offeror and (ii)&#160;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer
(excluding the purchaser, its controlling shareholders, holders of 25% or more of the voting rights in the company and any person having
a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and
entities under their control).</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event that a special tender offer is made, a company&#8217;s
board of directors is required to express its opinion on the advisability of the offer, or may abstain from expressing any opinion if
it is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal
interest that any of the directors has with respect to the special tender offer or in connection therewith. An office holder in a target
company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing
or foreseeable special tender offer or to impair the chances of its acceptance, is liable to the potential purchaser and shareholders
for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit
of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms
of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If a special tender offer is accepted, then shareholders who did
not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the offer
and they will be considered to have accepted the offer from the first day it was made.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event that a special tender offer is accepted, then the
purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity at the
time of the offer may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to
effect such an offer or merger in the initial special tender offer.&#160;Shares purchased in contradiction to the special tender offer
rules&#160;under the Companies Law will have no rights and will become dormant shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Merger</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law permits merger transactions if approved by each
party&#8217;s board of directors and, unless certain conditions described under the Companies Law are met, a simple majority of the outstanding
shares of each party to the merger that are represented and voting on the merger. The board of directors of a merging company is required
pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a
proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into
account the financial condition of the merging companies. If the board of directors determines that such a concern exists, it may not
approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors
must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For purposes of the shareholder vote of a merging company whose
shares are held by the other merging company, or by a person or entity holding 25% or more of the voting rights at the general meeting
of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the
other merging company, unless a court rules&#160;otherwise, the merger will not be deemed approved if a majority of the shares voted on
the matter at the general meeting of shareholders (excluding abstentions) that are held by shareholders other than the other party to
the merger, or by any person or entity who holds 25% or more of the voting rights of the other party or the right to appoint 25% or more
of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote
against the merger. In addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved
by each class of shareholders. If the transaction would have been approved but for the separate approval of each class or the exclusion
of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25%
of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the
merging companies and the consideration offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or
if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, each merging company must deliver to its
secured creditors the merger proposal and inform its unsecured creditors of the merger proposal and its content. Upon the request of a
creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable
concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the surviving company, and
may further give instructions to secure the rights of creditors.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, a merger may not be completed unless at least 50 days
have passed from the date that a proposal for approval of the merger is filed with the Israeli Registrar of Companies and 30 days from
the date that shareholder approval of both merging companies is obtained.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Anti-Takeover Measures</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law allows us to create and issue shares having rights
different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to voting, distributions
or other matters and shares having preemptive rights. As of the date of this prospectus, no preferred shares are authorized under our
amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares,
such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover
or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization
and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires
the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting
of our shareholders. The convening of the meeting, the shareholders entitled to participate and the vote required to be obtained at such
a meeting will be subject to the requirements set forth in the Companies Law and our amended articles of association, as described above
in &#8220;&#8212;Shareholder Meetings.&#8221; In addition, as disclosed under &#8220;&#8212;Election of Directors,&#8221; we have a classified
board structure, which effectively limits the ability of any investor or potential investor or group of investors or potential investors
to gain immediate control of our board of directors.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Borrowing Powers</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the Companies Law and our amended and restated articles
of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended
and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Changes in Capital</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our amended and restated articles of association enable us to increase
or reduce our share capital. Any such changes are subject to Israeli law and must be approved by a resolution duly passed by our shareholders
at a general meeting of shareholders. In addition, transactions that have the effect of reducing capital, such as the declaration and
payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and
an Israeli court.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Exclusive Forum</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our amended and restated articles of association provide that unless
we consent in writing to the selection of an alternative forum, the United States District Court for the Southern District of New York
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and/or the
Exchange Act. Our amended and restated articles of association also provide that unless we consent in writing to the selection of an alternative
forum, the competent courts in Tel Aviv,&#160;Israel shall be the exclusive forum for any derivative action or proceeding brought on behalf
of the Company, any action asserting a breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company
or our shareholders or any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Transfer Agent and Registrar</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The transfer agent and registrar for our ordinary shares and ADSs
is Computershare. Its address is 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, and its telephone number is (212) 805-7100.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Listing</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The ADSs are listed on Nasdaq under the symbol &#8220;CMMB.&#8221;</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="DESCRIPTIONOFSECURITIES"><!--Anchor--></span>DESCRIPTION
OF SECURITIES WE ARE OFFERING</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">ADSs</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Bank of New York Mellon, as depositary, will register and deliver
the ADSs. Each ADS represents twenty (20) ordinary shares (or a right to receive twenty (20) ordinary shares). Each ADS will also represent
any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s office at which the ADSs will
be administered and its principal executive office are located at 240 Greenwich Street, New York, New&#160;York&#160;10286.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You may hold ADSs either (A)&#160;directly (i)&#160;by having an
ADR, which is a certificate evidencing a specific number of ADSs, registered in your name or (ii)&#160;by having uncertificated ADSs registered
in your name or (B)&#160;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that
is a direct or indirect participant in DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder.
This description assumes you are an ADS holder. If you hold ADSs indirectly, you must rely on the procedures of your broker or other financial
institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution
to find out what those procedures are.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Registered holders of uncertificated ADSs will receive statements
from the depositary confirming their holdings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As an ADS holder, we will not treat you as one of our shareholders
and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary will be the holder of the ordinary shares
underlying the ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS
holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations
of the depositary. New York law governs the deposit agreement and the ADSs.</div> </div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following is a summary of the material provisions of the deposit
agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. For directions on how to obtain
copies of those documents see &#8220;<span style="font-style: italic">Where You Can Find More Information</span>.&#8221;</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Dividends and Other Distributions</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How will you receive dividends and other distributions on the
shares?</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The depositary has agreed to pay or distribute to ADS holders the cash dividends or
other distributions it or the custodian receives on ordinary shares or other deposited securities, upon payment or deduction of its fees
and expenses. You will receive these distributions in proportion to the number of ordinary shares the ADSs represent.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold">Cash.</span>&#160;&#160;&#160;The
depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if it can do so
on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is
needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders
to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of our ADS holders who have not been
paid. It will not invest the foreign currency and it will not be liable for any interest.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before making a distribution, any withholding taxes or other governmental
charges that must be paid will be deducted. See &#8220;Taxation and Government Programs.&#8221; It will distribute only whole U.S. dollars
and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary
cannot convert the foreign currency, you may lose some or all of the value of the distribution.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold">Shares.</span>&#160;&#160;&#160;The
depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing
those ordinary shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional
ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or
ADSs representing those ordinary shares) sufficient to pay its fees and expenses in connection with that distribution.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold">Rights to purchase additional shares.</span>&#160;&#160;&#160;If
we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may (i)&#160;exercise
those rights on behalf of ADS holders, (ii)&#160;distribute those rights to ADS holders or (iii)&#160;sell those rights and distribute
the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does
not do any of those things, it will allow the rights to lapse.&#160;<span style="font-style: italic">In that case, you will receive no
value for them.</span>&#160;The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances
to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights
relate and distribute those securities or, in the case of ordinary shares, new ADSs representing the new ordinary shares, to subscribing
ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of
the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities
distributed may be subject to restrictions on transfer.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold">Other Distributions.</span>&#160;&#160;&#160;The
depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical.
If it cannot make the distribution in that way, the depositary will have a choice. It may decide to sell what we distributed and distribute
the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent
the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders
unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the
distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws
may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may
be subject to restrictions on transfer.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The depositary is not responsible if it decides that it is unlawful
or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights or
other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares,
rights or anything else to ADS holders. This means that you may not receive the distributions we make on our ordinary shares or any value
for them if it is illegal or impractical for us to make them available to you.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Deposit, Withdrawal and Cancellation</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How are ADSs issued?</div>

<div style="text-align: justify; line-height: 1.25"><br />

<div style="text-indent: 36pt; line-height: 1.25">The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence
of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp
taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver
the ADSs to or upon the order of the person or persons that made the deposit.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">How can ADS holders withdraw the deposited securities?</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">You may surrender your ADSs for the purpose of withdrawal of the ordinary shares at
the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer
taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to the ADS holder
or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver
the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent
it would require delivery of a fraction of a deposited share or other securities. The depositary may charge you a fee and its expenses
for instructing the custodian regarding delivery of deposited securities.</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How do ADS holders interchange between certificated ADSs and uncertificated
ADSs?</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You may surrender your ADR to the depositary for the purpose of
exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming
that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction
from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will
execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Voting Rights</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How do you vote?</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">ADS holders may instruct the depositary how to vote the number
of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required
to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials
will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid,
they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel
and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other
deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still
send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Except by instructing the depositary as described above,
you won&#8217;t be able to exercise voting rights unless you surrender the ADSs and withdraw the ordinary shares. However, you may not
know about the meeting enough in advance to withdraw the ordinary shares.</span>&#160;In any event, the depositary will not exercise any
discretion in voting deposited securities and it will only vote or attempt to vote as instructed.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We cannot assure you that you will receive the voting materials
in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible
for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able
to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you requested.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In order to give you a reasonable opportunity to instruct the Depositary
as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the Depositary
notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days in advance of the meeting date.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fees and Expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc1d084e476be4cd8b8a3c3e92c7cfbf9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 40.72%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Persons depositing or withdrawing ordinary shares or ADS holders
        must pay</div> </td>
    <td style="width: 4.08%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 54.62%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">For</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 0.58%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Issuance of ADSs, including issuances resulting from a distribution of ordinary shares
        or rights or other property </div>
        <div style="text-align: justify; line-height: 1.25"> <br /> </div>
        <div style="text-align: justify; line-height: 1.25">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement
        terminates</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">$.05 (or less) per ADS</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Any cash distribution to ADS holders</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">A fee equivalent to the fee that would be payable if securities distributed to you
        had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Distribution of securities distributed to holders of deposited securities (including
        rights) that are distributed by the depositary to ADS holders</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">$.05 (or less) per ADS per calendar year</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Depositary services</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z19ca98092c9b403dbe8fbc38a32ffcc5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 40.72%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Persons depositing or withdrawing ordinary shares or ADS holders
        must pay</div> </td>
    <td style="width: 4.08%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 54.62%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">For</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 0.58%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Registration or transfer fees</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Transfer and registration of ordinary shares on our share register to or from the
        name of the depositary or its agent when you deposit or withdraw ordinary shares</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Expenses of the depositary</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25">Converting foreign currency to U.S. dollars</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Taxes and other governmental charges the depositary or the custodian has to pay on
        any ADSs or ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">As necessary</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 40.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Any charges incurred by the depositary or its agents for servicing the deposited securities</div>
        </td>
    <td style="width: 4.08%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 54.62%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">As necessary</div> </td>
    <td style="width: 0.58%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The depositary collects its fees for delivery and surrender of
ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting
for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by
selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction
from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them.
The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other
property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting
services until its fees for those services are paid.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">From time to time, the depositary may make payments to us to reimburse
us for costs and expenses generally arising out of establishment and maintenance of our ADS program, waive fees and expenses for services
provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit
agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are owned by or affiliated with the
depositary and that may earn or share fees, spreads or commissions.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The depositary may convert foreign currency itself or through any
of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary or broker on behalf of any
other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The revenue is
based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement
and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary
makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most
favorable rate that could be obtained at the time or that the method by which that rate will be determined will be most favorable to ADS
holders, subject to its obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions
is available upon request.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Payment of Taxes</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">You will be responsible for any taxes or other governmental charges payable on the ADSs
or on the deposited securities represented by any of the ADSs. The depositary may refuse to register any transfer of the ADSs or allow
you to withdraw the deposited securities represented by the ADSs until such taxes or other charges are paid. It may apply payments owed
to you or sell deposited securities represented by the ADSs to pay any taxes owed and you will remain liable for any deficiency. If the
depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any
proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Tender and Exchange Offers; Redemption, Replacement or Cancellation
of Deposited Securities</div>

<div style="text-align: justify; line-height: 1.25">

<div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The depositary will not tender deposited securities in any voluntary tender or exchange
offer unless instructed to do so by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">If deposited securities are redeemed for cash in a transaction that is mandatory for
the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute
the net redemption money to the holders of called ADSs upon surrender of those ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">If there is any change in the deposited securities such as a subdivision, combination
or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities
in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those
replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful
and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason,
the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">If there is a replacement of the deposited securities and the depositary will continue
to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender
your outstanding ADSs in exchange for new ADSs identifying the new deposited securities.</div> </div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If there are no deposited securities underlying ADSs, including
if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary
may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Amendment and Termination</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How may the deposit agreement be amended?</div>

<div style="text-align: justify; line-height: 1.25">&#160;

<div style="text-indent: 36pt; line-height: 1.25">We may agree with the depositary to amend the deposit agreement and the ADRs without
your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses
of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS
holders, it will not become effective for outstanding ADSs until 30&#160;days after the depositary notifies ADS holders of the amendment.
At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound
by the ADRs and the deposit agreement as amended.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">How may the deposit agreement be terminated?</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The depositary will initiate termination of the deposit agreement
if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd12b6a4123d346daaf3e9fd6eb2a4874" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>90&#160;days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted
        its appointment;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zccf7506513b14201acef559ca11e784b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="text-align: left; line-height: 1.25">we delist the ADSs from an exchange on which they were listed and do not list the ADSs
        on another exchange within a reasonable time;</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div>

<div><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">the depositary has reason to believe that the ADSs have become, or will become, ineligible for registration
        on Form F-6 under the Securities Act.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z9732f99dcad94c2494b38ac48b23f5f1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we appear to be insolvent or enter insolvency proceedings;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb1a184cbb3947ca9ed9f73a09b0a97a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b89a1d7b6bb4db8884ba760847860c3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="text-align: left; line-height: 1.25">there are no deposited securities underlying the ADSs or the underlying deposited securities
        have become apparently worthless; or</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcddfd925b1954acd9683293a0cd7e44d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>there has been a replacement of deposited securities.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If the deposit agreement will terminate, the depositary will notify
ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the depositary may sell the deposited
securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the
deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the ADS holders that have not surrendered
their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">After the termination date and before the depositary sells, ADS
holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a
surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind if it would interfere
with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited
securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date,
the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities
to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except
as described in this paragraph.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Limitations on Obligations and Liability</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Limits on our obligations and the obligations of the depositary;
Limits on liability to holders of ADSs</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The deposit agreement expressly limits our obligations and the
obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0b221cb0538d4bc08f0850e19360a4d1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith and the depositary
        will not be a fiduciary or have any fiduciary duty to holders of ADSs;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z96b6eeacabfe461199bae3d7c7b4cf7f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its
        obligations under the deposit agreement;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z66c5077e2ab94b13b323391bd6829b1b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>are not liable if we exercise or it exercises discretion permitted under the deposit agreement;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z233a77f41ef94598b976a228ad4d7336" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made
        available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach
        of the terms of the deposit agreement;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z886f909bc44040048a6e41a2319f1eb1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="text-align: left; line-height: 1.25">have no obligation to become involved in a lawsuit or other proceeding related to the
        ADSs or the deposit agreement on your behalf or on behalf of any other person;</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a7be97e1a684efba3c286c373e387e1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>are not liable for the acts or omissions of any securities depository, clearing agency or settlement system;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6f8c7335c666484094c5897ab0baf2dc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper
        person; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcdfe9b436d2f4fa7972c7990b34de3e6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the depositary has no duty to make any determinations or provide any information as to our status, or any liability for any tax consequences
        that may be incurred by ADS holders as a result of owning or holding ADSs or liable for the inability or failure of an ADS holder to obtain
        the benefit of a foreign tax credit reduced rate of withholdings or refund of amounts withheld in respect of tax or any other tax benefit.</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the deposit agreement, we and the depositary agree to indemnify
each other under certain circumstances.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Requirements for Depositary Actions</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before the depositary will deliver or register a transfer of ADSs,
make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6cc66cad8574461ea6ac167ad9bf08f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties
        for the transfer of any ordinary shares or other deposited securities;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf719ff09d4da41b49b3a5292e6c8e796" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd96c214d64a2433cae118671ab8fa160" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of
        transfer documents.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The depositary may refuse to deliver ADSs or register transfers
of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable
to do so.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">Your Right to Receive the Ordinary Shares Underlying the ADSs</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">ADS holders have the right to cancel their ADSs and withdraw the
underlying ordinary shares at any time except:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze2d4d80224f94fa08cf592e9c9966cd8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>when temporary delays arise because: (i)&#160;the depositary has closed its transfer books or we have closed our transfer books;
        (ii)&#160;the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting; or (iii)&#160;we are paying a
        dividend on our shares;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e6c67b739a94c29a0e8bb286d2a0a3b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>when you owe money to pay fees, taxes and similar charges; or</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5125d3c3b11a44648d04abce1f9f7921" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to
        the withdrawal of ordinary shares or other deposited securities.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This right of withdrawal may not be limited by any other provision
of the deposit agreement.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Direct Registration System</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">In the deposit agreement, all parties to the deposit agreement acknowledge that the
Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered
by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through
DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder
of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs
to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that
transfer.</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with and in accordance with the arrangements and
procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the
DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described
in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform
Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions
received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence
or bad faith on the part of the depositary.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Shareholder Communications; Inspection of Register of Holders of
ADSs</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The depositary will make available for your inspection at its office all communications
that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The
depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have
a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our
business or the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Jury Trial Waiver</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The deposit agreement provides that, to the extent permitted by law, ADS holders waive
the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or
the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand
based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance
with applicable case law.</div> </div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Warrants</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following summary of certain terms and provisions of Warrants
that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrants, the
form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should
carefully review the terms and provisions of the form of Warrant for a complete description of the terms and conditions of the Warrants.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Duration
and Exercise Price</span>. Each Warrant offered hereby has an assumed initial exercise price per share equal to $1.97, which is the assumed
offering price of the ADSs in this offering. The Warrants will be immediately exercisable and will have a term of five (5) years.&#160;
The exercise price and number of ADSs issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share
splits, recapitalizations or similar events affecting our ordinary shares and the exercise price.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Exercisability</span>.
The Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice
accompanied by payment in full for the number of ADSs purchased upon such exercise (except in the case of a cashless exercise, as discussed
below). A holder (together with its affiliates) may not exercise any portion of the Warrant to the extent that the holder would beneficially
own more than 4.99% (or, at the election of the purchaser, 9.99%)&#160;of the outstanding ordinary shares immediately after exercise.
No fractional ADSs will be issued in connection with the exercise of a Warrant. In lieu of fractional ADSs, we will either pay the holder
an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole ADS.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Cashless Exercise</span>.
If, at the time a holder exercises its Warrants, a registration statement registering the issuance of the ADS underlying the Warrants
under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available
for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in
payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net
number of Warrants determined according to a formula set forth in the Warrants.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Transferability</span>.
Subject to applicable laws, a Warrant may be transferred at the option of the holder upon surrender of the Warrant to us together with
the appropriate instruments of transfer.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Exchange Listing</span>.
We do not intend to list the Warrants on Nasdaq or any other national securities exchange or nationally recognized trading system. The
ADSs issuable upon exercise of the Warrants are currently listed on Nasdaq.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Right as a
Shareholder</span>. Except as otherwise provided in the Warrants or by virtue of such holder&#8217;s ownership of ADSs, the holders of
the Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until they exercise
their Warrants and receive the ordinary shares underlying the Warrant ADSs from our depositary.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Fundamental
Transaction</span>. In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization,
recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding ordinary
shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding ordinary shares,
the holders of the Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other
property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction (without
regard to any beneficial ownership limitations, as described above). In addition, in the event of a change of control, as described in
the Warrants, the holders of the Warrants have the right to require us or a successor entity to redeem the Warrants for cash in the amount
of the Black Scholes Value of the unexercised portion of the Warrants on the date of the consummation of the change of control. However,
in the event of a change of control that is not within the Company&#8217;s control, including not approved by the Company&#8217;s board
of directors, the holders of the Warrants shall only be entitled to receive from the Company or any successor entity, as of the date of
consummation of the change of control, the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of the Warrant, that is being offered and paid to the holders of the Company&#8217;s ordinary shares in connection
with the change of control, whether that consideration be in the form of cash, stock, or any combination thereof, or whether the holders
of the Company&#8217;s ordinary shares are given the choice to receive from among alternative forms of consideration in connection with
the change of control.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25"><br /> </div> <span id="MATERIALTAXCONSIDERATIONS"><!--Anchor--></span>

<div style="text-align: center; line-height: 1.25; font-weight: bold">MATERIAL TAX CONSIDERATIONS</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following is a brief summary of certain material tax consequences
concerning the ownership and disposition of our securities by purchasers or holders of our securities. Because parts of this discussion
are based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation, there can
be no assurance that the views expressed herein will be accepted by the tax or other authorities in question. The summary below does not
address all of the tax consequences that may be relevant to all purchasers or holders of our securities in light of each purchaser&#8217;s
or holder&#8217;s particular circumstances and specific tax treatment. For example, the summary below does not address the tax treatment
of residents of Israel and traders in securities who are subject to special tax regimes. As individual circumstances may differ, holders
of our securities should consult their own tax advisors as to United States, Israeli or other tax consequences of the purchase, ownership
and disposition of our securities. The discussion below is subject to change, including due to amendments under Israeli law or changes
to the applicable judicial or administrative interpretations of Israeli law, which change could affect the accuracy of the tax consequences
described below. This discussion is not intended, nor should it be construed, as legal or professional tax advice and it is not exhaustive
of all possible tax considerations. Each investor should consult his or her own tax or legal advisor.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Israeli Taxation</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Capital Gains Applicable to Non-Israeli
Shareholders</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Israeli Income Tax Ordinance [New Version], 5721-1961 (the
&#8220;Tax Ordinance&#8221;) generally imposes a capital gains tax on the sale of capital assets by non-Israeli tax residents if those
assets (i) are located in Israel, (ii) are shares or a right to shares in an Israeli resident corporation, including securities traded
on the Tel Aviv Stock Exchange (the &#8220;TASE&#8221;), on a recognized stock exchange outside Israel (such as Nasdaq) or on a regulated
market (which includes a system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant
jurisdiction) in or outside Israel, or (iii) represent, directly or indirectly, rights to assets located in Israel, unless a specific
exemption is available or unless a tax treaty between Israel and the shareholder&#8217;s country of residence provides otherwise. The
Tax Ordinance distinguishes between real capital gain and inflationary surplus. The inflationary surplus is a portion of the total capital
gain equivalent to the increase of the relevant asset&#8217;s tax basis attributable to an increase in the Israeli consumer price index
or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. Inflationary
surplus is not currently subject to tax in Israel. The real capital gain is the excess of the total capital gain over the inflationary
surplus. The capital gains tax rate applicable to individuals upon the sale of such securities is 25%, or 30% with respect to an individual
who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the securities or at any time during the
12 month-period preceding such date (or claims a deduction for interest and linkage differences expenses in connection with the purchase
and holding of such shares). A &#8216;Substantial Shareholder&#8217; is defined as a person who, either alone or together with another
person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means
of control&#8221; of a company (including, among other things, the right to receive profits of the company, voting rights, the right to
receive the company&#8217;s liquidation proceeds and the right to appoint a director). With respect to corporate investors, the capital
gains tax rate is equal to the corporate tax rate (23% in 2023).</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Notwithstanding the foregoing, dealers in securities in Israel
whose gains from selling or otherwise disposing of the shares or ADSs are deemed to be business income are taxed at regular tax rates
applicable to business income (a corporate tax rate for a corporation and a marginal tax rate of up to 47% for an individual in 2023,
excluding excess tax as discussed below) unless contrary provisions in a relevant tax treaty applies.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Generally, a non-Israeli resident (whether an individual or a corporation)
who derives capital gains from the sale of shares or ADSs in an Israeli resident company purchased upon or after the registration of the
shares on the TASE or on a regulated market outside of Israel (such as Nasdaq) may be generally be exempt from Israeli capital gains tax,
provided, among other things, that the capital gain derived from the sale&#160; of shares or ADSs was not attributed to a permanent establishment
that the non-Israeli tax resident investor maintains in Israel.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">However, non-Israeli resident &#8220;body of persons&#8221; (as
defined under the Tax Ordinance, which includes corporate entities, partnerships and other entities) will not be entitled to the foregoing
exemption if Israeli residents, whether directly or indirectly: (i) hold more than 25% of any of the means of control in such non-Israeli
entity or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli entity, whether
directly or indirectly. Such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares or
ADSs are deemed to be business income. In addition, a sale of shares by a non-Israeli resident may be exempt from Israeli capital gains
tax under the provisions of an applicable tax treaty.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, persons paying consideration for shares or ADSs, including
purchasers of shares or ADSs, Israeli securities dealers effecting a transaction, or a financial institution through which securities
being sold are held, are generally required to withhold Israeli tax at source upon the sale of publicly traded securities at a rate of
25% for individuals and at the corporate tax rate (23% in 2023) for corporations, regardless of whether such holder is liable for or exempt
from Israeli capital gains tax on such sale. Holders may be required to demonstrate that they are exempt from tax on their capital gains
by providing a valid certificate from the Israel Tax Authority allowing for an exemption from withholding tax at source at the time of
sale. Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise,
the Israel Tax Authority may require from securityholders who are not liable for Israeli tax to sign declarations in forms specified by
this authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as a non-Israeli resident for tax
purposes, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold Israeli taxes at
source.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Income Taxes on Dividend Distribution to Non-Israeli
Shareholders</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Non-Israeli residents (whether individuals or corporations) are
generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided
under the provisions of an applicable tax treaty between Israel and the shareholder&#8217;s country of residence (provided that a certificate
from the Israel Tax Authority allowing for a reduced withholding tax rate or a tax exemption is obtained in advance). With respect to
a person who is a Substantial Shareholder (as defined above) at the time of receiving the dividend or on any time during the preceding
12 months, the applicable tax rate is 30%.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In principle, non-Israeli residents (whether individuals or corporations)
are generally subject to Israeli withholding tax on the receipt of dividends paid on publicly traded shares at the rate of 25% and at
the rate of 30% on dividends paid to Substantial Shareholders. However, so long as the shares are registered with a Nominee Company, which
is a company incorporated to be a holder of record and distribution agent of publicly traded or other securities in accordance with the
Israeli Securities Law, 5728-1968, the dividends are generally subject to Israeli withholding tax at a rate of 25% (whether or not the
recipient is a Substantial Shareholder), unless a reduced rate is provided under an applicable tax treaty (provided that a certificate
from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance).</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The distribution of dividends to non-Israeli residents (either
individuals or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefited Enterprises (as such terms are
defined under the Israeli Law for the Encouragement of Capital Investments, 5719-1959), during the applicable benefits period is subject
to withholding tax at a rate of 15%, and 20% if the dividend is distributed from income attributed to a Preferred Enterprise, a Special
Preferred Enterprise, Preferred Technological Enterprise or Special Preferred Technological Enterprise (as such terms are defined under
the Israeli Law for the Encouragement of Capital Investments, 5719-1959),&#160;subject to the receipt in advance of a valid certificate
from the Israel Tax Authority allowing for such reduced tax rates, or such lower rate as may be provided under an applicable tax treaty
(provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance). We cannot
assure you that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A non-resident of Israel who has dividend and/or capital income
derived from or accrued in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax returns
in Israel in respect of such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer;
(ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed; and (iii)
the taxpayer is not obligated to pay Excess Tax (as further explained below).</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">U.S.- Israel Tax Treaty</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Convention between the Government of the State of Israel and
the Government of the United States of America with Respect to Taxes on Income (the &#8220;Treaty&#8221;) is generally effective as of
January 1, 1995. Under the Treaty, the maximum Israeli withholding tax on dividends paid to a holder of our ordinary shares who is a Treaty
U.S. Resident (as defined below) is generally 25%. However, generally, for dividends not generated by an Approved Enterprise, Benefited
Enterprise or Preferred Enterprises and paid to a U.S. corporation holding 10% or more of the outstanding voting capital throughout the
tax year in which the dividend is distributed as well as during the previous tax year, the maximum rate of Israeli withholding tax is
generally 12.5%, provided that not more than 25% of the gross income of the Israeli resident paying corporation for such preceding year
consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to an
Approved Enterprise are not entitled to such reduction under such tax treaty but are subject to withholding tax at the rate of 15% for
such a U.S. corporate shareholder, provided that the conditions related to the holding of 10% of our voting capital and to our gross income
for the previous year (as set forth in the previous sentence) are met. The aforementioned rates under the Treaty would not apply if the
dividend income is derived through a permanent establishment of the Treaty U.S. Resident in Israel.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the Treaty, the sale, exchange or disposition of our
ordinary shares or ADSs by a person who qualifies as a resident of the United States within the meaning of the Treaty that holds the shares
or ADSs as a capital asset, and who is entitled to claim the benefits afforded to such residents under the Treaty a (&#8220;Treaty U.S.
Resident&#8221;) generally will not be subject to the Israeli capital gains tax unless,&#160;<span style="font-style: italic">inter alia</span>:
(i) such Treaty U.S. Resident holds, directly or indirectly, shares or ADSs representing 10% or&#160; more of the voting power of the
Company during any part of the 12-month period preceding such sale, exchange or disposition subject to certain conditions; (ii) the capital
gain arising from such sale, exchange or disposition can be attributable to a permanent establishment of the holder maintained in Israel,
under certain terms; (iii) such U.S. resident is an individual and was present in Israel for a period or periods aggregating to 183 days
or more during the relevant taxable year; (iv) the capital gains arising from such sale, exchange or disposition is attributed to real
estate located in Israel, or (v) the capital gain arising from such sale, exchange or disposition is attributed to royalties.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As noted above, a sale, exchange or disposition of our ordinary
shares or ADSs by a Treaty U.S. Resident who holds, directly or indirectly, shares representing 10% or more of the voting power of the
Company at any time during such preceding 12-month period would not be exempt under the Treaty from such Israeli tax; however, under the
Treaty, a Treaty U.S. Resident may be permitted to claim a credit for such taxes against U.S. federal income tax imposed on any gain from
such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the Treaty and U.S. domestic law.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Excess Tax</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Individuals (whether Israeli or non-Israeli tax residents) who
are subject to tax in Israel are also subject to an additional tax at a rate of 3% on their annual income exceeding NIS 698,280 for 2023,
which amount is linked to the annual change in the Israeli Consumer Price Index, including, but not limited to, dividends, interest and
capital gain.</div>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Certain Material U.S. Federal Income Tax Consequences</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following discussion describes the material U.S. federal income
tax consequences relating to the ownership and disposition of our ordinary shares by U.S. Holders (as defined below). This discussion
applies to U.S. Holders that purchase ordinary shares pursuant to this offering and hold such ordinary shares as capital assets within
the meaning of Section 1221 of the Code. This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder and administrative
and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive
effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders
in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as
banks, financial institutions, insurance companies, broker-dealers and traders in securities, commodities or currencies, persons that
generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, retirement plans, individual retirement
accounts or other tax deferred accounts, regulated investment companies, real estate investment trusts, certain former citizens or residents
of the United States, persons who hold ordinary shares as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221;
&#8220;synthetic security&#8221; or integrated investment, persons who received their ordinary shares as compensatory payments, persons
that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own or are treated for tax purposes as owning directly,
indirectly or through attribution 10% or more of our shares by vote or value, persons who are subject to special tax accounting under
Section 451(b) of the Code, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through
entities and arrangements that are classified as partnerships for U.S. federal income tax purposes, and investors in such pass-through
entities, holders receiving or holding ordinary shares in connection with the performance of services, and any holders that are not U.S.
Holders). This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative
minimum tax consequences.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As used in this discussion, the term &#8220;U.S. Holder&#8221;
means a beneficial owner of ordinary shares that is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident
of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized
in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of which is subject
to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able
to exercise primary supervision over its administration and one or more United States persons have the authority to control all of its
substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal
income tax purposes.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If an entity or arrangement treated as a partnership for U.S. federal
income tax purposes holds ordinary shares, the U.S. federal income tax consequences relating to an investment in the ordinary shares will
depend in part upon the status and activities of such entity or arrangement and the particular partner. Any such entity or arrangement
should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its partners of the purchase,
ownership and disposition of ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold">Persons considering an investment in ordinary
shares should consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase, ownership
and disposition of ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Passive Foreign Investment Company Consequences</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In general, a corporation organized outside the United States will
be treated as a PFIC, for any taxable year in which either (1) at least 75% of its gross income is &#8220;passive income&#8221;, the PFIC
income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or
are held for the production of passive income, the PFIC asset test. Passive income for this purpose generally includes, among other things,
dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that
produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public
offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation
is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25%
interest (by value) is taken into account.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Our status as a PFIC will
depend on the nature and composition of our income and the nature, composition and value of our assets (which may be determined based
on the fair market value of each asset, with the value of goodwill and going concern value being determined in large part by reference
to the market value of the ADSs, which may be volatile). Based upon the value of our assets, including any goodwill and the nature and
composition of our income, we believe that we were classified as a PFIC for the taxable year ended December 31, 2021. Furthermore, we
presently anticipate that we will be classified as a PFIC for the current taxable year ending December 31, 2022 based upon the expected
value of our assets, including goodwill, and the expected nature and composition of our income and assets. Our status as a PFIC is a fact-intensive
determination made on an annual basis after the end of each taxable year. Even if we determine that we are not a PFIC for a taxable year,
there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position.
Our U.S. counsel expresses no opinion with respect to our PFIC status for any period</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to the discussion below relating to the making of a QEF
election or a mark-to-market election by a U.S. Holder, if we are a PFIC in any taxable year during which a U.S. Holder owns ordinary
shares, the U.S. Holder could be liable for additional taxes and interest charges under the &#8220;PFIC excess distribution regime&#8221;
upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding
taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on a sale,
exchange or other disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. Under the PFIC excess
distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the
U.S. Holder&#8217;s holding period for ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the
distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary
income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in
effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally
applicable to underpayments of tax, will be added to the tax.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we are a PFIC for any year during which a U.S. Holder holds
ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. Holder
holds the ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221;
election with respect to the ordinary shares. If the election is made, the U.S. Holder will be deemed to sell the ordinary shares it holds
at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such
deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holder&#8217;s ordinary
shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we are a PFIC for any taxable year during which a U.S. Holder
holds ordinary shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would
be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution
regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S.
Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors
regarding the application of the PFIC rules to our non-U.S. subsidiaries.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In general, if we are determined to be a PFIC, a U.S. Holder may
avoid application of the PFIC tax consequences described above in respect to our ordinary shares by making a timely QEF election (if eligible
to do so) to include in income its pro rata share of our net capital gains (as long-term capital gain) and other earnings and profits
(as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in which or
with which our taxable year ends. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed
income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. It should be noted that
dividends paid by a PFIC would generally not qualify for the preferred capital gains rates discussed above. The QEF election is made on
a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A U.S. Holder generally makes a QEF election by attaching a completed
IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including the
information provided in a PFIC annual information statement, to a timely filed U.S. federal income tax return for the tax year to which
the election relates. Retroactive QEF elections generally may be made only by filing a protective statement with such return and if certain
other conditions are met or with the consent of the IRS. U.S. Holders should consult their own tax advisors regarding the availability
and tax consequences of a retroactive QEF election under their particular circumstances.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In order to comply with the requirements of a QEF election, a U.S.
Holder must receive a PFIC annual information statement from us. If we determine we are a PFIC for any taxable year, we will endeavor
to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual information statement, in order to enable
the U.S. Holder to make and maintain a QEF election. However, there is no assurance that we will have timely knowledge of our status as
a PFIC in the future or of the required information to be provided.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If a U.S. Holder has made a QEF election with respect to our Class
A ordinary shares, and the special tax and interest charge rules do not apply to such shares (because of a timely QEF election for our
first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold) such shares), any gain recognized on the sale of our
Class A ordinary shares generally will be taxable as capital gain and no interest charge will be imposed under the PFIC rules. As discussed
above, U.S. Holders of a QEF are currently taxed on their pro rata shares of its earnings and profits, whether or not distributed. In
such case, a subsequent distribution of such earnings and profits that were previously included in income generally should not be taxable
as a dividend to such U.S. Holders. The tax basis of a U.S. Holder&#8217;s shares in a QEF will be increased by amounts that are included
in income, and decreased by amounts distributed but not taxed as dividends, under the above rules.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Although a determination as to our PFIC status will be made annually,
an initial determination that our company is a PFIC will generally apply for subsequent years to a U.S. Holder who held our ordinary shares
while we were a PFIC, whether or not we meet the test for PFIC status in those subsequent years. A U.S. Holder who makes the QEF election
discussed above for our first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold) our ordinary shares, however,
will not be subject to the PFIC tax and interest charge rules discussed above in respect to such shares. In addition, such U.S. Holder
will not be subject to the QEF inclusion regime with respect to our ordinary shares for any taxable year of us that ends within or with
a taxable year of the U.S. Holder and in which we are not a PFIC. On the other hand, if the QEF election is not effective for each of
our taxable years in which we are a PFIC and the U.S. Holder holds our ordinary shares, the PFIC rules discussed above will continue to
apply to such ordinary shares unless the holder makes a &#8220;deemed sale&#8221; election under the PFIC rules. If the U.S. Holder makes
such a deemed sale election, the U.S. Holder may thereafter make a QEF election. The deemed sale election creates a deemed sale of such
ordinary shares at their fair market value. The gain recognized by the deemed sale election attributable to the pre-QEF election period
will be subject to the special tax and interest charge rules treating the gain as an excess distribution under the general PFIC rules
described above. As a result of the deemed sale election, the U.S. Holder will have a new basis and holding period in the ordinary shares
for purposes of the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging
elections to their particular circumstances.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Alternatively, if we are a PFIC, a U.S. Holder will not be subject
to tax under the PFIC excess distribution regime on distributions or gain recognized on ordinary shares if such U.S. Holder makes a valid
&#8220;mark-to-market&#8221; election for our ordinary shares. A mark-to-market election is available to a U.S. Holder only for &#8220;marketable
stock.&#8221; Our ordinary shares will be marketable stock as long as they remain listed on Nasdaq and are regularly traded, other than
in de minimis quantities, on at least 15 days during each calendar quarter. If a mark-to-market election is in effect, a U.S. Holder generally
would take into account, as ordinary income for each taxable year of the U.S. holder, the excess of the fair market value of ordinary
shares held at the end of such taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into
account, as an ordinary loss each year, the excess of the adjusted tax basis of such ordinary shares over their fair market value at the
end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as
a result of the mark-to-market election. The U.S. Holder&#8217;s tax basis in ordinary shares would be adjusted to reflect any income
or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ordinary shares
in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition
would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as
capital loss.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A mark-to-market election will not apply to ordinary shares for
any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become
a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the future. Accordingly, a U.S. Holder
may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs that we may organize
or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for the ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Each U.S. person that is an investor of a PFIC is generally required
to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure
to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S.
federal income tax.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold">The U.S. federal income tax rules relating to
PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect to the impact of
PFIC status on the purchase, ownership and disposition of ordinary shares, the consequences to them of an investment in a PFIC, any elections
available with respect to the ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and
disposition of ordinary shares of a PFIC.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Distributions</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to the discussion above under &#8220;&#8212;Passive Foreign
Investment Company Consequences,&#8221; a U.S. Holder that receives a distribution with respect to ordinary shares generally will be required
to include the gross amount of such distribution (before reduction for any Israeli withholding taxes withheld therefrom) in gross income
as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our current and/or accumulated
earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder
is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and profits, it will
be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ordinary
shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s ordinary shares, the remainder will be
taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles,
U.S. Holders should expect all distributions to be reported to them as dividends. Such dividends will not be eligible for the &#8220;dividends
received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Dividends paid to non-corporate U.S. Holders by a &#8220;qualified
foreign corporation&#8221; are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable
to ordinary income provided that certain requirements are met. However, if we are a PFIC for the taxable year in which the dividend is
paid or the preceding taxable year (see discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences&#8221;),
we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply.
Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to
its particular circumstances.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A non-United States corporation (other than a corporation that
is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered
to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which
the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange
of information provision, or (b) with respect to any dividend it pays on ordinary shares that are readily tradable on an established securities
market in the United States. We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of,
the Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the Treaty is satisfactory for purposes
of the qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion above
under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; if the Treaty is applicable, such dividends will generally
be &#8220;qualified dividend income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Distributions on ordinary shares that are treated as dividends generally will constitute
income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject
to applicable limitations, some of which vary depending upon a U.S. Holder&#8217;s particular circumstances, Israeli income taxes withheld
from dividends on the ADSs at a rate not exceeding the rate provided by the Treaty (assuming such U.S. Holder is eligible for the benefits
of the Treaty) will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing foreign tax credits
are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances.
In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Israeli income tax,
in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead
of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Sale, Exchange or Other Disposition of Ordinary Shares</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to the discussion above under &#8220;&#8212;Passive Foreign
Investment Company Consequences,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes
upon the sale, exchange or other disposition of ordinary shares in an amount equal to the difference, if any, between the amount realized
(i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S.
Holder&#8217;s adjusted tax basis in the ordinary shares. Such capital gain or loss generally will be long-term capital gain taxable at
a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ordinary
shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital
gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from
the sale or other disposition of ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign
tax credit purposes.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Disposition of Foreign Currency</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">U.S. Holders are urged to consult their tax advisors regarding
the tax consequences of receiving, converting or disposing of any non-U.S. currency received as dividends on ordinary shares or on the
sale or retirement of ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Medicare Tax</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Certain U.S. Holders that are individuals, estates or trusts and
whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which
may include their gross dividend income and net gains from the disposition of ordinary shares. If you are a United States person that
is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this tax to your income
and gains in respect of your investment in ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Information Reporting and Backup Withholding</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">U.S. Holders may be required to file certain U.S. information reporting
returns with the IRS with respect to an investment in ordinary shares, including, among others, IRS Form 8938 (Statement of Specified
Foreign Financial Assets). As described above under &#8220;Passive Foreign Investment Company Consequences,&#8221; each U.S. Holder who
is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for ordinary
shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment.
Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Dividends on and proceeds from the sale or other disposition of
ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding (currently at
a rate of 24%) may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification
number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons. However, U.S. Holders
that are corporations generally are excluded from these information reporting and backup withholding tax rules. Backup withholding is
not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against
a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis
to the IRS.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">U.S. Holders should consult their own tax advisors regarding the
backup withholding tax and information reporting rules.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR
ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="UNDERWRITING"><!--Anchor--></span>UNDERWRITING</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We entered into an underwriting agreement with the underwriters
named below on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023. Oppenheimer &amp; Co. Inc. is acting as
the representative of the underwriters. The underwriting agreement provides for the purchase of a specific number of ADSs and accompanying
Warrants. The underwriters&#8217; obligations are several, which means that each underwriter is required to purchase a specified number
of ADSs and accompanying Warrants, but is not responsible for the commitment of any other underwriter to purchase ADSs and accompanying
Warrants. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase the number
of ADSs and accompanying Warrants set forth opposite its name below:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z4662cc7d735c4cdc81646aa450511436" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 83.35%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">Underwriter</div> </td>
    <td style="width: 0.5%; vertical-align: bottom; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 7.18%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of<br /> ADSs</div> </td>
    <td style="width: 0.06%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 8.41%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of Warrants</div> </td>
    <td style="width: 0.5%; vertical-align: top; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 83.35%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Oppenheimer &amp; Co. Inc.</div> </td>
    <td style="width: 0.5%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 7.18%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 0.06%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 8.41%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 0.5%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">&#8203;</div> </td> </tr>
  <tr>
    <td style="width: 83.35%; vertical-align: bottom; padding-bottom: 4px">
        <div style="line-height: 1.25">Aegis Capital Corporation</div> </td>
    <td style="width: 0.5%; vertical-align: bottom; padding-bottom: 4px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 4px double; width: 7.18%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.06%; vertical-align: top; padding-bottom: 4px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 4px double; width: 8.41%; vertical-align: top">&#160;</td>
    <td style="width: 0.5%; vertical-align: bottom; padding-bottom: 4px">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 83.35%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Total</div> </td>
    <td style="width: 0.5%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 7.18%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#8203;</div> </td>
    <td style="width: 0.06%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 8.41%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 0.5%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">&#8203;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The underwriters have agreed to purchase all of the ADSs and accompanying
Warrants offered by this prospectus (other than those covered by the over-allotment option described below), if any are purchased.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The ADSs and accompanying Warrants offered hereby are expected
to be ready for delivery on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023 against payment in
immediately available funds.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The underwriters are offering the ADSs and accompanying Warrants
subject to various conditions and may reject all or part of any order. The representative of the underwriters has advised us that the
underwriters propose initially to offer the ADSs and accompanying Warrants to the public at the public offering price set forth on the
cover page of this prospectus and to dealers at a price less a concession not in excess of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
per ADS and accompanying Warrant to brokers and dealers. After the ADSs are released for sale to the public, the representative may change
the offering price, the concession, and other selling terms at various times.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table provides information regarding the amount of
the discounts and commissions to be paid to the underwriters by us, before expenses:</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z9c5ea63543564190ad7a1eb1f75c3e6f" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total Per<br /> ADS and Accompanying Warrant</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 88%">
        <div style="line-height: 1.25">Public offering price</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%"><br />
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br />
        </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 88%">
        <div style="line-height: 1.25">Underwriting discounts and commissions(1)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"><br /> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br /> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 88%">
        <div style="line-height: 1.25">Proceeds, before expenses, to us</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%"><br />
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br />
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25">(1) We have agreed to pay the underwriters a commission of 6.5% of the gross proceeds of this offering.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We estimate that our total expenses of the offering, excluding the estimated underwriting
discounts and commissions, will be approximately $0.5 million, which includes the fees and expenses for which we have agreed to reimburse
the underwriters, including fees and expenses of their counsel, up to a maximum aggregate amount of $100,000.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have agreed to a 60-day &#8220;lock-up,&#8221; and our officers
and directors have agreed to a 90-day &#8220;lock-up,&#8221; with respect to our ordinary shares, ADSs and other of our securities that
we or they beneficially own, including securities that are convertible into ordinary shares or ADSs and securities that are exchangeable
for or exercisable into ordinary shares or ADSs. This means that, subject to certain exceptions, for a period of 60 or 90&#160;days, as
applicable, following the date of this prospectus, we and such persons may not offer, sell, pledge or otherwise dispose of these securities
without the prior written consent of Oppenheimer &amp; Co. Inc.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">Rules of the SEC may limit the ability of the underwriters to
bid for or purchase ADSs before the distribution of the ADSs is completed. However, the underwriters may engage in the following activities
in accordance with the rules:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zd8a3d38d4e2e4cb4baeb3e14a0099d5a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Stabilizing transactions&#8201;&#8212;&#8201;The representative may make bids or purchases for the purpose of pegging, fixing or
        maintaining the price of the ADSs, so long as stabilizing bids do not exceed a specified maximum.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z6995c8adf2a444f68946f2c5eb2cbf43" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Syndicate covering transactions&#8201;&#8212;&#8201;The underwriters may sell more ADSs in connection with this offering than the
        number of ADSs that they have committed to purchase. This over-allotment creates a short position for the underwriters. This short sales
        position may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. Covered short sales are short sales
        made in an amount not greater than the underwriters&#8217; over-allotment option to purchase additional ADSs, if applicable. The underwriters
        may close out any covered short position either by exercising their over-allotment option, if applicable, or by purchasing ADSs in the
        open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price
        of ADSs available for purchase in the open market, as compared to the price at which they may purchase ADSs through the over-allotment
        option, if applicable. Naked short sales are short sales in excess of the over-allotment option, if applicable. The underwriters must
        close out any naked short position by purchasing ADSs in the open market. A naked short position is more likely to be created if the underwriters
        are concerned that, in the open market after pricing, there may be downward pressure on the price of the ADSs that could adversely affect
        investors who purchase ADSs in this offering.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z9ceb1b7589e64e6eaf9e0b6201df7961" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Penalty bids&#8201;&#8212;&#8201;If the representative purchases ADSs in the open market in a stabilizing transaction or syndicate
        covering transaction, it may reclaim a selling concession from the underwriters and selling group members who sold those ADSs as part
        of this offering.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z9abdbdb058354fb39800e9e366e78e04" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Passive market making&#8201;&#8212;&#8201;Market makers in the ADSs who are underwriters or prospective underwriters may make bids
        for or purchases of ADSs, subject to limitations, until the time, if ever, at which a stabilizing bid is made.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">Similar to other purchase transactions, the underwriters&#8217;
purchases to cover the syndicate short sales or to stabilize the market price of the ADSs may have the effect of raising or maintaining
the market price of the ADSs or preventing or mitigating a decline in the market price of the ADSs. As a result, the price of the ADSs
may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect
on the price of the ADSs if it discourages resales of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">Neither we nor the underwriters make any representation or prediction
as to the effect that the transactions described above may have on the price of the ADSs. These transactions may occur on Nasdaq or otherwise.
If such transactions are commenced, they may be discontinued without notice at any time.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">The underwriters and certain of their affiliates are full service
financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial
advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters
and certain of their affiliates may in the future engage in investment banking and other commercial dealings in the ordinary course of
business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">In addition, in the ordinary course of their business activities,
the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or
related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers.
Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their
affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities
or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Electronic Delivery of Prospectus</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A prospectus in electronic format may be delivered to potential
investors by one or more of the underwriters participating in this offering. The prospectus in electronic format will be identical to
the paper version of such prospectus. Other than the prospectus in electronic format, the information on any underwriter&#8217;s website
and any information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement
of which this prospectus forms a part.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Notice to Non-U.S. Investors</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Belgium</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The offering is exclusively conducted under applicable private
placement exemptions and therefore it has not been and will not be notified to, and this document or any other offering material relating
to the securities has not been and will not be approved by, the Belgian Banking, Finance and Insurance Commission (&#8220;Commission bancaire,
financi&#232;re et des assurances/Commissie voor het Bank, Financie en Assurantiewezen&#8221;). Any representation to the contrary is
unlawful.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The underwriter has undertaken not to offer sell, resell, transfer
or deliver directly or indirectly, any securities, or to take any steps relating/ancillary thereto, and not to distribute or publish this
document or any other material relating to the securities or to the offering in a manner which would be construed as: (a)&#160;a public
offering under the Belgian Royal Decree of 7 July&#160;1999 on the public character of financial transactions; or (b)&#160;an offering
of securities to the public under Directive 2003/71/EC which triggers an obligation to publish a prospectus in Belgium. Any action contrary
to these restrictions will cause the recipient and the company to be in violation of the Belgian securities laws.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Canada</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This document constitutes an &#8220;exempt offering document&#8221;
as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission
or similar regulatory authority in Canada in connection with the offer and sale of the securities described herein (the &#8220;Securities&#8221;).
No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this document or on the merits
of the Securities and any representation to the contrary is an offence.</div>

<div style="text-align: justify; line-height: 1.25">Canadian investors are advised that this document has been prepared in reliance on
section 3A.3 of National Instrument 33-105 Underwriting Conflicts (&#8220;NI 33-105&#8221;). Pursuant to section 3A.3 of NI 33-105, this
document is exempt from the requirement to provide investors with certain conflicts of interest disclosure pertaining to &#8220;connected
issuer&#8221; and/or &#8220;related issuer&#8221; relationships as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Resale Restrictions</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The offer and sale of the securities in Canada is being made on
a private placement basis only and is exempt from the requirement to prepare and file a prospectus under applicable Canadian securities
laws. Any resale of Securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities
laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus
requirements, a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise
under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority.
These resale restrictions may under certain circumstances apply to resales of the Securities outside of Canada.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Representations of Purchasers</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Each Canadian investor who purchases the Securities will be deemed
to have represented to the issuer and to each dealer from whom a purchase confirmation is received, as applicable, that the investor (i)&#160;is
purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment
only and not with a view to resale or redistribution; (ii)&#160;is an &#8220;accredited investor&#8221; as such term is defined in section
1.1 of National Instrument 45-106 Prospectus Exemptions (&#8220;NI 45-106&#8221;) or, in Ontario, as such term is defined in section 73.3(1)
of the Securities Act (Ontario); and (iii)&#160;is a &#8220;permitted client&#8221; as such term is defined in section 1.1 of National
Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Taxation and Eligibility for Investment</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any discussion of taxation and related matters contained in this
document does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor
when deciding to purchase the Securities and, in particular, does not address any Canadian tax considerations. No representation or warranty
is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the Securities or with respect
to the eligibility of the Securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Rights of Action for Damages or Rescission</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Securities legislation in certain of the Canadian jurisdictions
provides certain purchasers of securities pursuant to an offering memorandum, including where the distribution involves an &#8220;eligible
foreign security&#8221; as such term is defined in Ontario Securities Commission Rule&#160;45-501&#160;<span style="font-style: italic">Ontario
Prospectus and Registration Exemptions</span>&#160;and in Multilateral Instrument 45-107&#160;<span style="font-style: italic">Listing
Representation and Statutory Rights of Action Disclosure Exemptions</span>, as applicable, with a remedy for damages or rescission, or
both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes
an offering memorandum, and any amendment thereto, contains a &#8220;misrepresentation&#8221; as defined under applicable Canadian securities
laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within
the time limits prescribed under, and are subject to limitations and defenses under, applicable Canadian securities legislation. In addition,
these remedies are in addition to and without derogation from any other right or remedy available at law to the investor.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Language of Documents</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Upon receipt of this document, each Canadian investor hereby confirms
that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including
for greater certainty any purchase confirmation or any notice) be drawn up in the English language only.&#160;<span style="font-style: italic">Par
la r&#233;ception de ce document, chaque</span>&#160;investisseur&#160;<span style="font-style: italic">canadien confirme par les pr&#233;sentes
qu&#8217;il a express&#233;ment exig&#233; que tous les documents faisant foi ou se rapportant de quelque mani&#232;re que ce soit &#224;
la vente des valeurs mobili&#232;res d&#233;crites aux pr&#233;sentes (incluant, pour plus de certitude, toute confirmation d&#8217;achat
ou tout avis) soient r&#233;dig&#233;s en anglais seulement.</span></div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">France</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Neither this prospectus nor any other offering material relating
to the securities has been submitted to the clearance procedures of the Autorit&#233; des march&#233;s financiers in France. The securities
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus
nor any other offering material relating to the securities has been or will be: (a)&#160;released, issued, distributed or caused to be
released, issued or distributed to the public in France; or (b)&#160;used in connection with any offer for subscription or sale of the
securities to the public in France. Such offers, sales and distributions will be made in France only: (i)&#160;to qualified investors
(investisseurs qualifi&#233;s) and/or to a restricted circle of investors (cercle restreint d&#8217;investisseurs), in each case investing
for their own account, all as defined in and in accordance with Articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1
of the French Code mon&#233;taire et financier; (ii)&#160;to investment services providers authorised to engage in portfolio management
on behalf of third parties; or (iii)&#160;in a transaction that, in accordance with article L.411-2-II-1&#176; -or-2&#176; -or 3&#176;
of the French Code mon&#233;taire et financier and article 211-2 of the General Regulations (R&#232;glement G&#233;n&#233;ral) of the
Autorit&#233; des march&#233;s financiers, does not constitute a public offer (appel public &#224; l&#8217;&#233;pargne). Such ADSs may
be resold only in compliance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code mon&#233;taire et
financier.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Israel</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The securities offered hereunder may not be offered or sold to
the public in Israel absent the publication of a prospectus that has been approved by the Israel Securities Authority (the &#8220;ISA&#8221;).
This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968 (the &#8220;Israeli Securities Law&#8221;),
and has not been filed with or approved by the ISA and the securities offered hereunder have not been registered for sale in Israel. In
Israel, this document is being distributed only to, and is directed only at, and any offer of the securities hereunder is directed only
at, (i) a limited number of persons in accordance with the Israeli Securities Law and (ii) investors listed in the first addendum to the
Israeli Securities Law (the &#8220;Addendum&#8221;), consisting primarily of joint investment in trust funds, provident funds, insurance
companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds,
entities with equity in excess of NIS 50 million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be
amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where
permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required
to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Italy</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">The offering of the securities offered hereby in Italy has not
been registered with the Commissione Nazionale per la Societ&#224; e la Borsa (&#8220;CONSOB&#8221;) pursuant to Italian securities legislation
and, accordingly, the securities offered hereby cannot be offered, sold or delivered in the Republic of Italy (&#8220;Italy&#8221;) nor
may any copy of this prospectus or any other document relating to the ADSs offered hereby be distributed in Italy other than to professional
investors (operatori qualificati) as defined in Article&#160;31, second paragraph, of CONSOB Regulation&#160;No. 11522 of 1 July, 1998
as subsequently amended. Any offer, sale or delivery of the securities offered hereby or distribution of copies of this prospectus or
any other document relating to the securities offered hereby in Italy must be made:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z91a19ab50a9a41f2b6a89dcdbb5c4565" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>by an investment firm, bank or intermediary permitted to conduct such activities in Italy in accordance with Legislative Decree No.
        58 of 24 February&#160;1998 and Legislative Decree No. 385 of 1 September&#160;1993 (the &#8220;Banking Act&#8221;);</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zde4241360cc940f883041f33fef54c00" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>in compliance with Article&#160;129 of the Banking Act and the implementing guidelines of the Bank of Italy; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z254ab17cd23e4dd3a5fb2791d9b1cd11" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>in compliance with any other applicable laws and regulations and other possible requirements or limitations which may be imposed
        by Italian authorities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Sweden</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus has not been nor will it be registered with or
approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this prospectus may not be made available,
nor may the securities offered hereunder be marketed and offered for sale in Sweden, other than under circumstances which are deemed not
to require a prospectus under the Financial Instruments Trading Act (1991: 980).</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Switzerland</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The securities offered pursuant to this prospectus will not be
offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as
that term is understood pursuant to art. 652a or art. 1156 of the Swiss Federal Code of Obligations. The company has not applied for a
listing of the securities being offered pursuant to this prospectus on the SWX Swiss Exchange or on any other regulated securities market,
and consequently, the information presented in this prospectus does not necessarily comply with the information standards set out in the
relevant listing rules. The securities being offered pursuant to this prospectus have not been registered with the Swiss Federal Banking
Commission as foreign investment funds, and the investor protection afforded to acquirers of investment fund certificates does not extend
to acquirers of securities.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Investors are advised to contact their legal, financial or tax
advisers to obtain an independent assessment of the financial and tax consequences of an investment in securities.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">United Kingdom/Germany/Norway/The Netherlands</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a &#8220;Relevant Member State&#8221;) an offer to the public of any ADSs which
are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State other than the offers contemplated
in this prospectus in name(s) of Member State(s) where prospectus will be approved or passported for the purposes of a non-exempt offer
once this prospectus has been approved by the competent authority in such Member State and published and passported in accordance with
the Prospectus Directive as implemented in name(s) of relevant Member State(s) except that an offer to the public in that Relevant Member
State of any ADSs may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented
in that Relevant Member State:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="za2481c474eac4a5b9443951b89a7a593" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
        corporate purpose is solely to invest in securities;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zb63b4dba9ab04b3397956be6777e77f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>to any legal entity which has two or more of (1)&#160;an average of at least 250 employees during the last financial year; (2)&#160;a
        total balance sheet of more than &#8364;43,000,000 and (3)&#160;an annual net turnover of more than &#8364;50,000,000, as shown in its
        last annual or consolidated accounts;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zbef10a7262c940689ad112672acf7be9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>by the representative to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive);
        or</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z6d47abbab23d407d8309e2c7c23ab0e4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(d)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive, provided that no such offer of ADSs shall
        result in a requirement for the publication by the company or any underwriter of a prospectus pursuant to Article&#160;3 of the Prospectus
        Directive.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25">For the purposes of this provision, the expression an &#8220;offer
to the public&#8221; in relation to any ADSs in any Relevant Member State means the communication in any form and by any means of sufficient
information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase any ADSs, as the same
may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression &#8220;Prospectus
Directive&#8221; means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Each underwriter has represented, warranted and agreed that:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="za456563ca4774dd5a03ec511dc2bca42" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement
        to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 (the FSMA)) received
        by it in connection with the issue or sale of any ADSs in circumstances in which section 21(1) of the FSMA does not apply to the company;
        and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z8502ea28e9614e8ab954d6ca61590875" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 20.25pt"><br /> </td>
    <td style="width: 27pt; vertical-align: top">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>it has complied with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to
        the ADSs in, from or otherwise involving the United Kingdom.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="LEGALMATTERS"><!--Anchor--></span>LEGAL MATTERS</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25">Certain legal matters as to United States
law in connection with this offering will be passed upon for us by Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C., Boulder, Colorado.&#160;The
validity of the securities and other matters of Israeli law will be passed upon for us by Meitar | Law Offices, Ramat Gan, Israel. Certain
matters of Israeli law will be passed upon for the underwriters by Gornitzky &amp; Co., Tel Aviv, Israel. Certain matters of U.S. federal
law will be passed upon for the underwriters by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="EXPERTS"><!--Anchor--></span>EXPERTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The consolidated financial statements of Chemomab Therapeutics Ltd. as of December 31,
2022 and 2021, and for each of the years in the two-year period ended December 31, 2022, have been included herein in reliance upon the
report of Somekh Chaikin, a member firm of KPMG International, independent registered public accounting firm appearing elsewhere&#160;&#160;
herein, and upon the authority of said firm as experts in accounting and auditing.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="ENFORCEMENTOFCIVILLIABILI"><!--Anchor--></span>ENFORCEMENT
OF CIVIL LIABILITIES</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Chemomab is incorporated under the laws of the State of Israel.
Not all of our directors or officers are residents of the United States. Most of our assets and those of our&#160;non-U.S.&#160;directors
and officers are located outside the United States. Service of process upon us and upon our&#160;non-U.S.&#160;resident directors and
officers and the Israeli experts named in this prospectus may be difficult to obtain within the United States.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have irrevocably appointed Chemomab Therapeutics, Inc. as our
agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase
or sale of securities in connection with this offering. The address of our agent is One Kendall Square, Building 1400E, Suite 14-105,
Cambridge, MA 02139.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have been informed by our legal counsel in Israel, Meitar |
Law Offices, that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a
judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on an
alleged violation of U.S. securities laws against us or our&#160;non-U.S.&#160;officers or directors reasoning that Israeli court is not
the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli
law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved
as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli
law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered
outside Israel, which may make it difficult to collect on judgments rendered against us or our&#160;non-U.S.&#160;officers and directors.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to specified time limitations, legal procedures and certain
exceptions, Israeli courts may enforce a U.S. judgment in a civil matter which is&#160;non-appealable,&#160;including judgements based
on the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a&#160;non-civil&#160;matter,
provided that, among other things:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z28e643a093ab428cbfe60c60e07616d9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment was rendered by a court which was, according to the laws of the state
        of the court, competent to render the judgment;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the obligation imposed by the judgment is enforceable according to the rules relating
        to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment is executory in the state in which it was given.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Even if these conditions are met, an Israeli court may not declare
a foreign civil judgment enforceable if:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z1a42d417bf70413db397c46e2cd4b470" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment was given in a state whose laws do not provide for the enforcement of
        judgments of Israeli courts (subject to exceptional cases);</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the enforcement of the judgment is likely to prejudice the sovereignty or security
        of the State of Israel;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment was obtained by fraud;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the opportunity given to the defendant to bring its arguments and evidence before
        the court was not reasonable in the opinion of the Israeli court;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment was rendered by a court not competent to render it according to the laws
        of private international law as they apply in Israel;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">the judgment is contradictory to another judgment that was given in the same matter
        between the same parties and that is still valid; or</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: middle">
        <div style="text-align: center; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">at the time the action was brought in the foreign court, a lawsuit in the same matter
        and between the same parties was pending before a court or tribunal in Israel.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If a foreign judgment is enforced by an Israeli court, it generally
will be payable in Israeli currency, which can then be converted into&#160;non-Israeli&#160;currency and transferred out of Israel. The
usual practice in an action before an Israeli court to recover an amount in a&#160;non-Israeli&#160;currency is for the Israeli court
to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the
judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli
currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulators
prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="WHERE"><!--Anchor--></span>WHERE YOU CAN FIND MORE INFORMATION</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are subject to the informational requirements of the Exchange
Act and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC
maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the SEC. The address of the SEC&#8217;s website is www.sec.gov.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">We make available free of charge on or through our website at www.chemomab.com, our
annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with
or otherwise furnish it to the SEC.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus, which constitutes a part of the registration statement,
does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith or the documents
incorporated by reference herein. For further information about us and the ADSs offered hereby, we refer you to the registration statement
and the exhibits and schedules filed thereto and to the documents incorporated by reference herein. Statements contained in this prospectus
regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement or to a document
incorporated by reference herein are not necessarily complete, and each such statement is qualified in all respects by reference to the
full text of such contract or other document filed as an exhibit to the registration statement or a document incorporated by reference
herein. You can obtain a copy of the registration statement, at prescribed rates, from the SEC at the address listed above, or for free
at www.sec.gov. The registration statement and the documents referred to below under &#8220;Incorporation by Reference&#8221; are also
available on our website, www.chemomab.com.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The information contained on, or accessible through, our website
does not form a part of this prospectus and is not incorporated by reference herein or therein.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="INCORPORATIONBYREFERENCE"><!--Anchor--></span>INCORPORATION
BY REFERENCE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221;
information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information
that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously
filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that
a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This prospectus incorporates by reference the documents set forth
below that have previously been filed with the SEC:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf18997808e7d41479a1e64ae4d305e8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The Registrant&#8217;s Annual Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322001304/zk2227534.htm">Form
        10-K</a> for the fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022 (the &#8220;Annual Report&#8221;);</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca8e322e3b074c9e93d44cb31150871a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The Company&#8217;s Quarterly Reports on Form 10-Q for the quarter ended <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001919/0001178913-22-001919-index.htm">March
        31, 2022</a>, filed with the SEC on May 12, 2022, for the quarter ended <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891321002696/0001178913-21-002696-index.htm">June
        30, 2022</a>, filed with the SEC on August 12, 2022, and for the quarter ended <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322003931/0001178913-22-003931-index.htm">September
        30, 2022</a>, filed with the SEC on November 10, 2022;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za5b7d7bf1b634b9e90cb3e45452516e5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The Company&#8217;s Current Reports on Form 8-K, as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322000575/form8k.htm">February
        11, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/0001178913-22-001896-index.htm">May 12, 2022</a>
        (excluding information furnished pursuant to Item 2.02), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322002261/form8k.htm">June
        1, 2022</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322002314/form8k.htm">June 8, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322002410/0001178913-22-002410-index.htm">June
        21, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/0001178913-22-003072-index.htm">August 12, 2022</a>
        (excluding information furnished pursuant to Item 2.02), <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm">November
        14, 2022</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322004061/zk2228768.htm">November 16, 2022</a>,
        <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/0001178913-22-004189-index.htm">November 29, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm">January
        3, 2023</a>,&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000147/0001178913-23-000147-index.htm">January
        11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm">February 21,
        2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm"><span style="text-decoration: underline">February
        21, 2023</span></a>;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z800315d2f16f42f6958afeee0e3a2f77" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The description of our share capital, which is set forth in exhibit 4.1 of our Annual
        Report, and as may be further updated or amended in any amendment or report filed for such purpose; and</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.99%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange
        Act of 1934, as amended (the &#8220;Exchange Act&#8221;), since the end of the fiscal year covered by the Annual Report.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">All filings filed by us pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Exchange Act of 1934 after the date of the initial filing of the registration statement of which this prospectus forms a
part and prior to the termination of the offering (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall
also be deemed to be incorporated by reference into this prospectus.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You should rely only on the information incorporated by reference
or provided in this prospectus. We have not authorized anyone else to provide you with different information. Any statement contained
in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this prospectus
to the extent that a later statement contained in this prospectus or in any other document incorporated by reference into this prospectus
modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded,
to constitute a part of this prospectus. You should not assume that the information in this prospectus is accurate as of any date other
than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We will provide without charge to each person to whom a copy of
this prospectus is delivered, upon written or oral request, a copy of any or all of the reports or documents that have been incorporated
by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings, unless we have specifically
incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at: Kiryat Atidim, Building 7,
Tel Aviv 6158002, Israel, Attention: Donald Marvin, Chief Financial Officer, or made by phone at +972-77-331-0156. You may also access
the documents incorporated by reference in this prospectus through our website at www.chemomab.com. Except for the specific incorporated
documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the
registration statement of which it forms a part. You may also access any of the documents incorporated by reference in this prospectus
by visiting <span style="font-style: italic">www.chemomab.com</span>, or our investor relations website is <span style="font-style: italic">www.investors.chemomab.com</span>.
The information on either of these websites, however, is not, and should not be deemed to be, a part of this prospectus.</div>

<div style="text-align: center; line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br /> </div>
<!-- Field: /Include-Text -->
<a id="a_001"></a><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:100%;vertical-align:top">
        <div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:12pt"><span><span><span><span><span>Chemomab
        Therapeutics Ltd. and</span></span></span></span></span></span></span></div>
        <div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-bottom:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:12pt"><span><span><span><span><span>its
        subsidiaries</span></span></span></span></span></span><span style="font-size:10pt"><span><span><span><span style="line-height:1.25">&#160;</span></span></span></span></span></span></div>
        <div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0px;text-align:center">&#160;</div>
        <div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:12pt"><span><span><span><span><span>Consolidated&#160;</span></span></span></span></span><span><span><span><span><span>Financial
        Statements</span></span></span></span></span><span><span><span><span><span style="line-height:1.25">&#160;</span></span></span></span></span></span></span></div>
        <div style="margin-top:0pt;margin-bottom:10px;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:12pt"><span><span><span><span><span>As
        of December&#160;31, 2022</span></span></span></span></span></span></span></div></td></tr>
  </table></div></div></div>

<div>

<div>

<div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Chemomab
Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div>

<div style="text-align:right;line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>Consolidated
Financial Statements as of December 31, 2022</span></span></span></span></span></span></span><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:0pt" /></div></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contents</span></span></span></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="text-align:right;text-indent:12pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Page</span></span></span></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25;margin-bottom:10pt">

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%" width="100%">
  <tr>
    <td style="font-family:Times New Roman,Times,serif">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="line-height:1.25;text-align:left"><span><span><span><span><span><span style="line-height:1.25;text-align:left"><span><span><a href="#reportOfIndependentRegisteredPublicAccountingFirm_integixAnchor"><span><span><span><span style="line-height:1.25;text-align:left"><span><span><span><span><span><span style="line-height:1.25;text-align:left"><span><span>Report
        of Independent Registered Public Accounting Firm</span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td>
    <td style="font-family:Times New Roman, Times, serif;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 2</span></span></span></span></span></span></td></tr>
  <tr>
    <td style="font-family:Times New Roman, Times, serif">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="color:rgb(33, 37, 41)">(PCAOB
        ID 1057)</span></strong></span></span></p></td>
    <td style="font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr>
  <tr>
    <td style="font-family:Times New Roman, Times, serif">
        <div>
        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><a href="#consolidatedBalanceSheets_integixAnchor"><span><span><span><span><span><span>Consolidated
        Balance Sheets</span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></div></div></td>
    <td style="font-family:Times New Roman, Times, serif;width:10%">
        <div style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 3</span></span></span></span></span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">
        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><a href="#consolidatedStatementsOfOperationsForTheYearEnded_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span>Consolidated
        Statements of Operations</span></span></span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div></td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 4</span></span></span></span></span></span></span></span></span></span></span></span></td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">
        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><a href="#consolidatedStatementsOfChangesInEquity_integixAnchor"><span><span><span><span><span><span><span><span><span><span>Consolidated
        Statements of Changes in Equity</span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></div></td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 5</span></span></span></span></span></span></td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr>
  <tr>
    <td rowspan="1">
        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><a href="#statementsOfCashFlows_integixAnchor"><span><span><span><span><span><span>Consolidated
        Statements of Cash Flows<span>&#160;</span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></div></td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 6</span></span></span></span></span></span></td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="font-family:Times New Roman, Times, serif">
        <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><a href="#notesToTheFinancialStatements_integixAnchor"><span><span><span><span><span><span><span><span><span><span>Notes
        to the Consolidated Financial Statements</span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></div></td>
    <td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F
        - 7</span></span></span></span></span></span></span></span></span></span></span></span></td></tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-bottom:10pt;margin-top:0pt">

<div><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always" />

<p style="text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="text-align:left"><img alt=" " src="cmmb_img01.jpg" style="width:114px;height:55px" /></p></div>

<div style="margin-top:10pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="width:80%;text-align:left">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Somekh
        Chaikin</span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>KPMG
        Millennium Tower</span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>17
        Ha&#8217;arba&#8217;a Street, PO Box 609</span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Tel
        Aviv 61006, Israel</span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>+972
        3 684 8000</span></span></span></span></span></span></span></p></td></tr>
  </table></div>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span id="reportOfIndependentRegisteredPublicAccountingFirm_integixAnchor" style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Report
of Independe</strong></span></span></span></span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">nt
Registered Public Accounting Firm</strong></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">To
the Shareholders and Board of Directors, </span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Chemomab
Therapeutics Ltd.:</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><i style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:normal;margin-top:0pt;margin-bottom:0pt">O</span></span></i></span></span></span><i style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">pinion
on the Consolidated Financial Statements</span></i></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:normal;margin-top:0pt;margin-bottom:0pt">We
</span></span></span></span></span><span style="margin-top:0pt;margin-bottom:0pt">have audited the accompanying consolidated balance sheets
of Chemomab Therapeutics Ltd. (the Company) as of December 31, 202</span><span style="margin-top:0pt;margin-bottom:0pt">2</span><span style="margin-top:0pt;margin-bottom:0pt">
and 202</span><span style="margin-top:0pt;margin-bottom:0pt">1</span><span style="margin-top:0pt;margin-bottom:0pt">, the related consolidated
statements of operations, changes in equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and
the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 202</span><span style="margin-top:0pt;margin-bottom:0pt">2</span><span style="margin-top:0pt;margin-bottom:0pt">
and 202</span><span style="margin-top:0pt;margin-bottom:0pt">1</span><span style="margin-top:0pt;margin-bottom:0pt">, and the results
of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with U.S. generally
accepted accounting principles</span><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:normal;margin-top:0pt;margin-bottom:0pt">.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><i style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Basis
for Opinion</span></i></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">These&#160;</span></span></span></span><span style="margin-top:0pt;margin-bottom:0pt">consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion</span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">.
</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:normal;margin-top:0pt;margin-bottom:0pt">Our</span></span></span></span></span><span style="margin-top:0pt;margin-bottom:0pt">&#160;audits
included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-right:57pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Somekh
Chaikin</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-right:57pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-right:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Member
Firm of KPMG International</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-right:0px;margin-bottom:0px;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0px;margin-right:0px;margin-bottom:0px;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:12pt"><span>We
have served as the Company&#8217;s auditor since </span></span><span>2015</span></span><span>.</span></span></span></span></p>

<p style="margin-top:0pt;margin-right:0px;margin-bottom:0px;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:12pt">Tel
Aviv, Israel</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-right:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal"><span>February
20, 2023</span></span></span></span></span></span></p>

<p style="margin-top:10pt;margin-right:57pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span>&#169;
2</span></span></span><span style="font-size:8pt">023 KPMG Somekh Chaikin, an Israeli partnership and a member firm of the KPMG global
organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All
rights reserve</span><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span>d.</span></span></span></p></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>F
- 2</span></span></span></span></p></div>

<div style="clear:both;margin-top:0pt;margin-bottom:10pt">

<div><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;page-break-after:always;background-color:#000000" /></div></div></div></div>

<table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics
        Ltd. and its subsidiaries</p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="consolidatedBalanceSheets_integixAnchor"><span style="font-weight:bold">Con</span></span><span><span style="font-weight:bold">solidated
        Balance Sheets as of</span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt">In USD thousands
        (except share and per share amounts)</p> </td> </tr>
  </table>

<div style="margin-top:0px">

<p style="text-align:center;margin-bottom:0px">&#160; &#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Assets</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Current
        assets</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">3</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,186</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Short-term bank deposit</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000040" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,374</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000041" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,975</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Restricted cash</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000040" name="us-gaap:RestrictedCashCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other receivables
        and prepaid expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">4</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        current assets</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000044" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,736</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,688</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Non-current
        assets</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000050" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></strong></td>
    <td style="vertical-align:bottom;width:1%;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000051" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Long-term prepaid
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span><ix:nonFraction id="Fxbrl_20230131220311598" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Property and equipment,
        net</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">5</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Operating lease right-of-use
        assets</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        non-current assets</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        assets</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000059" name="us-gaap:Assets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Current
        liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Trade payables</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000060" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,336</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,378</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,560</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">653</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Operating lease liabilities</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        current liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,749</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,650</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Non-current
        liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Non-current operating
        lease liabilities</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        non-current liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000072" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Commitments
        and contingent liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">7</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20230207202310124" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20230207202348403" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        liabilities</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,840</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000075" name="us-gaap:Liabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Shareholders'
        equity</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">8</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Ordinary
        Shares <ix:nonFraction id="Fxbrl_20230201163052384" name="us-gaap:CommonStockNoParValue" contextRef="C_20211231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20230131220607422" name="us-gaap:CommonStockNoParValue" contextRef="C_20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
        par value - Authorized: <ix:nonFraction id="Fxbrl_20230131221123913" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221114549" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">650,000,000
        </ix:nonFraction></ix:nonFraction>shares as of December 31, 2022 and 2021;&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Issued
        and outstanding: <ix:nonFraction id="Fxbrl_s_20230213101830929" name="us-gaap:SharesOutstanding" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230213101830930" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></ix:nonFraction>
        Ordinary shares at December 31, 2022 and <ix:nonFraction id="Fxbrl_s_20230131221353660" name="us-gaap:SharesOutstanding" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221353661" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></ix:nonFraction>
        Ordinary shares at December 31, 2021</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131221528825" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131221535249" name="us-gaap:CommonStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, serif">Treasury
        share at cost (<ix:nonFraction id="Fxbrl_20230207202558860" name="us-gaap:TreasuryStockShares" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,640,460</ix:nonFraction>
        shares as of </span><span style="font-size:10pt;font-family:Times New Roman, serif">December 31, 2022</span><span style="font-size:10pt;font-family:Times New Roman, serif">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:10pt;font-family:Times New Roman, serif">(<ix:nonFraction id="Fxbrl_20230207202444619" name="us-gaap:TreasuryStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20230207202534021" name="us-gaap:TreasuryStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Additional paid-in
        capital</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accumulated deficit</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        shareholders&#8217; equity</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000090" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000091" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:65%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total
        liabilities and shareholders&#8217; equity</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:16pt;margin-bottom:0pt">_____________________&#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;_____________________</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">Chief Executive Officer&#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Chief Financial Officer</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">Date of approval
of the financial statements: February 20, 2023</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0px">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px">The accompanying notes are an integral
part of the consolidated financial statements.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px;text-align:center">&#160;</p>

<div>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px">F - 3</p> </div> <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" />
</div>

<table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:4pt"><strong><span id="consolidatedStatementsOfOperationsForTheYearEnded_integixAnchor"><span>Consolidated
        Statements of Operations for the year ended</span></span></strong></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        USD thousands (except share and per share amounts)</span></span></p> </td> </tr>
  </table>

<div style="margin-top:0px;margin-bottom:0px">

<p style="margin-bottom:0px;text-align:center;margin-top:0px">&#160; &#160; &#160; &#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Operating
        expenses</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Total
        operating expenses</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,533</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000099" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,367</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financing
        (income) expenses, net</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230131223230473" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction>)</span></span></strong></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:1%">&#160;</td>
    <td style="vertical-align:top;text-align:right;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230131223237304" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">111</ix:nonFraction></span></span></span></td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Loss
        before taxes</span></strong></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:11pt;font-family:Times New Roman, serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000102" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></strong></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:11pt;font-family:Times New Roman, serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000103" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Taxes
        on income (benefit)</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">11</p> </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230131223639023" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></strong></td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000101" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">&#160;</p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Net
        loss for the year</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000102" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic
        and diluted loss per Ordinary Share</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%;border-bottom:3pt double black">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%;border-bottom:3pt double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131213305203" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%;border-bottom:3pt double black">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%;border-bottom:3pt double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213312166" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted
        average number of Ordinary Shares outstanding, basic, and diluted</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%;border-bottom:3pt double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:3pt double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230214141238310" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:3pt double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:3pt double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213329528" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000107" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  </table> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, serif;font-size:10pt;color:black">The
accompanying notes are an integral part of the consolidated financial statements.</span></p>

<div>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F
- 4</span></span></p> </div> <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" /> </div>

<table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics
        Ltd. and its subsidiaries</p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="consolidatedStatementsOfChangesInEquity_integixAnchor"><span style="font-weight:bold">Consolidated
        S</span></span><span><span style="font-weight:bold">tatements of Changes in Equity</span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt">In USD thousands
        (except share amounts)</p> </td> </tr>
  </table>

<div style="margin-top:0px">

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="bottom">&#160;
        &#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px">&#160;</td>
    <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
    <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="6" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Ordinary</span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Shares</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="6" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Treasury<br />share</strong></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Additional<br />paid
        in<br />capital</strong></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Accumulated
        Deficit</strong></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Total Shareholders'<br />equity</strong></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">Number</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">Number</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance
        as of January 1, 2021 </strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232832534" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,274,838</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004148281" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004108785" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004208753" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000128" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,497</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000129" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,695</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000130" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,802</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Share-based
        compensation</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right">-</span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004236209" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right">-</span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004232608" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232932528" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004229458" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232938175" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Effect
        of reverse capitalization transaction</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232946871" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">152,299,702</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004310594" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004631164" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004302609" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232952864" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004258843" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232958504" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Issuance
        of shares and warrants, net of issuance costs</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233006128" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">66,381,520</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004339738" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004626295" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004335122" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233012248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004332317" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233018475" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Exercise
        of options</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233039147" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,240</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004521301" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004621028" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004724885" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233033563" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004807831" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233028090" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Net
        loss for the year</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004352160" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004349447" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><ix:nonFraction id="Fxbrl_20230208004345432" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">(<ix:nonFraction id="Fxbrl_20230207233044479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
        <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">)</span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">(<ix:nonFraction id="Fxbrl_20230207233049858" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
        <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">)</span></span></span></p>
        </div> </td> </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;padding:0px;vertical-align:bottom;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance
        as of December 31, 2021</strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207234506438" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004359870" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><ix:nonFraction id="Fxbrl_20230208004449318" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004357072" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233106443" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(</strong><strong><ix:nonFraction id="Fxbrl_20230207234203847" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px 0px 2pt;background-color:rgb(255, 255, 255);width:1%">
        <div style="padding:0in 0in 1pt;text-align:left;margin:0px">
        <p style="margin:0px;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233116634" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="top">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance
        as of January 1, 2022 </strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction>
        </strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Share-based
        compensation</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>-</strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>-</strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Issuance
        of shares, net of issuance costs</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,576,400</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Exercise
        of options</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233237975" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004927217" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004915442" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004923369" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233227671" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004959684" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233221400" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Treasury
        share at cost</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>-
        </strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
        </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(255, 255, 255);width:1%">
        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
        </td> </tr>
  <tr style="height:15px;background-color:rgb(204, 238, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Net
        loss for the year</span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="top">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
        <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:7%" valign="bottom">
        <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(204, 238, 255);width:1%">
        <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
        <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
        </div> </td> </tr>
  <tr style="height:15px;background-color:rgb(255, 255, 255)">
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:30%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance
        as of December 31, 2022</strong></span></span></span></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);width:1%;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="top">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);width:1%;vertical-align:bottom">
        <div style="padding:0in 0in 1pt;text-align:left;margin:0px">
        <p style="margin:0px;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);width:1%;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
        <div>&#160;</div> </td>
    <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:7%" valign="bottom">
        <div style="padding:0in 0in 1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></strong></span></span></span></p>
        </div> </td>
    <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
  </table> </div>

<div>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0px">F - 5</p> </div> <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" />
</div>

<table cellpadding="0" style="border-spacing:0px;margin-top:auto;margin-bottom:auto" width="100%">
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="statementsOfCashFlows_integixAnchor"><span style="font-weight:bold">Statem</span></span><span><span style="font-weight:bold">ents
        of Cash flows for the year ended</span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
        USD thousands</span></span></span></span>&#160;</p> </td> </tr>
  </table>

<p style="margin-bottom:0px;text-align:center;margin-top:0px">&#160; &#160; &#160; &#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">December&#160;31,
        </span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">2022</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">December&#160;31,
        </span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">2021</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Cash
        flows from operating activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        loss for the year</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000149" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000150" name="us-gaap:ProfitLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0px">&#160;</p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Adjustments
        for operating activities:</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Depreciation</span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000151" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000152" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based
        compensation</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000154" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change
        in other receivables and prepaid expenses</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000156" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,058</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change
        in trade payables</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000157" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000158" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,175</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change
        in accrued expenses</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000159" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,823</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230201002431792" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,279</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change
        in employees and related expenses</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000161" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000162" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change
        in operating leases&#160;</span></span></span></span></p> </td>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000163" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="Fxbrl_20230201002424683" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Net
        cash used in operating activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000165" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,370</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000166" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,374</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Cash
        flows from investing activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Investment
        in deposits</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000167" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,601</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000168" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,951</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term
        lease deposit</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000169" name="cmmb:LongTermLeaseDeposit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="Fxbrl_20230131235620864" name="cmmb:LongTermLeaseDeposit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Sale
        of asset held for sale</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000171" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="Fxbrl_20230131235631064" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Purchase
        of property and equipment</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Net
        cash provided by (used in) investing activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,533</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000176" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">45,186</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Cash
        flows from financing activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash
        acquired in Merger</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000177" name="cmmb:CashAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235649216" name="cmmb:CashAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise
        of options</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><span><ix:nonFraction id="FFact_0000000000179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="Fxbrl_20230131235658097" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Treasury
        share at cost</span></span></span></span></p> </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201000241409" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000182" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance
        of shares and warrants, net of issuance costs</span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000183" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000184" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Net
        cash provided by (used in) financing activities</span></span></span></span></span></p> </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201002754453" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">808</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000186" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,074</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Change
        in cash, cash equivalents and restricted cash</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201002721687" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,645</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">)</span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Cash,
        cash equivalents and restricted cash at beginning of the year</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Cash,
        cash equivalents and restricted cash at end of the year</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong><span style="text-decoration:underline">Supplementary
        cash flows information:</span></strong></span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        Cash paid and received during the year for:</span></strong></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes received</span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214142748754" name="cmmb:IncomeTaxesReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214143241770" name="cmmb:IncomeTaxesReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Income
        taxes paid</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-bottom:0pt;margin-top:0pt;text-align:right"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230214142431448" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></span></span></span></span></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:2pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="display:none">&#160;</span>&#160;</span></span></span></span></td>
    <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-bottom:0pt;margin-top:0pt;text-align:right"><ix:nonFraction id="Fxbrl_20230207233750059" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Interest
        received</span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="text-align:right;vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233819452" name="cmmb:InterestReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233829491" name="cmmb:InterestReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></td>
    <td style="background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">B.&#160;
        &#160; &#160; &#160; &#160;Significant non- cash transaction:</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">Right-of-use
        asset recognized with corresponding lease liability</span></span></span></span></span></strong></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000193" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000194" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">Liabilities
        assumed, net of non-cash assets received in Merger</span></span></span></span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000195" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></strong></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230131235456185" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  </table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px">&#160;</p>

<div>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>F
- 6</span></span></span></span></p> </div> <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" /> </div>

<div>

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="notesToTheFinancialStatements_integixAnchor"><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:top"> <hr style="height:1.5pt;border-width:0px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);width:100%;margin-top:-1.34pt;text-align:left" />
        </td> </tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#8201;</span></span></span></span></p>
        </td> </tr>
  </table> </div> <ix:nonNumeric id="FFact_0000000000208" name="us-gaap:NatureOfOperations" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
1 - General</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">1.<span style="padding-left:28.5pt">Chemomab
Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September
2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"><br />The
Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical
need that involve inflammation and fibrosis.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><br />The
wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics
Inc.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">2.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:28.5pt">The
Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company
has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it
obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to
raise sources of financing.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.<span style="padding-left:28.5pt">Since
</span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2020, the COVID-19 pandemic
has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial
markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19
pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining
populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the
enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a
result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials,
patients might still drop out because of possible COVID-19 implications. Based on management&#8217;s assessment, the extent to which the
lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments,
which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment
following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and
will adjust activities accordingly<span><span><span>.</span></span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.<span style="padding-left:28.5pt">On
</span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 14, 2020, the Company
(formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;)
with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of
the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant
to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd.
surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its
name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became
primarily the business conducted by the Company.</span></span></p>

<div>

<div style="width:100%;clear:both">

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt">At
the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into
number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd.
option was assumed by the Company, based on the same exchange ratio.</p>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;7</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><br /><strong>Note 1 - General (cont&#8217;d)</strong></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">4.
(cont'd)</p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For&#160;<span>accounting
purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger
has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets
acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired
in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion
of the Merger.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">The
exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd.
The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive
Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately <ix:nonFraction id="Fxbrl_20230131220949272" name="cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger" contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12.86</ix:nonFraction>
multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt">The
following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion
of the Merger (in USD thousands):</p>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20230201024915457" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000202" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000203" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other
        assets</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000204" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000205" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000206" name="cmmb:EstimatedFairValueOfNetAssetsAcquired" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;8</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div> <ix:nonNumeric id="FFact_0000000000234" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies</span></p> <ix:nonNumeric id="FFact_0000000000209" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis
of Preparation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S
GAAP&#8221;).</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000210" name="us-gaap:UseOfEstimates" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use
of estimates</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
</ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000211" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign
currency</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221;
or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the
currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary
assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets
and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements
of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction
dates, except for depreciation, which is translated using historical exchange rate.</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000212" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash
and cash equivalents</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or
less at the date acquired.</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000213" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted
cash</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted
cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20230201130501547" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property
and equipment</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property
and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred.
Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets
are ready for their intended use.</p>

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual
rates at depreciation are as follows:</p>

<div style="margin-left:36pt"> <ix:nonNumeric id="Fxbrl_20230201131108956" name="cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000214" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement
        - <ix:nonNumeric id="FFact_0000000000217" name="cmmb:AnnualRatesOfDepreciation" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">over
        the shorter of the lease term or the estimated useful life of the improvement</ix:nonNumeric></p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </div> </div> </ix:nonNumeric>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;9</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p> </ix:exclude></div> <ix:nonNumeric id="FFact_0000000000220" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment
of long-lived assets</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p> </ix:nonNumeric>
<ix:nonNumeric id="FFact_0000000000221" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research
and Development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research
and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and
wages.</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000222" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income
taxes</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized.
In making such a determination, management considers all available positive and negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management
determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management
would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p> </ix:nonNumeric>
<ix:nonNumeric id="FFact_0000000000223" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair
value of financial instruments</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC
820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for
measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant
assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date, essentially an exit price.</p>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;10</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair
value of financial instruments (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In
addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described
below includes the Company&#8217;s own credit risk.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As
a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation
methodologies in measuring fair value:</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar
or identical assets or liabilities.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due
to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates
their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">-
</span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred
during the periods presented.</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000224" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based
compensation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified
and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation
cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting
schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation
cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing
model at the grant date, using the inputs detailed in Note 8(C).</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The
Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000225" name="cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored
research and development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab
records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that
the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants
as a reduction to research and development expenses.</p> </ix:nonNumeric>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;11</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p> </ix:exclude></div> <ix:nonNumeric id="FFact_0000000000229" name="cmmb:SeverancePayPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance
pay</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits,
at a rate of <ix:nonFraction id="Fxbrl_20230215220314714" name="cmmb:PercentageOfMonthlyDepositsRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>%
of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability
exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee.
This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $<ix:nonFraction id="Fxbrl_20230215220321806" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction>
thousand and $<ix:nonFraction id="Fxbrl_20230215220329094" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction>
thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000230" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations
of credit risk:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
<span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold
the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
arrangements.</p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20230213125125767" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under
</span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities
are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the
Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what
its credit rating would be <ix:nonFraction id="Fxbrl_20230213132631771" name="cmmb:IncrementalBorrowingRateOfLeases" contextRef="C_20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>%
and <ix:nonFraction id="Fxbrl_20230213132641931" name="cmmb:IncrementalBorrowingRateOfLeases" contextRef="C_20211231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction>%
in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based,
asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account
for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to
measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain
any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br />&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease
expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br />&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU
assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance
in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the
amount of the impairment loss to recognize. See Note 2(G).</span></span></p> </div> </ix:nonNumeric>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;12</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p> </ix:exclude></div> <ix:nonNumeric id="FFact_0000000000232" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles
of consolidation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
<span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions
have been eliminated in consolidation.</span></span></span></p> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000233" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings
per ordinary share</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic
earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant,
gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares,
using the treasury stock method, from the assumed exercise of share options.</p> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000244" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
3 - Cash and Cash Equivalents</span></p> <ix:nonNumeric id="FFact_0000000000243" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,663</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000236" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,720</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000237" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,756</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000239" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000240" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,350</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000241" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000242" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,186</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000252" name="cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
4 - Other Receivables and Prepaid Expenses</span></p> <ix:nonNumeric id="FFact_0000000000251" name="cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000245" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000246" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000247" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000248" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,348</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000249" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000250" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;13</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div> <ix:nonNumeric id="FFact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
5 - Property and Equipment, Net</span></p> <ix:nonNumeric id="FFact_0000000000269" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000253" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000254" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000255" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000256" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000257" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">399</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000258" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000259" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000260" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000261" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong><ix:nonFraction id="Fxbrl_20230201032006902" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">464
        </ix:nonFraction></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less
        - accumulated depreciation</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000265" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong><ix:nonFraction id="Fxbrl_20230201033845372" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">357
        </ix:nonFraction></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000294" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
6 - Leases</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On
May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According
to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of <ix:nonNumeric id="Fxbrl_20230131233210356" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20200510" format="ixt-sec:durwordsen">three
years</ix:nonNumeric>, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to
extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230131233301410" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20200501to20200510">three
years</ix:nonNumeric>.&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On
October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab
returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of <ix:nonNumeric id="Fxbrl_20230131233734834" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20211024" format="ixt-sec:duryear">3</ix:nonNumeric>
years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to
extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230201000916081" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20211001to20211024">three
years</ix:nonNumeric>. The annual rent and management fees are approximately $<ix:nonFraction id="Fxbrl_20230131234005244" name="cmmb:AnnualRentAndManagementFees" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction>
thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $<ix:nonFraction id="Fxbrl_20230131234014829" name="cmmb:BankGuaranteesToPropertyOwner" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction>
thousand was issued to the property owner during 2022.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets
as of December 31, 2022 and 2021 and represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s
obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current
liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December
31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease
agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $<ix:nonFraction id="Fxbrl_20230131234456429" name="cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20211212" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction>
thousand on December 12, 2021.&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">During
the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $<ix:nonFraction id="Fxbrl_20230131234508150" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction>
thousand and $<ix:nonFraction id="Fxbrl_20230131234513790" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction>
thousand, respectively.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As&#160;of
December 31, 2022, and 2021 operating right-of-use asset was $<ix:nonFraction id="Fxbrl_20230214143811730" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction>
thousand and $<ix:nonFraction id="Fxbrl_20230214143818906" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction>
thousand, respectively. The operating lease liabilities were $<ix:nonFraction id="Fxbrl_20230214143827206" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction>
thousand and $<ix:nonFraction id="Fxbrl_20230214143833566" name="us-gaap:OperatingLeaseLiability" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction>
thousand, respectively.</span></span></p>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;14</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
6 - Leases (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As
most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information
available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing
rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was <ix:nonFraction id="Fxbrl_20230131234937485" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>%
in 2022 and <ix:nonFraction id="Fxbrl_20230131234957047" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction>%
in 2021.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Maturities
of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):</p>

<div style="margin-left:40pt;margin-bottom:0pt"> <ix:nonNumeric id="Fxbrl_20230201025037730" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000288" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">126
        </ix:nonFraction></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000289" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">93
        </ix:nonFraction></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum
        lease payments</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219
        </ix:nonFraction></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000291" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of
        operating lease liabilities</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214
        </ix:nonFraction></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<div>&#160;</div> <ix:nonNumeric id="FFact_0000000000311" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note
7 - Commitments and Contingent Liabilities</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive
License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv
Souraski Medical Center (&#8220;Fund&#8221;), pursuant to which it was granted with an exclusive license to certain inventions (as defined
in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant
to and subject to certain terms and limitation fully set in the License Agreement.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Chemomab
has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term
defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(i)<span style="padding-left:26.56pt">Royalties
in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to </span>certain additional terms set
forth therein.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"><span>In
addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable,
non-creditable amounts:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt">(a)<span style="padding-left:24.9pt"><ix:nonNumeric id="Fxbrl_20230215222406006" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">$100
thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent
for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar
application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission
of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not
be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</ix:nonNumeric></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt"><ix:nonNumeric id="Fxbrl_20230215222519809" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">$200
thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the
aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only
once.</ix:nonNumeric></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">As
of December 31, 2022&#160;no payments were made to the Fund.</p>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;15</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive
License Agreement (hereinafter- &#8220;the License Agreement&#8221;) (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
addition to the payments described above, <ix:nonNumeric id="Fxbrl_20230215222713212" name="us-gaap:OtherCommitmentsDescription" contextRef="C_20220101to20221231">upon
the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction,
Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering,
or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction
of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in
any event not more than $3,000 thousand.</ix:nonNumeric></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="padding-left:26.83pt">&#160;
&#160;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel </span>Innovation Authority
(&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of <ix:nonFraction id="Fxbrl_20230201002925810" name="cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>%
of sales of the developed product (linked to U.S. dollar), up to <ix:nonFraction id="Fxbrl_20230201002935951" name="cmmb:MaximumPercentageOfPaymentsOfRoyalties" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>%
of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology
or development out of Israel.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt">Chemomab
did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Since
Chemomab &#8217;s incorporation through December 31, 2022 Chemomab received $<ix:nonFraction id="Fxbrl_20230201002951961" name="cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction>
thousand from the IIA, which were recognized as a reduction of research and development expenses.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">As
of December 31, 2022, Chemomab has no commitment for royalties payable.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:26.28pt">In
</span></span></span>June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under
which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in
the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization
thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients.
According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with
Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements
for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to
pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt">During
2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $<ix:nonFraction id="Fxbrl_20230213125722009" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,222</ix:nonFraction>
thousand and $<ix:nonFraction id="Fxbrl_20230213125731080" name="us-gaap:RoyaltyExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,590</ix:nonFraction>
thousand, respectively. The expenses were recorded under research and development expenses.</p>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;16</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-weight:bold">C.</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="padding-left:26.28pt">As&#160;</span></span>of
December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $<ix:nonFraction id="Fxbrl_20230213125744104" name="us-gaap:RestrictedInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction>
thousand for the purpose of secure lease payments under an office lease agreement.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span><span style="padding-left:26.28pt">During&#160;</span></span><span>2022,
the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through
202</span><span>2</span><span>. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger
Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which
the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $<ix:nonFraction id="Fxbrl_20230207215117039" name="cmmb:RecoverabilityOfVatAmount" contextRef="C_20220701to20220731" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction>
thousand. The Company filed an appeal against the ITA&#8217;s assessments. The Company has recorded an appropriate provision which considers
inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded
by the Company during the period</span><span>.</span></span></span></p> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="FFact_0000000000385" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
8 - Share Capital</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Right
attached to shares</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-weight:bold;font-style:italic">Ordinary
shares</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">All
of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary
shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote
and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when
the Company is dissolved.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">1.</span><span style="font-weight:bold;padding-left:28.5pt">Voting</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The
holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">2.</span><span style="font-weight:bold;padding-left:28.5pt">Dividends</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The
holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally
available.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">Since
its inception, the Company has not declared any dividends.</p>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;17</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
8 - Share Capital (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="padding-left:26.83pt;font-weight:bold">Financing
rounds</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.</span><span style="padding-left:28.5pt">In&#160;</span></span></span>connection
with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which
the Company agreed to sell approximately $<ix:nonFraction id="Fxbrl_20230213133908909" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction>
million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement
closed on March 22, 2021, at which time the Company sold to the purchasers <ix:nonFraction id="Fxbrl_20230213133843633" name="cmmb:NumberOfWarrantsPurchaseUpAdss" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,619,270</ix:nonFraction>
ADSs together with warrants to purchase up to <ix:nonFraction id="Fxbrl_20230213133849363" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">261,929</ix:nonFraction>
ADSs at an exercise price of $<ix:nonFraction id="Fxbrl_20230213133830904" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.35</ix:nonFraction>
per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds
of approximately $<ix:nonFraction id="Fxbrl_20230213133820824" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction>
million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.</span><span style="padding-left:28.5pt">On&#160;</span></span></span>April
30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor").
According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to
$<ix:nonFraction id="Fxbrl_20230213133808746" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction>
million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133801744" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">699,806</ix:nonFraction>
ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133754484" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">22.75</ix:nonFraction>
per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133747440" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,917</ix:nonFraction>
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>3.</span><span style="padding-left:28.5pt">On
</span></span></span></span></span></span>April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and
sale of up to $<ix:nonFraction id="Fxbrl_20230213133711976" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">18,125,000</ix:nonFraction>&#160;of
its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject
to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third
of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;<ix:nonFraction id="Fxbrl_20230213133726969" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">130,505</ix:nonFraction>
ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133719951" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">2.11</ix:nonFraction>
per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133734136" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction>
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4.</span><span style="padding-left:28.5pt">On&#160;</span></span></span></span>September
19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder
of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together
with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section
303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to
repurchase up to <ix:nonFraction id="Fxbrl_20230213133614438" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction>&#160;ADSs
owned by the Co-Founders, for consideration not to exceed an aggregate amount of $<ix:nonFraction id="Fxbrl_20230213133621142" name="cmmb:RepurchaseOfAmericanDepositaryReceipts" contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction>,
depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the
entire amount of <ix:nonFraction id="Fxbrl_20230213133633159" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction>
ADSs from the Co-Founders at a weighted average price of $<ix:nonFraction id="Fxbrl_20230213133700406" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="USD_Per_Share" scale="0" decimals="4" format="ixt:num-dot-decimal">2.0848</ix:nonFraction>
and for total consideration of approximately $<ix:nonFraction id="Fxbrl_20230213133643190" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction>
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">The
Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".</span></span></span></p>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;18</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
8 - Share Capital (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based
compensation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(1)<span style="padding-left:24.34pt">Share-based
compensation plan:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">The
Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017
Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company from Chemomab
upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs
of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.<br />&#160;</p>

<p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As
of December 31, 2022, a total of <ix:nonFraction id="Fxbrl_20230207224906305" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">28,443,060</ix:nonFraction>
of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223247056" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,422,153</ix:nonFraction>
of ADSs) were reserved for issuance under the 2015 Plan, of which <ix:nonFraction id="Fxbrl_20230207225529762" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,445,520</ix:nonFraction>
Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223254041" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">172,276</ix:nonFraction>
ADSs) had been issued pursuant to previous exercises options, and <ix:nonFraction id="Fxbrl_20230207225556251" name="cmmb:NumberOfOptionsIssuableOutstanding" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,460,740</ix:nonFraction>
&#160;Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223300376" name="cmmb:NumberOfAdssOptionsIssuableOutstanding" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,173,037</ix:nonFraction>
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225618055" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,400,720</ix:nonFraction>
Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223309640" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">620,036</ix:nonFraction>
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207224602275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.30</ix:nonFraction>
per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207223316544" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">5.96</ix:nonFraction>
per ADS). During the year ended December 31, 2022, options to purchase <ix:nonFraction id="Fxbrl_20230207224845387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction>
Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223324626" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">62,006</ix:nonFraction>
ADS) were canceled.</span></span></span></p>

<p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As
of December 31, 2022, a total of <ix:nonFraction id="Fxbrl_20230207225827725" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,511,620</ix:nonFraction>
of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225729518" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">625,581</ix:nonFraction>
ADSs) were reserved for issuance under the 2017 Plan, of which <ix:nonFraction id="Fxbrl_20230207225858382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,730,800</ix:nonFraction>
Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225738550" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">586,540</ix:nonFraction>
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225916606" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">427,540</ix:nonFraction>
Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225743877" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">21,377</ix:nonFraction>
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207225929980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.35</ix:nonFraction>
per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207225750293" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">6.98</ix:nonFraction>
per ADS). During the year ended December 31, 2022 no options were canceled.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(2)<span style="padding-left:24.34pt">The
expenses that were recognized in the consolidated statements of operations for services received from employees </span>and service providers
are as follows:</p>

<div style="margin-left:108pt"> <ix:nonNumeric id="Fxbrl_20230201040228557" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000338" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000340" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based
        compensation expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000342" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;19</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Note
8 - Share Capital (cont&#8217;d)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt">(3)<span style="padding-left:24.34pt">The
number and weighted average exercise price of options are as follows:</span></p>

<div style="margin-left:108pt"> <ix:nonNumeric id="Fxbrl_20230201040244110" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">exercise price</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January
        1</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20201231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20201231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">10,455,580</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20200101to20201231" format="ixt-sec:duryear">7.8</ix:nonNumeric></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><ix:nonFraction id="Fxbrl_20230214225414206" name="cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000351" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><ix:nonFraction id="Fxbrl_20230201024457584" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">609,535</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000352" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000353" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201024523067" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.08</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201024530820" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,220</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000356" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000358" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">1.25</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000359" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,712,275</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,398,400</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.62</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">17,784,640</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20210101to20211231" format="ixt-sec:duryear">9.79</ix:nonNumeric></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December
        31</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(4)<span style="padding-left:24.34pt">Fair
value measurement:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt">The
fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate
the fair value of the options are as follows:</p>

<div style="margin-left:108pt"> <ix:nonNumeric id="Fxbrl_20230201040432498" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average
        share price (in U.S. dollar)<sup>(a)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000373" name="us-gaap:SharePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in
        U.S. dollar)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMinimumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.10</ix:nonFraction></span><span style="font-weight:bold">-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMaximumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.257</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of
        options (in years)<sup>(b)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000377" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.51</ix:nonNumeric></span><span style="font-weight:bold">-</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.28</ix:nonNumeric></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">83.69</ix:nonFraction></span><span style="font-weight:bold">%-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.31</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest
        rate<sup>(d)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.75</ix:nonFraction></span><span style="font-weight:bold">%-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.14</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231" unitRef="Pure" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;20</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
8 - Share Capital (cont&#8217;d)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based
compensation (cont&#8217;d)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.
(cont'd)</span></span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(a)<span style="padding-left:24.34pt">The
weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">Expected
life for the periods presented was determined according to the simplified method since, at the date of </span>grant, the Company did not
have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration,
and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method
is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition
is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if
the service period is explicitly stated.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(c)<span style="padding-left:24.34pt">Expected
volatility is based on historical volatility over the most recent period commensurate with the expected </span>term of the option. As
the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term,
the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s
industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(d)<span style="padding-left:24.34pt">The
risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the </span>yields of U.S. Treasury
securities with maturities appropriate for the expected term of employee share option awards.</p> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="FFact_0000000000399" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
9 - Research and Development</span></p> <ix:nonNumeric id="FFact_0000000000398" name="cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000386" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,052</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000387" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,894</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000388" name="us-gaap:OfficersCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867
        </ix:nonFraction></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000389" name="us-gaap:OfficersCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,789</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000390" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000391" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000392" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000393" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000394" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000395" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000396" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000397" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;21</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div> <ix:nonNumeric id="FFact_0000000000417" name="cmmb:GeneralAndAdministrativeDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
10 - General and Administrative&#160;</span></p> <ix:nonNumeric id="FFact_0000000000416" name="cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000400" name="us-gaap:SalariesAndWages" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000401" name="us-gaap:SalariesAndWages" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000402" name="us-gaap:ProfessionalFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,596</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000403" name="us-gaap:ProfessionalFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000404" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000405" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span><ix:nonFraction id="Fxbrl_20230201004651041" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000408" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000409" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000410" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000411" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000413" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000414" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000415" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric id="FFact_0000000000458" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note
11 - Income Taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Tax
rates</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
taxable income in Israel is subject to a corporate tax rate of <ix:nonFraction id="FFact_0000000000418" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab
Inc. is subject to a federal flat tax rate of <ix:nonFraction id="FFact_0000000000419" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction>%
and state tax as applicable.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital
gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Tax
assessments</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the Company&#8217;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the
Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has not yet been assessed by the ITA since inception.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Losses
for tax purposes carried forward to future years</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2022, the Company and its subsidiaries had approximately $<ix:nonFraction id="Fxbrl_20230213140532094" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">159</ix:nonFraction>
million&#160;(approximately $<ix:nonFraction id="Fxbrl_20230213140537759" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20211231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">143</ix:nonFraction>
million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation
on the period of use.</span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On
March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and
Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA
provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on
interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes
provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January
1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></p>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;22</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Note
11 - Income Taxes (cont&#8217;d)</span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.<span style="font-weight:bold;padding-left:26.28pt">Losses
for tax purposes carried forward to future years (cont'd)</span></span></span></span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Chemomab
Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net
operating losses. Chemomab Therapeutics Inc received $<ix:nonFraction id="Fxbrl_20230213140710654" name="cmmb:ReceivedAmountOfChemomabTherapeuticsInc" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction>
thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $<ix:nonFraction id="Fxbrl_20230213140716671" name="cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc" contextRef="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction>
thousand in 2023. Accordingly, a tax benefit in the total amount of $<ix:nonFraction id="Fxbrl_20230213140722797" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction>
thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Deferred
taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
respect of:</span></span></p>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20230201025152633" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        operating loss carry-forwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,550</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000423" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,396</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation expense</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000424" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,774</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000425" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development costs</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000426" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000427" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000428" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000429" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000430" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less
        - Valuation allowance</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000432" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000433" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction>)</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000426" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000427" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of
the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is
more likely than not that the deferred tax assets will not be realized.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing
future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance
for the year ended at December 31, 2022 was an increase of approximately $<ix:nonFraction id="Fxbrl_20230201010356964" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20220101to20221231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction>
million.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Roll
forward of valuation allowance</span></span></span></p>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20230201025212924" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20220101to20221231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at January 1, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,200</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction loss</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000439" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,425</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        assets acquired through merger</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010515039" name="cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,535</ix:nonFraction></span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000440" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,870</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction Income</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,316</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,481</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2022</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<p style="margin:0pt">&#160;</p>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;23</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note
11 - Income Taxes (cont&#8217;d)</span></span></span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Reconciliation
of theoretical income tax expense to actual income tax expense</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></p>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20230201025228669" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        before income taxes</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000447" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000448" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory
        tax rate</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical
        tax benefit</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000451" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,481</ix:nonFraction></span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000452" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,870</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in temporary differences for which deferred taxes were not recognized</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000453" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,696</ix:nonFraction></strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000454" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,332</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        rate differential</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">101</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible
        expenses</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">744</ix:nonFraction></strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses
        and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000453" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,879</ix:nonFraction></strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000454" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,064</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual
        income tax expense (Benefit)</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230219173841544" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">)</span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201011121606_Fact_0000000000454" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Accounting
for uncertainty in income taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized
tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties
related to unrecognized tax benefits as a component of income tax expense.</span></span></p> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="FFact_0000000000477" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
12 - Related Parties Balances and Transactions</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:10.28pt">Balances
with Related Parties:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The
following Related Party payables are included in the consolidated Balance Sheets:</p>

<div style="margin-left:36pt"> <ix:nonNumeric id="Fxbrl_20230207220029774" name="cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000460" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000461" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000462" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000463" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">949</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000464" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">350</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p>&#160;</p> </td> </tr>
  </table> </div> </ix:nonNumeric>

<p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On September 19, 2022, the Company entered
into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></span></p> </div>

<div><ix:exclude>

<div>

<div style="width:100%;clear:both">

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;24</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note
12 - Related Parties Balances and Transactions (cont'd)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:10.83pt">Transactions
with Related Parties:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The
following transactions with related parties are included in the consolidated Statements of Operations:</p>

<div style="margin-left:36pt;margin-bottom:0pt"> <ix:nonNumeric id="Fxbrl_20230201025305978" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000466" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000467" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,255</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000468" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,466</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000469" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000470" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000471" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000472" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000473" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000474" name="us-gaap:RelatedPartyCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,142</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000475" name="us-gaap:RelatedPartyCosts" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,310</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<div>&#160;</div> <ix:nonNumeric id="FFact_0000000000488" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20220101to20221231" escape="true">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Basic
net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares
outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to
include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and
if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share,
as the effect of potentially dilutive securities is antidilutive.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The
following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods
presented:</p>

<div style="margin-left:36pt"> <ix:nonNumeric id="Fxbrl_20230201025331788" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In
        USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000478" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average
        number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_s_20230215224008037" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230215224008037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131213429326" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000481" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share
        attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131213444247" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000482" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131213458553" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000483" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<div><ix:exclude>

<div style="width:100%;clear:both">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F
-&#160;25</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always" />

<div style="margin-top:10pt">

<table cellpadding="0" style="border-spacing:0" width="100%">
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab
        Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes
        to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr>
  <tr>
    <td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr>
  </table></div>

<p style="margin:0pt">&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
13 - Net Loss Per Share Attributable to Ordinary Shareholders (cont'd)</span></p> </ix:exclude></div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The
potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders
for the periods presented since including them would have been anti-dilutive are as follows:</p>

<div style="margin-left:36pt"> <ix:nonNumeric id="Fxbrl_20230201025347421" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number
        of shares</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options
        to purchase ordinary shares</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000485" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000486" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20230201020943165" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note
14&#160;- Subsequent Events</span></span></span></p>

<p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">On
January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20230213104715713" name="cmmb:SaleOfStockValueOfSharesIssuedInTransaction" contextRef="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>
of its ADSs.</p> </div> </ix:nonNumeric>

<p style="margin:11pt 0pt 0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F
- 26</span></span></p>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div>

<div>

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><img src="cmmb_img02.jpg" alt=" " /></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Up
to 7,614,212 American Depositary Shares</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Warrants
to Purchase 7,614,212 American Depositary Shares</span></span></span>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,614,212
American Depositary Shares Underlying the Warrants</span></span></p><hr style="height:1px;width:100%;color:#000000;background-color:#000000;margin-left:auto;margin-right:auto;border:none;text-align:center" /></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>PROSPECTUS</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Sole
Book-Running Manager</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif"><span>Oppenheimer
&amp; Co.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Manager</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:top;background-color:rgb(255, 255, 255);font-weight:bold;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:12pt;font-style:normal;font-variant:normal;text-transform:none">
        <div style="text-align:center;line-height:1.25"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif"><span>Aegis
        Capital Corp.</span></span></span></span></div></td></tr>
  </table>

<div>&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>,
2023</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Through
and including &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023 (the 25th day after
the date of this prospectus), all dealers</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>effecting
transactions in these securities, whether or not participating in this offering, may be required to</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>deliver
a prospectus. This is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>underwriter
and with respect to an unsold allotment or subscription.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>PART
II</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>INFORMATION
NOT REQUIRED IN PROSPECTUS</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Item
13. Other Expenses of Issuance and Distribution.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
following table sets forth the fees and expenses in connection with the issuance and distribution of the securities being registered (excluding
the underwriting discount). Except for the Securities and Exchange Commission registration fee and the FINRA filing fee, all amounts are
estimates.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amount
        Paid</span></span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>or to be Paid</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>SEC
        registration fee</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>3,306</span></span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>FINRA
        filing fee</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>3,500</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Legal
        fees and expenses&#160;(including underwriters' legal fees)</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>235,000</span></span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Accounting
        fees and expenses</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>45,710</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Printing
        expenses</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>15,000</span></span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Depositary and
        transfer agent fees and expenses</span></span></span></div></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>152,280</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);padding-bottom:2px;width:86%" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Miscellaneous</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:11%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>10,000</span></span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:86%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Total</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:11%;background-color:rgb(255, 255, 255);white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>464,796</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Item
14. Indemnification of Directors and Officers.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Under
the Israeli Companies Law, 5759-1999, or the Companies Law, a company may not exculpate an office holder from liability for a breach of
the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability, in whole or in part, for damages caused
as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association.
Our amended and restated articles of association contain such a provision.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>An
Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event provided
that a provision authorizing such indemnification is inserted in its articles of association. Our amended and restated articles of association
contain such a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a financial
liability imposed on him or her in favor of another person pursuant to a judgment, settlement or arbitrator&#8217;s award approved by
a court must be limited to events which in the opinion of the Board of Directors can be foreseen based on the company&#8217;s activities
when the undertaking to indemnify is given, and to an amount or a criteria determined by the Board of Directors as reasonable under the
circumstances, and such undertaking must detail the abovementioned events and amount or criteria.</span></span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In
addition, a company may indemnify an office holder against the following liabilities incurred for acts performed as an office holder:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>reasonable litigation
        expenses, including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against
        him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such
        office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty (as defined
        in the Companies Law), was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding
        or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent
        or in connection with a monetary sanction;</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>reasonable litigation
        expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against him
        or her by the company, on its behalf or by a third party, or (ii) in connection with criminal proceedings in which the office holder was
        acquitted, or (iii) as a result of a conviction for a crime that does not require proof of criminal intent;</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 1</span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a financial liability
        imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by
        a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an
        undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities
        when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable
        under the circumstances, and such undertaking shall detail the abovementioned events and amount or criteria; and</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>expenses, including
        reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against
        such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding,
        pursuant to certain provisions of the Israeli Securities Law.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>An
Israeli company may insure a director or officer against the following liabilities incurred for acts performed as a director or officer:</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a breach of duty
        of care to the company or to a third party, including a breach arising out of the negligent conduct of an office holder;</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a breach of duty
        of loyalty to the company, provided the director or officer acted in good faith and had a reasonable basis to believe that the act would
        not prejudice the interests of the company;</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>financial liabilities imposed on the office
        holder for the benefit of a third party;</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>financial liabilities
        imposed in an administrative proceeding on the office holder in favor of a third party harmed by a breach, pursuant to certain provisions
        of the Israeli Securities Law; and</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>expenses, including
        reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against
        him or her, pursuant to certain provisions of the Israeli Securities Law.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>An
Israeli company may not, however, indemnify or insure an office holder against any of the following:</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a breach of duty
        of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not
        prejudice the company;</span></span></span></div></td></tr>
  </table>

<div style="text-indent:-27pt;margin-left:27pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a breach of duty
        of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></span></span></div></td></tr>
  </table>

<div style="text-indent:-27pt;margin-left:27pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>an act or omission committed with intent
        to derive unlawful personal benefit; or</span></span></span></div></td></tr>
  </table>

<div style="text-indent:-27pt;margin-left:27pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#8226;</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a fine, monetary sanction, penalty or forfeit
        levied against the office holder.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Under
the Companies Law, exculpation, indemnification and insurance of office holders must be approved by our compensation committee, our Board
of Directors and, in certain circumstances, by our shareholders. We have obtained directors&#8217; and officers&#8217; liability insurance
for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest
extent permitted by the Companies Law. In addition, we have entered into indemnification agreements with each of our directors providing
them with indemnification for liabilities or expenses incurred as a result of acts performed by them in their capacity as our, or our
subsidiaries&#8217;, directors and officers. This indemnification is limited both in terms of amount and coverage and it covers certain
amounts regarding administrative proceedings insurable or indemnifiable under the Companies Law and our amended and restated articles
of association. In the opinion of the U.S. Securities and Exchange Commission, however, indemnification of directors and office holders
for liabilities arising under the U.S.&#160;Securities Act of 1933, as amended, or the&#160;Securities Act, is against public policy and
therefore unenforceable.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 2</span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:left;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Item
15. Recent Sales of Unregistered Securities</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
following is a summary of transactions during the preceding three fiscal years involving sales of our securities that were not registered
under the Securities Act:</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In
connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant
to which the Company agreed to sell approximately USD $45.5 million of its ADSs in a private placement transaction (&#8220;The Private
Placement&#8221;). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together
with warrants to purchase up to 261,929 ADSs at an exercise price of USD $17.35088 per ADS. The warrants will expire five years from the
date of issuance, and if exercised in full, will provide to the Company proceeds of approximately USD $4.5 million.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:left;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item
16. Exhibits and Financial Statement Schedules.</span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-align:left;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)
Exhibits</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:8%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit
        No.</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:90%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_1-1.htm">1.1**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_1-1.htm">Form
        of Underwriting Agreement</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">3.1</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended
        and Restated Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s current report on Form 8-K filed
        with the SEC on March 17, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">4.1**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">Form
        of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics Ltd.), the Bank of New York Mellon as Depositary,
        and owners and holders from time to time of ADSs issued by the Company, dated February 14, 2019 (incorporated by reference to Exhibit
        4.1 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_4-2.htm">4.2**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_4-2.htm">Form
        of Warrant</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-1.htm">5.1**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-1.htm">Opinion
        of Meitar | Law Offices, Israeli counsel to the registrant</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">5.2**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">Opinion
        of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C., U.S. counsel to the registrant</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">10.1+</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">Form
        of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement
        on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">10.2+</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">Compensation
        Policy for Officers and Directors (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s annual report on Form 10-K filed
        with the SEC on March 30, 2022)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">10.3+</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">2011
        Incentive Plan for Employees, Officers and Consultants (previously filed as Exhibit 10.6 of our Registration Statement on Form F-1 (File
        No. 333-229155) as filed with the SEC on January 7, 2019 and incorporated by reference herein)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">10.4+</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">2017
        Equity-Based Incentive Plan (previously filed as Exhibit 10.8 of our Registration Statement on Form F-1 (File No. 333-229155) as filed
        with the SEC on January 7, 2019 and incorporated by reference herein)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">10.5+</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab
        Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4
        (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">10.6&#8734;</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">Tel-Aviv
        Souraski Medical Center (TASMC) License Agreement between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund
        of the Tel Aviv Souraski Medical Center., dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">10.7&#8734;</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">CMC
        Collaboration Agreement between Chemomab Ltd. and CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">10.8</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">Controlled
        Equity Offering SM Sales Agreement, dated April 30, 2021, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by
        reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on
        April 30, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">10.9**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">Employment
        Agreement, dated September 1, 2021, by and between Chemomab Therapeutics, Inc. and Dale Pfost (incorporated by reference to Exhibit 10.9
        to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">10.10**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">Employment
        Agreement, dated November 8, 2021, by and between Chemomab Therapeutics, Inc. and Donald Marvin (incorporated by reference to Exhibit
        10.10 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">10.11**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">Consulting
        Agreement, dated April 18, 2022, by and between Chemomab Ltd. and Dr. Adi Mor (incorporated by reference to Exhibit 10.11 to the Registrants
        registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_21-1.htm">21.1**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_21-1.htm">List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Registrants registration statement on Form S-1 filed with the SEC on
        January 13, 2023)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm">23.1*</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm">Consent of Somekh Chaikin, member firm of KPMG International, independent registered public accounting firm</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-1.htm">23.2**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-1.htm">Consent
        of Meitar | Law Offices, Israeli counsel to the registrant (included in Exhibit 5.1)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">23.3**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">Consent of Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C., U.S. counsel to the registrant (included in Exhibit 5.2)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#signatures_integixAnchor">24.1**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top">&#160;</td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#signatures_integixAnchor">Power
        of Attorney (included in the signature page of the Registration Statement)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_107.htm">107**</a></span></span></div></td>
    <td style="width:2%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_107.htm">Filing
        Fee Table</a></span></span></div></td></tr>
  <tr>
    <td colspan="3" rowspan="1" style="vertical-align:top">&#160;</td></tr>
  <tr>
    <td colspan="3" style="vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*&#160;&#160; Filed herewith</span></span></div></td></tr>
  <tr>
    <td colspan="3" style="vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">** Previously filed</span></span></div></td></tr>
  <tr>
    <td colspan="3" style="vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">+&#160;&#160; Indicates
        management contract or compensatory plan</span></span></div></td></tr>
  <tr>
    <td colspan="3" style="vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8734; &#160; Portions
        of this Exhibit (indicated with [***]) have been omitted as the Registrant has determined that (i) the omitted information is not material
        and (ii) the omitted information would likely cause competitive harm to the Registrant if publicly disclosed</span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">II
- 3</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:left;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(b)
Financial Statement Schedules</span></span></span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>All financial statement
schedules have been omitted because they are not required or because the required information is given in the financial statements or
notes to those statements.</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-align:left;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Item
17. Undertakings.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Insofar as indemnification
for liabilities arising under the&#160;Securities Act&#160;may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the&#160;Securities Act&#160;and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the&#160;Securities Act&#160;and will be governed by the final adjudication of such issue.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The undersigned
registrant hereby undertakes:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>To file, during any period in which offers
        or sales are being made, a post-effective amendment to this registration statement:</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>To include any prospectus required by Section
        10(a)(3) of the Securities Act;</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>b.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>To reflect in the prospectus any facts or
        events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
        or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
        any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
        was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
        filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in
        the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration
        statement; and</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>c.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>To include any material information with
        respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
        in the registration statement.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>provided, however,
that paragraphs (1)(a), (b) and (c) of this section do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d)
of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 4</span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>That, for the purpose of determining any
        liability under the&#160;Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
        to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
        thereof.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>3.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>To remove from registration by means of
        a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>4.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>That, for the purpose of determining liability
        under the&#160;Securities Act&#160;to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement
        relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule
        430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
        however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
        incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
        will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
        registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
        date of first use.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>That, for the purpose of determining liability
        of the registrant under the&#160;Securities Act&#160;to any purchaser in the initial distribution of the securities, the undersigned registrant
        undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
        of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means
        of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or
        sell such securities to such purchaser.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>a.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Any free writing prospectus relating to
        the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>b.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The portion of any other free writing prospectus
        relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of
        the undersigned registrant; and</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.25pt">&#160;</td>
    <td style="width:27pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>c.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Any other communication that is an offer
        in the offering made by the undersigned registrant to the purchaser.</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 5</span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span id="signatures_integixAnchor"></span> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>SIGNATURES</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to the
requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Tel-Aviv, Israel, on February 22, 2023.</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="2" style="width:50.11%;vertical-align:top">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>CHEMOMAB
        THERAPEUTICS LTD.</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.2%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.91%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.2%;vertical-align:bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>By:</span></span></span></div></td>
    <td style="width:46.91%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>/s/ Dale Pfost</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.91%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Dale Pfost</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.91%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chairman of the
        Board,</span></span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chief Executive
        Officer</span></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div>

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the
registrant in the capacities and on the dates indicated.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Signature</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ <span style="font-style:italic">Dale
        Pfost</span></span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chairman
        of the Board and</span></span></div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Executive Officer</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dale Pfost</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Executive Officer)</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ <span style="font-style:italic">Donald
        Marvin</span></span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Financial Officer, Executive Vice President and Chief Operating Officer</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Donald Marvin</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Financial and Accounting Officer)</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adi Mor</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nissim Darvish</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Alan Moses</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Claude Nicaise</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></p></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Neil Cohen</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February
        22, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Jill M. Quigley</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:2.01%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">&#160;</td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ <span style="font-style:italic">Dale
        Pfost</span></span></span></div></td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dale Pfost</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:32%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Attorney in Fact</span></span></div></td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td>
    <td style="width:2.01%;vertical-align:top">&#160;</td>
    <td style="width:32%;vertical-align:bottom">&#160;</td></tr>
  </table></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 6</span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;AUTHORIZED
REPRESENTATIVE</span></span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant
to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States
of Chemomab Therapeutics Ltd., has signed this registration statement on February 22, 2023.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="2" style="width:50.11%;vertical-align:top">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>CHEMOMAB
        THERAPEUTICS, INC.</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.21%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.9%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.21%;vertical-align:bottom">
        <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>By:</span></span></span></div></td>
    <td style="width:46.9%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>/s/ Dale Pfost</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.21%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.9%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Dale Pfost</span></span></span></div></td></tr>
  <tr>
    <td style="width:49.89%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3.21%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:46.9%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>President</span></span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25">

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:normal;font-style:normal">II
- 7</span></span></span></span><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;margin-left:auto;margin-right:auto;text-align:center" /></div></div></div></div></div>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 23.1</u></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Board of Directors<br>
        Chemomab Therapeutics Ltd.:</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We consent to the use of our report dated February 20, 2023, with respect to the consolidated financial statements of Chemomab
        Therapeutics Ltd., included herein&#160;and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">/s/ Somekh Chaikin</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Somekh Chaikin</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Member Firm of KPMG International</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Tel Aviv, Israel</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">February 21, 2023</div>
      <div style="line-height: 1.25;">&#160;<br style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cmmb-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cmmb="http://www.anchiano.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.anchiano.com/20221231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>0004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>0005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0006 - Statement - Statements of Cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General" id="General">
        <link:definition>0007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
        <link:definition>0009 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses" id="OtherReceivablesAndPrepaidExpenses">
        <link:definition>0010 - Disclosure - Other Receivables and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>0011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/Leases" id="Leases">
        <link:definition>0012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
        <link:definition>0013 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0014 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopment" id="ResearchAndDevelopment">
        <link:definition>0015 - Disclosure - Research and Development</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrative" id="GeneralAndAdministrative">
        <link:definition>0016 - Disclosure - General and Administrative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
        <link:definition>0018 - Disclosure - Related Parties Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders" id="NetLossPerShareAttributableToOrdinaryShareholders">
        <link:definition>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDate" id="EventsAfterBalanceSheetDate">
        <link:definition>0020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralTables" id="GeneralTables">
        <link:definition>0022 - Disclosure - General (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
        <link:definition>0024 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables" id="OtherReceivablesAndPrepaidExpensesTables">
        <link:definition>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>0026 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>0028 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables" id="ResearchAndDevelopmentTables">
        <link:definition>0029 - Disclosure - Research and Development (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables" id="GeneralAndAdministrativeTables">
        <link:definition>0030 - Disclosure - General and Administrative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>0031 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables" id="RelatedPartiesBalancesAndTransactionsTables">
        <link:definition>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables" id="NetLossPerShareAttributableToOrdinaryShareholdersTables">
        <link:definition>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralDetails" id="GeneralDetails">
        <link:definition>0034 - Disclosure - General (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" id="GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
        <link:definition>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
        <link:definition>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
        <link:definition>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails" id="OtherReceivablesAndPrepaidExpensesDetails">
        <link:definition>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>0041 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" id="LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
        <link:definition>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails" id="CommitmentsAndContingentLiabilitiesDetails">
        <link:definition>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>0044 - Disclosure - Share Capital (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails" id="ShareCapitalShare-basedCompensationExpensesDetails">
        <link:definition>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" id="ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
        <link:definition>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" id="ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
        <link:definition>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" id="ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
        <link:definition>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" id="GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
        <link:definition>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0050 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" id="IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
        <link:definition>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" id="IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
        <link:definition>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" id="IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
        <link:definition>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
        <link:definition>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
        <link:definition>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
        <link:definition>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
        <link:definition>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails" id="EventsAfterBalanceSheetDateNarrativeDetails">
        <link:definition>0058 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AdditionalWorkOrderAmount" id="cmmb_AdditionalWorkOrderAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateAmountCommitmentToPay" id="cmmb_AggregateAmountCommitmentToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateAmountOfCommitmentPaid" id="cmmb_AggregateAmountOfCommitmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateOfferingPriceOfAtMarketOfferingAgreement" id="cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmericanDepositarySharesMember" id="cmmb_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRatesOfDepreciation" id="cmmb_AnnualRatesOfDepreciation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRentAndManagementFees" id="cmmb_AnnualRentAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtmAgreementMember" id="cmmb_AtmAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuaranteesToPropertyOwner" id="cmmb_BankGuaranteesToPropertyOwner" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CantorMember" id="cmmb_CantorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalAdditionsOneMember" id="cmmb_CapitalAdditionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashAcquiredInMerger" id="cmmb_CashAcquiredInMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidAndReceivedDuringYearForAbstract" id="cmmb_CashPaidAndReceivedDuringYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" id="cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConsultantsAndSubcontractorsExpense" id="cmmb_ConsultantsAndSubcontractorsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CumulativeAmountsOfGrantsReceivedAndRecognized" id="cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrencyTransactionLossValuationAllowance" id="cmmb_CurrencyTransactionLossValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" id="cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EarningsPerShareCalculationNumeratorAbstract" id="cmmb_EarningsPerShareCalculationNumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfReverseCapitalizationTransaction" id="cmmb_EffectOfReverseCapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EffectOfReverseCapitalizationTransactionShares" id="cmmb_EffectOfReverseCapitalizationTransactionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfNetAssetsAcquired" id="cmmb_EstimatedFairValueOfNetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExpectsToReceiveAmountOfChemomabTherapeuticsInc" id="cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FinanceIncomeExpensesNet" id="cmmb_FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FormerChemomabSecurityHoldersMember" id="cmmb_FormerChemomabSecurityHoldersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralAndAdministrativeDisclosureTextBlock" id="cmmb_GeneralAndAdministrativeDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" id="cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureLineItems" id="cmmb_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureTable" id="cmmb_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncomeTaxesReceived" id="cmmb_IncomeTaxesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxExpenseValuationAllowance" id="cmmb_IncomeTaxExpenseValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalBorrowingRateOfLeases" id="cmmb_IncrementalBorrowingRateOfLeases" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestReceived" id="cmmb_InterestReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InvestorsMember" id="cmmb_InvestorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="cmmb_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LienOnBankDeposit" id="cmmb_LienOnBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermLeaseDeposit" id="cmmb_LongTermLeaseDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" id="cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaximumPercentageOfPaymentsOfRoyalties" id="cmmb_MaximumPercentageOfPaymentsOfRoyalties" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" id="cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsDisclosureAbstract" id="cmmb_NatureOfOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdsIssuedAndOutstandingAfterMerger" id="cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssOptionsIssuableOutstanding" id="cmmb_NumberOfAdssOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssVestedAndExercisable" id="cmmb_NumberOfAdssVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsIssuableOutstanding" id="cmmb_NumberOfOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsVestedAndExercisable" id="cmmb_NumberOfOptionsVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesConsistedInDs" id="cmmb_NumberOfOrdinarySharesConsistedInDs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockAdssResveredForIssuance" id="cmmb_NumberOfStockAdssResveredForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockReservedForIssuance" id="cmmb_NumberOfStockReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfVestedAndExercisable" id="cmmb_NumberOfVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsPurchaseUpAdss" id="cmmb_NumberOfWarrantsPurchaseUpAdss" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" id="cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" id="cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsForInvestmentInDeposits" id="cmmb_PaymentsForInvestmentInDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfMonthlyDepositsRate" id="cmmb_PercentageOfMonthlyDepositsRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltyPaymentsOnSaleOfProduct" id="cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromSaleOfAdss" id="cmmb_ProceedsFromSaleOfAdss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivablesFromGovernmentInstitutions" id="cmmb_ReceivablesFromGovernmentInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivedAmountOfChemomabTherapeuticsInc" id="cmmb_ReceivedAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecoverabilityOfVatAmount" id="cmmb_RecoverabilityOfVatAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RelatedPartyMember" id="cmmb_RelatedPartyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceGeneralAndAdministrativeExpense" id="cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceResearchAndDevelopmentExpense" id="cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepurchaseArrangementMember" id="cmmb_RepurchaseArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RepurchaseOfAmericanDepositaryReceipts" id="cmmb_RepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepurchaseOfAmericanDepositaryReceiptsShares" id="cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockLineItems" id="cmmb_SaleOfStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStocksPricePerShare" id="cmmb_SaleOfStocksPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockTable" id="cmmb_SaleOfStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SaleOfStockValueOfSharesIssuedInTransaction" id="cmmb_SaleOfStockValueOfSharesIssuedInTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ScheduleOfAnnualRateOfDeprecationTableTextBlock" id="cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfGeneralAndAdministrativeTableTextBlock" id="cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" id="cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyPayablesTableTextBlock" id="cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfResearchAndDevelopmentTableTextBlock" id="cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" id="cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayPolicyTextBlock" id="cmmb_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationGeneralAndAdministrativeExpense" id="cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationResearchAndDevelopmentExpense" id="cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareholdingPercentageImmediatelyFollowingMerger" id="cmmb_ShareholdingPercentageImmediatelyFollowingMerger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" id="cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsExercised1" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAssetsAcquiredThroughMergerValuationAllowance" id="cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TwoThousandsFifteenPlanMember" id="cmmb_TwoThousandsFifteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandsSeventeenPlanMember" id="cmmb_TwoThousandsSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>cmmb-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_TreasuryStockValue_22" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingExpenses_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_18"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_10" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_LongTermLeaseDeposit_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_cmmb_CashAcquiredInMerger_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_18" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_ProfessionalFees_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>cmmb-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDateNarrativeDetails" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_49"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentType_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFileNumber_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityRegistrantName_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_22" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCountry_23" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_24" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CityAreaCode_25" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_26" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_27" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_Security12bTitle_28" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_TradingSymbol_29" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SecurityExchangeName_30" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_31" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_32" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_33" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_34" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFilerCategory_35" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_36" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_37" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_38" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_39" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityShellCompany_40" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityPublicFloat_41" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_42" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorName_43" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorLocation_44" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorFirmId_45" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_WrittenCommunications_46" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SolicitingMaterial_47" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementTenderOffer_48" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_49" order="430" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_TreasuryStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cmmb_LaboratoryEquipmentMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_AnnualRentAndManagementFees_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_15" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_EUR_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_ILS_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_15" xlink:to="loc_srt_ScenarioForecastMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsDescription_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_26" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_28" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_29" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_30" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_31" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_LienOnBankDeposit_32" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RestrictedInvestments_33" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_34" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_46"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_InvestorsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_PrivatePlacementMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_AtmAgreementMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_RepurchaseArrangementMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_39" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_42" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_43" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_44" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_45" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_46" order="250" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" order="80" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_srt_RangeAxis_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_us-gaap_AwardTypeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_US_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10" xlink:to="loc_us-gaap_DomesticCountryMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4" order="30" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_cmmb_RelatedPartyMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_6" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cmmb-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_56"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_57"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_67"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_68"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_69"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_70"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_71"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_78"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_79"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_80"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_81"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_82"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_83"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_84"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_85"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_86"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_87"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_88"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_89"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_90"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_91"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_92"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_93"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_94"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_95"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_96"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_97"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_98"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_99"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_100"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_101"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_102"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_103"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_107"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_108"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_109"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_110"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_111"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_112"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_113"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_114"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_115"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_116"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_117"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_118"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_119"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_120"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_121"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_122"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_123"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_124"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_125"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_126"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_127"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_128"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_129"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_130"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_131"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_132"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_133"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_134"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_135"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_136"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_137"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_138"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_139"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_140"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_141"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_142"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_143"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_144"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_145"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_146"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_147"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_148"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_149"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_150"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_151"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_152"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_153"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_154"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_155"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_156"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_157"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_158"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_159"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_160"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_161"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_162"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_163"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_164"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_165"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_166"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_167"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_168"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_169"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_170"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_171"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_172"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_173"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_174"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_175"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_176"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_177"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_178"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_179"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_180"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_181"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_182"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_183"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_184"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_185"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_186"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_187"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_188"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_189"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_190"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_191"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_192"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_193"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_194"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_195"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_196"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_197"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_198"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_199"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_200"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_201"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_202"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_203"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_204"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_205"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_206"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_207"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_208"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_209"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_210"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_211"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_212"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_213"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_214"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_215"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_216"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_217"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_218"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_219"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_220"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_221"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_222"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_223"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_224"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_225"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_227"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_228"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_230"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_231"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_232"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_233"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_234"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_235"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_236"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_237"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_238"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_239"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_240"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_241"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_242"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_243"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_244"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_245"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_246"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_247"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_248"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_249"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_250"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_251"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_252"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_253"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_254"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_255"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_256"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_257"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_258"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_259"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_260"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_261"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_262"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_263"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_264"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_265"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_266"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_267"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_268"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_269"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_270"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_271"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_272"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_273"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_274"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_275"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_276"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_277"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_278"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_279"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_280"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_746"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_0" xml:lang="en-US">Additional work order amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_1" xml:lang="en-US">Additional Work Order Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_2" xml:lang="en-US">Additional work order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_0" xml:lang="en-US">Aggregate amount commitment to pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_1" xml:lang="en-US">Aggregate amount commitment to pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_0" xml:lang="en-US">Aggregate amount of commitment paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_1" xml:lang="en-US">Aggregate amount of commitment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0" xml:lang="en-US">It represents as a aggregate offering price of at the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1" xml:lang="en-US">Aggregate Offering Price Of At Market Offering Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2" xml:lang="en-US">Aggregate offering price of at the market offering agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositarySharesMember_0" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_0" xml:lang="en-US">Annual rates of depreciation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_1" xml:lang="en-US">Annual Rates Of Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_2" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRentAndManagementFees_0" xml:lang="en-US">Annual rent and management fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRentAndManagementFees_1" xml:lang="en-US">Annual rent and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AtmAgreementMember_0" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AtmAgreementMember_1" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_0" xml:lang="en-US">Bank guarantees to property owner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_1" xml:lang="en-US">Bank guarantees to property owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0" xml:lang="en-US">The amount of of asset held for sale recogized prior to the completion of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" xml:lang="en-US">Asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0" xml:lang="en-US">Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CantorMember_0" xml:lang="en-US">Represents about Cantor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CantorMember_1" xml:lang="en-US">Cantor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CapitalAdditionsOneMember_0" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CapitalAdditionsOneMember_1" xml:lang="en-US">Capital Additions One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CapitalAdditionsOneMember_2" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashAcquiredInMerger_0" xml:lang="en-US">Cash acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashAcquiredInMerger_1" xml:lang="en-US">Cash acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1" xml:lang="en-US">Cash Paid And Received During Year For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2" xml:lang="en-US">A. Cash paid and received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0" xml:lang="en-US">It represents as a change in temporary differences for which deferred taxes were not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1" xml:lang="en-US">Change In Temporary Differences For Deferred Taxes Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2" xml:lang="en-US">Change in temporary differences for which deferred taxes were not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_0" xml:lang="en-US">Consultants and subcontractors expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_1" xml:lang="en-US">Consultants And Subcontractors Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_2" xml:lang="en-US">Consultants and subcontractors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0" xml:lang="en-US">The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1" xml:lang="en-US">Cumulative Amounts Of Grants Received And Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2" xml:lang="en-US">Cumulative amounts of grants received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_1" xml:lang="en-US">Currency Transaction Loss Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_2" xml:lang="en-US">Currency transaction income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Numerator Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_0" xml:lang="en-US">The amount of effect due reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_1" xml:lang="en-US">Effect of reverse capitalization transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0" xml:lang="en-US">The number of shares isued due to effect of reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1" xml:lang="en-US">Effect Of Reverse Capitalization Transaction Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2" xml:lang="en-US">Effect of reverse capitalization transaction (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xml:lang="en-US">The amount of estimated fair value of the net assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1" xml:lang="en-US">Estimated Fair Value Of Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2" xml:lang="en-US">Net acquired assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The amount expects to receive of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Expects To Receive Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Expects to receive amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_0" xml:lang="en-US">The net amount of finance income earned and finance expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_1" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_2" xml:lang="en-US">Finance Income (Expenses), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_0" xml:lang="en-US">This represents former Chemomab security holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_1" xml:lang="en-US">Former Chemomab Security Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0" xml:lang="en-US">The entire disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" xml:lang="en-US">General And Administrative Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2" xml:lang="en-US">General and Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1" xml:lang="en-US">Government Sponsored Research And Development [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2" xml:lang="en-US">Government-sponsored research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_1" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_0" xml:lang="en-US">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_1" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxesReceived_0" xml:lang="en-US">It represents income taxes received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxesReceived_1" xml:lang="en-US">Income Taxes Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxesReceived_2" xml:lang="en-US">Income taxes received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to income tax expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_1" xml:lang="en-US">Income Tax Expense Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_2" xml:lang="en-US">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_0" xml:lang="en-US">It represents incremental borrowing rate of leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_1" xml:lang="en-US">Incremental Borrowing Rate Of Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_2" xml:lang="en-US">incremental borrowing rate of leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InterestReceived_0" xml:lang="en-US">The amount of interest received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InterestReceived_1" xml:lang="en-US">Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_InterestReceived_2" xml:lang="en-US">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InvestorsMember_0" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InvestorsMember_1" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LienOnBankDeposit_0" xml:lang="en-US">Lien on bank deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LienOnBankDeposit_1" xml:lang="en-US">Lien on bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LongTermLeaseDeposit_0" xml:lang="en-US">Long-term lease deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LongTermLeaseDeposit_1" xml:lang="en-US">Long Term Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_LongTermLeaseDeposit_2" xml:lang="en-US">Long-term lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0" xml:lang="en-US">Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1" xml:lang="en-US">Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0" xml:lang="en-US">The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1" xml:lang="en-US">Maximum Percentage Of Payments Of Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2" xml:lang="en-US">Maximum percentage of payments of royalties (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0" xml:lang="en-US">This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" xml:lang="en-US">Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2" xml:lang="en-US">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_0" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_1" xml:lang="en-US">Nature Of Operations Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_2" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0" xml:lang="en-US">Number of ADS issued and outstanding after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1" xml:lang="en-US">Number of ADS issued and outstanding after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0" xml:lang="en-US">Number of ADSs options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1" xml:lang="en-US">Number of ADSs options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_0" xml:lang="en-US">Number of ADSs vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_1" xml:lang="en-US">Number of ADSs vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_0" xml:lang="en-US">It represents number of options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_1" xml:lang="en-US">Number Of Options Issuable Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_2" xml:lang="en-US">Number of options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_0" xml:lang="en-US">It represents number of options vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_1" xml:lang="en-US">Number Of Options Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_2" xml:lang="en-US">Number of options vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0" xml:lang="en-US">Represent the number of ordinary shares consisted in one American depository share (ADS).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1" xml:lang="en-US">Number Of Ordinary Shares Consisted In Ds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2" xml:lang="en-US">Number of ordinary shares represented by each ADS (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_0" xml:lang="en-US">Number of stock option ADSs resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_1" xml:lang="en-US">Number Of Stock Adss Resvered For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_2" xml:lang="en-US">Number of stock option ADSs reversed for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_0" xml:lang="en-US">It represents number of stock resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_1" xml:lang="en-US">Number Of Stock Reserved For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_2" xml:lang="en-US">Number of stock reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_0" xml:lang="en-US">It represents number of vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_1" xml:lang="en-US">Number Of Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_2" xml:lang="en-US">Number of vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0" xml:lang="en-US">Number of warrants purchase ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1" xml:lang="en-US">Number Of Warrants Purchase Up Adss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2" xml:lang="en-US">Number of warrants purchase ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1" xml:lang="en-US">Operating Right Of Use Assets And Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">Other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">Other Receivables and Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0" xml:lang="en-US">Payment on commencement of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1" xml:lang="en-US">Payment On Long Term Purchase Commitment Commencement Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2" xml:lang="en-US">Payment on commencement of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_0" xml:lang="en-US">The amount of payments for investm,ents in deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_1" xml:lang="en-US">Investment in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_2" xml:lang="en-US">Payments for Investment in Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_0" xml:lang="en-US">Percentage of monthly deposits rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_1" xml:lang="en-US">Percentage of monthly deposits rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0" xml:lang="en-US">The percentage of royalty payments on sale of product developed with funding received from the IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1" xml:lang="en-US">Percentage Of Royalty Payments On Sale Of Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2" xml:lang="en-US">Royalty payments on sale of product (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_0" xml:lang="en-US">Proceeds from sale of ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_1" xml:lang="en-US">Proceeds from sale of ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_0" xml:lang="en-US">Government institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_1" xml:lang="en-US">Receivables From Government Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_2" xml:lang="en-US">Government institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The received amount of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Received Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Received amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_0" xml:lang="en-US">It represents recoverability of VAT amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_1" xml:lang="en-US">Recoverability Of Vat Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_2" xml:lang="en-US">Recoverability of VAT amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyMember_0" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyMember_1" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to professional services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Professional Services From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to research and develeopment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Research And Development Expense From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to salaries and related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Salaries And Related Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Share Based Payments From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" xml:lang="en-US">Share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1" xml:lang="en-US">Rent And Maintenance General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1" xml:lang="en-US">Rent And Maintenance Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseArrangementMember_0" xml:lang="en-US">This member stands for Repurchase Arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseArrangementMember_1" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseArrangementMember_2" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">Represents the amount of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0" xml:lang="en-US">It represents repurchase of American Depositary Receipts shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1" xml:lang="en-US">Repurchase Of American Depositary Receipts Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2" xml:lang="en-US">Number of shares repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockLineItems_1" xml:lang="en-US">Sale Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_0" xml:lang="en-US">Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_1" xml:lang="en-US">Sale Of Stocks Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_2" xml:lang="en-US">Share price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockTable_0" xml:lang="en-US">Different names of stock transactions and the different attributes of each transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockTable_1" xml:lang="en-US">Sale Of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0" xml:lang="en-US">Represents the amount of sale of stock value of shares issued in transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1" xml:lang="en-US">Sale Of Stock Value Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2" xml:lang="en-US">Issuance and sale of of ADS upto</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rate of deprecation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" xml:lang="en-US">Schedule Of Annual Rate Of Deprecation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2" xml:lang="en-US">Schedule of annual rate of deprecation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" xml:lang="en-US">Schedule Of General And Administrative [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2" xml:lang="en-US">Schedule of general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Payables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2" xml:lang="en-US">Schedule of related party payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0" xml:lang="en-US">Tabular disclosure of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" xml:lang="en-US">Schedule Of Research And Development [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2" xml:lang="en-US">Schedule of research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0" xml:lang="en-US">This represents security holders of Anchiano as of immediately prior to the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1" xml:lang="en-US">Security holders of Anchiano as of immediately prior to the merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2" xml:lang="en-US">Options to purchase ordinary shares cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise price of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average price of shares acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1" xml:lang="en-US">Share Based Compensation General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1" xml:lang="en-US">Share Based Compensation Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0" xml:lang="en-US">shareholding percentage immediately following the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1" xml:lang="en-US">Shareholding percentage immediately following the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0" xml:lang="en-US">it represents number of shares and warrants issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0" xml:lang="en-US">Number of new stocks of American Depository Shares ("ADS") issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1" xml:lang="en-US">Stock Issued During Period American Depository Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2" xml:lang="en-US">Number of ADSs issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0" xml:lang="en-US">Number of options acquired, including both vested and non-vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Acquired In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1" xml:lang="en-US">Tax Assets Acquired Through Merger Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2" xml:lang="en-US">Tax assets acquired through merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents Total consideration of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Total Consideration Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Total consideration of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_0" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_1" xml:lang="en-US">Two Thousands Fifteen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_2" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_0" xml:lang="en-US">2017 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_1" xml:lang="en-US">Two Thousands Seventeen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_2" xml:lang="en-US">2017 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents weighted average price of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Weighted Average Price Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Weighted average price of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Less - accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Balance at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Balance at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Change in other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less imputed interest:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Financing (income) expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Options to purchase ADS cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue_0" xml:lang="en-US">Treasury share at cost (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue_1" xml:lang="en-US">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockValue_2" xml:lang="en-US">Treasury stock (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes on income (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Actual income tax expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">U.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR_0" xml:lang="en-US">Euro [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_ILS_0" xml:lang="en-US">ILS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_ILS_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD_0" xml:lang="en-US">USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_XXX_0" xml:lang="en-US">Other currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems_0" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable_0" xml:lang="en-US">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName_0" xml:lang="en-US">Entity Information, Former Legal or Registered Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementTenderOffer_0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SolicitingMaterial_0" xml:lang="en-US">Soliciting Material</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_WrittenCommunications_0" xml:lang="en-US">Written Communications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis_0" xml:lang="en-US">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember_0" xml:lang="en-US">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain_0" xml:lang="en-US">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0" xml:lang="en-US">Recognized liability for royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments for operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Outstanding options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalAdditionsMember_0" xml:lang="en-US">New Drug Application and Biological License Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0" xml:lang="en-US">Deferred taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0" xml:lang="en-US">Incremental borrowing rate based on credit rating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Short-term bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_0" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_1" xml:lang="en-US">Related Party Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Net Loss Per Share Attributable to Ordinary Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Corporate tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair value of financial instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0" xml:lang="en-US">Furniture and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US">Furniture and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralInsuranceExpense_0" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0" xml:lang="en-US">Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Tax rate differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Theoretical tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-deductible expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Change in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Change in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Change in employees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Change in leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Change in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember_0" xml:lang="en-US">2020 Lien [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1_0" xml:lang="en-US">Lease expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_1" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturity of lease liabilities under our non-cancelable operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1" xml:lang="en-US">Lease term, option to extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1_0" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1_1" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_0" xml:lang="en-US">Payment for licensed agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentDescription_0" xml:lang="en-US">Description of application payment for licensed product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">General</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">B. Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees_0" xml:lang="en-US">Fees to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0" xml:lang="en-US">Decrease in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_1" xml:lang="en-US">Increase in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Operating Lease, Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Non-current operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Non-current&#160;operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription_0" xml:lang="en-US">Decsription of occurrence for payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense_0" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred shares par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">The Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_0" xml:lang="en-US">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_1" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0" xml:lang="en-US">Sale of asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0" xml:lang="en-US">Proceeds from Sale of Treasury Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1" xml:lang="en-US">Treasury stock at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equpment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyCosts_0" xml:lang="en-US">Related Party Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RelatedPartyCosts_1" xml:lang="en-US">Total related party expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Parties Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research and Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent_0" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestments_0" xml:lang="en-US">Bank restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_0" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royality expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesAndWages_0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalariesAndWages_1" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0" xml:lang="en-US">Schedule of components of cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Summary of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Significant Components of the Company's Deferred Tax Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of significant components of the company's deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of computation of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule of net assets acquired based on their estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Transaction With Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of transaction with related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Summary of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0" xml:lang="en-US">Summary of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Exercise price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life of options (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Weighted average share price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_0" xml:lang="en-US">Website Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_1" xml:lang="en-US">Website development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Shareholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0" xml:lang="en-US">Reverse stock split conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercise of Options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1" xml:lang="en-US">Treasury share at cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1" xml:lang="en-US">Treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Events After Balance Sheet Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Schedule of Roll Forward of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of roll forward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplementary cash flows information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0" xml:lang="en-US">Capital losses carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember_0" xml:lang="en-US">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockMember_1" xml:lang="en-US">Treasury share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares_0" xml:lang="en-US">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Net change in the total valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_1" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_2" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_3" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_4" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_5" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_6" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_7" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_11" xlink:to="lab_cmmb_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_12" xlink:to="lab_cmmb_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_13" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_14" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_15" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_16" xlink:to="lab_cmmb_AnnualRentAndManagementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_17" xlink:to="lab_cmmb_AnnualRentAndManagementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_18" xlink:to="lab_cmmb_AtmAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_19" xlink:to="lab_cmmb_AtmAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_20" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_21" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_28" xlink:to="lab_cmmb_CantorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_29" xlink:to="lab_cmmb_CantorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_30" xlink:to="lab_cmmb_CapitalAdditionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_31" xlink:to="lab_cmmb_CapitalAdditionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_32" xlink:to="lab_cmmb_CapitalAdditionsOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_33" xlink:to="lab_cmmb_CashAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_34" xlink:to="lab_cmmb_CashAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_41" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_42" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_43" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_47" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_48" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_49" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_56" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_57" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_67" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_68" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_69" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_70" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_71" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_78" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_79" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_80" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_81" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_82" xlink:to="lab_cmmb_IncomeTaxesReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_83" xlink:to="lab_cmmb_IncomeTaxesReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_84" xlink:to="lab_cmmb_IncomeTaxesReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_85" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_86" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_87" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_88" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_89" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_90" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_91" xlink:to="lab_cmmb_InterestReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_92" xlink:to="lab_cmmb_InterestReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_93" xlink:to="lab_cmmb_InterestReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_94" xlink:to="lab_cmmb_InvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_95" xlink:to="lab_cmmb_InvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_96" xlink:to="lab_cmmb_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_97" xlink:to="lab_cmmb_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_98" xlink:to="lab_cmmb_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_99" xlink:to="lab_cmmb_LienOnBankDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_100" xlink:to="lab_cmmb_LienOnBankDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_101" xlink:to="lab_cmmb_LongTermLeaseDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_102" xlink:to="lab_cmmb_LongTermLeaseDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_103" xlink:to="lab_cmmb_LongTermLeaseDeposit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_107" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_108" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_109" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_110" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_111" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_112" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_113" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_114" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_115" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_116" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_117" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_118" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_119" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_120" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_121" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_122" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_123" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_124" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_125" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_126" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_127" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_128" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_129" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_130" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_131" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_132" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_133" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_134" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_135" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_136" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_137" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_138" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_139" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_140" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_141" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_142" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_143" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_144" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_145" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_146" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_147" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_148" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_149" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_150" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_151" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_152" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_153" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_154" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_155" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_156" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_157" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_158" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_159" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_160" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_161" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_162" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_163" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_164" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_165" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_166" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_167" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_168" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_169" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_170" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_171" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_172" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyMember_173" xlink:to="lab_cmmb_RelatedPartyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyMember_174" xlink:to="lab_cmmb_RelatedPartyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_175" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_176" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_177" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_178" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_179" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_180" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_181" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_182" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_183" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_184" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_185" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_186" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_187" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_188" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_189" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_190" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_191" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_192" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_193" xlink:to="lab_cmmb_RepurchaseArrangementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_194" xlink:to="lab_cmmb_RepurchaseArrangementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_195" xlink:to="lab_cmmb_RepurchaseArrangementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_196" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_197" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_198" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_199" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_200" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_201" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_202" xlink:to="lab_cmmb_SaleOfStockLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_203" xlink:to="lab_cmmb_SaleOfStockLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_204" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_205" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_206" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_207" xlink:to="lab_cmmb_SaleOfStockTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_208" xlink:to="lab_cmmb_SaleOfStockTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_209" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_210" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_211" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_212" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_213" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_214" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_215" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_216" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_217" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_218" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_219" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_220" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_221" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_222" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_223" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_224" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_225" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_226" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_227" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_228" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_229" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_230" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_231" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_232" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_233" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_234" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_235" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_236" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_237" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_238" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_239" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_240" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_241" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_242" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_243" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_244" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_245" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_246" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_247" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_248" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_249" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_250" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_251" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_252" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_253" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_254" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_255" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_256" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_257" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_258" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_259" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_260" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_261" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_262" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_263" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_264" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_265" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_266" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_267" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_268" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_269" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_270" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_271" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_272" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_273" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_274" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_275" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_276" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_277" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_278" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_279" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_280" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_281" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_282" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_283" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_284" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_285" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_288" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_289" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_290" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_291" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_292" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_293" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_294" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_295" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_296" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_297" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_298" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_299" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_300" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_301" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_302" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_303" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_304" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_305" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_306" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_307" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_308" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_309" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_310" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_311" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_312" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_314" xlink:to="lab_us-gaap_TreasuryStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_315" xlink:to="lab_us-gaap_TreasuryStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_316" xlink:to="lab_us-gaap_TreasuryStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_317" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_318" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_319" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_326" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_327" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_328" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_329" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_330" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_331" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_332" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_333" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_334" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_335" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_336" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_337" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_338" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_339" xlink:to="lab_currency_EUR_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_340" xlink:to="lab_currency_ILS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_341" xlink:to="lab_currency_ILS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_342" xlink:to="lab_currency_USD_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_XXX_343" xlink:to="lab_currency_XXX_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_344" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_345" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_346" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_347" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_348" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_349" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_350" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_351" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_352" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_353" xlink:to="lab_dei_DocumentInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_354" xlink:to="lab_dei_DocumentInformationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_355" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_356" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_357" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_358" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_359" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_360" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_361" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_362" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_363" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_364" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_365" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_366" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_367" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_368" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_369" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_370" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName_371" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_372" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_373" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_374" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_375" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_376" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_377" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_378" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_379" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_380" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_381" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_382" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_383" xlink:to="lab_dei_PreCommencementTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_384" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_385" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_386" xlink:to="lab_dei_SolicitingMaterial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_387" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_388" xlink:to="lab_dei_WrittenCommunications_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_389" xlink:to="lab_srt_CurrencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_390" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_391" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_392" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_393" xlink:to="lab_srt_ScenarioForecastMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_394" xlink:to="lab_srt_ScenarioUnspecifiedDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_395" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_396" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_397" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_398" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_399" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_400" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_401" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_402" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_403" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_404" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_405" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_408" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_409" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_410" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_411" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_412" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_413" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_414" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_416" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_417" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_418" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_419" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_420" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_421" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_422" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_423" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_424" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_425" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAdditionsMember_427" xlink:to="lab_us-gaap_CapitalAdditionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_428" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_429" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_430" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_431" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_432" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_433" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_434" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_435" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_436" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_439" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_440" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_441" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_442" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_443" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_444" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_445" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_446" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_447" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_448" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_449" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_450" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_451" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_452" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_453" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_454" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_455" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_456" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_457" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_458" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_459" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_460" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_461" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_462" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_463" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_464" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_465" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_466" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_467" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_468" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_469" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_470" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_471" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_472" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_473" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_474" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_475" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_476" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_477" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_478" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_479" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_480" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_481" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_482" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_483" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_484" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_485" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_486" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_487" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_488" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense_489" xlink:to="lab_us-gaap_GeneralInsuranceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_490" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_491" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_492" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_493" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_495" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_496" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_497" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_498" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_499" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_500" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_501" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_502" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_503" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_504" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_505" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_506" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_507" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_508" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_509" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_510" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_511" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember_512" xlink:to="lab_us-gaap_LeaseAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_513" xlink:to="lab_us-gaap_LeaseExpirationDate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_514" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_515" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_516" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_517" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_518" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_519" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_520" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_521" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_522" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_523" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_524" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_525" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_526" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_527" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_528" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_529" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_531" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_532" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_533" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_534" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_535" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_536" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_537" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_538" xlink:to="lab_us-gaap_LiabilitiesAssumed1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_539" xlink:to="lab_us-gaap_LiabilitiesAssumed1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_540" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_541" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_542" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_543" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_544" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_545" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_546" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount_547" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_548" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentDescription_549" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_550" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_551" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_552" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_553" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_554" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_555" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_556" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_557" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_558" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_559" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_560" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_561" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseDirectorsFees_562" xlink:to="lab_us-gaap_NoninterestExpenseDirectorsFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_563" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_564" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_565" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_566" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_567" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_568" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_569" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_570" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_571" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_572" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_573" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_574" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_575" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_576" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_577" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription_578" xlink:to="lab_us-gaap_OtherCommitmentsDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_579" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_580" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_581" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_582" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense_583" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_584" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_585" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_586" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_587" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_588" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_589" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_590" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_591" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_592" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_593" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_594" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_595" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_596" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_597" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_598" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_599" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_600" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_601" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_602" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_603" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_604" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_605" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_606" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_607" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_608" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_610" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_611" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_612" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_613" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_614" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_615" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_616" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_617" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_618" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_619" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts_620" xlink:to="lab_us-gaap_RelatedPartyCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts_621" xlink:to="lab_us-gaap_RelatedPartyCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_622" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_623" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_624" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_625" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_626" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_627" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_628" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_629" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_631" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_632" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_633" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_634" xlink:to="lab_us-gaap_RestrictedCashCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_635" xlink:to="lab_us-gaap_RestrictedCashCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_636" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_637" xlink:to="lab_us-gaap_RestrictedInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_638" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_639" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_640" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_641" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_642" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_643" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_644" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_645" xlink:to="lab_us-gaap_SalariesAndWages_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_646" xlink:to="lab_us-gaap_SalariesAndWages_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_648" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_649" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_650" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_651" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_652" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_653" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_654" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_655" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_656" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_657" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_658" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_660" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_661" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_662" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_663" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_664" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_665" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_667" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_668" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_669" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_670" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_671" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_672" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_673" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_674" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_675" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_677" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_680" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_681" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_682" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_683" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_684" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_687" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_688" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_689" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_690" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_691" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_692" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_693" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_694" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_695" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_696" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_697" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_698" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_699" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_700" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_701" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_702" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_703" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_704" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_705" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_706" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_707" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_708" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_709" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_710" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_711" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_712" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_713" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_714" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_715" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_716" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_717" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_718" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_719" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_720" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_721" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_722" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_723" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_724" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_725" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_726" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_727" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_728" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_729" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_730" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_731" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_732" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_733" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_734" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_735" xlink:to="lab_us-gaap_TreasuryStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_736" xlink:to="lab_us-gaap_TreasuryStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_737" xlink:to="lab_us-gaap_TreasuryStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_738" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_740" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_742" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_743" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_744" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_746" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cmmb-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#BalanceSheetsParenthetical" roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#General" roleURI="http://www.anchiano.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalents" roleURI="http://www.anchiano.com/role/CashAndCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpenses" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNet" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#Leases" roleURI="http://www.anchiano.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilities" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapital" roleURI="http://www.anchiano.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopment" roleURI="http://www.anchiano.com/role/ResearchAndDevelopment"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrative" roleURI="http://www.anchiano.com/role/GeneralAndAdministrative"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxes" roleURI="http://www.anchiano.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholders" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralTables" roleURI="http://www.anchiano.com/role/GeneralTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesTables" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesTables" roleURI="http://www.anchiano.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalTables" roleURI="http://www.anchiano.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentTables" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeTables" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesTables" roleURI="http://www.anchiano.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsTables" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersTables" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDateNarrativeDetails" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDate" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDate"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_47"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_DocumentInformationLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCentralIndexKey_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AmendmentFlag_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentType_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentAnnualReport_12" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentTransitionReport_13" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityFileNumber_14" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityRegistrantName_15" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityTaxIdentificationNumber_17" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine1_18" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine2_19" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressCityOrTown_20" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressCountry_21" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressPostalZipCode_22" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_CityAreaCode_23" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_LocalPhoneNumber_24" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_25" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_Security12bTitle_26" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_TradingSymbol_27" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_SecurityExchangeName_28" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_29" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityVoluntaryFilers_30" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCurrentReportingStatus_31" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityInteractiveDataCurrent_32" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityFilerCategory_33" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntitySmallBusiness_34" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityEmergingGrowthCompany_35" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityExTransitionPeriod_36" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_37" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityShellCompany_38" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityPublicFloat_39" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_40" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorName_41" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorLocation_42" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorFirmId_43" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_WrittenCommunications_44" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_SolicitingMaterial_45" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_PreCommencementTenderOffer_46" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_47" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_TreasuryStockValue_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_SharesOutstanding_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_TreasuryStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_LongTermLeaseDeposit_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_cmmb_CashAcquiredInMerger_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_19" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_27" xlink:to="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_cmmb_IncomeTaxesReceived_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_cmmb_InterestReceived_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_us-gaap_LiabilitiesAssumed1_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_SeverancePayPolicyTextBlock_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" order="160" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralTables">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_PercentageOfMonthlyDepositsRate_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SeveranceCosts1_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_IncrementalBorrowingRateOfLeases_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_AnnualRentAndManagementFees_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiability_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_13" order="90" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6" xlink:to="loc_currency_AllCurrenciesDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_EUR_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_ILS_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_12" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_12" xlink:to="loc_srt_ScenarioForecastMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_OtherCommitmentsDescription_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RoyaltyExpense_23" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_24" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_25" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_LienOnBankDeposit_27" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RestrictedInvestments_28" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_InvestorsMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_us-gaap_PrivatePlacementMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_AtmAgreementMember_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_RepurchaseArrangementMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_13" xlink:to="loc_us-gaap_PlanNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_13" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_13" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_cmmb_SaleOfStockLineItems_17" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_22" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_27" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_28" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_31" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_33" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharePrice_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="70" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_ProfessionalFees_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_US_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8" xlink:to="loc_us-gaap_DomesticCountryMember_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_cmmb_IncomeTaxDisclosureLineItems_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_CurrencyTransactionLossValuationAllowance_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxExpenseValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RelatedPartyMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyCosts_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4" xlink:to="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDate">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cmmb_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cmmb_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W '(# 2(  A$! Q$!_\0
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M.>F0:D\9?ZC2?^PG;?\ H8H\ _\ (JVG^_-_Z->KM#DY[$7ES<MP_P"$F/\
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M"9;/$PYT[(TKXN-*7+:Y]H^,O]1I/_83MO\ T,4G@,A?"EJ20 'FR3_UU>N
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MC((.T<$=C17J-%>4\2V[V.U4D(54]5!^HI:**YS4;L7^ZOY4I12<E1GZ444
M+01GK110 @4#H /H*-HSG SZXHHH 7KUI H'0 ?A110 M026=K(^Z2VA=O5H
9P3111<"6.-(QB-%0>BC%.HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cmmb_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cmmb_img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !' 04# 2(  A$! Q$!_\0
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MI0E!VDK&B:>P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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4(P1XU**X]0I^[]****F6XUL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image00003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !' 04# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHK*\3Z
MU#H&B7&HW"EQ$,*@/+L> *J$)3DHQ5VQ-V5V:M,F#F%Q"5$FT[2W(![9KP:7
MXG^(GN_-22VCBSQ#Y0*X],]:].\(^.--US35DN9X+.\7B6%WQCW&>H->CBLH
MQ.%@IS5UY:V]3.%:,G9'R]X8\._$1/C+;RS6VJKJ:WP>ZNWW>68=_P Q+]"A
M7( Z=*^SZY2U\?>'[K5UTZ&[8RL_EI(4(C9O0-75,P12S$*H&22< "N?%NJW
M'VL.73L%-12=G<6BO.M#^,G@S6_$RZ'8:B[7<DABBD>(K%*WHK'U[>O:O1:Y
MI0E!VDK&B:>P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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4(P1XU**X]0I^[]****F6XUL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322136592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHEMOMAB
THERAPEUTICS LTD.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321623440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,519<span></span>
</td>
<td class="nump">$ 15,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term bank deposit</a></td>
<td class="nump">26,374<span></span>
</td>
<td class="nump">45,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepaid expenses</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">41,736<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,063<span></span>
</td>
<td class="nump">64,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,749<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current&#160;operating lease liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,840<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury share at cost (11,640,460 shares as of December 31, 2022)</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">101,260<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(63,819)<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,223<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 43,063<span></span>
</td>
<td class="nump">$ 64,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318163712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">11,640,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915413271712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,556<span></span>
</td>
<td class="nump">6,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,533<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financing (income) expenses, net</a></td>
<td class="num">(353)<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="nump">28,180<span></span>
</td>
<td class="nump">12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (benefit)</a></td>
<td class="num">(534)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per Ordinary Share</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per Ordinary Share</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares outstanding, basic</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary Shares outstanding, diluted</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321623888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Treasury share [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,497<span></span>
</td>
<td class="num">$ (23,695)<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">9,274,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransaction', window );">Effect of reverse capitalization transaction</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransactionShares', window );">Effect of reverse capitalization transaction (In shares)</a></td>
<td class="nump">152,299,702<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Stock And Warrants Issued During Period New Issues</a></td>
<td class="nump">66,381,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options, shares</a></td>
<td class="nump">134,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
<td class="nump">$ 61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Stock And Warrants Issued During Period New Issues</a></td>
<td class="nump">2,576,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options, shares</a></td>
<td class="nump">1,970,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Treasury share at cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Treasury share at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">$ 101,260<span></span>
</td>
<td class="num">$ (63,819)<span></span>
</td>
<td class="nump">$ 36,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,636,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of effect due reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares isued due to effect of reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>it represents number of shares and warrants issued during period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915313780512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (27,646)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in other receivables and prepaid expenses</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(2,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Change in trade payables</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">2,823<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Change in employees and related expenses</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating leases</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,370)<span></span>
</td>
<td class="num">(12,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PaymentsForInvestmentInDeposits', window );">Investment in deposits</a></td>
<td class="nump">19,601<span></span>
</td>
<td class="num">(45,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LongTermLeaseDeposit', window );">Long-term lease deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Sale of asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">19,533<span></span>
</td>
<td class="num">(45,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashAcquiredInMerger', window );">Cash acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Treasury share at cost</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(808)<span></span>
</td>
<td class="nump">61,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,645)<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the year</a></td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the year</a></td>
<td class="nump">13,596<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashPaidAndReceivedDuringYearForAbstract', window );"><strong>A. Cash paid and received during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxesReceived', window );">Income taxes received</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_InterestReceived', window );">Interest received</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>B. Significant non- cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed, net of non-cash assets received in Merger</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashPaidAndReceivedDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashPaidAndReceivedDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents income taxes received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LongTermLeaseDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term lease deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LongTermLeaseDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PaymentsForInvestmentInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for investm,ents in deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PaymentsForInvestmentInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915319369872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
1 - General</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">1.<span style="padding-left:28.5pt">Chemomab
Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September
2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"><br/>The
Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical
need that involve inflammation and fibrosis.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><br/>The
wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics
Inc.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">2.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:28.5pt">The
Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company
has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it
obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to
raise sources of financing.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.<span style="padding-left:28.5pt">Since
</span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2020, the COVID-19 pandemic
has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial
markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19
pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining
populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the
enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a
result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials,
patients might still drop out because of possible COVID-19 implications. Based on management&#8217;s assessment, the extent to which the
lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments,
which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment
following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and
will adjust activities accordingly<span><span><span>.</span></span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.<span style="padding-left:28.5pt">On
</span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 14, 2020, the Company
(formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;)
with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of
the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant
to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd.
surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its
name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became
primarily the business conducted by the Company.</span></span></p>

<div>

<div style="width:100%;clear:both">

<p style="margin:0pt">&#160;</p> </div> </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt">At
the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into
number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd.
option was assumed by the Company, based on the same exchange ratio.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For&#160;<span>accounting
purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger
has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets
acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired
in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion
of the Merger.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">The
exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd.
The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive
Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86
multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt">The
following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion
of the Merger (in USD thousands):</p>

<div style="margin-left:72pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,427</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,000</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other
        assets</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">236</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,187</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,476</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915319449776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
2 - Summary of Significant Accounting Policies</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis
of Preparation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S
GAAP&#8221;).</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use
of estimates</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>


<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign
currency</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221;
or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the
currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary
assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets
and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements
of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction
dates, except for depreciation, which is translated using historical exchange rate.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash
and cash equivalents</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or
less at the date acquired.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted
cash</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted
cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p>

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property
and equipment</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property
and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred.
Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets
are ready for their intended use.</p>

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual
rates at depreciation are as follows:</p>

<div style="margin-left:36pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  </table>  </div> </div> </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment
of long-lived assets</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p>


<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research
and Development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research
and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and
wages.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income
taxes</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized.
In making such a determination, management considers all available positive and negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management
determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management
would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p>


<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair
value of financial instruments</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC
820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for
measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant
assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date, essentially an exit price.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In
addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described
below includes the Company&#8217;s own credit risk.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As
a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation
methodologies in measuring fair value:</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar
or identical assets or liabilities.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due
to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates
their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">-
</span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred
during the periods presented.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based
compensation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified
and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation
cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting
schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation
cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing
model at the grant date, using the inputs detailed in Note 8(C).</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The
Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored
research and development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab
records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that
the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants
as a reduction to research and development expenses.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance
pay</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits,
at a rate of 8.33%
of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability
exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee.
This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142
thousand and $116
thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations
of credit risk:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
<span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold
the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
arrangements.</p>

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under
</span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities
are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the
Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what
its credit rating would be 5%
and 5.2%
in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based,
asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account
for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to
measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain
any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease
expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU
assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance
in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the
amount of the impairment loss to recognize. See Note 2(G).</span></span></p> </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles
of consolidation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
<span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions
have been eliminated in consolidation.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings
per ordinary share</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic
earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant,
gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares,
using the treasury stock method, from the assumed exercise of share options.</p>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915323107056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
3 - Cash and Cash Equivalents</span></p>

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">10,663</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,720</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,756</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,116</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">100</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,350</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,519</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">15,186</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320585104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">Other Receivables and Prepaid Expenses</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
4 - Other Receivables and Prepaid Expenses</span></p>

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">459</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">179</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,307</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,348</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,766</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,527</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322056432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
5 - Property and Equipment, Net</span></p>

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">70</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">43</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">33</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">399</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">364</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">14</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">14</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">16</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>532</strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">464
        </p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less
        - accumulated depreciation</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">165</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(107</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>367</strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">357
        </p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915323098464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
6 - Leases</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On
May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According
to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of three
years, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to
extend the lease term by additional three
years.&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On
October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab
returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of 3
years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to
extend the lease term by additional three
years. The annual rent and management fees are approximately $122
thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77
thousand was issued to the property owner during 2022.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets
as of December 31, 2022 and 2021 and represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s
obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current
liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December
31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease
agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $345
thousand on December 12, 2021.&#160;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">During
the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $17
thousand and $345
thousand, respectively.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As&#160;of
December 31, 2022, and 2021 operating right-of-use asset was $227
thousand and $345
thousand, respectively. The operating lease liabilities were $214
thousand and $343
thousand, respectively.</span></span></p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As
most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information
available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing
rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 5%
in 2022 and 5.2%
in 2021.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Maturities
of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):</p>

<div style="margin-left:40pt;margin-bottom:0pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">126
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">93
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum
        lease payments</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">219
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">5</span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of
        operating lease liabilities</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">214
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  </table>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915323098464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note
7 - Commitments and Contingent Liabilities</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive
License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv
Souraski Medical Center (&#8220;Fund&#8221;), pursuant to which it was granted with an exclusive license to certain inventions (as defined
in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant
to and subject to certain terms and limitation fully set in the License Agreement.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Chemomab
has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term
defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(i)<span style="padding-left:26.56pt">Royalties
in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to </span>certain additional terms set
forth therein.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"><span>In
addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable,
non-creditable amounts:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt">(a)<span style="padding-left:24.9pt">$100
thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent
for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar
application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission
of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not
be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">$200
thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the
aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only
once.</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">As
of December 31, 2022&#160;no payments were made to the Fund.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
addition to the payments described above, upon
the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction,
Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering,
or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction
of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in
any event not more than $3,000 thousand.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="padding-left:26.83pt">&#160;
&#160;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel </span>Innovation Authority
(&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">In
return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of 3%
of sales of the developed product (linked to U.S. dollar), up to 100%
of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology
or development out of Israel.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt">Chemomab
did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Since
Chemomab &#8217;s incorporation through December 31, 2022 Chemomab received $1,227
thousand from the IIA, which were recognized as a reduction of research and development expenses.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">As
of December 31, 2022, Chemomab has no commitment for royalties payable.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:26.28pt">In
</span></span></span>June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under
which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in
the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization
thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients.
According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with
Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements
for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to
pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt">During
2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $5,222
thousand and $2,590
thousand, respectively. The expenses were recorded under research and development expenses.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-weight:bold">C.</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="padding-left:26.28pt">As&#160;</span></span>of
December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $77
thousand for the purpose of secure lease payments under an office lease agreement.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span><span style="padding-left:26.28pt">During&#160;</span></span><span>2022,
the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through
202</span><span>2</span><span>. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger
Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which
the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $1,046
thousand. The Company filed an appeal against the ITA&#8217;s assessments. The Company has recorded an appropriate provision which considers
inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded
by the Company during the period</span><span>.</span></span></span></p> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322036752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
8 - Share Capital</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Right
attached to shares</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-weight:bold;font-style:italic">Ordinary
shares</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">All
of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary
shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote
and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when
the Company is dissolved.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">1.</span><span style="font-weight:bold;padding-left:28.5pt">Voting</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The
holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">2.</span><span style="font-weight:bold;padding-left:28.5pt">Dividends</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The
holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally
available.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">Since
its inception, the Company has not declared any dividends.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="padding-left:26.83pt;font-weight:bold">Financing
rounds</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.</span><span style="padding-left:28.5pt">In&#160;</span></span></span>connection
with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which
the Company agreed to sell approximately $45.5
million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement
closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270
ADSs together with warrants to purchase up to 261,929
ADSs at an exercise price of $17.35
per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds
of approximately $4.5
million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.</span><span style="padding-left:28.5pt">On&#160;</span></span></span>April
30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor").
According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to
$75
million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806
ADSs at an average price of $22.75
per ADS under the ATM Agreement, resulting in gross proceeds of $15,917
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>3.</span><span style="padding-left:28.5pt">On
</span></span></span></span></span></span>April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and
sale of up to $18,125,000&#160;of
its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject
to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third
of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;130,505
ADSs at an average price of $2.11
per ADS under the ATM Agreement, resulting in gross proceeds of $275
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4.</span><span style="padding-left:28.5pt">On&#160;</span></span></span></span>September
19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder
of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together
with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section
303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to
repurchase up to 582,023&#160;ADSs
owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000,
depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the
entire amount of 582,023
ADSs from the Co-Founders at a weighted average price of $2.0848
and for total consideration of approximately $1,218
thousand.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">The
Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".</span></span></span></p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based
compensation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(1)<span style="padding-left:24.34pt">Share-based
compensation plan:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">The
Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017
Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company from Chemomab
upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs
of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.<br/>&#160;</p>

<p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As
of December 31, 2022, a total of 28,443,060
of our Ordinary Shares (equal to 1,422,153
of ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520
Ordinary Shares (equal to 172,276
ADSs) had been issued pursuant to previous exercises options, and 23,460,740
&#160;Ordinary Shares (equal to 1,173,037
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 12,400,720
Ordinary Shares (equal to 620,036
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.30
per Ordinary Share (or $5.96
per ADS). During the year ended December 31, 2022, options to purchase 1,240,120
Ordinary Shares (equal to 62,006
ADS) were canceled.</span></span></span></p>

<p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As
of December 31, 2022, a total of 12,511,620
of our Ordinary Shares (equal to 625,581
ADSs) were reserved for issuance under the 2017 Plan, of which 11,730,800
Ordinary Shares (equal to 586,540
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 427,540
Ordinary Shares (equal to 21,377
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.35
per Ordinary Share (or $6.98
per ADS). During the year ended December 31, 2022 no options were canceled.</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(2)<span style="padding-left:24.34pt">The
expenses that were recognized in the consolidated statements of operations for services received from employees </span>and service providers
are as follows:</p>

<div style="margin-left:108pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based
        compensation expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,211</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,019</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt">(3)<span style="padding-left:24.34pt">The
number and weighted average exercise price of options are as follows:</span></p>

<div style="margin-left:108pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">exercise price</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January
        1</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.38</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,003,260</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.07</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,455,580</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7.8</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right">-</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">-</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">609,535</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.07</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,970,000</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.32</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,240,120</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1.25</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,712,275</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,398,400</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.8</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.62</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">17,784,640</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">9.79</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December
        31</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.33</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.42</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.38</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(4)<span style="padding-left:24.34pt">Fair
value measurement:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt">The
fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate
the fair value of the options are as follows:</p>

<div style="margin-left:108pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average
        share price (in U.S. dollar)<sup>(a)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in
        U.S. dollar)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.10</span><span style="font-weight:bold">-</span><span style="font-weight:bold">0.257</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of
        options (in years)<sup>(b)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">5.51</span><span style="font-weight:bold">-</span><span style="font-weight:bold">6.28</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">83.69</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">84.31</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest
        rate<sup>(d)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">1.75</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">4.14</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(a)<span style="padding-left:24.34pt">The
weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">Expected
life for the periods presented was determined according to the simplified method since, at the date of </span>grant, the Company did not
have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration,
and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method
is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition
is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if
the service period is explicitly stated.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(c)<span style="padding-left:24.34pt">Expected
volatility is based on historical volatility over the most recent period commensurate with the expected </span>term of the option. As
the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term,
the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s
industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(d)<span style="padding-left:24.34pt">The
risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the </span>yields of U.S. Treasury
securities with maturities appropriate for the expected term of employee share option awards.</p> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320397936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
9 - Research and Development</span></p>

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,052</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,894</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,867
        </span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,789</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">245</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">114</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">365</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">400</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16,977</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,334</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318153232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock', window );">General and Administrative</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note
10 - General and Administrative&#160;</span></p>

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,435</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">943</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,596</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,695</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span>244</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,084</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,024</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">24</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,423</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">216</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,556</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,033</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GeneralAndAdministrativeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320267808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note
11 - Income Taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Tax
rates</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
taxable income in Israel is subject to a corporate tax rate of 23%.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab
Inc. is subject to a federal flat tax rate of 21%
and state tax as applicable.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital
gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Tax
assessments</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the Company&#8217;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the
Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has not yet been assessed by the ITA since inception.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Losses
for tax purposes carried forward to future years</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2022, the Company and its subsidiaries had approximately $159
million&#160;(approximately $143
million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation
on the period of use.</span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On
March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and
Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA
provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on
interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes
provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January
1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Chemomab
Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net
operating losses. Chemomab Therapeutics Inc received $351
thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $183
thousand in 2023. Accordingly, a tax benefit in the total amount of $534
thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Deferred
taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
respect of:</span></span></p>

<div style="margin-left:72pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        operating loss carry-forwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,550</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,396</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation expense</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1,774</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,147</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development costs</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,858</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,449</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">13</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less
        - Valuation allowance</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(36,030)</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of
the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is
more likely than not that the deferred tax assets will not be realized.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing
future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance
for the year ended at December 31, 2022 was an increase of approximately $5.2
million.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Roll
forward of valuation allowance</span></span></span></p>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at January 1, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,200</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction loss</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,425</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        assets acquired through merger</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,535</span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,870</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,030</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction Income</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(1,316</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,481</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2022</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  </table>  </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Reconciliation
of theoretical income tax expense to actual income tax expense</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></p>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        before income taxes</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">28,180</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,478</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory
        tax rate</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">23</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical
        tax benefit</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold">6,481</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,870</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in temporary differences for which deferred taxes were not recognized</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(1,696</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,332</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        rate differential</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>20</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible
        expenses</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>744</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses
        and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,879</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,064</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual
        income tax expense (Benefit)</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(534</span></span></span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">)</span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table>  </div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Accounting
for uncertainty in income taxes</span></span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized
tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties
related to unrecognized tax benefits as a component of income tax expense.</span></span></p> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320182576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties Balances and Transactions</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
12 - Related Parties Balances and Transactions</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:10.28pt">Balances
with Related Parties:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The
following Related Party payables are included in the consolidated Balance Sheets:</p>

<div style="margin-left:36pt">

<div>

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">891</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">278</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">58</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">72</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">949</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">350</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p>&#160;</p> </td> </tr>
  </table> </div>

<p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On September 19, 2022, the Company entered
into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></span></p> </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:10.83pt">Transactions
with Related Parties:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The
following transactions with related parties are included in the consolidated Statements of Operations:</p>

<div style="margin-left:36pt;margin-bottom:0pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,409</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,255</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,466</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,775</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">244</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">36</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">36</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">5,142</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,310</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320156640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Ordinary Shareholders</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note
13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Basic
net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares
outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to
include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and
if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share,
as the effect of potentially dilutive securities is antidilutive.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The
following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods
presented:</p>

<div style="margin-left:36pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In
        USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,646</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">12,478</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average
        number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">227,589,288</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">207,468,650</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share
        attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.121</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.060</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The
potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders
for the periods presented since including them would have been anti-dilutive are as follows:</p>

<div style="margin-left:36pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number
        of shares</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options
        to purchase ordinary shares</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915401955616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Events After Balance Sheet Date</a></td>
<td class="text">

<div>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note
14&#160;- Subsequent Events</span></span></span></p>

<p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">On
January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $20,000,000
of its ADSs.</p> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320567424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis
of Preparation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S
GAAP&#8221;).</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use
of estimates</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign
currency</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221;
or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the
currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary
assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets
and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements
of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction
dates, except for depreciation, which is translated using historical exchange rate.</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash
and cash equivalents</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or
less at the date acquired.</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted
cash</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted
cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property
and equipment</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property
and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred.
Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets
are ready for their intended use.</p>

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual
rates at depreciation are as follows:</p>

<div style="margin-left:36pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  </table>  </div> </div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment
of long-lived assets</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research
and Development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research
and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and
wages.</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income
taxes</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized.
In making such a determination, management considers all available positive and negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management
determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management
would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair
value of financial instruments</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC
820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for
measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant
assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date, essentially an exit price.</p>

<div/>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In
addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described
below includes the Company&#8217;s own credit risk.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As
a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation
methodologies in measuring fair value:</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar
or identical assets or liabilities.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due
to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates
their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">-
</span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred
during the periods presented.</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based
compensation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified
and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation
cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting
schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation
cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing
model at the grant date, using the inputs detailed in Note 8(C).</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The
Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock', window );">Government-sponsored research and development</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored
research and development</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab
records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that
the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants
as a reduction to research and development expenses.</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SeverancePayPolicyTextBlock', window );">Severance Pay [Policy Text Block]</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance
pay</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits,
at a rate of 8.33%
of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability
exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee.
This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142
thousand and $116
thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations
of credit risk:</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
<span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold
the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The
Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
arrangements.</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">

<div>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under
</span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities
are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the
Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what
its credit rating would be 5%
and 5.2%
in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based,
asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account
for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to
measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain
any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease
expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU
assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance
in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the
amount of the impairment loss to recognize. See Note 2(G).</span></span></p> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles
of consolidation</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
<span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions
have been eliminated in consolidation.</span></span></span></p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per ordinary share</a></td>
<td class="text">

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings
per ordinary share</span></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic
earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant,
gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares,
using the treasury stock method, from the assumed exercise of share options.</p> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320267808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired based on their estimated fair value</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,427</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,000</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other
        assets</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">236</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,187</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,476</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915324019648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock', window );">Schedule of annual rate of deprecation</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
        </td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement</p> </td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td>
    <td style="vertical-align:top;width:9%">&#160;</td>
    <td style="vertical-align:top;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rate of deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320156640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of components of cash and cash equivalents</a></td>
<td class="text">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">10,663</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,720</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,756</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,116</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">100</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,350</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,519</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">15,186</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320267808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">459</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">179</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,307</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,348</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,766</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,527</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321575136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, Net</a></td>
<td class="text">

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">70</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">43</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">33</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">399</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">364</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">14</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">14</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">16</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>532</strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">464
        </p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less
        - accumulated depreciation</span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">165</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(107</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>367</strong><strong>
        </strong></strong><strong> </strong></strong><strong> </strong></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">357
        </p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915410633888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities under our non-cancelable operating leases</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">126
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">93
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum
        lease payments</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">219
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">5</span></p>
        </td>
    <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of
        operating lease liabilities</p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">214
        </span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317125168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of the effect of share-based compensation on the statements of operations</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based
        compensation expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,211</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,019</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of number and weighted average exercise prices of option</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise
        </span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">exercise price</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number
        of </span><span style="font-weight:bold">options</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average
        </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life
        (in years)</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January
        1</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.38</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,003,260</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.07</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,455,580</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7.8</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right">-</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">-</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">609,535</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.07</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,970,000</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.32</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,240,120</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1.25</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,712,275</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,398,400</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.8</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.62</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">17,784,640</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">9.79</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:10%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:27%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December
        31</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.33</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.42</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.38</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair value of the options</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average
        share price (in U.S. dollar)<sup>(a)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.16</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in
        U.S. dollar)</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.10</span><span style="font-weight:bold">-</span><span style="font-weight:bold">0.257</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of
        options (in years)<sup>(b)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">5.51</span><span style="font-weight:bold">-</span><span style="font-weight:bold">6.28</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">83.69</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">84.31</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest
        rate<sup>(d)</sup></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">1.75</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">4.14</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:84%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
    <td style="vertical-align:bottom;width:12%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0</span><span style="font-weight:bold">%</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322747296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock', window );">Schedule of research and development</a></td>
<td class="text">

<div style="margin-left:36pt;margin-bottom:11pt">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,052</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,894</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,867
        </span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,789</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">245</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">114</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">365</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">400</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16,977</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,334</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320195824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock', window );">Schedule of general and administrative</a></td>
<td class="text">

<div style="margin-left:36pt;margin-bottom:11pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,435</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">943</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,596</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,695</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span>244</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,084</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,024</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">24</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,423</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">216</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,556</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,033</p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915413270192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the company's deferred tax asset</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        operating loss carry-forwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,550</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,396</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation expense</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1,774</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,147</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development costs</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,858</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,449</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">13</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less
        - Valuation allowance</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(36,030)</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        deferred tax assets</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of roll forward of valuation allowance</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at January 1, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,200</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction loss</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,425</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        assets acquired through merger</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,535</span></span></strong></td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,870</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2021</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,030</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency
        transaction Income</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(1,316</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax expense</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,481</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        at December 31, 2022</span></span></p> </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD
        thousands</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        before income taxes</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">28,180</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,478</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory
        tax rate</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">23</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical
        tax benefit</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold">6,481</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,870</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in temporary differences for which deferred taxes were not recognized</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(1,696</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,332</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        rate differential</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>20</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible
        expenses</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>744</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses
        and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,879</strong></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,064</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual
        income tax expense (Benefit)</span></span></p> </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(534</span></span></span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">)</span></strong></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915319383360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock', window );">Schedule of related party payables</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">891</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">278</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">58</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">72</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">949</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">350</p>
        </td>
    <td style="vertical-align:bottom;width:1%">
        <p>&#160;</p> </td> </tr>
  </table> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of transaction with related parties</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year
        ended</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD
        thousands</span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related
        expenses</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,409</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,255</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,466</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,775</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">244</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">36</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
    <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">36</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">5,142</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,310</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320161008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In
        USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,646</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">12,478</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average
        number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">227,589,288</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">207,468,650</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share
        attributable to ordinary shareholders, basic and diluted</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.121</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.060</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:90%" width="100%">
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year
        ended</span></span></span></p> </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td style="vertical-align:bottom;text-align:right">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
        </td>
    <td style="vertical-align:bottom;text-align:center">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number
        of shares</span></span></span></p> </td>
    <td style="vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:9%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  <tr style="background-color:#CCEEFF">
    <td style="vertical-align:bottom;width:76%">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options
        to purchase ordinary shares</p> </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black">&#160;</td>
    <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
        </td>
    <td style="vertical-align:bottom;width:1%">&#160;</td> </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915319366944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember', window );">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger', window );">Number of ADS issued and outstanding after the merger</a></td>
<td class="nump">12.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADS issued and outstanding after the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320531968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Schedule of net assets acquired based on their estimated fair value) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale', window );">Asset held for sale</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued liabilities</a></td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EstimatedFairValueOfNetAssetsAcquired', window );">Net acquired assets</a></td>
<td class="nump">$ 2,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of of asset held for sale recogized prior to the completion of merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EstimatedFairValueOfNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated fair value of the net assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EstimatedFairValueOfNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321604880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfMonthlyDepositsRate', window );">Percentage of monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncrementalBorrowingRateOfLeases', window );">incremental borrowing rate of leases</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncrementalBorrowingRateOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents incremental borrowing rate of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncrementalBorrowingRateOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfMonthlyDepositsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly deposits rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfMonthlyDepositsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915316652416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRatesOfDepreciation', window );">Annual rates of depreciation</a></td>
<td class="text">over
        the shorter of the lease term or the estimated useful life of the improvement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRatesOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rates of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRatesOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317101264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 13,519<span></span>
</td>
<td class="nump">$ 15,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">10,663<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,756<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_XXX', window );">Other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 3,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_XXX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_XXX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915323050016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivablesFromGovernmentInstitutions', window );">Government institutions</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses, Total</a></td>
<td class="nump">$ 1,766<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivablesFromGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivablesFromGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317070784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant And Equipment Net</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Website development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318122880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2020</div></th>
<th class="th"><div>Oct. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">three
years<span></span>
</td>
<td class="text">three
years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRentAndManagementFees', window );">Annual rent and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BankGuaranteesToPropertyOwner', window );">Bank guarantees to property owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Operating Right Of Use Assets And Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Increase in the carrying amount of the right-of-use asset due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental borrowing rate based on credit rating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRentAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rent and management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRentAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BankGuaranteesToPropertyOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantees to property owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BankGuaranteesToPropertyOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating right-of-use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317157776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest:</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317082272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Decsription of occurrence for payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">upon
the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction,
Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering,
or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction
of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in
any event not more than $3,000 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties', window );">Maximum percentage of payments of royalties (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized', window );">Cumulative Amounts Of Grants Received And Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royality expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,222<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Bank restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RecoverabilityOfVatAmount', window );">Recoverability of VAT amount</a></td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">New Drug Application and Biological License Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$100
thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent
for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar
application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission
of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not
be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct', window );">Royalty payments on sale of product (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember', window );">Capital Additions One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$200
thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the
aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only
once.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_MaximumPercentageOfPaymentsOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments on sale of product developed with funding received from the IIA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RecoverabilityOfVatAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents recoverability of VAT amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RecoverabilityOfVatAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317438816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="nump">1,712,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember', window );">2015 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,443,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssOptionsIssuableOutstanding', window );">Number of ADSs options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsIssuableOutstanding', window );">Number of options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,460,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod', window );">Options to purchase ordinary shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember', window );">2017 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,511,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,730,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">The Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfWarrantsPurchaseUpAdss', window );">Number of warrants purchase ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember', window );">ATM agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement', window );">Aggregate offering price of at the market offering agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember', window );">Repurchase Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceipts', window );">Repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares', window );">Number of shares repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a aggregate offering price of at the market offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockAdssResveredForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock option ADSs resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockAdssResveredForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of stock resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfWarrantsPurchaseUpAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants purchase ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfWarrantsPurchaseUpAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ProceedsFromSaleOfAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ProceedsFromSaleOfAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents repurchase of American Depositary Receipts shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceiptsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStocksPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStocksPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stocks of American Depository Shares ("ADS") issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Total consideration of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents weighted average price of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320847904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Share-based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 3,211<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 2,763<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318151312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning</a></td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice', window );">Acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.32<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger', window );">Acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Exercise</a></td>
<td class="num">(1,970,000)<span></span>
</td>
<td class="num">(134,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,240,120)<span></span>
</td>
<td class="num">(1,712,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">11,398,400<span></span>
</td>
<td class="nump">17,784,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of shares acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options acquired, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317384768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price (in U.S. dollar)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">83.69%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.31%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.14%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">6 years 3 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321712336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Schedule of Research and Development) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ConsultantsAndSubcontractorsExpense', window );">Consultants And Subcontractors Expense</a></td>
<td class="nump">$ 13,052<span></span>
</td>
<td class="nump">$ 3,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense', window );">Rent And Maintenance Research And Development Expense</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense', window );">Share-based compensation</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other expenses</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ConsultantsAndSubcontractorsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consultants and subcontractors expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ConsultantsAndSubcontractorsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320874944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Schedule of General and Administrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related expenses</a></td>
<td class="nump">$ 3,435<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense', window );">Share-based compensation</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Fees to Directors</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense', window );">Rent and maintenance</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other expenses</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 11,556<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915317412048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the total valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc', window );">Received amount of Chemomab Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital losses carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc', window );">Expects to receive amount of Chemomab Therapeutics Inc</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expects to receive of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The received amount of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivedAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322085584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 36,550<span></span>
</td>
<td class="nump">$ 33,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">41,195<span></span>
</td>
<td class="nump">36,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - valuation allowance</a></td>
<td class="num">(41,195)<span></span>
</td>
<td class="num">(36,030)<span></span>
</td>
<td class="num">$ (6,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915323152720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at January 1</a></td>
<td class="nump">$ 36,030<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CurrencyTransactionLossValuationAllowance', window );">Currency transaction income (loss)</a></td>
<td class="num">(1,316)<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance', window );">Tax assets acquired through merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxExpenseValuationAllowance', window );">Income tax expense</a></td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at December 31</a></td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 36,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CurrencyTransactionLossValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CurrencyTransactionLossValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxExpenseValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxExpenseValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915322093120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (28,180)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">$ (6,481)<span></span>
</td>
<td class="num">$ (2,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized', window );">Change in temporary differences for which deferred taxes were not recognized</a></td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Tax rate differential</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</a></td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual income tax expense (Benefit)</a></td>
<td class="num">$ (534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a change in temporary differences for which deferred taxes were not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915321757664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related Party Payables</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915320518800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty', window );">Salaries and related expenses</a></td>
<td class="nump">$ 2,409<span></span>
</td>
<td class="nump">$ 1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty', window );">Share-based payments</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty', window );">Professional services</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Research and development</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Total related party expenses</a></td>
<td class="nump">$ 5,142<span></span>
</td>
<td class="nump">$ 3,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to research and develeopment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to salaries and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318178400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Numerator Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318081136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding options to purchase ordinary shares</a></td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915318805072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 13, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockValueOfSharesIssuedInTransaction', window );">Issuance and sale of of ADS upto</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of sale of stock value of shares issued in transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>zk2329281_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://www.anchiano.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmmb-20221231.xsd" xlink:type="simple"/>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220701to20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-13</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20200101to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-05-10</instant>
        </period>
    </context>
    <context id="C_20200501to20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-10</endDate>
        </period>
    </context>
    <context id="C_20211001to20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-24</endDate>
        </period>
    </context>
    <context id="C_20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-10-24</instant>
        </period>
    </context>
    <context id="C_20211212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-12</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20220101to20221231" id="FFact_0000000000489">0001534248</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_20220101to20221231" id="FFact_0000000000491">false</dei:AmendmentFlag>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233234992">2023-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230131233722905">2024-10-31</us-gaap:LeaseExpirationDate1>
    <dei:DocumentType
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230213103251859">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230213104107012">CHEMOMAB THERAPEUTICS LTD.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230218110119689">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230218110154128">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230213103758108">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230218131330535">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000038"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000039"
      unitRef="usd">15186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000040"
      unitRef="usd">26374000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000041"
      unitRef="usd">45975000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000040"
      unitRef="usd">77000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000041"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000042"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000043"
      unitRef="usd">1527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000044"
      unitRef="usd">41736000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">62688000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000050"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000051"
      unitRef="usd">55000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">733000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230131220311598"
      unitRef="usd">908000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000052"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">1327000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1665000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">43063000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">64353000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">1688000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">1336000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">3378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">1560000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">653000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">123000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">6749000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">2650000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">91000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">237000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">91000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">237000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230207202310124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20230207202348403"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">6840000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">2887000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20211231"
      decimals="0"
      id="Fxbrl_20230201163052384"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20221231"
      decimals="0"
      id="Fxbrl_20230131220607422"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230131221123913"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230131221114549"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_s_20230213101830929"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230213101830930"
      unitRef="Share">232636700</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_s_20230131221353660"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230131221353661"
      unitRef="Share">228090300</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230131221528825"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230131221535249"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230207202558860"
      unitRef="Share">11640460</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207202444619"
      unitRef="usd">1218000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207202534021"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">101260000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000087"
      unitRef="usd">97639000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000088"
      unitRef="usd">-63819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000089"
      unitRef="usd">-36173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000090"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000091"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000092"
      unitRef="usd">43063000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000093"
      unitRef="usd">64353000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000094"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">28533000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">12367000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131223230473"
      unitRef="usd">353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131223237304"
      unitRef="usd">-111000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000102"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000103"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131223639023"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213305203"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000104"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213312166"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000105"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230214141238310"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000106"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213329528"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000107"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232832534"
      unitRef="Share">9274838</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004148281"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004108785"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004208753"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000128"
      unitRef="usd">34497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000129"
      unitRef="usd">-23695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000130"
      unitRef="usd">10802000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004236209"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004232608"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232932528"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004229458"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232938175"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232946871"
      unitRef="Share">152299702</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004310594"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004631164"
      unitRef="Share">0</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004302609"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232952864"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004258843"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232958504"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233006128"
      unitRef="Share">66381520</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004339738"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004626295"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004335122"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233012248"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004332317"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233018475"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233039147"
      unitRef="Share">134240</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004521301"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004621028"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004724885"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233033563"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004807831"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233028090"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004352160"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004349447"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004345432"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233044479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233049858"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234506438"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004359870"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004449318"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004357072"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233106443"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207234203847"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233116634"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234515566"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004835440"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004846448"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233129314"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233133644"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233141194"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233154315"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233147476"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233201211"
      unitRef="Share">2576400</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233210018"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233216009"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233237975"
      unitRef="Share">1970000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004927217"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004915442"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004923369"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233227671"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004959684"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233221400"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230207233301376"
      unitRef="Share">-11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230207233406606"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004932393"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233411324"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233416622"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233422744"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233430996"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230207233657770"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230207233728393"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233439472"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233445148"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207233450251"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-27646000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000150"
      unitRef="usd">-12478000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000151"
      unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000152"
      unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000153"
      unitRef="usd">3211000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000154"
      unitRef="usd">2019000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000155"
      unitRef="usd">64000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000156"
      unitRef="usd">2058000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">352000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">1175000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">2823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201002431792"
      unitRef="usd">-1279000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000161"
      unitRef="usd">907000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000162"
      unitRef="usd">215000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000163"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201002424683"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000165"
      unitRef="usd">-20370000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">-12374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">-19601000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">45951000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000169"
      unitRef="usd">0</cmmb:LongTermLeaseDeposit>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235620864"
      unitRef="usd">4000</cmmb:LongTermLeaseDeposit>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000171"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235631064"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000173"
      unitRef="usd">68000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">19533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">-45186000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">0</cmmb:CashAcquiredInMerger>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235649216"
      unitRef="usd">2427000</cmmb:CashAcquiredInMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000179"
      unitRef="usd">143000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235658097"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201000241409"
      unitRef="usd">1218000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000182"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000183"
      unitRef="usd">267000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000184"
      unitRef="usd">58637000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002754453"
      unitRef="usd">-808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000186"
      unitRef="usd">61074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002721687"
      unitRef="usd">-1645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000188"
      unitRef="usd">3514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000189"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">11727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000192"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214142748754"
      unitRef="usd">351000</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214143241770"
      unitRef="usd">0</cmmb:IncomeTaxesReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214142431448"
      unitRef="usd">5000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233750059"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <cmmb:InterestReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233819452"
      unitRef="usd">972000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233829491"
      unitRef="usd">74000</cmmb:InterestReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000193"
      unitRef="usd">17000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000194"
      unitRef="usd">345000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000195"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235456185"
      unitRef="usd">49000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:NatureOfOperations contextRef="C_20220101to20221231" id="FFact_0000000000208">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
1 - General&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;1.&lt;span style="padding-left:28.5pt"&gt;Chemomab
Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September
2011. The Company&#x2019;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"&gt;&lt;br/&gt;The
Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical
need that involve inflammation and fibrosis.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;br/&gt;The
wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics
Inc.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;2.&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="padding-left:28.5pt"&gt;The
Company currently has no products approved for sale. The Company&#x2019;s operations are funded primarily by its Shareholders. The Company
has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it
obtains marketing approval for its products. Continuation of the Company&#x2019;s development programs depend on its future ability to
raise sources of financing.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;span style="padding-left:28.5pt"&gt;Since
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;January 2020, the COVID-19 pandemic
has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial
markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19
pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining
populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the
enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a
result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials,
patients might still drop out because of possible COVID-19 implications. Based on management&#x2019;s assessment, the extent to which the
lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments,
which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment
following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and
will adjust activities accordingly&lt;span&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.&lt;span style="padding-left:28.5pt"&gt;On
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 14, 2020, the Company
(formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#x201c;Merger Agreement&#x201d;)
with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of
the Company (&#x201c;Merger Sub&#x201d;). On March 16, 2021, (the &#x201c;Effective Time&#x201d;), the Company consummated the Merger pursuant
to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd.
surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its
name from &#x201c;Anchiano Therapeutics Ltd.&#x201d; To &#x201c;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became
primarily the business conducted by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;div style="width:100%;clear:both"&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt"&gt;At
the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into
number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd.
option was assumed by the Company, based on the same exchange ratio.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For&#160;&lt;span&gt;accounting
purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger
has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets
acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired
in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion
of the Merger.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;The
exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd.
The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive
Plan (the &#x201c;2015 Plan&#x201d;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86
multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt"&gt;The
following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion
of the Merger (in USD thousands):&lt;/p&gt;

&lt;div style="margin-left:72pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,427&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Asset held for sale&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,000&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid and other
        assets&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;236&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued liabilities&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,187&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net acquired assets&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,476&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; </us-gaap:NatureOfOperations>
    <cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger
      contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember"
      decimals="INF"
      id="Fxbrl_20230131220949272"
      unitRef="Share">12.86</cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201024915457">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,427&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Asset held for sale&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,000&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid and other
        assets&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;236&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued liabilities&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,187&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net acquired assets&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,476&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000202"
      unitRef="usd">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000203"
      unitRef="usd">1000000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000204"
      unitRef="usd">236000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000205"
      unitRef="usd">1187000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <cmmb:EstimatedFairValueOfNetAssetsAcquired
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000206"
      unitRef="usd">2476000</cmmb:EstimatedFairValueOfNetAssetsAcquired>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000234">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
2 - Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Basis
of Preparation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S
GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Use
of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;


&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Foreign
currency&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d;
or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the
currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Monetary
assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets
and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Statements
of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction
dates, except for depreciation, which is translated using historical exchange rate.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or
less at the date acquired.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Restricted
cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;Restricted
cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Property
and equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred.
Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets
are ready for their intended use.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Annual
rates at depreciation are as follows:&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.&lt;/p&gt;


&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Research
and Development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Research
and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and
wages.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Income
taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized.
In making such a determination, management considers all available positive and negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management
determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management
would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/p&gt;


&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;J.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;ASC
820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for
measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant
assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date, essentially an exit price.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;In
addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described
below includes the Company&#x2019;s own credit risk.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As
a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation
methodologies in measuring fair value:&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar
or identical assets or liabilities.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due
to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates
their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;-
&lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred
during the periods presented.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Share-based
compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified
and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation
cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting
schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation
cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing
model at the grant date, using the inputs detailed in Note 8(C).&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;The
Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Government-sponsored
research and development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Chemomab
records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that
the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants
as a reduction to research and development expenses.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:24.06pt"&gt;Severance
pay&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant
to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits,
at a rate of 8.33%
of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability
exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee.
This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142
thousand and $116
thousand for the year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Concentrations
of credit risk:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash
&lt;span&gt;and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold
the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
arrangements.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Under
&lt;/span&gt;&lt;/span&gt;Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities
are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the
Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what
its credit rating would be 5%
and 5.2%
in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based,
asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account
for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to
measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain
any residual value guarantees or restrictive covenants&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease
expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU
assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance
in ASC Subtopic 360-10, Property, Plant, and Equipment &#x2013; Overall, to determine whether an ROU asset is impaired, and if so, the
amount of the impairment loss to recognize. See Note 2(G).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Principles
of consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
&lt;span&gt;consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions
have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Earnings
per ordinary share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;Basic
earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant,
gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares,
using the treasury stock method, from the assumed exercise of share options.&lt;/p&gt;  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000209">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Basis
of Preparation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S
GAAP&#x201d;).&lt;/p&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20220101to20221231" id="FFact_0000000000210">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Use
of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000211">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Foreign
currency&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d;
or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the
currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Monetary
assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets
and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Statements
of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction
dates, except for depreciation, which is translated using historical exchange rate.&lt;/p&gt; </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000212">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or
less at the date acquired.&lt;/p&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20220101to20221231" id="FFact_0000000000213">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Restricted
cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;Restricted
cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.&lt;/p&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201130501547">

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Property
and equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred.
Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets
are ready for their intended use.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Annual
rates at depreciation are as follows:&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201131108956">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement
        - over
        the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="FFact_0000000000214"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="2"
      id="FFact_0000000000215"
      unitRef="Pure">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="2"
      id="FFact_0000000000216"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <cmmb:AnnualRatesOfDepreciation
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="FFact_0000000000217">over
        the shorter of the lease term or the estimated useful life of the improvement</cmmb:AnnualRatesOfDepreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000220">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.&lt;/p&gt; </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20220101to20221231" id="FFact_0000000000221">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Research
and Development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Research
and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and
wages.&lt;/p&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000222">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Income
taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized.
In making such a determination, management considers all available positive and negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management
determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management
would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/p&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000223">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;J.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;ASC
820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for
measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant
assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date, essentially an exit price.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;In
addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described
below includes the Company&#x2019;s own credit risk.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As
a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation
methodologies in measuring fair value:&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar
or identical assets or liabilities.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due
to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates
their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;-
&lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred
during the periods presented.&lt;/p&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_20220101to20221231" id="FFact_0000000000224">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Share-based
compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified
and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation
cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting
schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation
cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing
model at the grant date, using the inputs detailed in Note 8(C).&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;The
Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000225">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Government-sponsored
research and development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Chemomab
records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that
the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants
as a reduction to research and development expenses.&lt;/p&gt; </cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock>
    <cmmb:SeverancePayPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000229">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:24.06pt"&gt;Severance
pay&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant
to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits,
at a rate of 8.33%
of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability
exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee.
This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142
thousand and $116
thousand for the year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; </cmmb:SeverancePayPolicyTextBlock>
    <cmmb:PercentageOfMonthlyDepositsRate
      contextRef="C_20220101to20221231"
      decimals="4"
      id="Fxbrl_20230215220314714"
      unitRef="Pure">0.0833</cmmb:PercentageOfMonthlyDepositsRate>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230215220321806"
      unitRef="usd">142000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230215220329094"
      unitRef="usd">116000</us-gaap:SeveranceCosts1>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_20220101to20221231" id="FFact_0000000000230">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Concentrations
of credit risk:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash
&lt;span&gt;and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold
the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
arrangements.&lt;/p&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230213125125767">

&lt;div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Under
&lt;/span&gt;&lt;/span&gt;Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities
are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the
Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what
its credit rating would be 5%
and 5.2%
in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based,
asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account
for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to
measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain
any residual value guarantees or restrictive covenants&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease
expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU
assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance
in ASC Subtopic 360-10, Property, Plant, and Equipment &#x2013; Overall, to determine whether an ROU asset is impaired, and if so, the
amount of the impairment loss to recognize. See Note 2(G).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <cmmb:IncrementalBorrowingRateOfLeases
      contextRef="C_20221231"
      decimals="2"
      id="Fxbrl_20230213132631771"
      unitRef="Pure">0.05</cmmb:IncrementalBorrowingRateOfLeases>
    <cmmb:IncrementalBorrowingRateOfLeases
      contextRef="C_20211231"
      decimals="3"
      id="Fxbrl_20230213132641931"
      unitRef="Pure">0.052</cmmb:IncrementalBorrowingRateOfLeases>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000232">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Principles
of consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
&lt;span&gt;consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions
have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000233">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Earnings
per ordinary share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;Basic
earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant,
gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares,
using the treasury stock method, from the assumed exercise of share options.&lt;/p&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000244">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note
3 - Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In USD&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;10,663&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,720&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In NIS&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,756&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,116&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In other currencies&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;100&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,350&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,519&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;15,186&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000243">

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In USD&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;10,663&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,720&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In NIS&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,756&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,116&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In other currencies&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;100&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,350&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,519&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;15,186&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000235"
      unitRef="usd">10663000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">10720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000237"
      unitRef="usd">2756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">1116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="FFact_0000000000239"
      unitRef="usd">100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="FFact_0000000000240"
      unitRef="usd">3350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">15186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000252">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note
4 - Other Receivables and Prepaid Expenses&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Government institutions&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;459&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;179&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,307&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,348&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,766&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,527&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  </cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000251">

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Government institutions&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;459&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;179&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,307&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,348&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,766&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,527&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">459000</cmmb:ReceivablesFromGovernmentInstitutions>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000246"
      unitRef="usd">179000</cmmb:ReceivablesFromGovernmentInstitutions>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">1307000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">1348000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000250"
      unitRef="usd">1527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000270">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note
5 - Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Cost:&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;70&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;43&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;33&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;399&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;364&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Website development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;14&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;16&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;532&lt;/strong&gt;&lt;strong&gt;
        &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;464
        &lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Less
        - accumulated depreciation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;165&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(107&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;367&lt;/strong&gt;&lt;strong&gt;
        &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;357
        &lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000269">

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Cost:&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;70&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;43&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;33&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;399&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;364&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Website development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;14&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;16&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;532&lt;/strong&gt;&lt;strong&gt;
        &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;464
        &lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Less
        - accumulated depreciation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;165&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(107&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;367&lt;/strong&gt;&lt;strong&gt;
        &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;357
        &lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000253"
      unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201032006902"
      unitRef="usd">532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">464000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">165000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">107000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201033845372"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000294">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
6 - Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;On
May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#x2013; &#x201c;The Agreement&#x201d; .(According
to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of three
years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233234992"&gt;May 2023&lt;/span&gt;. Chemomab was granted an option to
extend the lease term by additional three
years.&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;On
October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab
returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of 3
years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233722905"&gt;October 2024&lt;/span&gt;. In addition, Chemomab was granted an option to
extend the lease term by additional three
years. The annual rent and management fees are approximately $122
thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77
thousand was issued to the property owner during 2022.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The
above operating leases are included in &#x201c;Operating lease right-of-use assets&#x201d; on the Company&#x2019;s Consolidated Balance sheets
as of December 31, 2022 and 2021 and represent the Company&#x2019;s right to use the underlying asset for the lease term. The Company&#x2019;s
obligations to pay lease payments are included in the current liabilities as &#x201c;Operating lease liabilities&#x201d; and in the non-current
liabilities as &#x201c;Non-current operating lease liabilities&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December
31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#x2019;s existing lease
agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $345
thousand on December 12, 2021.&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;During
the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $17
thousand and $345
thousand, respectively.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As&#160;of
December 31, 2022, and 2021 operating right-of-use asset was $227
thousand and $345
thousand, respectively. The operating lease liabilities were $214
thousand and $343
thousand, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As
most of the Chemomab&#x2019;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information
available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#x2019;s incremental borrowing
rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 5%
in 2022 and 5.2%
in 2021.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Maturities
of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):&lt;/p&gt;

&lt;div style="margin-left:40pt;margin-bottom:0pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;126
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2024&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;93
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total future minimum
        lease payments&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;219
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Less imputed interest:&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;5&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Present value of
        operating lease liabilities&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;214
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20200510" id="Fxbrl_20230131233210356">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233301410">three
years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20211024" id="Fxbrl_20230131233734834">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230201000916081">three
years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <cmmb:AnnualRentAndManagementFees
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234005244"
      unitRef="usd">122000</cmmb:AnnualRentAndManagementFees>
    <cmmb:BankGuaranteesToPropertyOwner
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234014829"
      unitRef="usd">77000</cmmb:BankGuaranteesToPropertyOwner>
    <cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="C_20211212"
      decimals="-3"
      id="Fxbrl_20230131234456429"
      unitRef="usd">345000</cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131234508150"
      unitRef="usd">17000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131234513790"
      unitRef="usd">345000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143811730"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230214143818906"
      unitRef="usd">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143827206"
      unitRef="usd">214000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230214143833566"
      unitRef="usd">343000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230131234937485"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20210101to20211231"
      decimals="3"
      id="Fxbrl_20230131234957047"
      unitRef="Pure">0.052</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025037730">

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;126
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2024&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;93
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total future minimum
        lease payments&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;219
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Less imputed interest:&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;5&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Present value of
        operating lease liabilities&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;214
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000288"
      unitRef="usd">126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000289"
      unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000291"
      unitRef="usd">5000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">214000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000311">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
7 - Commitments and Contingent Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Exclusive
License Agreement (hereinafter- &#x201c;the License Agreement&#x201d;)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;In
December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv
Souraski Medical Center (&#x201c;Fund&#x201d;), pursuant to which it was granted with an exclusive license to certain inventions (as defined
in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant
to and subject to certain terms and limitation fully set in the License Agreement.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;Chemomab
has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term
defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(i)&lt;span style="padding-left:26.56pt"&gt;Royalties
in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to &lt;/span&gt;certain additional terms set
forth therein.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"&gt;&lt;span&gt;In
addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable,
non-creditable amounts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt"&gt;(a)&lt;span style="padding-left:24.9pt"&gt;$100
thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent
for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar
application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission
of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not
be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt"&gt;(b)&lt;span style="padding-left:24.34pt"&gt;$200
thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the
aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only
once.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"&gt;As
of December 31, 2022&#160;no payments were made to the Fund.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;In
addition to the payments described above, upon
the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction,
Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering,
or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction
of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in
any event not more than $3,000 thousand.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="padding-left:26.83pt"&gt;&#160;
&#160;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel &lt;/span&gt;Innovation Authority
(&#x201c;IIA&#x201d;) for the support of certain research and development activities conducted in Israel.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;In
return for the IIA&#x2019;s participation, Chemomab is committed to pay royalties at rate of 3%
of sales of the developed product (linked to U.S. dollar), up to 100%
of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology
or development out of Israel.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;Chemomab
did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;Since
Chemomab &#x2019;s incorporation through December 31, 2022 Chemomab received $1,227
thousand from the IIA, which were recognized as a reduction of research and development expenses.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;As
of December 31, 2022, Chemomab has no commitment for royalties payable.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="padding-left:26.28pt"&gt;In
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;June 2015, Chemomab entered into a license agreement with subcontractor (&#x201c;the Subcontractor&#x201d;), under
which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in
the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization
thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients.
According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with
Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements
for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to
pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt"&gt;During
2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $5,222
thousand and $2,590
thousand, respectively. The expenses were recorded under research and development expenses.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="padding-left:26.28pt"&gt;As&#160;&lt;/span&gt;&lt;/span&gt;of
December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $77
thousand for the purpose of secure lease payments under an office lease agreement.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span&gt;&lt;span style="padding-left:26.28pt"&gt;During&#160;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;2022,
the Israeli tax authority ("ITA&#x201d;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through
202&lt;/span&gt;&lt;span&gt;2&lt;/span&gt;&lt;span&gt;. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger
Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which
the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $1,046
thousand. The Company filed an appeal against the ITA&#x2019;s assessments. The Company has recorded an appropriate provision which considers
inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded
by the Company during the period&lt;/span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      id="Fxbrl_20230215222406006">$100
thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent
for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar
application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission
of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not
be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"
      id="Fxbrl_20230215222519809">$200
thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the
aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only
once.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:OtherCommitmentsDescription
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230215222713212">upon
the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction,
Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering,
or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction
of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in
any event not more than $3,000 thousand.</us-gaap:OtherCommitmentsDescription>
    <cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      decimals="2"
      id="Fxbrl_20230201002925810"
      unitRef="Pure">0.03</cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct>
    <cmmb:MaximumPercentageOfPaymentsOfRoyalties
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230201002935951"
      unitRef="Pure">1</cmmb:MaximumPercentageOfPaymentsOfRoyalties>
    <cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201002951961"
      unitRef="usd">1227000</cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213125722009"
      unitRef="usd">5222000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213125731080"
      unitRef="usd">2590000</us-gaap:RoyaltyExpense>
    <us-gaap:RestrictedInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230213125744104"
      unitRef="usd">77000</us-gaap:RestrictedInvestments>
    <cmmb:RecoverabilityOfVatAmount
      contextRef="C_20220701to20220731"
      decimals="-3"
      id="Fxbrl_20230207215117039"
      unitRef="usd">1046000</cmmb:RecoverabilityOfVatAmount>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000385">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
8 - Share Capital&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Right
attached to shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;font-style:italic"&gt;Ordinary
shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;All
of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary
shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote
and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when
the Company is dissolved.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Voting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;The
holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Dividends&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;The
holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally
available.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;Since
its inception, the Company has not declared any dividends.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="padding-left:26.83pt;font-weight:bold"&gt;Financing
rounds&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;In&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;connection
with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which
the Company agreed to sell approximately $45.5
million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement
closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270
ADSs together with warrants to purchase up to 261,929
ADSs at an exercise price of $17.35
per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds
of approximately $4.5
million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;On&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;April
30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp;amp; Co., ("Cantor").
According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to
$75
million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806
ADSs at an average price of $22.75
per ADS under the ATM Agreement, resulting in gross proceeds of $15,917
thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;On
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and
sale of up to $18,125,000&#160;of
its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject
to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third
of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;130,505
ADSs at an average price of $2.11
per ADS under the ATM Agreement, resulting in gross proceeds of $275
thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;On&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;September
19, 2022, the Company entered&#160; into a share purchase agreement (the &#x201c;Repurchase Arrangement&#x201d;) with Dr. Adi Mor, co-founder
of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together
with Dr. Adi Mor, the &#x201c;Co-Founders&#x201d;), whereby the Company agreed, subject to the requisite court approval required under Section
303(a) of the Israeli Companies Law, 5759-1999 (the &#x201c;Companies Law&#x201d;), which the Company received on November 14, 2022, to
repurchase up to 582,023&#160;ADSs
owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000,
depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the
entire amount of 582,023
ADSs from the Co-Founders at a weighted average price of $2.0848
and for total consideration of approximately $1,218
thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:110%"&gt;The
Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Share-based
compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;(1)&lt;span style="padding-left:24.34pt"&gt;Share-based
compensation plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"&gt;The
Company maintains (i) the 2011 Share Option Plan (the &#x201c;2011 Plan&#x201d;), (ii) the 2017 Equity-Based Incentive Plan (the &#x201c;2017
Plan&#x201d;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#x201c;2015 Plan&#x201d;), which was assumed by the Company from Chemomab
upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs
of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As
of December 31, 2022, a total of 28,443,060
of our Ordinary Shares (equal to 1,422,153
of ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520
Ordinary Shares (equal to 172,276
ADSs) had been issued pursuant to previous exercises options, and 23,460,740
&#160;Ordinary Shares (equal to 1,173,037
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 12,400,720
Ordinary Shares (equal to 620,036
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.30
per Ordinary Share (or $5.96
per ADS). During the year ended December 31, 2022, options to purchase 1,240,120
Ordinary Shares (equal to 62,006
ADS) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As
of December 31, 2022, a total of 12,511,620
of our Ordinary Shares (equal to 625,581
ADSs) were reserved for issuance under the 2017 Plan, of which 11,730,800
Ordinary Shares (equal to 586,540
ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 427,540
Ordinary Shares (equal to 21,377
ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.35
per Ordinary Share (or $6.98
per ADS). During the year ended December 31, 2022 no options were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt"&gt;(2)&lt;span style="padding-left:24.34pt"&gt;The
expenses that were recognized in the consolidated statements of operations for services received from employees &lt;/span&gt;and service providers
are as follows:&lt;/p&gt;

&lt;div style="margin-left:108pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;General and administrative&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total share-based
        compensation expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,211&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,019&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt"&gt;(3)&lt;span style="padding-left:24.34pt"&gt;The
number and weighted average exercise price of options are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:108pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted
        &lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;exercise
        &lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number
        of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life
        (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;exercise price&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number
        of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life
        (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at January
        1&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.38&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,003,260&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.07&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,455,580&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7.8&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Acquired in Merger&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;-&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;609,535&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.07&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,970,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.32&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,240,120&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1.25&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,712,275&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Granted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,398,400&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.8&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.62&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;17,784,640&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;9.79&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at December
        31&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.33&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.42&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.38&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;(4)&lt;span style="padding-left:24.34pt"&gt;Fair
value measurement:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt"&gt;The
fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate
the fair value of the options are as follows:&lt;/p&gt;

&lt;div style="margin-left:108pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;2022&#160;grants&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Weighted average
        share price (in U.S. dollar)&lt;sup&gt;(a)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercise price (in
        U.S. dollar)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.10&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;0.257&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected life of
        options (in years)&lt;sup&gt;(b)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;5.51&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;6.28&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected volatility&lt;sup&gt;(c)&lt;/sup&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;83.69&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;84.31&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest
        rate&lt;sup&gt;(d)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;1.75&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;4.14&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(a)&lt;span style="padding-left:24.34pt"&gt;The
weighted average share price is based on the Company&#x2019;s Ordinary Share valuation as at the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(b)&lt;span style="padding-left:24.34pt"&gt;Expected
life for the periods presented was determined according to the simplified method since, at the date of &lt;/span&gt;grant, the Company did not
have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration,
and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method
is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition
is not probable, the Company will use the awards&#x2019; contractual term if the service period is implied, or the simplified method, if
the service period is explicitly stated.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(c)&lt;span style="padding-left:24.34pt"&gt;Expected
volatility is based on historical volatility over the most recent period commensurate with the expected &lt;/span&gt;term of the option. As
the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term,
the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s
industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(d)&lt;span style="padding-left:24.34pt"&gt;The
risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the &lt;/span&gt;yields of U.S. Treasury
securities with maturities appropriate for the expected term of employee share option awards.&lt;/p&gt; </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133908909"
      unitRef="usd">45500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfWarrantsPurchaseUpAdss
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133843633"
      unitRef="Share">2619270</cmmb:NumberOfWarrantsPurchaseUpAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133849363"
      unitRef="Share">261929</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230213133830904"
      unitRef="USD_Per_Share">17.35</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133820824"
      unitRef="usd">4500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-6"
      id="Fxbrl_20230213133808746"
      unitRef="usd">75000000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133801744"
      unitRef="Share">699806</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20230213133754484"
      unitRef="USD_Per_Share">22.75</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133747440"
      unitRef="usd">15917000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="0"
      id="Fxbrl_20230213133711976"
      unitRef="usd">18125000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133726969"
      unitRef="Share">130505</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133719951"
      unitRef="USD_Per_Share">2.11</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133734136"
      unitRef="usd">275000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133614438"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:RepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="0"
      id="Fxbrl_20230213133621142"
      unitRef="usd">2500000</cmmb:RepurchaseOfAmericanDepositaryReceipts>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133633159"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="4"
      id="Fxbrl_20230213133700406"
      unitRef="USD_Per_Share">2.0848</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="-3"
      id="Fxbrl_20230213133643190"
      unitRef="usd">1218000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224906305"
      unitRef="Share">28443060</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223247056"
      unitRef="Share">1422153</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225529762"
      unitRef="Share">3445520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223254041"
      unitRef="Share">172276</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsIssuableOutstanding
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225556251"
      unitRef="Share">23460740</cmmb:NumberOfOptionsIssuableOutstanding>
    <cmmb:NumberOfAdssOptionsIssuableOutstanding
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223300376"
      unitRef="Share">1173037</cmmb:NumberOfAdssOptionsIssuableOutstanding>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225618055"
      unitRef="Share">12400720</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223309640"
      unitRef="Share">620036</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224602275"
      unitRef="USD_Per_Share">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223316544"
      unitRef="USD_Per_Share">5.96</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224845387"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223324626"
      unitRef="Share">62006</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225827725"
      unitRef="Share">12511620</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225729518"
      unitRef="Share">625581</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225858382"
      unitRef="Share">11730800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225738550"
      unitRef="Share">586540</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225916606"
      unitRef="Share">427540</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225743877"
      unitRef="Share">21377</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225929980"
      unitRef="USD_Per_Share">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225750293"
      unitRef="USD_Per_Share">6.98</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040228557">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;General and administrative&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total share-based
        compensation expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,211&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,019&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000338"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000339"
      unitRef="usd">137000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000340"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000341"
      unitRef="usd">1882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000342"
      unitRef="usd">3211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000343"
      unitRef="usd">2019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040244110">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted
        &lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;exercise
        &lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number
        of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life
        (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;exercise price&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number
        of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average
        &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life
        (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at January
        1&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.38&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,003,260&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.07&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,455,580&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7.8&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Acquired in Merger&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;-&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;609,535&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.07&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,970,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.32&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,240,120&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1.25&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,712,275&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Granted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,398,400&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.8&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.62&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;17,784,640&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;9.79&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:27%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at December
        31&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.33&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.42&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:10%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.38&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000345"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000346"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000347">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000348"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000349"
      unitRef="Share">10455580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20200101to20201231" id="FFact_0000000000350">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="0"
      id="Fxbrl_20230214225414206"
      unitRef="USD_Per_Share">0</cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000351"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024457584"
      unitRef="Share">609535</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000352"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000353"
      unitRef="Share">1970000</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024523067"
      unitRef="USD_Per_Share">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024530820"
      unitRef="Share">134220</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000356"
      unitRef="USD_Per_Share">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000357"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000358"
      unitRef="USD_Per_Share">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000359"
      unitRef="Share">1712275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000360"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000361"
      unitRef="Share">11398400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20220101to20221231" id="FFact_0000000000362">P7Y9M18D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000363"
      unitRef="USD_Per_Share">0.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000364"
      unitRef="Share">17784640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20210101to20211231" id="FFact_0000000000365">P9Y9M14D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000366"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000367"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20220101to20221231" id="FFact_0000000000368">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000369"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000370"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000371">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040432498">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;2022&#160;grants&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Weighted average
        share price (in U.S. dollar)&lt;sup&gt;(a)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercise price (in
        U.S. dollar)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.10&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;0.257&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected life of
        options (in years)&lt;sup&gt;(b)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;5.51&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;6.28&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected volatility&lt;sup&gt;(c)&lt;/sup&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;83.69&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;84.31&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest
        rate&lt;sup&gt;(d)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;1.75&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;4.14&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:84%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:12%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000373"
      unitRef="USD_Per_Share">0.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMinimumMember"
      decimals="INF"
      id="FFact_0000000000375"
      unitRef="USD_Per_Share">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMaximumMember"
      decimals="INF"
      id="FFact_0000000000376"
      unitRef="USD_Per_Share">0.257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember"
      id="FFact_0000000000377">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember"
      id="FFact_0000000000378">P6Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000379"
      unitRef="Pure">0.8369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000380"
      unitRef="Pure">0.8431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000381"
      unitRef="Pure">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000382"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000383"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000399">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note
9 - Research and Development&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Consultants and subcontractors&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,052&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,894&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,867
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,789&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;245&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;114&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;365&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;400&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16,977&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,334&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  </us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000398">

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Consultants and subcontractors&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,052&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,894&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,867
        &lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,789&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;245&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;114&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;365&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;400&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16,977&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,334&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000386"
      unitRef="usd">13052000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000387"
      unitRef="usd">3894000</cmmb:ConsultantsAndSubcontractorsExpense>
    <us-gaap:OfficersCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000388"
      unitRef="usd">2867000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000389"
      unitRef="usd">1789000</us-gaap:OfficersCompensation>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000390"
      unitRef="usd">245000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000391"
      unitRef="usd">114000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000392"
      unitRef="usd">448000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000393"
      unitRef="usd">137000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000394"
      unitRef="usd">365000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000395"
      unitRef="usd">400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000396"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000397"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <cmmb:GeneralAndAdministrativeDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000417">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note
10 - General and Administrative&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,435&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;943&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional services&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,596&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,695&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Fees to Directors&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Insurance&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,084&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,024&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;24&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,423&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;216&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,556&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,033&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  </cmmb:GeneralAndAdministrativeDisclosureTextBlock>
    <cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000416">

&lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,435&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;943&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional services&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,596&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,695&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Fees to Directors&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Insurance&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,084&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,024&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;24&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,423&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;216&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,556&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,033&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000400"
      unitRef="usd">3435000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000401"
      unitRef="usd">943000</us-gaap:SalariesAndWages>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000402"
      unitRef="usd">2596000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000403"
      unitRef="usd">1695000</us-gaap:ProfessionalFees>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000404"
      unitRef="usd">2763000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000405"
      unitRef="usd">1882000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">231000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201004651041"
      unitRef="usd">244000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">1084000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">1024000</us-gaap:GeneralInsuranceExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">24000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">29000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">1423000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">216000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000414"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000415"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000458">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Note
11 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Tax
rates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ordinary
taxable income in Israel is subject to a corporate tax rate of 23%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company&#x2019;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab
Inc. is subject to a federal flat tax rate of 21%
and state tax as applicable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Capital
gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Tax
assessments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As
of December 31, 2022, the Company&#x2019;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the
Israeli Tax Authority (&#x201c;ITA&#x201d;) due to statute of limitation rules effective in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company has not yet been assessed by the ITA since inception.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Losses
for tax purposes carried forward to future years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As
of December 31, 2022, the Company and its subsidiaries had approximately $159
million&#160;(approximately $143
million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation
on the period of use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On
March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and
Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA
provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on
interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes
provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January
1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Chemomab
Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net
operating losses. Chemomab Therapeutics Inc received $351
thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $183
thousand in 2023. Accordingly, a tax benefit in the total amount of $534
thousand was recorded in the Company&#x2019;s statement of operations during 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Deferred
taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In
respect of:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:72pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net
        operating loss carry-forwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based
        compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research
        and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less
        - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(36,030)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of
the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is
more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing
future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance
for the year ended at December 31, 2022 was an increase of approximately $5.2
million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Roll
forward of valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:72pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency
        transaction loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax
        assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency
        transaction Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Reconciliation
of theoretical income tax expense to actual income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A
reconciliation of the Company&#x2019;s theoretical income tax expense to actual income tax expense is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin-left:72pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss
        before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory
        tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical
        tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change
        in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(1,696&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax
        rate differential&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;20&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;744&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses
        and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,879&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual
        income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Accounting
for uncertainty in income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For
the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized
tax benefits will change significantly within the next 12 months. The Company&#x2019;s accounting policy is to accrue interest and penalties
related to unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL"
      decimals="2"
      id="FFact_0000000000418"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="2"
      id="FFact_0000000000419"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20221231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140532094"
      unitRef="usd">159000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20211231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140537759"
      unitRef="usd">143000000</us-gaap:TaxCreditCarryforwardAmount>
    <cmmb:ReceivedAmountOfChemomabTherapeuticsInc
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140710654"
      unitRef="usd">351000</cmmb:ReceivedAmountOfChemomabTherapeuticsInc>
    <cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember"
      decimals="-3"
      id="Fxbrl_20230213140716671"
      unitRef="usd">183000</cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140722797"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025152633">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net
        operating loss carry-forwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based
        compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research
        and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less
        - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(36,030)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000422"
      unitRef="usd">36550000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000423"
      unitRef="usd">33396000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">1774000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">1147000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">2858000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">1449000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">38000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000430"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000426"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000427"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="Fxbrl_20230201010356964"
      unitRef="usd">5200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025212924">

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency
        transaction loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax
        assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency
        transaction Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
        at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">6200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">2425000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201010515039"
      unitRef="usd">24535000</cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000440"
      unitRef="usd">2870000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000441"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201010936607"
      unitRef="usd">-1316000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">6481000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025228669">

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss
        before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory
        tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical
        tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change
        in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(1,696&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax
        rate differential&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;20&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;744&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses
        and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,879&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual
        income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000449"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20210101to20211231"
      decimals="2"
      id="FFact_0000000000450"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">-6481000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">-2870000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000453"
      unitRef="usd">-1696000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000454"
      unitRef="usd">-1332000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000453"
      unitRef="usd">20000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000454"
      unitRef="usd">-101000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000453"
      unitRef="usd">744000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000454"
      unitRef="usd">239000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000453"
      unitRef="usd">6879000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000454"
      unitRef="usd">4064000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230219173841544"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201011121606_Fact_0000000000454"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000477">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
12 - Related Parties Balances and Transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:10.28pt"&gt;Balances
with Related Parties:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;The
following Related Party payables are included in the consolidated Balance Sheets:&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Employee and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;891&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;278&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;58&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;72&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;949&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;350&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On September 19, 2022, the Company entered
into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:10.83pt"&gt;Transactions
with Related Parties:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;The
following transactions with related parties are included in the consolidated Statements of Operations:&lt;/p&gt;

&lt;div style="margin-left:36pt;margin-bottom:0pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,409&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,255&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based payments&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,466&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,775&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional Services&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;244&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;36&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;36&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;5,142&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,310&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230207220029774">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Employee and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;891&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;278&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued expenses&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;58&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;72&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;949&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;350&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;
        &lt;p&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">891000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000460"
      unitRef="usd">278000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">58000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">72000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">949000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">350000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025305978">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD
        thousands&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related
        expenses&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,409&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,255&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based payments&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,466&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,775&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional Services&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;244&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;36&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;36&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;5,142&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,310&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">2409000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">1255000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000468"
      unitRef="usd">2466000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">1775000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">231000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">244000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">5142000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000475"
      unitRef="usd">3310000</us-gaap:RelatedPartyCosts>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000488">

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note
13 - Net Loss Per Share Attributable to Ordinary Shareholders&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Basic
net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares
outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to
include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and
if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share,
as the effect of potentially dilutive securities is antidilutive.&lt;/p&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;The
following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods
presented:&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;In
        USD thousands, except share and per &lt;/span&gt;&lt;span style="font-weight:bold"&gt;share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,646&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;12,478&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt"&gt;Weighted-average
        number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;227,589,288&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;207,468,650&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss per share
        attributable to ordinary shareholders, basic and diluted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.121&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.060&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;The
potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders
for the periods presented since including them would have been anti-dilutive are as follows:&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Number
        of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding options
        to purchase ordinary shares&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025331788">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;In
        USD thousands, except share and per &lt;/span&gt;&lt;span style="font-weight:bold"&gt;share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,646&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;12,478&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt"&gt;Weighted-average
        number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;227,589,288&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;207,468,650&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss per share
        attributable to ordinary shareholders, basic and diluted&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.121&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.060&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000478"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213429326"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000481"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213444247"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000482"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213458553"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000483"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025347421">

&lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Number
        of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:#CCEEFF"&gt;
    &lt;td style="vertical-align:bottom;width:76%"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding options
        to purchase ordinary shares&lt;/p&gt; &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black"&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000485"
      unitRef="Share">35191540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000486"
      unitRef="Share">27003260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201020943165">

&lt;div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Note
14&#160;- Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On
January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $20,000,000
of its ADSs.&lt;/p&gt; &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <cmmb:SaleOfStockValueOfSharesIssuedInTransaction
      contextRef="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="Fxbrl_20230213104715713"
      unitRef="usd">20000000</cmmb:SaleOfStockValueOfSharesIssuedInTransaction>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#FFact_0000000000373"
          xlink:label="FFact_0000000000373"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025135527" xlink:label="FN20230201025135527" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted average share price is based on the Company&#x2019;s ordinary share valuation as at the grant date. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000373"
          xlink:to="FN20230201025135527"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000377"
          xlink:label="FFact_0000000000377"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025203207" xlink:label="FN20230201025203207" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#x2019; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000377"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000378"
          xlink:label="FFact_0000000000378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000378"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000379"
          xlink:label="FFact_0000000000379"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025249960" xlink:label="FN20230201025249960" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000379"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000380"
          xlink:label="FFact_0000000000380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000380"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000381"
          xlink:label="FFact_0000000000381"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025314607" xlink:label="FN20230201025314607" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000381"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000382"
          xlink:label="FFact_0000000000382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000382"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M6/7*9HS_&2"T <YO.5>GCEZ@_G/Q_P%02P,$%     @ 4C!65O3MWD+J!0
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M:V!^7PFAGT_LVX?V;=/B?U!+ P04    " !2,%96,-J?(*X"  #]!P  &
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ME<JV&6X?M-@T_>12:.A.F]L"_D P:0S@^TH(_?I@!NC^DJ3_ E!+ P04
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M:_CDO:(W0LEL(QZ5A!78IU@</=21S$PN<JO(]B#40PV.$\&*-4<8"'N]-AI
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M!,[ :,_M1<?MFXL'*;YS^=Q<+F;FXOSBX@%ZE[WTET+O\AYZ1\0T_[I:QB;
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MUH085+7=V6I/956P:IS#>$V+E> +6!7!?EL6IO X)9A5J+>@6,<1@W/S=FX
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MM_+GQJ'F"5R ]ZL:>DT_>$#__QIX_7]02P,$%     @ 4C!65F5/MOE= @
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M)0*UW(I&2:L+$_== [5EKHN,R[(R>@5.9UG8=U\OCEC2=T;6LB.: FE=UH5
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MC_+1XFC4H62R .VDT=S"\B::QY>W4[(/!G]*V+B]9TZ1+(SY3H/?LIMH3(1
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MT;$-"&)5BE!L7> MPLD=NNO.W*[E0,@,"P HVG_C13HT#R$/:L2R[0UI%]>
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M(I 3FBKJF/\)GN'::1P'<-[W\3Q+@,!YS/X<E+-#*$-<ACH_CYXS:SJ?!5/
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M7OKP)<*@C8>?/)])J7GT!W2,ZG (Y [)&C)6KH@W@M7C'PQM9&A0P1.K"A'
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MV%$O=G0*_7^]N)-,A_VXU@Y(-J1G]*U"Z"6SHB *S:4WK]'<!G-A::&KNG'
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M3V"&@.^&^TML:Q"N?9@]6_LNYW\R\E&1;[=7B*H;BQIMO$NP3A?*?E+)\;-
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M<#Z.J&GGMG;C=!UFI95V.'F%98FC+AA_ -^O-29'M_$$_?"\_!=02P,$%
M  @ 4C!65KM9'AML @  2@4  !D   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&ULC51-;]LP#+WW5Q#>L%,;?Z5=T24&DK3#.J!;46/;8=A!L>E8J"RYDMRT
M_WZ4['H9E@8[V"8I\NF1UM-LJ_2]J1$M/#5"FGE06]M>A*$I:FR8F:@6):U4
M2C?,DJLWH6DULM(7-2),HN@L;!B703;SL5N=S51G!9=XJ\%T3</T\Q*%VLZ#
M.'@)W/%-;5T@S&8MVV".]EM[J\D+1Y22-R@-5Q(T5O-@$5\LIR[?)WSGN#4[
M-KA.UDK=.^>ZG >1(X0""^L0&'T><85".""B\3!@!N.6KG#7?D'_Z'NG7M;,
MX$J)'[RT]3PX#Z#$BG7"WJGM)QSZ.75XA1+&OV';YZ9) $5GK&J&8F+0<-E_
MV=,PAYV"\^B5@F0H2#SO?B//\I)9ELVTVH)VV83F#-^JKR9R7+J?DEM-JYSJ
M;)9W:X,/'4H+5X_T-K/0$JQ;#(L!8ME#)*] Q G<*&EK U>RQ/)O@)#XC*22
M%U++Y"#B)1832.-C2*(D.8"7CDVF'B_]WR;AYV)MK*8C\6M?OSW:=#^:D\F%
M:5F!\X!T8% _8I"]>Q.?11\.<)V.7*>'T+.!X**RJ&')!),%0N[U23\8]]$]
M#/A%63R*IW "_X[AJSSZS&1':H0X]>-.P=8(*]6T3#Y#Q066=")M[</YU0H8
M27'#W?"\JHPE4HV#),?=$9"?Q,[P!=R8SC? 9 F&"0150=>"5? VB8ZCR#]'
M%.2NY\O<3/:-,-PYWPWJC5>Q@4)UTO9'?8R.%\6BU\>?]/Z6N6%ZPZ4!@165
M1I/WIP'H7KF]8U7KU;)6EK3GS9HN.]0N@=8K1?,<'+?!>'UFOP%02P,$%
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M>>XJ0E5;'T1JV.1<T2Z!=G\V%HJ%HU> 1IJA:H>GKZ9;:J;^:(J-4-,5)!R
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MT""<)[>4W#G8POAVLBC'%+-DK$E5\IDDL:GL_]S?6E?WT%.75*;M9=WV>M!
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M#-YARLQ[<?T+[T?4/3,U5Y885I2:GIR?QF!ZV?>&TVV0VEH[$FY8-C0IT?@
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M?1-!N02[OY+2[!W78'AE\[]02P,$%     @ 4C!65D[0(45X @  @04  !D
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M61FD(6S-FEX]L"& ]BMC<.N$ X9W-/\-4$L#!!0    ( %(P5E;1P/])CP0
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M_&XM%-!W8E,94=/1)[&H08_/I@:QK<2T&' N>QS^#1S&Z8ULS5K3Z[:$\B7
M%)W:>\:?/+OD)Q&OH AHQ'S*0\Y/X$7[2".'%WTK4B.+^[6L2U#Z)WK]M:O,
M(_T@#="_+Q;:*.3'/\?B[E'CXZBV9M[JC2C@W,.BT*"VX,U__(&EX<\G?([W
M/L>GT.=W6(-E5P.52VK60&&Y1#;;G;9YFU@^EK20#=:H%H[F^&<EM1$&L'B,
MMM)8P\J]UL<B/.G#\0C_ J$(V$R3@R6F#)H%*)NVEQN;0_M@Y//=%3%KV6G1
MEOK5[A;AA2K6%'=86EML&1L; XGCG+ H(^^AQ4!J]UZ46 Z539RM:\+]+(T(
M\_.<DT_2DOG@BLB+*X('NP9-(I\SAIHAF]$3V4KVV4J^.UMMYV*WCNY<9\ \
MB2TZO\(L/H J*@UTHZH"A@19SXXEYZ3)X\GY,A@DKPT29Y!\<+Z1O5E-OKQR
MD2BP#;UJ5TBNUM5&AS=:5TL@HZJECY@F/?ZOVLO(_C]#3_3A!T1Z?OS1&:1[
M6UH48>COHNWP^T(8"8,H)SSSPQ SG88D#QC'PS C+/3C)/&3/"19D).+ MN!
M0K?0Y VH%69N0B;XGX8S/XD27%T/H94]P(@R?Y:%"!V2,9G8PYR,6!3[G(?4
MGN!'8PF5<0H1=PH\#GW&>P46\ 05_(QQGV>).WNO1-LKL)0PYD>SW(_#WL4P
M2#EAF9_EL9_&(9D%V>QUY$\E1R(7>T2BQ&<SYB>QQ8CYT0LYQ?QTS_STNYDO
M-'[@^W33SK8G(VDAZJ*KL2.YWK04E:);47?[OC;0XQC_3QH^SG_+$;JR=WF$
M<*XK]/RDEF&?@[N EK*NA1K3D1CWEW_]@LA6D!P*6J&03FB(2<Q0>(-=&6U8
MVF)(9 B'/C.8CA9CD@0)0Z4TX/FSSE;BO52U_1B-BC')HR"=T3<3FL=!Q.@;
M<EOI^\E2 2 W#6",ABA[D:-RC!S*$BL;!RQ&T:MJ6Y78B>EC!36RB+XYFMOI
MP;306++;F4AC_76MZ0>'_>E^[+KHIXUG\7YFNQ%J56&@-2Q1-41W/*KZ.:C?
M&+EQL\="&IQDW'*-HR,H*X#OEQ(_P,/&&M@/H_-_ 5!+ P04    " !2,%96
M!'(]\JX"  #:!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R55-]O
MTS 0?O=?804)@126GVVZT49:5Q \3$PM R'$@Y-<FVB.'6RG'?\]YZ3-.M15
MXB7VV7???>?+?=.=5 ^Z!##TL>9"SYS2F.;*\W1>0LWTA6Q X,U:JIH9--7&
MTXT"5G1!-?="WQ][-:N$DTZ[LSN53F5K>"7@3E'=UC53?^; Y6[F!,[A8%EM
M2F,/O'3:L VLP-PW=PHM;T IJAJ$KJ2@"M8SYSJXFL?6OW/X5L%.'^VIK223
M\L$:GXN9XUM"P"$W%H'ALH4;X-P"(8W?>TQG2&D#C_<'](]=[5A+QC3<2/Z]
M*DPY<R8.+6#-6FZ6<O<)]O6,+%XNN>Z^=-?[1HE#\U8;6>^#D4%=B7YEC_MW
M. J8^"\$A/N L./=)^I8+IAAZ53)'576&]'LIBNUBT9RE;!-61F%MQ7&F70)
M&IC*2\I$01>PQ2XU^.:&OOG*,@[Z[=0SF,8Z>_D><MY#AB] !B&]E<*4FGX0
M!13/ 3SD-Y ,#R3GX5G$!>07- I<&OIA> 8O&HJ..KSH?XO^>9UIH_!/^76J
M[!XT/@UJI^=*-RR'F8/CH4%MP4E?OPK&_OLSE..!<GP./5WA-!8M!RK75!W3
M+Y[HG^)\%O4TYQ\(3L"VCAQML0=09Z!L'YX;MBGV$Y#[U8*84K8:B>E_K!LI
M-$X*$T9WO'6;Y?B7V,>62I,@<OU12")W<AF3%>-,5= [*N#,( %X1"'2H$GH
M3L8)"=QD<DF6MFO6R^J/ <%$#B2,1R0($*9D"M[9F2UH+FL;SJP4D#B>8,*$
M?#$EUC  1^,1B7V?!&/W,DG(V(VBF)[JG7<T;S6H3:<J&G.TPO2C-YP.PG7=
MS^N3>Z]ZMTQM*J$IAS6&^A?)R*&J5Y+>,++IIC>3!K6@VY8HOJ"L ]ZOI30'
MPR88Y#S]"U!+ P04    " !2,%96F5G>O\H"   0!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6R555%OVC 0?O>OL#)IVB36)$Y(H0,D:->M#]50
M63=-TQY,<I"HCLULIW3_?F<',CI1I+TX=^>[[[[S<<=HJ_2#*0$L?:J%-..@
MM'9S$88F+Z'FYDQM0.+-2NF:6U3U.C0;#;SP0;4(611E8<TK&4Q&WC;7DY%J
MK*@DS#4U35US_7L&0FW'01SL#7?5NK3.$$Y&&[Z&!=C[S5RC%G8H156#-)62
M5,-J'$SCBUGJ_+W#UPJVYD"FKI*E4@].N2G&0>0(@8#<.@2.GT>X!"$<$-+X
MM<,,NI0N\%#>HU_[VK&6)3=PJ<2WJK#E.!@$M( 5;X2]4]M/L*NG[_!R)8P_
MZ;;U3;. YHVQJMX%(X.ZDNV7/^W>X2!@$+T0P'8!S/-N$WF65]SRR4BK+=7.
M&]&<X$OUT4BNDJXI"ZOQML(X._D($C07E,N"3@M,4!FKN7LI^N8+7PHP;T>A
MQ43./<QWH+,6E+T &C-ZJZ0M#?T@"RB> X3(L*/)]C1G["3B%>1G-(E[E$6,
MG<!+NK(3CY?\?]D?GO ';X#^F"Z=+;<_CSU "Y\>AW>3=&$V/(=Q@*-B0#]"
M,'G]*LZB]R?(IQWY]!3Z9(&3630"J%K1]4$A_%DAQUB?Q#W.^CMP3<"UD1R(
MV ^HEZ!=3YXKKD'NB,G]XHK84C4&N9E_M 477%=@/&\-@EL$A?;E#4EZ:=(G
MPS0A<ZU68-P&P!H=HRK'>];K#S,2][)AGRQ*KN&=&\R"YJIV"-S-.SJ=9PDZ
M#0:,7 .FLHI>51JW@=((D<2$I2FYD:;17.: GM$@=2=+R1U(ZZFYM69!>@>T
MLR'Y;$NLM*,:]U*6$!8CG;C7[V<DZT5)0H]U.3R8TAKTVN\B@Z0;:=N![:S=
MNINV4_[7O=V5MURO*VFH@!6&1F?G_8#J=O^TBE4;/_-+97&#>+'$E0W:.>#]
M2BF[5UR"[D]@\@=02P,$%     @ 4C!65NM :EYW!   QPH  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULM59-<]LV$+WC5V#8+WM&CO@E2G(ES5AV
MVJ:3I![+20^='B!R)6)" @H 6G9_?1< Q<@-J_K2"PD0BX>W^W:7F.VE^J1+
M $,?ZTKH>5 :L[L<#G5>0LWT*[D#@2L;J6IF<*JV0[U3P JWJ:Z&<1AFPYIQ
M$2QF[MNM6LQD8RHNX%91W=0U4T]+J.1^'D3!X<,=WY;&?A@N9CNVA168#[M;
MA;-AAU+P&H3F4E %FWEP%5TN,VOO##YRV.NC,;6>K*7\9"=OBGD06D)006XL
M L/7 UQ#55D@I/&YQ0RZ(^W&X_$!_2?G._JR9AJN9?4[+TPY#R8!+6##FLK<
MR?TOT/HSLGBYK+1[TGUK&P8T;[21=;L9&=1<^#=[;./PD@UQNR%VO/U!CN4-
M,VPQ4W)/E;5&-#MPKKK=2(X+*\K**%SEN,\LWHA<UD#OV2-H>G;/UA7H\]G0
M(+0U&.8MS-+#Q/\"$\7TG12FU/2U**!X#C!$3AVQ^$!L&9]$O('\%4VB 8W#
M.#Z!EW2.)@XO^4]'Z0W7>25UHX#^<;761F%J_-GGLT=,^Q%MN5SJ'<MA'F ]
M:% /$"R^_R;*PA]/\$T[ONDI],4*RZ]H*J!R0S7?"K[A.1.&HA<[*4 8;5=,
M">X+$T\_:)N-H!04U*"73&LP?5Z=/+??*Q0#ZC4H*PAY-K'JV$=$/JQNB"EE
MHYDH]#]F[\$0[".*&2ZV%&.O:<Z4>KK KK)G"BV2;# :A21)!LDT(ZN2*;BP
MU580ZQXV >:*&![M&$@T&(]3?$;IF-PA2Z;RDN!1&((';#0[;!LV5-IH$@\F
MHPF:INF4_(;Q4B1*2#(A/RND0;X.F28IXDY'EE*8A.0MH-D%_<BJQG-@%78R
M)G(@9[0U/2=GWOK<N=H'>H$8)])BU*7%Z,5IH615T3:"=O[P-<4^_4\>T*__
MDE7.86;HKTPTV+VIK\R(?$NR ?X!R'6#'HO\B6 YH5J^YUJE48 T'A$L/.)#
M@9WX<\-=>$HEFVU):U!;S*<X'8R2$?&52FSL#G*CAN.0'+$XSL$#CU:O7B(M
MYEDT2**,GO>=D0W2273JC!C/\'J?$C+KA,Q>+B3D4N2\XEX]7]=2@<&2KRCW
MG>N(*S72_LZ:WL4^R4]2^7]*_JV5?@V8GG!$$C0633P91)/0%DV$N3&>X&AE
MF&F,5$].$NP3J'E"OO./^R_!<,MK$+#A!I&\9@CD$^2<7)=,;(%P00U@GU0V
M4PN^P7+$E, _'-*A^Y+GY;->B0M[M*!"&J<%=MN_L/-@MF13FRTV;9(8!S:)
M+;D.TW#D%(=H$4:X_EZ*"_S]-9AT^",EK2*:C-,479FZH.#4-BII6Q'E2/.8
M%>LK8KIGFNZ4?."(3=&V#0#=*%D?==.NF688C2E)!V&6DBN7)Z0GB<Z6'@;]
M&R4I!J^_00V/+A>N4.T5"D^4C3#^GM%][6YI5_YR\L7<7_'>,;7E0M,*-K@U
M?#7&5J3\M<E/C-RYJ\I:&KSXN&&)-TU0U@#7-U*:P\0>T-U=%W\#4$L#!!0
M   ( %(P5E;YZ")MY@(  .P&   9    >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;*55;6_:,!#^[E]A9=*T2:QY!]H!$K2;M@^5$+2;IFD?3'*0J$Z<V4XI
M_WYG)Z2P451I$@H^^^ZYYQ[G+J.MD \J ]#TJ>"E&CN9UM65ZZHD@X*I"U%!
MB2=K(0NFT90;5U426&J#"NX&GM=W"Y:7SF1D]^9R,A*UYGD)<TE5711,[F;
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MR:!\<@H]O6.Z))A,DMD!X+5@TJ$VH\GMH&8.RK[+;4JG-$[\[8B Z2!@>E+
MC:T(4H+ .Y?XKI%]C+H#B0ZHPR (QJEG _7L)/520<-X[NQ++$#5E^<8_^P5
M/YU$X_310!^==IYEJL52%YRMN>"&PRAS](KY?1A>'<EZ/'#')[GO[5O</\+C
MKN.1"X__M^T?] G;<O&1;3C6OX "PX++&.-5U\:ZB9&-:QUK:; 1N6&)G1^4
M/8#[A91F/['=:/@O2?\"4$L#!!0    ( %(P5E8,TK-)P0(  $\'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U576_3,!3]*U:8T"9!\]6&::21
M^@&"AZ%J9?" >'"=F\::8P?;;;=_C^VDH:W2"B%>$G_<<WS.M7V=[H1\4B6
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M%DIA@2LJ']CZ&S1^ LV7,"K,+UHWM8Z%DDI(EC=@I2 G17W%+TT?M@#NX C
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MZM SPTQ]E@#7!>KY@C&YF>B3K_W0B?\#4$L#!!0    ( %(P5E:?)<QIC (
M +0&   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*U5RV[;,!#\%4(-
MB@1(K9=EIZDL(+'[.A0UXJ0]%#W0TMHB0HDJ2=GNWW=)R:KCRD$.O4A\[(QF
MELM5O!7R4>4 FNP*7JJ)DVM=7;NN2G,HJ!J("DK<60E94(U3N795)8%F%E1P
M-_"\D5M05CI);-?F,HE%K3DK82Z)JHN"RM^WP,5VXOC.?N&.K7-M%MPDKN@:
M%J ?JKG$F=NQ9*R 4C%1$@FKB7/C7T\C$V\#OC'8JH,Q,4Z60CR:R>=LXGA&
M$'!(M6&@^-K %#@W1"CC5\OI=)\TP,/QGOV#]8Y>EE3!5/#O+-/YQ+ER2 8K
M6G-])[:?H/5C!::"*_LDVS;6<TA:*RV*%HP*"E8V;[IK\W  \(<G $$+"%X*
M"%M :(TVRJRM&=4TB:78$FFBD<T,;&XL&MVPTISB0DO<98C3R5>=@R1WD +;
MT"4'16B9D;F$BK*,O-]AM2A</%]@^60U!R)6Y&68"W(^ TT9Q]$;\K"8D?.S
M"W)&6$GN<U$KQ*C8U>C!*''35N]MHS<XH7<&Z8"$_B4)O"#H@4]?#O>?PEW,
M7)>^H$M?8/G"$WQ'IFTBFO3<* 5:D1\W2Z4E%NO//J\-^;"?W%S@:U71%"8.
MWE %<@-.\OJ5/_+>]3G_3V1/\A!V>0B?8T\^B@W($F^WQO-5FNG:7-+>\VV(
M(DMD>LPF&49O8W=S:.7?&'_\-^:)PF&G</BLPOU)05N>?=(:AM'A9T-O?*2M
M+VAXU2\NZL1%SXIK2H:FJ:A++!K972U;4-61]$MR+S3E?0ZBGL2-1D<.>H*B
M8'SDP#WH*::??Z%RC4=+.*P0Y@W&B)=-CVPF6E2VS2R%QJ9EASG^5D": -Q?
M":'W$].YNA]5\@=02P,$%     @ 4C!65A"J6NW- P  <!,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&ULM5A=;YLP%/TK%INF5NH*AH0T78*TI9LV
MJ9NB=1\/TQX<N&FL 6:V2=9_/QLHA(1XS41>$B#WGIQ[[S$</-DP_DNL "3Z
MD\2IF%HK*;-KVQ;A"A(B+ED&J?IER7A"I#KE][;(.)"H2$IBVW4<WTX(3:U@
M4ER;\V#"<AG3%.8<B3Q)"']X S';3"UL/5[X3.]74E^P@TE&[N$.Y-=LSM69
M7:-$-(%44)8B#LNI]1I?SUQ')Q01WRALQ-8QTJ4L&/NE3SY$4\O1C""&4&H(
MHK[6,(,XUDB*Q^\*U*K_4R=N'S^BORN*5\4LB( 9B[_32*ZFUI6%(EB2/):?
MV>8]5 4--5[(8E%\HDT5ZU@HS(5D296L&"0T+;_)GZH16PEX<"#!K1+<IR9X
M58)7%%HR*\JZ(9($$\XVB.MHA:8/BMX4V:H:FNHQWDFN?J4J3P9SKA3!Y0,B
M:83>_LYIIF8D+] GI:"S.R6:*(\!L24R!)ZCLQN0A,;B'+U$7^]NT-GS<_0<
MT11]6;%<J PQL:5BJ__3#BMF;TIF[@%F-Q!>(@]?(-=QW8[TV=/3<3O=5CVJ
M&^76C7(+/.\?C;I \YBDLMT&].-6A:,/$A+QLZO4$GO0C:V7ZK7(2 A32ZU%
M 7P-5O#B&?:=5UV%]P36:H-7M\$SH0<S)F17@676L,C2MXYU,/34U-;;O/=C
M!OZ@CFG1&=1T!D8ZMR"$TAP)PSS)8R(A4FM8E1U2HN\274Q+0'^+Q4OL#W>H
M=@4YHVZNPYKKT,BU7D&E@%ZW!*2641?9X1X/SQ_M<.V(&1Z@ZM=4_7],.<ER
M"5R@'Q\A60#O%+41XUA1]P36*G=4ESLZX=H>]=F&GL!:;;BJVW#U7VO[:D]@
M(V='@_LA Z];@N.:S-A(YEW.4RIS#L4TH)F&09!&Q&,GT1-8JWCL-(]EYX22
MK,![ZD1?:.U6;#D4_%^RK-):-SYO1Y<=,>Z!>R-NG  V/F&#6[)@G$C&'YZH
M2S/>T>,XQ?,?-P8 >Z=4IM%>'-V*GM#:K6C,!S:[CX/*W+</WGB\*\V.H$-V
M"#<> YM-QG=8""I!N:"U>D5[@C2-<$?/HR>T=O&-:\'^*:79JY_I"ZW=BL;1
M8*-3."S-T9[J\&!7F<:8-J'&6V"SN;@%];*]8G&$:))QM@8]$[._-",>/9">
MT-KU-W8&CT^IS5ZM35]H[1?IQMNX1L-P4)M5VO8+(O9WM&F.*0G96]LA>B_J
M(^'W-!4HAJ5*<BY'*IN7VSOEB619L4.R8%*RI#A< 8F ZP#U^Y(Q^7BB-UWJ
M3;;@+U!+ P04    " !2,%96LS7(U9\$  "1&   &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6RMF5U/ZS88Q^_W*:SL: ():%[Z JRM1$FK(<$..HSM
M8MJ%29ZV%HG=8[N4?OO93AJ:XN:TFV]HG/C_]\LO?F(_]%>,OXHY@$3O>4;%
MP)M+N;ANM40RAQR+"[8 JIY,&<^Q5$4^:XD%!YP:49ZU0M_OMG),J#?LFWN/
M?-AG2YD1"H\<B66>8[X>0<96 R_P-C>^D=E<ZANM87^!9_ $\GGQR%6I5;FD
M) <J"*.(PW3@W037DR#2 E/C3P(KL76-]%!>&'O5A;MTX/FZ1Y!!(K4%5C]O
M< M9IIU4/[Z7IE[5IA9N7V_<)V;P:C O6, MR_XBJ9P/O$L/I3#%RTQ^8ZO?
MH!Q01_LE+!/F+UH5=7M=#R5+(5E>BE4/<D*+7_Q>3L26(&CO$82E(-P5=/8(
MHE(0[0KV=:E="MJ'=JE3"CJ'"KJEH&OFOI@L,],QEGC8YVR%N*ZMW/2%P674
M:H()U6_6D^3J*5$Z.;P'A46@D]\QYUA#/D4G,4A,,G&*SM'S4XQ.OIRB+XA0
M],><+06FJ>BWI&I:&[22LIG;HIEP3S,!>F!4S@4:TQ12BS[^@3YL,&BI,5<#
M#S<#'X6-C@]XC0+_#(5^Z-O&TZS^FL@+%+:-/+ -IUD>0W*!HL#(0XM\?+C<
MUOKD 'D0VN2UJ8RJ=R@R?M'>=T@(@#-DWJ4S%(-(.%F8P/'WO:J+[B3DXA]+
M1T>%<=MNK*/JM5C@! :>"IL"^!MXPU]^#KK^KS9D+LUBEV9CEV831V8UU.T*
M=;O)O0@72 +/;32;M1%: ^;6X/%?A7&C\%A*+LTFCLQJE#H5I<X!E.!]0?@:
MI5B"#5:SA0Z/.L+H&!'9D#7+37S<Z-LV<HWZ8\FY-)LX,JN1ZU;DN@>NKS/$
MBA JF2(I@=J^FJ-F-SGG #_M777_1QPWBH_EY])LXLBLQJ]7\>LU3MH-I4N<
MJ2TWE4CME-1.C:K]>:Z+4P#;1(X:#8_]!!9F'6.F#Q5O:N>D-AAOV^1<-CAV
M:39Q9%8C=UF1NVPD-\+T%<V6F&,J%2F][!9<'>"X7".VHL!M[!HMCV5W^8E=
MK[>#SF5[8Y=F$T=F-717%;JKYH^-HJ3.+G2&,A,^N3Y-GK/I^5(5L-J;2NO"
M:S0]%IY+L_CJTYL0ACNOPOASG:C=J=>9..I4#4K@?YPL_:.P9 2_D(Q(8H^#
MS6['\G#J%I=NW6TB07N'B*52U(YVD+CJ5YW)UFD_.)")R2&AKU/TK-#<F$6"
M;M07ZZ-&L1>Y_P&UQO:.IN;2+7;J-G;J-BG=]JW?.M[P V_8B/>.)MQ0(VK?
M. >48,[7FB7.V5+M0=C4W/X<(%&Z!/W)(_D"$Z[W*U;8C:T?#=NE6URZU;8^
MNS'34N=ST'35K3K"CUQ*T'A^+Q!J &H;^<*XTFM^:DF"R:"F2!T)5(V42%2L
M4RLHIWD5IVYQZ18$6Q3\"[^SRZJLYN]4"W=Q.4V'M+8RJ3GPF<EY"Y3HU5/D
M%JN[55[]QF23=^['P?6XR(Y_V!3)^@?,9X0*]5&<*DO_HJ=>1U[DOXN"9 N3
MKWUA4K+<7,X!I\!U!?5\RIC<%'0#U7\AAO\"4$L#!!0    ( %(P5E8@5GM%
MT@(  & (   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U676_:,!3]
M*U9639W4-N0#6!E$:D'3)K5K5=KM8=J#22Y@U8DSVX'R[W?MI!F%-*O07A)_
MW'-\SHU]G>%:R$>U!-#D*>69&CE+K?.!ZZIX"2E59R*'#&?F0J948U<N7)5+
MH(D%I=SU.YV>FU*6.='0CMW*:"@*S5D&MY*H(DVIW%P"%^N1XSG/ W=LL=1F
MP(V&.5W %/1#?BNQY]8L"4LA4TQD1,)\Y%QX@W'?Q-N [PS6:JM-C).9$(^F
M\S49.1TC"#C$VC!0?*U@#)P;(I3QN^)TZB4-<+O]S/[9>D<O,ZI@+/@/ENCE
MR/GHD 3FM.#Z3JR_0.6G:_ABP95]DG45VW%(7"@MT@J,"E*6E6_Z5.5A"^"%
MKP#\"N"_%1!4@, :+9596Q.J:3248DVDB48VT["YL6ATPS+S%:=:XBQ#G(ZN
M '.@R/$4MT=2<"!B3JZI+B33&].V\^2*T1GC3#,,?<@2D.2FD.2;R$YCFL7
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M=<[Z")?E?59VM,CME3 3&B\8VUSB+P!($X#S<R'T<\?<,O5/1?0'4$L#!!0
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M^Y<\9G.=+O$3;628"8,&(8_2__0I(Z(D #CU EXFX&T)O+C"(!,8;*]P](+
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MK@.>=G:%CZ2+X4(T@'H\$I FH8&I]_B6_*3J\9N/(&[CMX&TGH,TOND88-.
M;MM%9!OQ>M_0O,C.SCYXWCDXA\Y@JPAJ:]$J<YO/'F[S)X4)C;F!&#$. H[;
M#^T#N$-C%F_U@T>K:-.VT*ID;KI8][CM+-YJK]HJVK0MM"J9F\;6;>YLV\SB
MK7:WK^B]YSW+XAC$%]B2HR&0 ZN9-@__(54/#+_1HZT0J,$K*XFJ#U*8'UY.
M-MN9HU.3.4@U<PS_G\S1P<Q1^]FIK;U)3UF_=&$2,K6P%T^:V,]IZ15!,5I<
M;HWME<[6^ 0OO>Q%S 8FO3&[H6K!(4X*-@=(Y_ $W$2EEU#IBY&QO9:926-D
M:!^7#(A0. %^GTMI\A=<H+@*'/T#4$L#!!0    ( %(P5E;@F]QX> H  $U]
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+6=77.;2!:&_PJEG=I-
MJF8MNOF0E+5=Y9CNAJI-)A5G=BZF]H)(K8^*!!K =N;?+R L:$!MR+P[%V-+
MUGF.L)] TV\+KI_CY%NZE3(SOA_V47HSV6;9\=UTFBZW\A"F5_%11OE/UG%R
M"+/\8;*9IL=$AJNRZ+"?4M-TIX=P%TUNK\OG/B6WU_%CMM]%\E-BI(^'0YC\
M^5[NX^>;"9F\//%YM]EFQ1/3V^MCN)$/,OOU^"G)'TW/E-7N(*-T%T=&(M<W
MDSOR+K#=HJ!\Q7]V\CEM?&\4F_(UCK\5#X+5S<0LWI'<RV56(,+\RY.\E_M]
M0<K?QQ\5='+N610VOW^A\W+C\XWY&J;R/M[_MEMEVYO)?&*LY#I\W&>?XV=?
M5AOD%+QEO$_+_QO/I]>Z><?E8YK%AZHX?WS81:>OX??J%]$H(/:% EH5T':!
M<Z' J@JLH1WLJL >6N!4!<[0 K<J<-L%[H6"654P&]IA7A7,AQ8LJH)%J</I
M[U?^\;TP"V^OD_C92(I7Y[3BF]*@LCK_F^^B0O:'+,E_NLOKLMN';9A(XSX\
M[K)P;[SY&"9)6.CWUGCCR2S<[=.WQC^-7Q\\X\U/;Z^G6=ZR*)PN*_S]"4\O
MX(GQ(8ZR;6JP:"57/?7BE7JJ 4SS;3UO,'W9X/=42_P0)E<&<7XVJ$E)WP;I
MRS_&3WFY6Y;3GG)/7_X@CWGYXF(YTY??'?,W;YD7WSP?L.W4NE@N].6>7.;=
MR<4W[P\O[^L>#/C55=M.-2)89_.MDF==XH5[:?RR-AZR>/G-^/W?^8^-().'
M]+\][^W]B67WLXHCTKOT&"[ES20_Y*0R>9*3V[__C;CFO_H40\(\)(PA81P)
M$TB8CX0%()@BL7V6V-;1;W\Y%D.&U,ABX_B8++?Y8=^X\QZ,91@M\P%$[R[W
MO18YUF4DS$/"&!+&D3!Q@KDEK!B-/N7'.=LDU+R>/C4U[7G=C% Z<]37!: W
MIQCHG UTM 92DSC&<1]&QN\?Y.&K3'IWGUK&6.60, \)8T@81\($$N8C80$(
MILCKGN5U@6, %RDQ$N8A80P)XTB80,)\)"P P12)9V>)9]H]\,?'8K=KQ.OB
MR)\:NS1][#_N:S%C_47"/"2,(6$<"1.SGN-Y?CAW6X=]9,\ !%/,G)_-G \T
M,RUWL%6'E;&.D]+38I3:9ZH6.]94),Q#PA@2QI$P,>^82N>V;9EN>XB*[!J
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M4F.=Q <C+>0^#7C_T3OBK6A.\VS6<<SB/_4X=J_O.]I5:! &I?'>WTG/KT1
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MO;X^00'WJ0G_@'].QC';H/7#-X0D-Q)B\:M*X.S\5O7YZF*X$BGU8&C@ER^
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MF P0]Y=%P5]/Y /:/>+Y?U!+ P04    " !2,%960T332Y4&   (%@  &0
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ME]2!I\]']H^E=_2RI!*F//^6)2H=&Z%!$EC1;:[F?/\)#GX&FB_FN2Q_R?Z
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MZ&)BD&1[2VD[6FS=07\OM+DVN&9M;G8@;8!YOA9"/W7L!/U=L?@74$L#!!0
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M)*@@*=J1=$NJD)/*H$?R$/J@:L6'0JW$)J68"L0[?R+C\MS>M6$9&K$#:]+
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M7760S]>4BL<;-4!3(?5_ 5!+ P04    " !2,%96^1:!!%8#  #("P  &0
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M3Z+]*LWES4[J(*'FZS%ZFO,!2^"ZR[!'/+3R(\?OW?-D,JP+H1<=]&(2^G=
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M>LO>^H2:;]TK?\/4G?N6J54N-'!<$J1W-2!.JNZ&]<3(==50%M)0>ZJ&&?U
MH+(&]'TII7F>V W:7Y+X%U!+ P04    " !2,%96$[YQ&.L#  !-"P  &0
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MZ=T/"8^J9[=Z8>2V&G]6TM P57UF-.^BL@+T?RVE.2[L <T$/?L74$L#!!0
M   ( %(P5E8=I.I2U0(  +X)   9    >&PO=V]R:W-H965T<R]S:&5E=#4T
M+GAM;+5676^;,!3]*Q:KID[:RE<@H2-(;;)IE58I:MKMH=J# S<)JL',=I+F
MW\\V!)% LU;+7L"&>P[G'NZU'6XH>^)+ (&>,Y+SH;$4HK@T31XO(</\@A:0
MRS=SRC(LY)0M3%XPP(D&9<1T+,LW,YSF1A3J9Q,6A70E2)K#A"&^RC+,MM=
MZ&9HV,;NP5VZ6 KUP(S" B]@"N*AF# Y,VN6),T@YRG-$8/YT+BR+T>!BM<!
M/U+8\,88J4QFE#ZIR4TR-"PE" C$0C%@>5O#" A11%+&[XK3J#^I@,WQCOVK
MSEWF,L,<1I3\3!.Q'!H# R4PQRLB[NCF&U3Y>(HOIH3K*]I4L9:!XA47-*O
M4D&6YN4=/U<^- !V[P6 4P&<UP+<"N#J1$ME.JTQ%C@*&=T@IJ(EFQIH;S1:
M9I/FZB].!9-O4XD3T1T0+"!!$\Q$"AQ=8X+S6 YPGJ![AG..M=\<G4]E!24K
M HC.41.VE=<MGA'@']#Y& 1.B1Q]0@_3,3H_^X#.4)JC^R5=<<G)0U-(V>KC
M9EQ)O"XE.B]('$-\@5S[(W(LQ^F CUX/M_?AIC2K=LRI'7,TG_L*Q[9-B]#C
M=QF*;@1D_%=7FB5OKYM7M>LE+W ,0T/V(P>V!B-Z_\[VK<]=29^(;,\"M[;
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M5]B$S##!SP00V@#W5YRK_40_H/[P"/\"4$L#!!0    ( %(P5E;73,?31P,
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M1I%5H\BJ4635*++J_Y3UR=KU7__;T-_SUM3=>SX;?B"Y>@502P$"% ,4
M" !2,%96!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( %(P5E:+V5E([0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %(P5E:97)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 4C!65J?V^[OH @  Q0@  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %(P5E;T[=Y"
MZ@4  'D:   8              " @2H+  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " !2,%96,-J?(*X"  #]!P  &
M@(%*$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4C!6
M5D5G=IO6 P  G@P  !@              ("!+A0  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( %(P5E8)@G'&_04  -LA   8
M      " @3H8  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" !2,%96<EW,B:(&  #S'   &               @(%M'@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 4C!65A_>A:/L"0  :1<  !@
M             ("!124  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( %(P5E:[@"H'"Q(  $$P   8              " @6<O  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !2,%9694^V^5T"  !Q
M!0  &               @(&H00  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ 4C!65O:"1B=D @  E 4  !D              ("!.T0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !2,%967ML0
M]J<"  #8!0  &0              @('61@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( %(P5E;%?-KSA@4  /P-   9
M  " @;1)  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M4C!65KR;6R ^"0  !A<  !D              ("!<4\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " !2,%96[V(\;4X)  !K%P  &0
M            @('F6   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( %(P5E8?KKE0H0(  .<%   9              " @6MB  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 4C!65EY?"N^^ @
M( 8  !D              ("!0V4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " !2,%96R2KW*= )  #S%P  &0              @($X
M:   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %(P5E:'
ME!Q 9@,   ,(   9              " @3]R  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ 4C!65FZ4CB ^!   2 L  !D
M     ("!W'4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %(P5E:^+F*:<0(  '$%   9              "
M@?V5  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 4C!6
M5D[0(45X @  @04  !D              ("!I9@  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " !2,%96HX*KUK$"  #(!0  &0
M        @(%4FP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( %(P5E9>+W,,? (  %,%   9              " @3R>  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 4C!65M' _TF/!   F H
M !D              ("![Z   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " !2,%96!'(]\JX"  #:!0  &0              @(&UI0
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %(P5E:96=Z_
MR@(  ! &   9              " @9JH  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ 4C!65NM :EYW!   QPH  !D
M ("!FZL  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !2
M,%96^>@B;>8"  #L!@  &0              @(%)L   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %(P5E;2+KF&/0,  !$(   9
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M970S-RYX;6Q02P$"% ,4    " !2,%96''1@HY<"  #T"   &0
M    @(&QP@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M %(P5E:?)<QIC (  +0&   9              " @7_%  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ 4C!65A"J6NW- P  <!,  !D
M             ("!0L@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " !2,%96LS7(U9\$  "1&   &0              @(%&S   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %(P5E8@5GM%T@(
M & (   9              " @1S1  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ 4C!65GI$Z7F_!@  %AP  !D              ("!
M)=0  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !2,%96
MX)O<>'@*  !-?0  &0              @($;VP  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( %(P5E;[ O3O*@,  ,<+   9
M      " @<KE  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ 4C!65IVH'C*#!   +Q8  !D              ("!*^D  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !2,%960T332Y4&   (%@
M&0              @('E[0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( %(P5E9>=W- '@,  "$)   9              " @;'T  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 4C!65HOCGU)(
M P  -PH  !D              ("!!O@  'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " !2,%96/'!*(!<$   M%0  &0
M@(&%^P  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %(P
M5E;Y%H$$5@,  ,@+   9              " @=/_  !X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ 4C!65HX^+R47 P  G@@  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( %(P5E:ZE\)!C (   0&   9
M  " @9,4 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M4C!65H1ME&8; @  S@0  !D              ("!5A<! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " !2,%960OL5LDH#  #P%   #0
M            @ &H&0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %(P5E:7
MBKL<P    !,"   +              "  1T= 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( %(P5E8>,JZ^M@0  )\F   /              "  08> 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !2,%96$R?LNN\!  "E(@  &@
M        @ 'I(@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !2,%968B/G&-@!  !((@  $P              @ $0)0$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     0@!"  42   9)P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Statements of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Other Receivables and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</Role>
      <ShortName>Other Receivables and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Research and Development</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopment</Role>
      <ShortName>Research and Development</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - General and Administrative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrative</Role>
      <ShortName>General and Administrative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/EventsAfterBalanceSheetDate</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - General (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralTables</Role>
      <ShortName>General (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/General</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapital</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Research and Development (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentTables</Role>
      <ShortName>Research and Development (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - General and Administrative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeTables</Role>
      <ShortName>General and Administrative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrative</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</Role>
      <ShortName>Related Parties Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - General (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralDetails</Role>
      <ShortName>General (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails</Role>
      <ShortName>General (Schedule of net assets acquired based on their estimated fair value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Share Capital (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share Capital (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails</Role>
      <ShortName>Share Capital (Schedule of Share-based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails</Role>
      <ShortName>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails</Role>
      <ShortName>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails</Role>
      <ShortName>Research and Development (Schedule of Research and Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails</Role>
      <ShortName>General and Administrative (Schedule of General and Administrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrativeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zk2329281.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0058 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/EventsAfterBalanceSheetDate</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LeaseExpirationDate1 -  zk2329281.htm 19, 20</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1/A" original="zk2329281.htm">zk2329281.htm</File>
    <File>cmmb-20221231.xsd</File>
    <File>cmmb-20221231_cal.xml</File>
    <File>cmmb-20221231_def.xml</File>
    <File>cmmb-20221231_lab.xml</File>
    <File>cmmb-20221231_pre.xml</File>
    <File>exhibit_23-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cmmb_img01.jpg</File>
    <File>cmmb_img02.jpg</File>
    <File>image00003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="411">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2329281.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 411,
    "http://xbrl.sec.gov/dei/2022": 8
   },
   "contextCount": 80,
   "dts": {
    "calculationLink": {
     "local": [
      "cmmb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmmb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2329281.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmmb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 446,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 5
   },
   "keyCustom": 71,
   "keyStandard": 182,
   "memberCustom": 8,
   "memberStandard": 23,
   "nsprefix": "cmmb",
   "nsuri": "http://www.anchiano.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - Other Receivables and Prepaid Expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses",
     "shortName": "Other Receivables and Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.anchiano.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - Commitments and Contingent Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - Share Capital",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.anchiano.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - Research and Development",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopment",
     "shortName": "Research and Development",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - General and Administrative",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrative",
     "shortName": "General and Administrative",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.anchiano.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - Related Parties Balances and Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions",
     "shortName": "Related Parties Balances and Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepositsAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.anchiano.com/role/EventsAfterBalanceSheetDate",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - General (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.anchiano.com/role/GeneralTables",
     "shortName": "General (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - Cash and Cash Equivalents (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsTables",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables",
     "shortName": "Other Receivables and Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.anchiano.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0028 - Disclosure - Share Capital (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.anchiano.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - Research and Development (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentTables",
     "shortName": "Research and Development (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.anchiano.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - General and Administrative (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeTables",
     "shortName": "General and Administrative (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.anchiano.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - Related Parties Balances and Transactions (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables",
     "shortName": "Related Parties Balances and Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - General (Narrative) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.anchiano.com/role/GeneralDetails",
     "shortName": "General (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails",
     "shortName": "General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cmmb:SeverancePayPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cmmb:SeverancePayPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
     "shortName": "Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231_srtCurrencyAxis_currencyUSD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
     "shortName": "Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.anchiano.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "strong",
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "strong",
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20200510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - Leases (Narrative) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.anchiano.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20200510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails",
     "shortName": "Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
     "shortName": "Commitments and Contingent Liabilities (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0044 - Disclosure - Share Capital (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
     "shortName": "Share Capital (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember",
      "decimals": "INF",
      "lang": null,
      "name": "cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails",
     "shortName": "Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails",
     "shortName": "Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "0",
      "lang": null,
      "name": "cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
     "shortName": "Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
     "shortName": "Research and Development (Schedule of Research and Development) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
     "shortName": "General and Administrative (Schedule of General and Administrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - Consolidated Statements of Changes in Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.anchiano.com/role/StatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0050 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.anchiano.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails",
     "shortName": "Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
     "shortName": "Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "cmmb:CurrencyTransactionLossValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
     "shortName": "Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails",
     "shortName": "Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cmmb:SaleOfStockValueOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0058 - Disclosure - Subsequent Events (Narrative) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cmmb:SaleOfStockValueOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - Statements of Cash flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.anchiano.com/role/StatementsOfCashFlows",
     "shortName": "Statements of Cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - General",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.anchiano.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - Cash and Cash Equivalents",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalents",
     "shortName": "Cash and Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329281.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "cmmb_AdditionalWorkOrderAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional work order amount.",
        "label": "Additional Work Order Amount",
        "verboseLabel": "Additional work order"
       }
      }
     },
     "localname": "AdditionalWorkOrderAmount",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateAmountCommitmentToPay": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount commitment to pay.",
        "label": "Aggregate amount commitment to pay"
       }
      }
     },
     "localname": "AggregateAmountCommitmentToPay",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateAmountOfCommitmentPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of commitment paid.",
        "label": "Aggregate amount of commitment paid"
       }
      }
     },
     "localname": "AggregateAmountOfCommitmentPaid",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a aggregate offering price of at the market offering agreement.",
        "label": "Aggregate Offering Price Of At Market Offering Agreement",
        "terseLabel": "Aggregate offering price of at the market offering agreement"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfAtMarketOfferingAgreement",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares [Member]",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_AnnualRatesOfDepreciation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rates of depreciation.",
        "label": "Annual Rates Of Depreciation",
        "verboseLabel": "Annual rates of depreciation"
       }
      }
     },
     "localname": "AnnualRatesOfDepreciation",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_AnnualRentAndManagementFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rent and management fees.",
        "label": "Annual rent and management fees"
       }
      }
     },
     "localname": "AnnualRentAndManagementFees",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM agreement [Member]",
        "label": "ATM agreement [Member]"
       }
      }
     },
     "localname": "AtmAgreementMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_BankGuaranteesToPropertyOwner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantees to property owner.",
        "label": "Bank guarantees to property owner"
       }
      }
     },
     "localname": "BankGuaranteesToPropertyOwner",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 20.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of of asset held for sale recogized prior to the completion of merger.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale",
        "verboseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 0.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CantorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about Cantor.",
        "label": "Cantor [Member]"
       }
      }
     },
     "localname": "CantorMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_CapitalAdditionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FDA or equivalent agency marketing approval [Member]",
        "label": "Capital Additions One [Member]",
        "verboseLabel": "FDA or equivalent agency marketing approval [Member]"
       }
      }
     },
     "localname": "CapitalAdditionsOneMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_CashAcquiredInMerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash acquired in merger.",
        "label": "Cash acquired in Merger"
       }
      }
     },
     "localname": "CashAcquiredInMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CashPaidAndReceivedDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Cash Paid And Received During Year For [Abstract]",
        "terseLabel": "A. Cash paid and received during the year for:"
       }
      }
     },
     "localname": "CashPaidAndReceivedDuringYearForAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a change in temporary differences for which deferred taxes were not recognized.",
        "label": "Change In Temporary Differences For Deferred Taxes Not Recognized",
        "terseLabel": "Change in temporary differences for which deferred taxes were not recognized"
       }
      }
     },
     "localname": "ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ConsultantsAndSubcontractorsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants and subcontractors expenses.",
        "label": "Consultants And Subcontractors Expense",
        "verboseLabel": "Consultants and subcontractors"
       }
      }
     },
     "localname": "ConsultantsAndSubcontractorsExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.",
        "label": "Cumulative Amounts Of Grants Received And Recognized",
        "verboseLabel": "Cumulative amounts of grants received"
       }
      }
     },
     "localname": "CumulativeAmountsOfGrantsReceivedAndRecognized",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CurrencyTransactionLossValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to currency transaction loss.",
        "label": "Currency Transaction Loss Valuation Allowance",
        "terseLabel": "Currency transaction income (loss)"
       }
      }
     },
     "localname": "CurrencyTransactionLossValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract",
        "label": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_EarningsPerShareCalculationNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Numerator Abstract",
        "label": "Earnings Per Share Calculation Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareCalculationNumeratorAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of effect due reverse capitalization transaction.",
        "label": "Effect of reverse capitalization transaction"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransaction",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransactionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares isued due to effect of reverse capitalization transaction.",
        "label": "Effect Of Reverse Capitalization Transaction Shares",
        "verboseLabel": "Effect of reverse capitalization transaction (In shares)"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransactionShares",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_EstimatedFairValueOfNetAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated fair value of the net assets acquired.",
        "label": "Estimated Fair Value Of Net Assets Acquired",
        "totalLabel": "Net acquired assets"
       }
      }
     },
     "localname": "EstimatedFairValueOfNetAssetsAcquired",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount expects to receive of Chemomab Therapeutics Inc.",
        "label": "Expects To Receive Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Expects to receive amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "localname": "ExpectsToReceiveAmountOfChemomabTherapeuticsInc",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_FormerChemomabSecurityHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents former Chemomab security holders.",
        "label": "Former Chemomab Security Holders [Member]"
       }
      }
     },
     "localname": "FormerChemomabSecurityHoldersMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_GeneralAndAdministrativeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of general and administrative expenses.",
        "label": "General And Administrative Disclosure [Text Block]",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeDisclosureTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrative"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Government Sponsored Research And Development [Policy Text Block]",
        "verboseLabel": "Government-sponsored research and development"
       }
      }
     },
     "localname": "GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_IncomeTaxExpenseValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to income tax expense.",
        "label": "Income Tax Expense Valuation Allowance",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_IncomeTaxesReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents income taxes received.",
        "label": "Income Taxes Received",
        "verboseLabel": "Income taxes received"
       }
      }
     },
     "localname": "IncomeTaxesReceived",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_IncrementalBorrowingRateOfLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents incremental borrowing rate of leases.",
        "label": "Incremental Borrowing Rate Of Leases",
        "verboseLabel": "incremental borrowing rate of leases"
       }
      }
     },
     "localname": "IncrementalBorrowingRateOfLeases",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_InterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest received.",
        "label": "Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceived",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_LienOnBankDeposit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lien on bank deposit.",
        "label": "Lien on bank deposit"
       }
      }
     },
     "localname": "LienOnBankDeposit",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_LongTermLeaseDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term lease deposit.",
        "label": "Long Term Lease Deposit",
        "verboseLabel": "Long-term lease deposit"
       }
      }
     },
     "localname": "LongTermLeaseDeposit",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.",
        "label": "Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded",
        "terseLabel": "Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards"
       }
      }
     },
     "localname": "LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_MaximumPercentageOfPaymentsOfRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.",
        "label": "Maximum Percentage Of Payments Of Royalties",
        "verboseLabel": "Maximum percentage of payments of royalties (as a percent)"
       }
      }
     },
     "localname": "MaximumPercentageOfPaymentsOfRoyalties",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.",
        "label": "Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]",
        "verboseLabel": "Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]"
       }
      }
     },
     "localname": "MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_NatureOfOperationsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature Of Operations Disclosure [Abstract]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperationsDisclosureAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADS issued and outstanding after the merger.",
        "label": "Number of ADS issued and outstanding after the merger"
       }
      }
     },
     "localname": "NumberOfAdsIssuedAndOutstandingAfterMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfAdssOptionsIssuableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs options issuable outstanding.",
        "label": "Number of ADSs options issuable outstanding"
       }
      }
     },
     "localname": "NumberOfAdssOptionsIssuableOutstanding",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfAdssVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs vested and exercisable.",
        "label": "Number of ADSs vested and exercisable"
       }
      }
     },
     "localname": "NumberOfAdssVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOptionsIssuableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options issuable outstanding.",
        "label": "Number Of Options Issuable Outstanding",
        "verboseLabel": "Number of options issuable outstanding"
       }
      }
     },
     "localname": "NumberOfOptionsIssuableOutstanding",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOptionsVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options vested and exercisable.",
        "label": "Number Of Options Vested And Exercisable",
        "verboseLabel": "Number of options vested and exercisable"
       }
      }
     },
     "localname": "NumberOfOptionsVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOrdinarySharesConsistedInDs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of ordinary shares consisted in one American depository share (ADS).",
        "label": "Number Of Ordinary Shares Consisted In Ds",
        "verboseLabel": "Number of ordinary shares represented by each ADS (in shares)"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesConsistedInDs",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfStockAdssResveredForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option ADSs resvered for issuance.",
        "label": "Number Of Stock Adss Resvered For Issuance",
        "verboseLabel": "Number of stock option ADSs reversed for issuance"
       }
      }
     },
     "localname": "NumberOfStockAdssResveredForIssuance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfStockReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of stock resvered for issuance.",
        "label": "Number Of Stock Reserved For Issuance",
        "verboseLabel": "Number of stock reserved for issuance"
       }
      }
     },
     "localname": "NumberOfStockReservedForIssuance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of vested and exercisable.",
        "label": "Number Of Vested And Exercisable",
        "verboseLabel": "Number of vested and exercisable"
       }
      }
     },
     "localname": "NumberOfVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfWarrantsPurchaseUpAdss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants purchase ADS's.",
        "label": "Number Of Warrants Purchase Up Adss",
        "verboseLabel": "Number of warrants purchase ADS's"
       }
      }
     },
     "localname": "NumberOfWarrantsPurchaseUpAdss",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating right-of-use assets and operating lease liabilities.",
        "label": "Operating Right Of Use Assets And Operating Lease Liabilities",
        "verboseLabel": "Operating right-of-use assets and operating lease liabilities"
       }
      }
     },
     "localname": "OperatingRightOfUseAssetsAndOperatingLeaseLiabilities",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares, No Par Value Per Share [Member]",
        "label": "Ordinary Shares, No Par Value Per Share [Member]"
       }
      }
     },
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses [Text Block]",
        "verboseLabel": "Other Receivables and Prepaid Expenses"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on commencement of agreement.",
        "label": "Payment On Long Term Purchase Commitment Commencement Of Agreement",
        "verboseLabel": "Payment on commencement of agreement"
       }
      }
     },
     "localname": "PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_PaymentsForInvestmentInDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payments for investm,ents in deposits.",
        "label": "Payments for Investment in Deposits",
        "negatedLabel": "Investment in deposits"
       }
      }
     },
     "localname": "PaymentsForInvestmentInDeposits",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_PercentageOfMonthlyDepositsRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of monthly deposits rate.",
        "label": "Percentage of monthly deposits rate"
       }
      }
     },
     "localname": "PercentageOfMonthlyDepositsRate",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty payments on sale of product developed with funding received from the IIA.",
        "label": "Percentage Of Royalty Payments On Sale Of Product",
        "verboseLabel": "Royalty payments on sale of product (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnSaleOfProduct",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_ProceedsFromSaleOfAdss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of ADS's.",
        "label": "Proceeds from sale of ADS's"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAdss",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ReceivablesFromGovernmentInstitutions": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government institutions.",
        "label": "Receivables From Government Institutions",
        "verboseLabel": "Government institutions"
       }
      }
     },
     "localname": "ReceivablesFromGovernmentInstitutions",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ReceivedAmountOfChemomabTherapeuticsInc": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The received amount of Chemomab Therapeutics Inc.",
        "label": "Received Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Received amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "localname": "ReceivedAmountOfChemomabTherapeuticsInc",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RecoverabilityOfVatAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents recoverability of VAT amount.",
        "label": "Recoverability Of Vat Amount",
        "verboseLabel": "Recoverability of VAT amount"
       }
      }
     },
     "localname": "RecoverabilityOfVatAmount",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party [Member]",
        "label": "Related Party [Member]"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to professional services.",
        "label": "Related Party Transaction Professional Services From Transactions With Related Party",
        "verboseLabel": "Professional services"
       }
      }
     },
     "localname": "RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to research and develeopment expense.",
        "label": "Related Party Transaction Research And Development Expense From Transactions With Related Party",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to salaries and related expenses.",
        "label": "Related Party Transaction Salaries And Related Expenses From Transactions With Related Party",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to share based payments.",
        "label": "Related Party Transaction Share Based Payments From Transactions With Related Party",
        "verboseLabel": "Share-based payments"
       }
      }
     },
     "localname": "RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 50.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related rent and maintenance expenses.",
        "label": "Rent And Maintenance General And Administrative Expense",
        "verboseLabel": "Rent and maintenance"
       }
      }
     },
     "localname": "RentAndMaintenanceGeneralAndAdministrativeExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RentAndMaintenanceResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related rent and maintenance expenses.",
        "label": "Rent And Maintenance Research And Development Expense",
        "terseLabel": "Rent and maintenance"
       }
      }
     },
     "localname": "RentAndMaintenanceResearchAndDevelopmentExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RepurchaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Repurchase Arrangement.",
        "label": "Repurchase Arrangement [Member]",
        "verboseLabel": "Repurchase Arrangement [Member]"
       }
      }
     },
     "localname": "RepurchaseArrangementMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of repurchase of american depositary receipts.",
        "label": "Repurchase Of American Depositary Receipts",
        "verboseLabel": "Repurchase of ADSs"
       }
      }
     },
     "localname": "RepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceiptsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents repurchase of American Depositary Receipts shares",
        "label": "Repurchase Of American Depositary Receipts Shares",
        "verboseLabel": "Number of shares repurchase of ADSs"
       }
      }
     },
     "localname": "RepurchaseOfAmericanDepositaryReceiptsShares",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_SaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SaleOfStockLineItems",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_SaleOfStockTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Sale Of Stock [Table]"
       }
      }
     },
     "localname": "SaleOfStockTable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_SaleOfStockValueOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of sale of stock value of shares issued in transaction.",
        "label": "Sale Of Stock Value Of Shares Issued In Transaction",
        "terseLabel": "Issuance and sale of of ADS upto"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesIssuedInTransaction",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_SaleOfStocksPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by the company for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stocks Price Per Share",
        "verboseLabel": "Share price per share"
       }
      }
     },
     "localname": "SaleOfStocksPricePerShare",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rate of deprecation.",
        "label": "Schedule Of Annual Rate Of Deprecation [Table Text Block]",
        "terseLabel": "Schedule of annual rate of deprecation"
       }
      }
     },
     "localname": "ScheduleOfAnnualRateOfDeprecationTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative [Table Text Block]",
        "terseLabel": "Schedule of general and administrative"
       }
      }
     },
     "localname": "ScheduleOfGeneralAndAdministrativeTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other accounts receivable and prepaid expenses.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]",
        "verboseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party payables.",
        "label": "Schedule Of Related Party Payables [Table Text Block]",
        "terseLabel": "Schedule of related party payables"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyPayablesTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of research and development expenses.",
        "label": "Schedule Of Research And Development [Table Text Block]",
        "terseLabel": "Schedule of research and development"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents security holders of Anchiano as of immediately prior to the merger.",
        "label": "Security holders of Anchiano as of immediately prior to the merger [Member]"
       }
      }
     },
     "localname": "SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay [Policy Text Block]",
        "verboseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period",
        "verboseLabel": "Options to purchase ordinary shares cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price of ADSs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of shares acquired in merger.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price",
        "terseLabel": "Acquired in Merger"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related share-based compensation.",
        "label": "Share Based Compensation General And Administrative Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationGeneralAndAdministrativeExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ShareBasedCompensationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related share-based compensation.",
        "label": "Share Based Compensation Research And Development Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationResearchAndDevelopmentExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ShareholdingPercentageImmediatelyFollowingMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shareholding percentage immediately following the merger.",
        "label": "Shareholding percentage immediately following the merger"
       }
      }
     },
     "localname": "ShareholdingPercentageImmediatelyFollowingMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents number of shares and warrants issued during period",
        "label": "Stock And Warrants Issued During Period New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs (In shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stocks of American Depository Shares (\"ADS\") issued during the period.",
        "label": "Stock Issued During Period American Depository Shares New Issues",
        "verboseLabel": "Number of ADSs issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options acquired, including both vested and non-vested options.",
        "label": "Stock Issued During Period Shares Stock Options Acquired In Merger",
        "verboseLabel": "Acquired in Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised 1",
        "negatedLabel": "Exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.",
        "label": "Tax Assets Acquired Through Merger Valuation Allowance",
        "verboseLabel": "Tax assets acquired through merger"
       }
      }
     },
     "localname": "TaxAssetsAcquiredThroughMergerValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Total consideration of repurchase of american depositary receipts.",
        "label": "Total Consideration Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Total consideration of repurchase of ADSs"
       }
      }
     },
     "localname": "TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_TwoThousandsFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 plan [Member]",
        "label": "Two Thousands Fifteen Plan [Member]",
        "verboseLabel": "2015 plan [Member]"
       }
      }
     },
     "localname": "TwoThousandsFifteenPlanMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_TwoThousandsSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 plan.",
        "label": "Two Thousands Seventeen Plan [Member]",
        "terseLabel": "2017 plan [Member]"
       }
      }
     },
     "localname": "TwoThousandsSeventeenPlanMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents weighted average price of repurchase of american depositary receipts.",
        "label": "Weighted Average Price Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Weighted average price of repurchase of ADSs"
       }
      }
     },
     "localname": "WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_ILS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILS [Member]",
        "terseLabel": "NIS [Member]"
       }
      }
     },
     "localname": "ILS",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_XXX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other currencies [Member]"
       }
      }
     },
     "localname": "XXX",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Name of Exchange on which Security is Registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r221",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r221",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r219",
      "r221",
      "r250",
      "r251",
      "r252",
      "r321",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r423",
      "r426",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r219",
      "r221",
      "r250",
      "r251",
      "r252",
      "r321",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r423",
      "r426",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r222",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r153",
      "r222",
      "r398",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373",
      "r381",
      "r428"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r347",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373",
      "r381",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r153",
      "r222",
      "r398",
      "r399",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r421",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r0",
      "r13"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DueToRelatedPartiesCurrent",
       "weight": 1.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r92",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Recognized liability for royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53",
      "r120"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r415",
      "r416",
      "r417",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "verboseLabel": "Additional paid in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Exercise of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Outstanding options to purchase ordinary shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r100",
      "r121",
      "r137",
      "r178",
      "r180",
      "r182",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r380",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r116",
      "r126",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r380",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r283",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r79",
      "r80",
      "r283",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 30.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 10.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Prepaid and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalAdditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases.",
        "label": "New Drug Application and Biological License Application [Member]"
       }
      }
     },
     "localname": "CapitalAdditionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r118",
      "r366"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r37",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r36",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r85"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r137",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r186",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r294",
      "r365",
      "r397",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r93",
      "r104"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingent liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingent Liabilities"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r415",
      "r416",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020",
        "terseLabel": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computers [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r99",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of credit risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Incremental borrowing rate based on credit rating"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Share-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less - valuation allowance",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Short-term bank deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r34",
      "r51"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r13",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r315",
      "r414"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "totalLabel": "Related Party Payables"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r292",
      "r293",
      "r336",
      "r339",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted loss per Ordinary Share",
        "terseLabel": "Basic loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r292",
      "r293",
      "r336",
      "r339",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings per ordinary share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss Per Share Attributable to Ordinary Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r138",
      "r263",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Corporate tax rate (as a percent)",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DueToRelatedPartiesCurrent",
       "weight": 1.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r114",
      "r130",
      "r131",
      "r132",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r167",
      "r187",
      "r218",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r311",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralInsuranceExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "Insurance"
       }
      }
     },
     "localname": "GeneralInsuranceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r21",
      "r88",
      "r95",
      "r109",
      "r178",
      "r179",
      "r181",
      "r183",
      "r337",
      "r371"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss before income tax",
        "negatedTotalLabel": "Loss before taxes",
        "positiveTerseLabel": "Loss before income taxes",
        "positiveVerboseLabel": "Loss before taxes",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r20",
      "r94",
      "r96",
      "r106",
      "r133",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r293",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share attributable to ordinary shareholders, basic and diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r20",
      "r106",
      "r108",
      "r133",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r161",
      "r293",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r190",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r264",
      "r265",
      "r271",
      "r275",
      "r278",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r139",
      "r151",
      "r152",
      "r177",
      "r262",
      "r276",
      "r279",
      "r340"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "positiveTerseLabel": "Taxes on income (benefit)",
        "positiveVerboseLabel": "Actual income tax expense (Benefit)",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r260",
      "r261",
      "r265",
      "r266",
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Theoretical tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedLabel": "Income taxes paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Change in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Change in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Change in employees and related expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r410",
      "r462"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Change in leases",
        "terseLabel": "Change in operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Change in other receivables and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "2020 Lien [Member]"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease expiry date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases",
        "terseLabel": "Schedule of maturity of lease liabilities under our non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r370",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r91",
      "r102",
      "r380",
      "r413",
      "r422",
      "r459"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities assumed, net of non-cash assets received in Merger",
        "verboseLabel": "Liabilities assumed, net of non-cash assets received in Merger"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r117",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r380",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Payment for licensed agreement"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.",
        "label": "Description of application payment for licensed product"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r170",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "General"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r35",
      "r97",
      "r107",
      "r115",
      "r127",
      "r128",
      "r132",
      "r137",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r158",
      "r178",
      "r179",
      "r181",
      "r183",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r293",
      "r294",
      "r371",
      "r424"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss for the year",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss for the year"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant non- cash transaction:",
        "terseLabel": "B. Significant non- cash transaction:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.",
        "label": "Fees to Directors"
       }
      }
     },
     "localname": "NoninterestExpenseDirectorsFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financing (income) expenses, net",
        "terseLabel": "Financing expenses (income), net",
        "totalLabel": "Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salaries and related expenses"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Decrease in the carrying amount of the right-of-use asset due to impairment",
        "terseLabel": "Increase in the carrying amount of the right-of-use asset due to impairment"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liabilities",
        "verboseLabel": "Non-current\u00a0operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Decsription of occurrence for payments"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 60.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Treasury share at cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred shares par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other receivables and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses, Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r125",
      "r188",
      "r189",
      "r367"
     ],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Long-term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "The Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities.",
        "label": "Sale of asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r69"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r115",
      "r127",
      "r128",
      "r134",
      "r137",
      "r143",
      "r151",
      "r152",
      "r178",
      "r179",
      "r181",
      "r183",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r284",
      "r287",
      "r288",
      "r293",
      "r294",
      "r337",
      "r371",
      "r377",
      "r378",
      "r406",
      "r424"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "verboseLabel": "Net loss for the year"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r52",
      "r119"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r54",
      "r103",
      "r338",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property Plant And Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.",
        "label": "Annual rates of depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property And Equpment, Net",
        "terseLabel": "Schedule of property and equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r24",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r414"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "totalLabel": "Total related party expenses"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r220",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r220",
      "r314",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r312",
      "r313",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Parties Balances and Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72",
      "r112",
      "r474"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r400",
      "r411"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r349",
      "r401",
      "r411"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Bank restricted deposit"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r60",
      "r101",
      "r345",
      "r346",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r114",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r187",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r308",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use asset recognized with corresponding lease liability",
        "verboseLabel": "Right-of-use asset recognized with corresponding lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royality expenses"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share",
        "terseLabel": "Schedule of weighted average number of shares excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of components of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Summary of the effect of share-based compensation on the statements of operations",
        "terseLabel": "Schedule of the effect of share-based compensation on the statements of operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Significant Components of the Company's Deferred Tax Asset",
        "terseLabel": "Schedule of significant components of the company's deferred tax asset"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "terseLabel": "Schedule of computation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense",
        "terseLabel": "Schedule of reconciliation of theoretical income tax expense to actual income tax expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of net assets acquired based on their estimated fair value"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Transaction With Related Parties",
        "terseLabel": "Schedule of transaction with related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Summary of assumptions used to calculate the fair value of the options",
        "terseLabel": "Schedule of assumptions used to calculate the fair value of the options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Summary of number and weighted average exercise prices of option",
        "terseLabel": "Schedule of number and weighted average exercise prices of option"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r402",
      "r403",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Exercise price (in U.S. dollar)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Options to purchase ADS cancelled",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercise"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Weighted average share price (in U.S. dollar)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Share Capital"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Website Development [Member]",
        "terseLabel": "Website development [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r137",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r186",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r294",
      "r365",
      "r397",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r59",
      "r114",
      "r130",
      "r131",
      "r132",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r167",
      "r187",
      "r218",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r311",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r167",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of Options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r7",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Treasury share at cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r60",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of Options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Treasury share at cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r49",
      "r380",
      "r413",
      "r422",
      "r459"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity:",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Events After Balance Sheet Date"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Schedule of Roll Forward of Valuation Allowance",
        "terseLabel": "Schedule of roll forward of valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplementary cash flows information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Capital losses carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r18",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury share [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r18",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r18",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury share at cost (11,640,460 shares as of December 31, 2022)",
        "terseLabel": "Treasury stock (11,640,460 shares as of December 31, 2022)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r171",
      "r172",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in the total valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, diluted",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, basic",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r391": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r392": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r393": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r394": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r395": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r396": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001178913-23-000694-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-000694-xbrl.zip
M4$L#!!0    ( %(P5E8Z!?H) !0  %S<   1    8VUM8BTR,#(R,3(S,2YX
M<V3M75]SV[@1?^^G8/W2ZTP5Q\[EVF22ZRBQG7K&L3RVTER?.A )29Q0@ X
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MIE2@1&U?B?+]@!#!:3FUM@^3HZBD)SI=TI3+ 22_BN<"8W(G<UG!GQUT_9I
M-86%& [Q4JN6LE^*588S^4G_K8UZ/S9_]*CIW2D/EW(<_?/_ %!+ P04
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M%BD-"]';MO-&CK&4'B<(F?PC_85[%$@U<QR>(L[78"EC[RP'>R-XYU1E733
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M(!* "%MM9JK?>\ R]CKJCUI"4PIG-6FFV:H71+)9,BLA>/0"*-:EOA(:QR^
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MM/-BEA;3MEP%VOD34YUI6^("W5/.5&S:ELI ^Y0S-9RV93AH@OQ('RK*:6#
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M$5@[FK?]N=](6='1/'L!O9^4NGN2KGJS=Y:"O0P(T(ZF$Q_:?ZAUPVPI ,O
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MPXC@T_EUD<<K]8VM>0L VHY.= O:4C@)QZ MZ;@BCPB)R_,B7[ OZ/:5\M(
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MVK%A'H )E*[H:5M>T&ZLJB*Y7U74LRO'@#BXA\Y30/$@[FZ,1LKFAZ"GG-L
MK[:GG-L4.P2N\HKLQ;Q=$9@XMRZD@%BNPV6:5"=Y!AM#3+MQ@_L(K;=*SZ:
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M1HONII] 3PZ#!!2TR%](&F-2L# ETO&\>VSO*-#>PEK!(U0+YGD1E% 1U@:
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M3X^HIX!4ZC6=,I*IL$\GZ)\!T]3%;*C')O&,"/VCXM2E0^1S?LTK3OJ.N [
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ME077I GH!GO19;1>&!*19U;B1*X')M(Y&-Q=@P;V9+Z#2ND198-689]RQ.&
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MXV99G79B\;B)5)<=6W]KG0C]D:7E4[)J8M*7+@F/FSIUV;'UMTX\;H+4:2<
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M)Q4MS<'F-%T&296)BRA(KD(C-6N&5>LF(1!4'NJ'K?\.Q@O(PD _;/UX,%[
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MU6GP\HIL..M?"^'HZP45-\"J;]L%&2,F1AL7M[.=5UNKZO\?U6OYC4K_DZ#
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MKM:;&BSCN5.2L04?@B3(*[GF/X.Y/A^"I3NMLK+BAFS"*LO81ZJ#7.;8D[Y
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M%7W6!.^T6UM$OMD$ 5\ 7'6(=]JMS2&-$,+[51R);<[A,._4ALVIQ$;7^ >
M;L'2#Z<H-S  @;G4%JDMX9UV:Z,>04!K34Y.GV8PY69<#H=YI]U:'^S@D+8=
MC]OU4QQR8*J-\4Z[M2X[ ER]!/1"K>#SLH9ZIS9LRC<0AO\;8:7["/P$2\3\
M)DDRB;7FS/%.;=B6W^,0:V$?49\1\6(;YECOS(9=*6*_W,LFS(:],&X,)IKB
MG=FP,S<15ASD*.H9X.#*+T"1J"'6%.^L6UNSCQ30!?9KE['$:-=&>F<VHIW'
MM1^&YUF"/:U$_,5K([TS&_;G"MN+)6:NSRC^D:Z*<@0AD,P9WIF-".CJ91^O
MYL&_&-*CX=Y9M];F)EB@23:'>)U)FH(D/^@1Y,[X$[PS&U'.XPIK;96O7AWH
MG=FP0??94PB#ZS#VQ7JG,LX[LV%K2/$I":/CX'N>D9]F*>G417P(L4(73/0^
M=FN%"B83>!N5$=[';FU,L=5MT:%,#-!NE/>Q6TM2;'<-T?J&IU=J8[R/W5J/
M;]CW2T%$N":+B@P(SWXPQWH?N[4@C_3>!W%-OF"#BJ#/<["/!WH?N[47]P@0
M6H HH">D,T#KW1<+K@_+G^!][-9F'.R<>\W: !]-\S[N[4>UZF""ZBCX*-CM
M@'\\*CFHMP,L1GS8T.Y)[X,5#$M16:!XS3_TW^T9*QV^OXL1QN,?/^%Y68(!
MBFF]\:YO1C\8B<"M(Z=R0.\:ADHPL]%D'NB[BA\;V#IB:G4!@\=0N:Q@A^F)
M*ZCJB2-G]&VE%&$H&-9@/L:25\G@&JLVPTY4 S&2#WA82K%#ZW38:!V49.RP
M.ALV5H)RCAV&'X>-H: 69(?A7\>!X5$IR0Z_7\:!WV$IR@Z]7\>!'JN,98?B
M;\-&D54*LT/MTQA0.RZEV1OS,> G+;XIT1VX\R(MVBD1';@[(RSX*9$<N'<C
M+!8JD1RX@R,H-2I1'+B'PZM5*O$;N(<C+G,JL1RXHW-8+U7B-7#OAE5T5>(V
M"O=&O3IK'^P/&V]6B5>)V\!]G*-2L1*Q@?LTO%JS$K]1N#."&K42T5&X-(P:
MMQ+!43@T_.*X$L]1.#;\JKH2SX&[-E?LNKP2O8%[.%?LRKX2O5$X.=R:P'VJ
M?Q1H,@L*2QP'[MN(:Q%++ ?NZ%PQRQE+[$;AYAR41);(C<*UD551EM@.W,\Y
MJ,<LT1JX6\.HZBQ1&[@G<U0=6B(V<!^&6UU:(GCLQ;S#F.4]#6_SPD4NY!3L
M</\$YU"HPJYJW1_]OT*2B*MH2](<.TJOCC3,>MV20,<^5G,"_?W#8=.Q3CJ1
M*3P!VT]'K>GB&D88"BR?]W'NNPL:ENE,;]7+K E.Q3L:<NCK ZWW \NW+W(5
MRN >C+??Q8SY',0DO? 1VF(M3XMC!5@HS;>.55&_G-1H+,"".;Y5;[$F4#_@
M\!/! *L00DXYU,SQ7IO[.4V@KC_'@7F!/MFA2GF%V5Z;"SVM)5E5@EOU3FL.
MY5T<!9HJYWA*J_YE[3E]#Y RL^^G6(>]SK%*L/.FM.K4U@SV_'6:^]#/VZ;6
MGF 6P,^?UJJ/6Q,<ZN^U/) >O]/%5ZP["',+D!#.:]?IS83X:HAMNZYOS8&5
M@MBND5H3P"IOWV"^I/FQH@\TX=%TJZ 459=HU^^L)7+J;B5_DGT$BM?2DJ*[
M/:DC  IFE3^K%Q10AN//(ZJ*$6#/:==UK@GX5^M-&&\!*-KJ:Z$AG=NN)UU[
MW;^#:"O'13RQ7<\Z,Z*M)=+M>M>U!%C+Y13.:]<^SB #*9EAZ5S[Z#"IJ_LU
MVG7&:Y1T8+]DES]%ST\U\&>U:UO7DO)J]&[7BJY9,O#0E;F)@C";T\=+$<WI
MU5[3(!R!B8KB$$.QI#4X..922AN:W*A=<[RF[%@<KDK370=#[0,[0UC[9&BK
M!.[QX':=_AIY4/,YS//Y]S@&OHF*M_=$_A-[1KLN@,W2%*D/(S"_\E&$.37!
MCEVVIL\"SB_!@IR#"1,6LLGMN@2:40E:8MVN:V 7\5V+N*[:I*_OOB/B\Y:#
M@[5ZS%TY.7"MXP$?4!%"QR<B7+PTSP>QG<%^6Y^GJ%),V811/61QFP&4T>6=
MQCC7[Z(A?KQS&W[C"TU&?P;H*1XFJZN=!SG73*,AMH<G2/P6&KJJ+L8.DT/?
M7Y44S+,IQ^6>#;.*Z-=.L=Q6WCI("HZ[1O0I)8=BSG4Q:HZI].2,KXX'[J'I
M4(EU2O?J]7FU)TUKM\8=(K0+W'1.')U5F%I(2.G .*H<7]0GP9<C1^+34%>]
MAJ:X\@].AR )ZJ@J':XZZT,T0EE^!CM"/Z(1I=@'OB-T)LP:$?8!\Q#T!@=R
M+3FJGT.;LIXNI9*:$HQ[ZLUGC=<L49)S]B$8)0/*I-J<J+T]&A-_F#_N-V?9
MG+'['1")+ZV'%0GC"YVLD9-=,='>4'S**1J!)77W7Q5-!?4<SAH3:\11*Q-Q
M]L#+&IW8U2AO,5&3!&.UD]9QPY"6E+-T];IVR_J>4G8%4AA@!-ZN7)LKB-R_
MD*-6%;D?;_\J\V&/G$F6KF($_]SSE1CVPUG6+P ?P4(;)FA!G\^P?@E8Y4U(
M[ECK%WQK3EX.CFH1;3ZZ<MEWD"=0/(%U]33!&+8,$7<V/V@8Z5(S..QSMT&8
MI58<=IO;H,K62,9\X1[[Z"3319'>)L^^6C4*Y,F2-2@A4?#=.#.LNVOE@4!1
M<:72+(<[Q[K;]H!9"0L/*7"^!,\@C&D150&6  /A/.M8? 81)FB(@9G,US"B
MC_N0_L5R/"0SK3NA1YRAPT76'<^[.(IW0.3R**<X=X[U'B[Y[K=QDEQC$Y$?
MM608JKT./ >+&(%\W,Q_ <G5"^:/N'C%E+9>8Z=4I'JKDUT]V]?A2AB+3WB.
MI6DAO)?%F6&]C\P=2/<?0L2MU7'6.\;LTI*[]W'/_00& FB9XZWWB#F$XA*&
M62H,I#DS[/>%^09(?2V83YZQ,"Z+%V*FBR/O5O8AM-:QWU&& UY!=IUT@N9*
MY"'(GIU_OM\HJ_A@.&NNANQ"F'E'(6*/;D2HRIT^<[4ISASB-J 3R\$<83VY
MMD80N;"C/*S6IE"W3FY['JS3>#9<5N3[T\;*I^AU8*P=9\ZH,GV!/?#BVR?K
M1L- O)#!W GU<-E&$);P'VM_/>31#G+X3\"_>J*) B;^L_(MR=;#^<(%?>HQ
MN8F*#C)]58LT:E:J--_Z 40)U8P4>:F 3P=:3]*7V^?T(D]AQ1&M<W^!HA2<
M<%Z?=2Y? )%=M?J0?*QU:&MGE5)X&:.M'X!PRE6EL OG63\8.:PKE8+/GF"]
M-N= Q"[C-89*E+AEC;=^D%-JB-O=@S@JZJ0<;/WPH6TC..OPMJHOLWUH0@F6
MU]M<9HB40M-W,VF5U2[$ 7/"LSA@IDZ.C/I:BUD_;A&!> =^T+^(!4)AOOVC
M& Y8.7^UP.M@@1[:^<__+TOR&WZSF&.VOOD(^<637:*#,^VUJ@<P2N@&Z_43
MQ>'D].R$XD%^XUTM%B# ?O #>"9!1;$5_).* 'VREKP@S10MK?G:CQJTA)=;
MC]I@%>]$TWQS8*>,/(GFQ8=,&LAZHW6T^_TWAM\ Z!6H;5=!"&T$^=N4QNO)
MU0M  4R$ JV]EOUG (1ZU1"^@L7L/Q<@^B:UD.D!0)G"UE[+_F,#PD]B"%_!
M8MZI;4^C62V0]><&VD8-UA\::!<VG)[UG=M53?=Q,KU'Z397*RB. 94@Q$G$
M.8\?#VXVNJSLW1@;NS0D#SM9:*QP9@04DJ4D1]EQNB&MN/E/8V4,(R 2+]O*
M+V=P!4]5RU+-R;I_-; &+0\S1O;6E!79Y+YTZJ/4+;96(0PC3VS,> R:,$TR
MSN[?*FV)>2T1[?[%TN;8,M+3[JMW!70;9:KY16@#P%P[S\VO*1L;MOO\N+&2
M,"?=.QF]FF3DC56#C91BM8. ';$^#5&D6IT)['VI$:(N.1XH<1]^Z*![5%"B
MWOY^CC,UML88AGO>4%)M1+W/=:AV=+)1$F30/B?[$*3$K?75ACS,O(K<N*35
M+OH^W?N?)ZTO-; (TT>QN9^LKL/XA^5>-I5SHQ("O>KRHVG6B\JQ1B! W*/X
M&>(/<+[]BFWK353>")U@/_XY[W$IQTQ_,>N%TABV!4PE!\#[0=;AJX7/#R"(
MHP"&H*:W9[&Y+];%=M9+R2\!5BX!E)5X5H=9AU&_()6= K1=X([Y@#A3X!+D
M_[V)BG<'+PL[P7Q#5(!7LP6M%\@?@\EZ(DH+3]8"??1".@;KX#DH7:P.IO?1
MG>@ */Z[3UJX\9>Q7II_#!SG@1HM!#EK6"_E5W<<C'@?]HO<.;#=1,\@,>5F
M"18S50V.51?U%:YCE.]&_G43[9X2YU7U2J:9@NXVCI8S@-:W.9/3Q7D@L<9J
MUZ";\$8# .:T><:C'X+IHF+S&-]3[+-J+:5=M-X>V8(+9O$DP$$Z MRW?45H
M*B^B7=5N4<B-"+?] G@.;$5O73-:3+"8=D4X1T^0;0ONP1M^ 6C)O++)'6N_
M,KTFW)J5]]*Y]BO/=T)<U-N2-"YY9>(B3H2A@VB:_6KR*EVIJI76:G-FV*\P
M5Q<](_)KOR*= $;^1PC\C(TA9IH'K#X1#+ ;3T4ZFM=_41F9GR0<.\O%@SM7
M+P'M;?& 0X+\'%Q )+N D(<#!T3HKNA&'A5\(T-"GGFRG.3*-IN0IK;]<)?:
MOLI_H9085YA.WHDSY0.0FB1*P # Y]TYXK^ CW"<(@!7:[XI>"L-]';[\4!C
M#-6&PES':) 0,F%C(4Y,' PFK]:9(5O>3%!.L_HX\AJ<]1;K >:IO9\?S4M3
M2@_Y5%QJU37(TV26&Z60;EC3!?81:$0Z?<JO =Q$.RN&948_H]5B5?LDJ+X7
MAUW7-9B?"%!CC/;.7+HJQSJ[Y)<=Z)\+NGK+K!DR;,+4#AK'>.?,)+$Z.JMT
M]OI)5_BRJ7MP.NJJ]-DE"O<0=I37'^W2MO%!L.FNT&^TYQ]..WL#QP%Z'1][
M.WN!IV]J"0_2G;W\TS?5^*?S(^Q*;=)3U*L$&.%+%T;#-$E=@;/^<T-TZK11
MK5]H';PYZ).8(R"OVF*4;K01LK4IZW#VDKA9RFA5@K1O+S)6 6U6>&+L&>21
M&DU)&<O01%2&#D/G\RIG7,TL&<%<J^AF:)Y30U)(JG9&F<[IC)D.ZH9&V37+
M*/'TRI3>S%IOA4O&6/E5DY[4/AEC8F?;:]FDYR^"!.4X[I%K45.U2&N$*4IE
MU#G>L&J]F*E"@/XIIX\Z@W2<>K8QE4NTI9.XD&Y43Q4;8JGC<C]SQP"]BUW+
MC(9.%>$(G_K4PY]-PY:%B6/2;2;)RBF*[/ 8P5(WF\\@PLP0:O6OX90\W_EI
MAL@Y0?D$^R5,@C!.\&]E5>TJ<^VWJ#D"2E0"?32XTL*E#U.E2%*>+F:A(\Z@
MVNJ_E*W7/MI.%X]P&<$%#,BA2UY$1+JQQ2$,R/TQN\USCO97:8'#G63_A5\1
M*6?X(YWC?;\+<%%;H#^)4*(Y+_!4Q<T)\2CR"H=7O:S?2CN&04$DQ!.MBP4;
MG+T:59$,Y37Z%PXI]05Y+E44G9 1>I:1AV"DYC3!P!<EP$7IKV5YJ6]>KSM6
MD!J5Z;JRP_'Q\I6+DMT]!8\)*!*-ABOU+R"*A&8%_HW0[2X:LR1HN\J8:E$,
MN9%INU\"NSQ'2;0D<ZW;)"Y$>F9)9QD7!$_^&?AGV#J(.F&?:%[&L@VZ!5B-
M :6(73;%NDSD@-336DIABWAB_WPOH# O427#R D&)R\?POR" W$<8QI2 =)8
M>M\OT:ZGSP:(1'A:(J&UCOUX9@^=9A CG-B_G.B2G1?(R-!T0GCHW=#BY1O;
M?<</V]W?Q:F*6(@GVD]W$0K6']N-YOLKMV6!MTKB2W.I_F5%^BUX:3!]3)T0
MEP>\'*80R5!<@F<0QGFG1[M-2)@P* B.>*)UP=F!4X4EHE?4LQ2@QWB1_L#\
MH&=;&J_9ORA)OP[OD+8%RD[(5'%JB(&>S-<P@@3A%#X#NU+%@V*7GY&+E^(*
MAI)GO-W4Y$5WB?[%0YVZK(R9'JJ#3Y55*JCL2E&YL5:@(YAEW2HQ8%$Q/*)I
M_0N/F, <PR)!R0G;4;1BN/<1"?//_9!<RB%A6^7Y3LLB4 %I6X5"R4$33^W!
M16,#I.N4*:_2OZ@H? .N(Z:#IA/B<P=HV[9[[">2V&N2I@@^92GMG1-/T1Q&
M/MI68S6[HG3EHPA&RSU\<A'B3;$N.H> J @*=T[_8B&@*T<<1,@XP?QJM5]O
M-6!-X#_W$YA,%P<0;?/_5Q$%M06L/VSW-0'3Q562PC56]:(*SOI ZP^U7<<(
M8*Z^R'"L$@5U0U8X1V%>B:G^21JO:?VY-W8-D3JF2O.M/^;&ANKH$B 3:FUD
MU9:U_O ;]P!>_>.J+F'_ ;CUQH>(7G1!V&?<Q(D?3A>DZ= MN=V35P:IX]ED
M.>L/PK&3GD5.1\JZ"K.M/P)71LT:7XHSQ;/=O?T:,PQ]L/T+?7D<[*5"PTJH
MKF'_^3IV']R\IPEF(?P9,*Q8-HAFD.O-!JMY)YK^"B_W&S\#%!'*/FZPN<5V
M><X6!?EG:[6>J2?O'O$.B&1N[GT%3I--L?\ WD5,/W9^M^4!)M\O, 5A2GX2
MUD%P9]E_UBXO]<DK?-2%73#+_L-U%X1U0SBG]-1P]@33[#].=Q@UJ^,AF>F=
M_-IW#J')?1GE.' \[0;:D.LH['2V.U<3[-I$H,[VJFM""-4 =92-M<P13#G(
M-=:+:.ATU B>W6V(W@#OAL$TOWW0 &F@%FT;:Z4Q=%$11/4[&OTV!K;0"OAW
MF'\: ^8-,P![E^RUBDCKI$-)PE&U7-<FH20)4E)I'#ZO.%U2(NO>(S\-D)4D
M5DID7[U#*LO>E)0:A1NJD.,I$>;XG':+NF>T)<);0RC6:42P O.,O(5!'F5:
M1O!/,+^9$X]A 7<1Q:[S/#:(QTW#*&V5KA69W6G0K:C,TV) M4P-I''HE4R\
M$Z>2#291E/DA:>(]7>2OA]*/(A6N)LOT7\:G[V)J8]A5(K[7EE=]2,Y8&E_M
M64A 6ST[IK)0_\+6M 66-IY.F"!Y'ZP^A&@XW;#V7UV]O9.FD6JX</^2U*)7
ME@GL!W\?D-,ZJQ^!?!4-M%I5HCHE>>:;98W(6RQ:(O4@1V-KL55VCO]"XGO\
M7V6WL,%J_<N5F69<<C0'+E_5]D1]2-EHFA3M0XK*425YO? Z1D=]=R8(D=<=
M\A98(86('&PNV >>] W$<ZKFFX1R]N"Q?EMLCV7U]<R'. PQEC]\U"2%J[22
M]?MF%?B./AX!KPHU*1;(U2W)J.:_:T(( QM5;J8-K8%63P(TOC+;]E] 522-
M/? R*N*9$>/.WKWJM;%<'RZ/(^WEI%DR <4T4F(JJ_0?+>CVAFN&Y,!C!5Z/
MKSZ$:&C=Y/:\(J2BAF"IK=._:+7K*]< WX%+6:6U7!^"-?P&<WN6N2P^-X:K
M.,JH%9PTB(FT5K0?#N^*5/8>'8Y%?I "5B4T%:;W&/CF;\!CB2^9C=1*D"JC
M*,#T5ZLJ,;%L_T%MHW:#S;EX?#%I,P*JR<<(H]"6_-9(Q(8?<"ITSNPG_G2F
M?Z9"#+K?\-[?4FKI1Z"R-7K,6_,HVJCV6&6IB@$?3 /0)A]T?#:K>>/4!CS2
MF1%SM?%J'YIXR.U7*];] "32420@F3 89FFC6Q1:*_:HO"=1"N<$)NS:/(*
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M*2Z$,7;[:U#:751;XRX'"*%F8\JNQAF50N>@R/GRXAH?US2Z)E\?5@,YUX.
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MPCA*]@5%]<HC#81;;V+]1"Z'AUC):RSI+(C/P0+S:H6MKUXPJ%A28>2C+:T
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MATT>+7OB*DWTD) 30MZ,S"&$>4W%^#;.5:SLL';50CJ; 56!G9,!5C"EKC)
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M,4!%107<_WL RD_ $*"GI:.GHZ6GIZ-G8*!G9.9@9F9B8@:QL;-R\('X^?E
MO+R"PE*B@N<EA'AY+\A?D)"6D;TH*R"J<%D!?%D*+ O^YQ(J!@8&9D9F;F9F
M;K @KR#X_QS*)X"3$3"AHJ.A$@>H.:EH.*DH78 H %#14?TKP'^&BIKF[WL9
M&)F86?X.-'( U%0T--2T-'1TM+1_NT_^]@%:3CHNL2OZ]-PVC@SBWB"ER+1"
M1@F#VDX>VR&2I+*33Q03,R\?OX"@E+0,6/:BBJJ:NH:FEN$U(V,34S/SF[=N
MWX'>O0=S=G%]X.:.]/#U\P\(# H.B7X6$QOW/#XA/>-E9E;VJ]<Y1<4EI67E
M%955=?4-C9BFYA;L9UQ7-[[G2^_7X9'1'V/C$Y.$V;GYA<6EW\LKJ]L[?W;W
M]@_(AT?_N*@ &JK_RK]U<?YU4=/2TM R_..BH@[\9X"3ED[L"CV7O@V#HS>W
MN%(D(\@@K;"VDTE"V9;$X^0SQ,PKJ3(KM?T/[5^R_QTLZO\E^V_8_[@( "L-
MU=_ET7 ">L!168*<7-?1J!9]O'?%E*PWQ^>W.JTB0-4S*4UP-Z)6W37 8T2:
MS=&;R49ZI*'I@L@DFCY[+N)Y_E:_F4)QHH[A(G7S[B!L=XN1/&\YKO(C?2E(
M?HLOWC$0KXL/B;9/D0-WS=XO5_5??-]V?1:F%&#2]XN?M-5UC=SG)3]&J%I%
MA8FL;AP$/Q"F %<4OQ?:/=7R0]>OO6S</HC;;/0?*6QUEM/+2@>)JWE=_?%#
MF=;VFT&%@&0N(%? N]HDBF)#:-.I@O+RNHL^KAF2>V?ZO;KZ"B<\+HW[F#HE
MF#Q_9]M45+NWL49HXVTI9=(GF./CRS_8&/%(,(.+GOZ?ZK=.1)$%FNRT-# 1
M^9@Q_;(5C=+^"4JFBP)PJ;1Q':[/Q:)^/A^8U*FC+MSM745!/T.NC(1=K\F*
MF<4FN<YDQ]*,AB1LQI[GCK/I!JMDYCQX=".[Q??WI%^>L1RZWLPQH$F@)WM1
M+2(SQ"T&PMOI729_)H9ZONFRH'^>:C%E<JT_I)=&.T6) ?:G@)<\L+\&3=4G
M!?2B'>(O\;%RC[)-!:JN??S)EWHZS=/K">]8&^(_YK\Y!GO90(P1=1DO;'ER
M33=)*?XVM9-A] NFE?&V$/]I+()@Z7596C:M^#$;Q/8RJJ]CEF_;R10FROLN
M)R<93QSTZCM)@CK.:)_Z'%B^#C-Y<+\EREK!1<(K1SLWPJ:SAC6T$G;Q757E
MSLKDZ1AT3Z7<?3DS]0(I=7W9SUH(YM&D19A"8J#42XQ9XG6U-U^RACSVSO7O
M\3@23) ;J(;Y(Y;Z)>B$HQ(6SR3(7WL^M?.TC/ESN$P^B^710);H@B*40@'4
MUP8O6C)Q[G;.ZIGZMM12LJ.?>F?IW;!72;O3*VEK&==D?2\AM2_XU-?I[N?L
M2 ;]6FW1$-#H#\KM8#@QG"W>1\?]4AE]FW9>?/!&A!J?<.?&T6TO@G]9"O%3
M9(FX]88KVXU,V@V!JEO.LF \M+DEQ[(AM(TGLB*H#P?S7*GK&&_H"VV\H&)K
M5U178*#<,P]/,\TPKKNVNMT\]:Y<+*Y"-='2XRM6U.C!&FPSL_!SW9I@<FG2
MP\=E<ZZ6Q.M[%;O67.[8%<=BCS'U;[EU/P=J3$9I<C01Z/O8B;&BJE7!Y*PW
M@I#B8$_W=+4NY.)=W)5E>FL90ETCNT"0EV6[&BRVM0R.2*)/L'AYQ^XH:=L@
M,?2"IT+_D9R>[=ANFU*GE[^P\?!8_S8&^>"V\>!UKN"3BPKL72%J;4L13JM9
M4#S$#OZM!KI*-9<"14U<PJBZET@"9C-L9C6/O$3(5N>C:=LEAWEO!&2J(SM/
MEFU\)FF0C_P:;@7\,?)FMJ2-E[=2JDD2N!L2I?5#5G5:6O/2L*55MWU_H%UE
M\U5'D1KEG3.5>TE#1;5^7CS+@M.=3<.J>9#]Q^K\,WGW:M>>^MIXY"N1?F4&
M>:HJ!%IBL YMH*:+[SIL\F5WS/<_U#2I+U=LE"<LT>80[B[%ZK=()D?+L=\P
M@>&VXY(:1!DFW_<\]^?WY/FS6+BXT'-PRP<);M&^@)U:!J,5AMJUR=RWVBT<
M-@36)\G0UL@B@R?J?J+) 9A\^2&TCH5:I&=(ND?:U:9S7%$F68\-Z9=-Q&MN
ME8O&,YGIOFY:DGE=[[.%#_A=\#7/7A84$^&Q]F+@FK-^+UVS$%IU^7=/. A>
M_##,I"0>YSFYW["V,A9OZS$V;A&5KF4NRQ,-=KU0*4 K%&WTP&8'4TK775;L
MZQ7"CS"1D&_%9@W*;+]G9UH)J:FNONCN.M^2Y*4L]Y(SU19%W!MD<2=,12',
M\9H/:$3N'\)%;: JR>(XDZ;+R*PT.-[*5'_T.+^LO:J<T^C[8I+N%NYH1Y-7
MX ^BC?W2N(["?._ZO0<_(),BFK&:"5FG]"CM63;YC]85]Z;9ZU:YX TVP<5T
M=ARFG5M$$AJ>W14B#RUPS;Y5#T^:=WSIIAHW[T6'FY.5Z*AK/A:IY#@O8Y_"
M<'V^H+!&*S@Q4]-QF],F"5OJA:M2&*Y?2L% W$D=./3S  K Z^F6-7 F6]3!
M;5VI72!;/)VE30$2?1:<B3S[*CZ2KW>F'9"=!-_H%7LG@GJ7V?UC4,Y[+"Y)
M '?2]>1JOW\[ ZDAG&]D,7&#W=?[\9G+L+K!Q+I<QGE^C4KS$OAR\5%[=$E.
M@.D*N"CAS[E!^M/BJVW;Y;CD2W\61]PZ%,2\L#T^K)SK[&>Z]J2W8*JK "N@
M#<T)"R%9$I-TY%@)BH)+F>J$==)CN]2/3X]RJ74_53FPAZLL:^'SL]JEL:G7
MQC=ZLOV]@H_?VOE?M$87+D M$BO-==H4?54.7;9&]W)(BH1A6>F1$V$0%W]I
MQDUP.ONLU&/V6<1!?+MBD*)^+9((P[2]*0D8LY).-UX'A/4$9R*0B9D?1\Y$
MI_#\DH0BT\)81CK]A9 1G(%-)>]WRW+>- *.!/]$ 29B\?,F*7-(;B[[+]_<
M B6RB?DMOX=;V"?'X6_,2,0DOS=K\9<>GF@&*WW:ZN6L68\D5VH<H .%Z<(.
M25S=_MJ#"5GRW7=^V^1SX3!++]SVBKA]RR\%/NFXC#2J%CK H3KH@VJ.CKLI
M $BU3>V)[5P '*&U/T/;^%P$8CC^$Z.Y=0<BKXX[U>K6L2:MP8?]*  W<N==
M/&^!5D6SW=-;;S565K9R&DGV$2SN3($S':(KV-ME'<Z/S^P.]E<27TTL<*SK
M70IQ_M6*YE\CLH8I"J&DLXM6^?YHE:C=X4VS5'F6_XG]-X(KLVHYKX,E(BT'
MFH+1V"+PW89(D:UGVFQ_'EA7(#J5W,@"\Y+AU\9#W4CP3A/<9_R!F47U:XG3
MO=VDZUMB0NWK)-_!4A]B0]>-SADB4P^*^N=5[#LJ,48.XU8K/O>55/,#<,=H
M^7'1ASPSXY?!PHVN%>4RODNB3R%,==NWQVKRY=(1L![<.#T>/Q @#=XQ>]"S
M>S16WH5F1Q+/M<L$B<))+VFL!&,F&[&89R_2+T%U0F/QNI'O(R8#3P-3.]8O
M1Z05[V=1@+3$V:;3F/.'/7#-WCDA^,@9U459@P4*(*BXIP@*.C @>Y4B>EV1
M3P1:1MU28]WQ5H-EH (?(W],!_U'.J\R%D6RB:>KY5L!%WD7YU6XYN!P\V"2
MA?_,8(*]$/D99F<*><7X(?JD-H,K-WEB%Q>.VK)_C=QF^ R%6>_G0L1&PO%7
M6@C^B)9U_051#[R5!^=^:'"@+&SKU<X@@XDWJ7Y>R)XM91-Y<N7]YY&)'N5'
M:CN^.ZG'"ZG>T6,?=/1FCMGYPX=$U)O& OO*X9?SX3>Z[\S64<?UW&"STD7Y
MXL9-Y@IZY!RXD!_,* #C8)R3>R'6GR#SZO<F!2 ZO!!I1,TZG.2:=!4<<%,
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MUL=OY]J %UJY-FE6RB_#^1Q5\A<1:I]'KM>GC%AA8L<(5YXE@)BKR<SEY>1
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M/A:IY#@O8Y_"<'V^H+!&*S@Q4]-QF],F"5OJA:M2&*Y?2L% W$D=./3S  K
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M5VH<H .%Z<(.25S=_MJ#"5GRW7=^V^1SX3!++]SVBKA]RR\%/NFXC#2J%CK
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M@,0((]AAD:3-:+8-<H.73 N6N"+& U400?\=9_?FM*1GTM!E,#NL2O&K(D5
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MM4_F)7/)]^.'TH$6Y_)AWCS?O&J:$BU+=E^R^_<GW8_"X/("'-4S,)P'X+K
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M2'BV:15I/A^$D7)D_-H1<0H,8,^5^T>6S_;YE43K7DJB]50USZW&QNL\6(F
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M1<^7SE?S:Q*.=M:G?AHH[W*0[#3JH^N/3NB'T<[?^O1_'WOP\V4$'H!;+?Z
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MGA*#EU\19[7=VEN:?F-KJY&/=OO'.!V9YTWO44H'AZ/BH"T9'P_!+L0#6\D
MB)&./HEN$BF55(2V!;$[Y]NAW.<P]4%W5JP@X*E M_]N^807/LMWK7KK?3[<
M9GNCVMZNWWLA'U87OS*UL2>O/->2-#7QLR_?EM(X1S2>?+B?U5_25SZ[>?\,
M YD,X 7'-7%"?[VEF1_#2@[4.!_P>>J&_FC <S]6X!E$XO^)(SD6IQPMX5\:
M&Z+3ZTGQBP?"TQ?GKO:US^50)N)G&%6[V:YOU+? $>>L-OV,$2SQKO5>;#3J
MU5;CCCOR(>W"E[@8AU?2YD(_Q=+BP=M*11U[0?*7I7V.U)475,1N.(#_'J@H
M\L /^]D/K^*O$XHTG(4C%6H+AGAHN[$M+@9>Y(K.E0I2]9:H<V)OQ3_"Z&M%
MG/PA8)\L%F!Z+=-\UVPT+?6\W6I76_5%A,';EP&[ ^D-+?\E\I3KPSY@WN]$
M'G_%'W\.H\!+_H*=PN;^;JCWR+] ;@>>%!<@FS&YP]]>A&/P@NC/9EW\(G^1
MD8P'VM[5E^@;*F)C<P-K&"O\_;00K[:JFR#"82\V[BS";T\>+JOVWDP6M3,:
M1>&U-Z1Z'!?^BS%A)QR":G,(.P(_PR6C,%:PG\'N$DE(QUM':<_WG$4#@R^=
M#/'J2AR& 1:TCB+IH(3"2"9%>&FZJM]7#J6E#)62@1<+^VRKR!!S%G+F'XB5
M_I/&B=>?E&S!QS:'^JLK,I@P*92(\^/./85Y!L[RJ0CX!FA#U#H(HR'F'Y"'
M>I3@,S]+X2I?3O!#1/767I"&*3Q*QG#?*(WB%.N-X;[S%-9EO=$6L/EY;597
MK*/6'8=8%L\C5(0S4,Y7&ET_]/UPC,/JA=<U,7?V_]U5EZ$27PY%=S($UOOO
M"C!]$%?U_/_QM^W-]?5;<KIO;I7SM8-_^90[+(197R&SCA V$V!*20:\QDCW
MV37<:+[KO<^74117L73U5E=@^<CN].'=)7=EN67:D+'9D#H-9GA5R<A'1)]\
M4\^Y#2=!S,VE[SR5)?M\ _M( :HDJ>:4E^:0IN:L4CYQ[L@GX@8V65U9\LE;
MY1-WR2=OG$\"%RLC0>?W)GI!P9[_*L8#117D2%SK?!(QD@\&/_"/XR@?L:N
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MU,^(<RK!K*/48]#M;!)%@9)BN)^>SLZSB4ZQ= ?]*RF:CNX5Q16M(7L)"?2
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MF$(N:N%IG!6G/KZZ]&A^\5OF[AD'5QLQ67*XF*;ELWT2*_#-J'"#F,H7XTC
M33(KI;&+9KACN<EYIP&UZ FR+L]H=+!KSZ$$+(R0NIP.]_/2<GBU&^DB%^G8
M4ZF8GIPI2:":$K"%2=9B*IUMT![8'+I&@)F#_N83&W8GIH.]#M<Z@9'"\3-]
ML;69\KMBTZ]<1FR<@Z&.>SI+DT[,079TQKE*2DF."TZ5NU%?='3.V5TUR16,
M55'-$S>E,HFU<#C$=EZ8=S'#RJ>ES?Y9349> _5$O\9Z>CH@$:A+KD%C^SQ$
MQY?B7SIQ8AMB^0;#9F/Z* 5EOO*\<#X@UG:<&Z\PH722N43EF>5#CP=3,#$W
MD(*AP]K$Z&G@9U:LG)GAR=G9+*-LS9 =#'CDX]'F)U*3DCR@SE449WW20HX\
M& -C*2]>J[PP/![0&0ME%4\B@ZD  Z)4<FH5[E#@:XH7[<BSS@&;0S_@^E,5
M#W%.?G;D]%^'>]7&=CX>*O(9>@[M$6U?<N=LC@4+1:<F L?$T\VQIC)3T"[V
M)=9&+]N%&R;<N2X_A:0Y&\NY:(3*77H_KYZMT?L)@\O09&]T5&=&@K*@OE)4
M26;[&5K:71'/H[3'$I$0N,]SO&12-:QG<@-Q9ENQV+?='A"C.@U.41Q?1\>8
M*XDE"84AHI<5M*'18J%1K9B24Z/$%$=IIZFHN):R^+4R[055"\XN?W[20<M.
M8W>5&%.6!44^A:^"RV2 ]A$BL/ 9,+,IO&"@,H=#1T0I.&G[0JX.85+\5-M7
M=(,)688]BEB6#1PM.%W?H?%>YH4-*@5SPH18*2.!9W$I9VH;)]$P$]-+1G]U
MC'Y('&6J()T!55YJ8?8?KI$NJ/*"$:\Q0,1EB(:O]H21N_L1P7P@KP9!F!+,
M$Z7X,=A9,35>Q:=8_O4<<1J;,BQC/)ALV0RS+KGR=7,EF,)]Z12$#G<!3S3J
M5)EOIS'!S'E)<O$T[^H#.S;/68>W8I-31N6._^9>NRWJ""@I73I8KYFKR)>F
MXM9+[/@,,N243YSM1>FEV*/()LLT2V%Z059DA A;? @&Z\7M R+&Z(R5^CKO
MH?EX^IE?-774K4P?XZ-UCK)G9TZ'6"PAM=CMJ4#U,<(@IRM"RL=B>8DVB]LU
MK?W<V%77'%[)"D;SV*6C,.IR$QE+)TKAX22>:X8L/;^WL-_R+NQ6Z,YV[RZC
M<)QD4?2\ !O5NAJ._'"BLJH#-)M-F1S(^%'F>.7 @Q4Z6X%!$QG9LMN*TL>Z
M8&XJCFE9.96"!=WO2T_7-2!$HMGI.FA)H4DR.^A<)ZD1/$6OIVPL%!LR;<JF
M'\^$-@MQ'RXPY/IKJC]BBA5BA:CSHA18L4B,A]54HNR?[Z>BNKFLJ'Y4[+$R
MZ+"EG'Y"'W"Z*@NQ25BB8!F9CKUEVGH$LBK!BE\#78CJG)[C!7VTO35XY.VW
M@CBV7#^RX2M902<9_%>*G#NJ/S>>7A%<MJ>R] @65L@A;#RW)@[S8U05?9(P
MUL>FT)GUY9AM+OY(.*JC*'55H5C"2%@\IQ3S\6<LX2'E8Z8'S[R$049X/B?1
MZ$/>$*N>R?/ ?+&N%YLF[3R[9VGNO+IMQ 79)AR-X;B"-D8FT4>JF:4LCLT3
M'\@UFC=N!%[669<2[.7'-)P74 Q+9GNRK H(T@"+?/',O')2SH:CZ6@"SJ%#
MK)@S'H7ON,K^]B@;T#OM2SS\PX?*P?J,W"K:UQ-S$MM35M[<>AVC"$P)X$*D
MCL\77DYR=&+[2 Y;SES<#YN$?4GZQ>,:@:EL>CYX.XU/GFE<%@ZOB0ZA!RD^
ML*G/"DPYSGF=Y_0@;MB_4B?E9S/R#[$AI_OE+47\T^ZZ7T+?Q1@C0OKM=7.0
M:2I[PUT2BT%^"3M^0'U"*AK Q4OM_F:6W@3 ,N ' D&Z8L [;=EJU,R;6:(T
MG*:?8T1,3( *9CP4"$'TN_RP BB R,$2"GB?IX'(\7MXSC(+_6IYKOBQ+-3!
M)"A9LC)VY2RN.8)'QQE,/%:G[B(9Q'T.P#$CL933,3?4BFXDQW;UGDZ#6X!0
M<R7>D@E?)1/J UMHF]$9242V&2H#"*X(VXCQ<[(,<6*@:AEUR;CYR$V9,.0N
M"L1U!'/,)UX&^9,JNAL10X2 ("RF*6;>7"GTBP#;F/M1Q/I &7YIO7\I%%\K
M/Y)(,EQDG=LK,"@&<R8:%&4:QQM6P!NB[>;1J<><$<M8R@JR9YEFR^5!5Z8O
MKT*N_ 'FP\.%&?K8R*?CS/W^N_B]Z3C"3,[P=M_,@\N0Z?,)10UM@3[?G,.V
M/<6$YJ8.A-(XDAJD0=>(Y2T,S/GU.3R7U4$B3)_H*Q>#C79^BTZU)O(ZK\77
M$.QTPR^/[)4L&?$9"Q5_0QP0:C*!M2L@Y@@HADZ-"U"<>.SZ;@M\.^9#E6==
M: RZODE4*^\-NN2/9^./B#%:BH#&NJ[#G-3/6(AA/DU#1(-Y8;JM+?GH>^4C
M2X$4^(44G4',SL,>DC4+FVD"6X90@<3$M U9:J$WQ1T%+62$![4&*0+F%()F
M: U3)G6Y\*]VX3LQ[62]]IE;-A6.S%B#@ ?,Q5EL:7[PB)-&EBB)=8,C;J88
M#[Q1/B!C<[N>GR:W5G_/J7?Y%D N1I?>RPO)%D?@NK%MWD+]Y4J'M.B3^G+H
M^9.=63[7#+[@Z_ PS"Y6*MFGH@Y/]D0G/WK,36EG0-K%A0T??*:/.#XO@MDM
MQ+%ILT@%6>FXOFT(!3ETOS>L?3H-Q('J12ENNR8#D;4(%"G#HB47\@!Q:7"[
M4HUOQZ5ZF(2+#L0[6/KW7*7&4"-F\1FE[5+G3FGH=/\[8(OW-E\4L'%R]LB!
MIC/(:.E2T0.%=69;>XAWP$#O&66:;EU=:8K.Y\[%OGD"6B?4ZH?K!"N(4^N&
M0\251A1W;+Y0!3,9S[43_G,5_F>Z'##RLCU4:IS5P3.%L!J$J_O9PM7MY+#
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MG=()^I[G^[" 51>4"YHD^4ZPA^MQ6)E[3\-0L(ZFRI^(YU)82C*@<:H$/B!
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MD5M=X>@74SUUPT ?)-CWYM-Q6V\\':=SKP\50+R_OF/19?POVR(<*D6>L86
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MAVL@OJFAF\](LK@"7K] ;0<D54HU0-MT9VA[ 7$0:-K!E=VQ4X6#E<WDHG-
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M(9INU;@V'"Y$B)QJ<ZH!1'K # [M89YG$8A6$;Y&(!)J/:195U3%$\2IJ76
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MENP%@PM239:Z_5L3U#-#65XRTK N3SP#S_1:M:2]-K&V<QT>Y0WY6&'"OC?
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M!;!NDE -9'I-8TI0R88(5Y/3_#X-L%MAB-?69:TIR]>L"W^.\XYI,4N<WPB
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M.*=L839:I]_RJ]EHX"!]WVGYQCQL[2:R>"?G^2XT?T84< %[C$B\VR 0KZ-
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ML'3D\GA&S)A*O ZYQY@QUQPEN!08+D-_CV7<JE54(QW(N47+)*5(^Q3K+.$
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MNUG)RO_$@J]EDE^9_EAU+GI6P"W.Y%939K8[J'I2\MNET9O'A3]%&MTTI/C
M"+$AB*UQIA^#<E!?KT ^/ESZ>7A!MMVPGOL!GU95WMIZ__&F[7Y@UGB(D40W
M*_A=[_$#L(&NZ;6+=Q=B8"?<44V=UX4JQ'UQ, K_CB?Y\(QS\WRYFYV5TV&K
MW[.*M]'*AA,=M#JW#-KS^][MOUL?[0/SY(VCRE;,_WK8QVZMH=8-_%H>\O4
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MV/C^"!^-@R;8]H=3O@(^C"X9RA]WWHR5F.=PC9D:!%05E2'2-KQV!,32<MZ
M?1]%\9S5D'DTS[, \C23!>#G^D*X;Y@5J'Z*(@MCTE)$(;9O 0H?]%8 .\]P
M\^GUWE7_XJ EWE_%A1MRN36=>GQT!60/O$[XR"4=S!C(:&$LDSDWGA U0R+D
M#V$/<;!2;I&< XL!N[F ?9^ $7PQ<=[2)!8E0;HT(XI&4+$G!4=<X- &6#EJ
M#L(]A[,HIRR^^>VFXIKD%QU@()VK/$LOF'OAG$.:!,4+4B#3O$80[? GBH,B
MRU*2!^#&&,H BAGC7QH'/)<7)=@I60[:BY39)4Z8 *D(![Z6[(H%4F/R*N!,
MXS&0+0@<()DI*B<XZ#_K#F/-+E(W!B>HQ'%:90Y;[QX?H:R$9X"$_"*9'%'Z
MX8B0."@/8)3%7?72[\"1"7 _D :<O'2=>.P -8-,IA.'/;V@N2B@!?36Y/ ]
M,G%1CF%K8Q3F"%T?3H@-<"X(G#KY_H@]7SL55GBR@B!/22-I$M5*R4B70L(I
MLEK$_=;7@2<(5)25\P(T*;$*GH@BLA:HRV!NZ]84M-,LEV.9HR9!)IE;NI=>
M65R*.$'V<XG(P0#.$G@9H=658@ 5A !:@BV@L3Q)/(U9Y>:F0(/^1.'&FX O
M/A=?X-5@&Y :@:Q#XBJ7-YXFI6&(GE9;2<0(W@/7\X6%R1+#%_C02((;3K^$
MLX?M2*/",)1 2\RZ(>Y4M=L7\!)YBF\'"T*6I5V=3^(\.L4PT+7>630M$MB=
MC$?76;L"+X S<N0%B&10'+'@B1D@H8&QZ&WR',-$O(6PVO7\4[O4)9U#,@*/
M@^0430H "H;C \(!F5"2N*38/8E,W/*Y#"<I>/L7,:Y##9PS!#L'73>%SW,]
MEPJ(]2*'CW!IRR+%P<%/\#T0.+\1BT5T42V!J$;?C<4E[ ^N")92FC/ &7IE
MJC^_X404:=*IVB2,&@*W [E%1LB:U=X$1NZ3_(I E%V[3);XHO!*$F^(BX;;
MS65-?-HSN> BM5\K).48Y"\J*KB(-Z3:=G4/.E ^7GW[==NJ)<L5*0PBNRO<
M%^;1U??<G]]9-^]^BV&O(SPE7-NY8LJ/6L,]B!+85KC?34^ >09V6"I)!+&1
M55G6+A(X6PI>CWT-5JPTI ;-\'EV?/2I$LL?M!=W5HE*NF<H\[DP48TL1P^C
MS-$O($V@PA-*Q!+I%A*,H,4D0J^*)^FY)NBNP&W)&E0.RLPX*"".TH+%JW.R
MTH=YP9-8EGV;,,G0$C(;X/MZ Y!<:;VH(G'1!=""X[M];^3Z@_;Q$2UIGEU(
M$J'T_E<DSYA%C*M;SO!/O^^Y(W_$+R)PG%;E-\,;A3R(R1NT.CT<EHG7\9K-
M/4$) ,.#@+C4B0'TV=A0CXC)Q\8)(_N,];IZ" <9RB2!HT7#4[FDE8>X*IG3
MNY\?_I C55/G#+8I<3KM-11ZD\-Y?/0ZGO]Y@>/>(N>_Q'3VDW.>M9P3_A8(
MY(-%J2ONY6KAF^',)9YP)G$[V7-&(L$?HCW%>\!'#6J,-1\0/=SJ O:6PB*2
MU+<Y>2:2[P<5X6O]P.MCNC[[_-9Y+4*R,&#%GY399#V/#9L4M,$F+QS./X!E
M(+4HGYZ(V^95U!@?0<?S/#Q8SZ<Y+)V51NJ\SO*I\^FT8T4<V29!6PM>+J01
M>L15UXXW4 $,\AGXX;"3$0V8(],/IQ7!O2/E8L!F_==_#GV__9.8TQLH%:.W
MC;[T?G*LN 3<Z6,)^K;K]4[$BY/N"R3L:9E<D(UO[44EQ<[ "U$[IX_>S %=
M.GMU"A.,M1GA!2('U\#6J[A0>R/@%< %4^H37:V8+=FRL-4LA69%D;&=H*]6
M(I$&@N$1!'(BDC':635)>,4& #S';!J=8,PSF/*(+&XCYY=>1X6-%E@$]]4;
M_%2H=!'*U8CSOT@A=(\9SJ&,>41:ZDS!=N#8@=H3M)(.1U;XK,U\8MUQG""M
M(UV@33X'E[LH9[/$$A2T5:_.JWF*6IPZ>@,L5O6&K@</0%!M%4ZC4NX56A:.
M&?F!V4B?HL7)/%K1XCTUE?+XZ$T*[%?R[=ZT?F[U\>>:]U2X'_V)X%\ZV*(4
ML/P:RIER-\@L+!:"K):3I0Q6;:[6Q1NS#KC"Z+/DMCPHC#R(2G9BP%.?7TET
MH:9@0TW4 &JZ)YP1^1C:QP/K&/S(A&,^*KPS3C+QL";?;FVJE_S:-\7G76,[
M>*"[>NV>-@&0K< 'A9.^L$R WS^]=/R6YVDCP*TYRD@V8T4VKIHUR],'P43'
MY+ZMSK_W!T2?NX^<[BY8<4/*VE'9ZK,"4XE7J<DFA"I82%XTL &V\A"Q*?\*
MN<M0,,>1R.%DGQRNX\%X*NRFYJ:1M@F1F4CG6W/=P>\-Z<?,=0M'(T@JE].2
M(T[J+F@%+LVP/#[B67I+QEC?Q,FK*)Z*K$3V2M"1XL"-CNQK^E%LQG-<%TQH
MHA?EB5:BH75\] ?*/A#X\0RO-TX<*O'EP*XN,;$2&CC LI"2A M[FLN#ZK>(
MG[(*J@50C251#TF9&"KL'DI%&=E!IRRU-F0A.,IG\#ESIA)G>"JW6#E[_/,K
M,)K8@4V5";#DW.L?W.3>XR<<?*FB*98?4ZCE_))=<60.I2L)87.'XR,K$F%B
M61R)0.5L!2<H>('!U#E:$NK6[V&3QO K?$V4T0%I#FLW.4Z1I76C!2@9B+RZ
M;RU,H=Q[HD[A(.UBX@"3"C(OI#(-'6W;E, VLB@TMW $L")E&AVKV17)C3>Y
M*?5YZ%(?KRGU>8A9H#2C=^Z\+^=)EGW9M[;%_)]*[%1B-E1K))%8I6A(E H<
M'JHR4?(K* 'R5"T^1761WIQDVO>+O^0X(D7'\_*B(&\'PY'L<$N3U"3=7L]P
MNDH,DGBMQ%X],X0ROBJ"I;M8P5-^BHJ%QH5*.($[;')FM-MU!6)E8I<BQ>24
MZDP+)4B,PLC(\(=[%Z15Z<8J,%Q+@]FWM"96LX9F1;<B_4C> V<_:#\HL@!O
MH +1%$='LJ#HR[:I8K/%5LK/J67\P%F@K %8#AON J3)M[G;*<GM'M-R2$O6
M;0$[Y:K2N&"44 (TQ35<HXG.T4^S>RYPT9R4-;EC=/:/-57WY:</KW\#\^JS
M-5I7#@;]MM\)VZ,@Z/:$-_*&/<\+O.&X%_5DVZ_IFQ^W&JU;$]TWS=G=,%I7
MWV>(&E5-:%WHJ5B^<KDK G0U;MRH/Q@M-J'4?R[*>;;RY_6W4%)H:3X6\I!A
M!2:S8F[1_T9YXU0Y.).?XA*;*D=3E0E5ILR#]6#<GY!Z[9$7#()Q.QQU!S(<
M#;O=4>CW^D&GWQG)=D-(MR&D(@392V59&;I@*A-'E?-D!CX@6>DT:(VH:C-F
M#H"Z_-XHB@9>V)&C=C<0XZ ['/7$:"@"T>\&_ETF@'_#U%6%_U1V7 NLU&3D
M"[LHA\/F2ON9_/Y"98!;%U8+>E8LI?FK=5& %.A3%XJL5L&'*/1$MR/"OA?U
MVN&X.^ZU@WXP&(]D,(J\;B\4HB'+VY"E49B+A 2F,S@<*FI>,TQ!TL7I.!<<
M'@?R/$0J\<9 (.,P&D=1IQN)MAB.!R,?/@P&:&YU&RJY/95011A8T%SO;)RU
M^SD3AT@\LAL.@F$OZ(M.OSL"M>>#<3[L1<.AU^M+.6Z(9UOBL:KR7*J*HF (
MTT*ER<A=LQQM6Q9-XP3+6=*%8E!-9Y6QA5IUKBKTS,\MC<<*=99AXC4F_[ZN
M6JTJNT.DR9X?#<+Q:""&W6&WW^D,AR#)@J'H=()>! JQH<D[J3U,A*)9A9EI
M#+O1'S(%\:5+63%E)+G@%?,P5+<DXJEMY\?I' X2\]J"BGM 4\ZO5<7>(=)2
MY(ON(.CU@M%@U/4[ U"/W4$X$,$XZ/3\0>,WWELY<AX/_ET/B]6J<U%%&M\1
M_UT%TY2:!&/K$,DG%..Q%P;]#@JC;M@;]3N]SEAZ/1F$@WZO$45W$T7D"@H.
ME:OZ%:S:((  ;A[2=8.JZ,G4ZBY%7)&T2M*%H#OAY.)B0@7[F,.T+ZR6 PJY
MP/*1@Y17W>&P/03BDN/!L.N-PV%_Y TBOQOV@;6"=M@0W)T(CGO]5#Z<S*,Y
MMS[<'%30)7.Z2T@94SKWXJXN[J^Z!:Y7SU4^$'H;>5[?[W=\T9?MKN?)4=3M
MA&,IQN&@(\?]3D-OMZ&WJ;A(XSEV\2C#GQN<V'87$:A,5=AV*4V'V$_XY0%*
MHN$@Z/@@>D0X&G>]06\D(M$=^R&F;H)!IZ&,K2D#I<92,ZJN<>*6L+#,ZV'0
M.#UEJ[N<GZYI>:+.0BH-S+;,,NY0$.V_SQ"[1$5:M13:B>E<ZA8X'9%>:.E$
MF)]B?$T;QR=P?+2BB="D9D5<*&427"^>41K]A4S<TZBJ$  G'JY0!4=X0-ME
MA?^@9:2J^$I7W1+I+*3OV9+B2K4515J+U51<O\]E6MA-QC586)^+S[(Z%DTG
MV/'1BE8PU0-F4DKT+F")8?*9&L),6J@>JU E'F/LSZ^Y XM*=R%VC]7@DCK%
M-N^<,AB_\-)2&<JB$+D&EM))@'HYH_4N":Y4W[W6% F[CP1(ZSH^JC;:U+@<
M"I+$'ZK:VM[U4S"0+Z3N;V<TA3G6CN"9S[*BB*E\D@QJJ@:9P9[$H:I:QY]$
M$@-';% !1XF0 3>  >"FYCS6Y@+5J;8<K*,ML:9\[?.=ZO%8^[#^^52P:+'Z
M/,<V5>Q+4>PRIW;-2((^BJA(9SJ-YZ9I5(72F*6HGU/U2ES#KG[!DEA8"-<9
M8B&D*C2L%QCJ>E2L@=<=?-F*%O4J+,CEBZ' 5HVJ]##&6,R4&0">BKNB21<+
M; /4"A%)D4MJ[M&ZHFKC-P6.^<J*1L>4>:K^$R EXD:U]VXE8K;?1:Z95?N(
M6VAP.[CT!\XWGLOI#NNUMNNN/,=,-\8?SL(0\Y.X7Z\T),&^B\FH_,><6%4Q
M3AL*?# 3"JADL>U&&9B(QL,R'IM/JA><@=(+XUE2 >#\GE)9$+59%<[)W\[.
M/JBN17Z,:1_)UBZ)Y@6H&O.XP-9&+1NKU2FFQ=OK0J9"L37)Y0H, F_WKS*Z
ML%KA!;.7PO(!D8$O14EE=N8(3<JU80!=K=A=*T:E+6R7290:&,UZ=1@"=HE\
MO]70DW&Z=A^XP)Q ALK<J8%; ,W/LYR(#=>0QY)Z);^DV54*@I5XR[&Y!OYY
M"4R>H;*F,*NJ[#)6HBYDKXDH:36<A7$>EE,L[B-!PUMGJIVY?0ZE"WU#O6+<
M?J00 *H#$ %(<[XE6)O4V(#]\-+:^:5=,M(3118L+T)Q!2:/H")0;F+@&G0-
MHX!5H]1FKXL_Z_1@HX-080K\]R+#M=#2N5Q.<!!:OR::*5%,744:9*BPZ8SW
MBJ]0)UX](Z^DY'T;RYJ*[ZKBVW_F%=\/:;!-XD35W=H5M98HSQ)LF%BA8]$6
MQM96T--H1#CO,K"\?6WEKFY+<A:ZDFJ=,MQ1@W7:C!]FUF!Q*=;R3K)"UL%+
MP$B:P%LAHQE33<L69>F#,OJJNQ%OL+BJSHX83-;*X%IAVRB,E.7V#I;]O%Q@
M?&P4XK;4B%JZ0VT5K'K+/=@L"TB$GPB0]F>"43JW &GW;:^@>P$N[;5M3(%)
MD48BQX5&1+\,E'#VZ?R%,_"&IU[;U?W6UFL='WT0U]0MK-NM65D9HX'B:D C
M)9="*_,CS##2IN'<5D'U<L 6/&(;U'?&SW+$%2RTX.YP[$, JLRNI534$L&#
M%RNKS34:=5 I%'8DZ<GLU/*#<"&*C")L?\J5%MU[VP(<ASH->XO9RK :.:2U
MZ*IICW?Q^&AA&S,V+34Z!*.XE"H:HG;G%%M/*4V813)AB[/^""H=Q!NB2ZA.
M^$\"#V44"SI6!X&%E'F#:#TQ&A"@;BZQKY4[@8W59MFLBDAR.>$F"?+7R PQ
M#ZK1":\#*&@LE><OB!+!L4/'$\Q-H1"-1'70QT?!-;,%O;GU<[Q<[OWHWZ3.
MKV4*JJ'M#=E$?&T$Z0H^+IR?,]R%D]=GGWY^X3"*P_'1RBM_G]'A [/__H+N
M?]H>&&ZW!=?I)T+NM#]R3CYGLSA$JGSQH_-F2BAPRAO(0)FEAO-6B0UKY4J
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M^;43IV%21K)PX-V* MZRD$Y!7[7N]PS;M;KS.OT7SL]96A:POB@NPB0K9.3
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M*Y$,?\Y$'KFTUVIZ+FP91]N3:VN/\-HU8Z68!;#+_P*5[CC/IDZ!W)]G< 9
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M3A0DG=+;']K2DA0Q4#: "O&[69X1@G8EQP3OS2F1"_1XA+6%"7O]3'ALD#_
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MQ[R)G^NR@K7C5.BS/HTHH3^@MUA5VAX+WWI\"SBA.M6UX\"7_C0ZG!Q%2UW
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M?'/PM#XMRZAR7>)$*O-=SFB"FY>J@K9HJC.-(;;[I];HRGSR>PAI-UIJ0L5
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M@IL2KK<^A]ZP,^P>W^23A]$K;!".3DXU34#7^*O*0&^EF;PX*V"[\<<34-%
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MILYAN_%%U-_\5(V<*G^HLK&D TE3I$O*U"AW\P@^%2HKYYS(S G5.WD.>&^
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MSO,D7P&A7.2D$Z&*0Y(;>:1H[B3'@ /BL9XG^H*=&6H5\S3F<(LRJH(GVF#
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MRV,[B[_,S@C?Y07\K<C3W=3+/Y'(H P QB).,?I@@[?B/+@DER0LP@9*.(.
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M22-79V1@\)!@;'SF>@NF7Y?<G @LFX'L)#U/B=7 58KRWS90P!]Y^>D%I=;
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MW@@X<_]U/;42QADHR'J&+9$-H,:<NCH(< &5@'JP# )@;'ORD'N$@>?SHN:
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M(O8-]5W@OFOCF%J@('$V$5U29CP+ ^IA0.A>KOEOS?BU2^ZHR=2TP0P6[E&
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MHH&T%+H\<-9 **#Y2HO2_^ZNT(WHI85+I+6N5<9%9J>35)W%U<:J[>G\1N)
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M@\*[NOH:+=V,: /O[OC[786CY8D<OE!9->%0Q) WEZ 30I+YL6NXX?%[',;
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M?"Y.X'-#8$E>8F:03ZP]R2\R'WBBPPKZ2"D\V*GI--^$N"B*(3%77$*$1;[
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M-H:_F>4&'/M.*^J,QT>'U.V.,HSX'#*K%^93NM@L;G.$JBZ*]@WJH@C.[_W
M%P\R!)^YU+[R>AG@$,S%FNC*V;GP4 &X>_QHX/30'UW#F3J+KN7-N=V=T-RH
M,U6*H(K4$+FQ1GW(ZB B*LPRZD)Y!BF)@N9<#M QH[<!:PO<A,16),JXR2 #
MA9R GBY*KOY5FFTHO0$/"[<T#Z2SNK5IH>-)G>XA6(BAA0!+7$GFPCLN\LSC
M9?AWE3"W2[#YQ7,VC@?NP<"I!ME.N-"5:E!G7(2^ 8%@"<1W&-V%1G)?V]*X
M7>[NU B0RSOHU+DWU!0E%]FC*MJU69>+C6IL=!T5Z%!"#>"?>,$$TA>8->6M
MHGR;HU15K.UK+B7FS'+',TN49)3[M\!?]/YZ%C$G<"BY:(&7B;'<1Y!" LP^
M7(%%LB8DJX']69!Z9==9M\D@A<&,#9)1OV%_!;+Q<C[XABZ<;2#)TD8 BH@I
MOR)424\<9O)> ?'+&IS8330W4[7V"^#5E;9DB"E 3( *5PJ;,:>OM"E:O<<4
M-0+ .A1T@1>9*C(!8JH"55@_2( &71*"R')R4?G^T.?-$>![)]C,9I *T<=1
M(@45@3+17G")XO;O[LC^U]2L:,Q,R?5KSC%3:(@=QBH#3XEN!Q69]:Q2P\FB
M/X.QRB9PK9C>@=8M[:TKI/#7%:.Y]*45L+\(DDUH)/BV032<ZLK2Z1Y@9#FJ
MAV'?+I*ZQE#0_DYQO8R<N1[6*$A# \H.W_T6ZVAB&+-<EW"7>G#D@X1 "WPG
M27@$#.,ON6P%QX3;Y?%L10F]B,)M"NF/K3P,<JMY.;.<_U4XID2F).R,>E%L
M;N@,X2XJ>T"C0'&^H*9A>%?!@K*\WG=!59&'<(_ YB3(F5E7@ /@K9HW/\"+
MLQLS7S=C6Y\3UI^1L!X\)ZRWCM*@[R$I.P':W74'5[B[PCNX5M]CV&<KG5^C
MZ[?7\C75-B4CO:SPO8'F88.52]<?<(4XL3LJGIW[ I#-D4'3L X2Z'2]=)Q%
M8.T':X6G:^]9,*J%F^,$O6E4@IQ*4F/)HJ)B@O&RY7WKAJJ1U[$=A,:"8OI2
M&"2VFL0ZL5_#@<9V>%84IZJ[S*.D:3X_F..C4T_24#Y5F2&7Y5-L"HW%Q/MP
MUBA1W%3HAXZ,?7 6M 'PR%*I_M=9E]YW'B1HELN-%T*H^*"S]?;T/!J,1ZWN
MJ(U2S,4A'&-DYO "R]6\0\</8_DL55B^D@I+;/P0G4*%I8*Q^L9@TJT74-.Q
M[U&@R^2@*XB_O!_$/?J*L<=7;*G])*0W>,S>L#Y0)>^O%%G$5QG95UP$+K9Y
MD@?VPZ5F+E)T',+747!,2^]?J,\IF!:PH^A>9QB8NXO)J.P>3_@&$IAP-619
M(1#AJC+"6@9?1B_8U2*77[4*?'O5"L5U'J9[K0+5*LID">2.4PA:^>/G7,3:
ML2ZNI\*+DUH*E*#Q&GRJ17.!FZJ /FVZ/_K*7IB;.6<O@ %)$I!QB=V%RF4=
M^TN9ZV4M!'B&8IRIL.,'1</T(7HZ 919188Z6WAKF%WE1I(WZSPS4QH,/;PZ
M_PKCD )"-QD26Q$P.4RQE@O,D3FN);HC&GF4B( T$*LZ"B-A1F(+I6G0P-0C
MY6;0;&_YT6K]VB($O V$_4J:GD!KR3S[:(UZ*6]H)%QJ8<_++':5W5R_3X5+
M7(E!G9E][ 5*Y 1+K4@V,JF=@UNR:6H>4FU_.F#3U-=*63G@[KS1:FYH>LX]
M]W^D%B\;9L?V'$RQ) SDSRU5V9<Z_(!>*60&8"]9?6*=6T4)R\,W%*#4(;1@
MQ_EK0CAO9YPX!L@2392LG[@)=3I"PC9&LDAP)N/8FK=2A\:_OX2F[N5?3B$7
MANPO0=4*?\H1P!0WUC=(P' 5W+ZK J>B^XN\M$+AX!TM+VUZG:H#FA'[_G66
MNWX[?@6XN)";0/&@9INE-%81T@@WJC63=R[]V8ZA>CX/A1+9E;C$#,\6Y \(
MO.\$#1-NUTNZOM@K(XB2=]A<<'KM,4\E)\VWY$0R]HQ J%? C!JNU2WL92R4
M,!3&P(CN[Q]U]B;[6ONW M@4 T*F5N.@,$?6'8<I$<?*59;&30>NL?QP96^E
M YXX%_2E["(%#<M=$SYA]*9\5_#4[0X\)8>DJ9W4%=:/PS&W*80MT]K5]AIJ
MH(-(<CBWKK-*D@/S%P\%_,I+;0)('HEBSZS&JX9$S36T9'.$M A0?653*H8&
MAP;_5&6(R_WW9-E(#;6BBW2VQ@]X&MC=';BP(6]8?M+33(D<%]&F$$\Z6#]*
MBV G.-8$ZMITFHOJ4$TM-WIY]YEMN+6E'.YU]DMQ7Y<09_6NM7N3<M_K[I?X
M!O8RS[[-RH@R**4$ZUTCW(>8"7X="^B0;!^2X\3+Y&,;T-"E-O'3(F[I-<.T
M''DQ?) *- CK\RJ;;Q:3U-C)]'!)$O<=E3MV/0,UEK%I#F%](*2!N/8-HLW]
M?:RNM((4[7W:;T3M< ]AG[P*LUJP4=@\R7Y%MR=:$+72"@XYGE-D[L%,E#)V
MF1>"25M0NX>/%UWN.-=-J9(,JZ+9\DSA\E<=": 63,HL[(1O]B-'>HJMDCP(
MT", F^UWPBD%LN0B4+2,97$"(:G(T]-4$*=8AN(+R=6E$TY9W33;S9<SFK6]
M)K9R$[1[BHK"684LD!5 33J?8S=ZRGV34>?+=KG>$.X<\'#8UF:L7?T*2.6-
M<CAX'0ZC8R*.;_@JA*\#,DJLI0]I3?F82F)JJT4ID5FMF3_36P(5SE-L-GB+
M7Q\NXE.4TMIPS7M6$%*83J& DI14D@GW89LM;?P=6V$_O:A$5+8FGFUNZ*/!
M[8C)A<]K46GQ%8-D76CPL.]*LAZ8/MAK_A%V^#E%Z%.$P^<4X=9G&%P9>[^_
M8=9"7UK@.G0\5,3Y,>OO."33*AF9SF9T+$9UV""XLLKFQ?LWIZ]:S&MP$^ 4
M/!"2B>_0BA;ZN2%!#^$Z"*"'UE9C&W_%*TY_8#.?[F1XJ;_([3X0-L':UV"L
M62,.6 #=J[@Q$MIUW.))-8A$,J=_;ZSRA*YAPJ*'F2$*PE*P-\^P#"$<%#*Y
M"%]'Y$%UF: (H9(N^(8?/ST>1W\8O0\?2T]*"S%0*JVUT&*OTD!Y/)W*^;0\
MO )B5]0E%=IUU3%JY2I%.HO"#DP72,B% $I$MNLA [^Z6RTDJ\+EXDC+ULM3
MG2CW6@&V'P -XI, /)OE'S72$2P4D[+[:+A\T?<I;W&@D>H"5"S31S?T;D/
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ML*9UJ>022YWM-1L,KUX-]II=08,E259#67?0WRE[=MR)G7PJ((W87A[9/K5
MHBAPNG0)@C7"E-%(]G%3W#1[=X05D0#R!EZ] \0.Z;_M:UI]0<8A3P01%.WN
M["E;D]\M;=W$QN1< 8";,3H+MW?)X5 \!8X-.-!P&HPL<BT7&F07\)+F'S=Y
M)88$C4V#+VO,+2X[;'V1K RU&) E1U;LF5!]DI7(1B*QE5@]XX?N;.U4XB3:
MY86]Q--#92AV,P54VY*6]5+$)49"6&]3,FJMT;&6[#>&<M9,B:#2&^3'8J2
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M29J!A2"9"@QX;C %ESF#SU$+ZKF1J2XWT=.T  "%&\;:#-M%I=N_+L7U"I3
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M1E]V. #7F4'5+F8S^5!=QZ G?99":A]!=L$LO[?7RF85_>+Q$D_RK)6# AI
M$@GR<JH/9"V8#3+"@ \H?/J V,C+,?C;-SEH^JXZ@$# RJ$_Q[U1M'?NF#ZL
M])Q3NV+P=N02?..: U/GCGVB 2AEV@*O\G,#PDDY.V>U#[?#T+19'G.+9"8E
M>"VMI$;0RJ*K]2[5TZW,#7S0.P;_:<V=EK5< K9DYV$T[:Y;V7%W$.UI@BH&
MZYIE85U.@@V_=SU30$DZD\,GH?85PI%2.D2_9AW <]47T(-S>5B.PJ$2S235
M#W#@XA8FF;A>,)]F6O*UMC(8'T*75*5A39W[4RV)=7L;8#YP:U7-L%Y4G\;"
MKJ+H?V-I%W:@1F%C%:8A7WN>'(,]:79\N_WO]G$4OO2 2X_4K>HE@Y,H?#2
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M]ZN>B;=D#%HI>BM-)4Y%AAYW')QV!0*5=%H[MN^3^46Z67SS4_E!5XQ"HS^
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MC_D[;D<I183W,62TK7)-YYAJ^5>68J8F2-KD$!/$UGTMN>"6[A>I%%Q %SB
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M_[ '.3BNGZPUB9:@L,VMN?2!S5FZ6R]2ZVI^<PQB<[=&=H37V.D$*(A2IN\
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MR*P& HH9 P7%37=WW-S06B6&61$<*Y@??7M8_RC 5 +Y?4Z[&2>?J-4S6K+
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MU]0B:/KXAR: O!?<&_2:OYM/V/G]HVN,>50,WLQ^_ A_?&]'_Z</+A3;F,,
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M#3GD4 KS7U#G0EDE$%IP'0?G5;#&OR5$Q\$[HI6\4+T9.XKX2DZ'>\7TG;O
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MAU!IVUHO2A(YG$I+<80$5,>^ H+:DX5:[K3M:H,=E=K&A0YV^CU"7UI!G59
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M5VT/ML78$K5<BE8DL#J5%30+;DG-+<O7J[;;:HT<#>4'*FJ]?@,PF2#M%%=
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M0VY!L;" E81M(X+M.3^+EAH]CG\38  Y!+X T_FQL(PQDF_0C8)_S#4><5;
M8C-S9 K.!>R8CT#(/[3X$$)R@^9C<XX%EA8FFMB6?\.I&3A#^!A,Q5DL+;X&
M UL')]#J;UZH.L!SN5/11&_D#*:@C!@#..(]A>'+ 'R9%-#BCT0;%E>QM/P6
MJAT $F-NWLJM.3]CM@OBE+\$1PEPL/)DC@TWOU^":8 ?^')_H_Q$TF*6\8Q7
MQ88\Q=@X' ^1_G"FXA.@#0&C6[!]X<3A_9_,LJZ4:Y@CX)&<9&P78B2+H A;
MRD=G8W<IMI]- 3'A+:3GB5")<-K,=4W?03*[4F[M\"U\-FK)R17#W $'Q5);
M2"#\*0#/:&&(20,?.0O8&NPC.3:6'B>3!<@-$_UVX<Z;\X4%^\:%U)7RCBO;
MP"# OJ#[X>-"Q$:R\3Q\2; O@!W.!I;Q<V:"$.('@U0E5$/&M\Q;I>;PJ$$+
MA$E.ERYJBC@-8^S')<7?$N*3?S@2#U(TQ(2(($4O^5H+]2Z<&TI?5#@!44)4
MX$<,D@]%XPCPQ$4MU(_".^TIP Q\N)5DNLG2C;11CZ$B#/@B5RF7 >\&!Q^=
MV_G9%'YS?@8#&3[L7U)(PFEQIVR"GH *QS#_Z1+Q<.[8G$KD&.)Y"$PF9^.I
MZ\PE[F1O.OR$/<'--"8HQA2\-7KD5U<*7B2XN$[K.5W:9,.MP$E+VTX.:7MG
M5R=J0^^?VFG%Y6V@5+[".T7F CG]L,$@05!#1Z1I@(J;,M9?*_SF(Q3!MG+]
MX#(!Q\@"7RR#TZ\(K5%>X9,NQ!\7_ ,((%K[5_E^^&7^LOKK:R1'X+>$Q=.*
M.0"$I(Q<  *:;WY_IUR/_[T$LN<,M.E;0JXHV588LN_Y6=P(>Y6<]/UR%$SW
M2KFS02UP 534'M]=M246+;_R@>,>FL!X)L'7$B? [^"6:-4R(8;D8Q9+UUL:
MB!32P[NZ9\H7^8G !0P',P\A=O73+26:/J@A\*O$-B[;\#!7-CU]$.=GH& \
M D!(O)$# L$DD7K-OG))!HNUF;A3YP^(QFDA4*[N96*?>.0BEZ3G9^@;Y  7
M[/1ZFI6[KGQS@L]F&\WPV8M0%PB50?14+ ,U)6F)HRC% D^1";?^F[&%I,!S
MWQM-@6L9;3J$MS6ZKJO".;()=@647?N"Q9+\\<IX+4S8Y#YS.82,Z:%IC'+1
M\PV1:6'.T5T$K .;#\< QJ?DA>3 7-^#\T //M*D8^$7D.J!DI8<'8%MKKD_
M&F#C/0/5""7KL[#&/>SQAFJ9(W4=08H*E_VHRH]=<R3\@MFLAU3%%Q:?^PIO
M.<(8P9G*(,85NFDIHT APU<]Y(#D5*X2M(1N=G@?M!56\4UY7#AGWIP7XK+)
M%(^QJW+!"OU-.HK@C[UOR\7-4G*75_;A@N[*2SKNLN[*#[UM$9KS*[6&WE1V
M*Z" >MR9%W%.^6[*Y3UY $JI*_+@C9=OQ^-!_1G'BIBVLB!YE9NE5&Q,(=BU
ML%1P=1)$:N-A*K'+4N45>LVD:V+R>B72N"H+-)>]V0%!SV?[-YPG5])B4KI"
M52W_E$LP23\ZKD0VSC?H:L#+!>Y27+J@>^&BDCJ@R?4W &YN? +_<C^B@4:?
M*^VFP$X06M)R(?6D+*M(.N[PI\,]3E-C#.J>]&"*#PG_L_!4B@G*&QZ#WTB+
M/& C9G6^PCL3UV/HWC,6I@][_Z=PZ,1*);Q&36W&+ZIQD+BU,!^9PN?:"DPJ
MD;."09UBF9&KTHJ"C./:8G+/)@Z_Z9DS)GQI$S8U;3-P,<6>+:[._[BZOU+^
M<7W]1>P")M#(I)G@^>=GYDL6'.RIRU>/2#5!%(7W3%=A0'W"O(UO%\:<PK[#
M^\+!KCP:UI+Q(YEFVH$3>9./1KS%< Q0FN/'6H=;GUPLQ>\55ZP(;J$8UE@Z
MU.$P#1[M#7^+2W#ALD9JQE0^> W@_@&=F7,/GF8_P%'8[,'Q3>DD'3'_)Q)O
MXCHY?A<LS(YO_-(!:0\&#3\G2<H 'HF\D:'E(DP5X59/.@T>X:R9Z&&"I"?^
M;,5B,X+/R\HBW*"[M=$J %OM_(S[C^(.%*VM=KE7*?*=<*KSEFA-R7FX; %&
M&K/]P#/!]2M$"8 3V&7@24.)V7GO[V,6';^Z?.($"C9ACL!_K3WL#+5^LG[<
M9S[ZW?1ZXMW"YK')M3VYB[;L&BV%P ^6D0R@J[WO2P_CG-Y)IHSYLZZ?3.\[
M/D4,$-J5_X2-N)F/8I^$0[@/_2UWT[NEZ\$\Q)[#MW&*L4P#OOOQ#(/;SQ\W
MI5IK5X-TI^7S,R!3WUQ89F2T1MO]DC&/%\7LT726'NQ]>(QBE/@15QRFL-&)
MH89L''/C<[N.N_)<>)B \ P439CQ"7CD:,AAT%N#@YG^CK6 J+P"O/[C_CV\
M!#L,E.B]?A-W$:QH;N%J+[)C].)EYM2VUAFJW4ZWOQJG=S^>L<G28G?3KV&1
MC%OTRYM3( ^>CRR(V^5,DDZ7^8;[^ T.Z9WEC'_L&.27;63CW]*TCAO=,JT)
M#.Q,:WMM[N]?;FX^?/CX,7?"KWC.8'#H9-Z+M[S=E+CR@E]8U/AY]Z2@?5+3
M]O]N+7+2<N1P M&N,DR ^#>1!ICF'"3G'+PC^WIOZ.2-XJ:0C#.MU=&RBF\4
M2D,[=6ZJ#ZOQ4U-FS(KBPXC)RF8R/:&<%<EA_"/_":<)1NP]G&6I_*6V8#65
M\M<1RKHOH%<&C16YM;]2S,O;NKP#<6$^+DS5I2E4U(EX7/%)><8?GA;,]AC:
M7GC0XKUR):">-H=(_B7DWWCL8CQCS&5U&/F7K'\0O]K+RB<K_Q%UX./LUD$I
M1NZ6)DXE%\??$/0B6;E<[E5;ZJ <_;46Q9KD*WHJH5X586BO7T[;.TIMX'/@
MM7=Y &\@_TD=+U,1Z"7PXT/@\/IHF.[_H+OK;@K'DD2+LNW6?I5R.TJ 3;C5
M8C%:R==WB@<[R?"> 87W4'@/A?=0> ^%]U02WO-RE'&NT@YZRBT0:S!Q'<:"
M? %8'@,3[WL35-MR#YIRJ=SSVT*>,13OLA'M@A)L0Z(@2YX"&JG>B^\,S_3N
MIBL[_"S^K?4NIS)\>(+/]OM^'4:(O/2YY.VOUKO2!C@VWSY^P<J=32+OZ_ Q
M)NNV0EQ.9U1TBV5@+OA"1."ZR/<R,&N<!UB(K'#,XX!WL&+&1(GBM/#N&<9=
M6"+M','V#YMGV'"D]6+1]&'VS!]7]^=G&%X4)L]$ 7 )E3@'<:OM5>+^PP,C
M(C L:ED9IB@B?K<;$0]T'/L/;&4!AQ/$''@U)^!%Q&JQ!/\D/8N8-+3W,/>2
M$V\8RJ:XC)N37BR'%=6#N?&#19O04OZUG#Q(_8"G''O+N8PMPMBK\S.1\BN"
M\N;(!#SHR'']*.LC<VY\M%1)QBL >!_#CT3&, ;_+2U,28>GN"*KR9\Y7FR&
M,OYE-V915YGEH^,"I=C"]P;8'X4G8K@0_],2460G)!QN]A$.<D?/S\9R3VO.
M5\$T@^@^D<+VK(3E$IC]:+J.':28ATG=\33L=*V:6,Z;*>*?."=.',LRW% 2
MB#^E&  X<H-@O_^()T@N/9&V++\LQYLN[;%,DE]=0Y1>5\\]CT4!"V 8&1;*
MV]1& A7#&=A!J:G8%HK*,5&47!ABZX#):>*F!.ADI+=?[. ^9Q],$ .C!1W(
M6$]13,83P6BB@ 7^+C\3(J2#$V?</R)R]NMX5K\[-O-A/P#T9=R>G;B\6CT>
M@_<8B&]TN,%X6+Y$4PQ)]\):'>+6(Y&^QV34K#V7$XC"OU<F(.*V>(1YH)/M
M/:N9Z6$E :R9D9C402,OUQU19,YS929>6*F@[5A-\Y3EE806$"061/Q\?C81
M>@1\!W1E'N@SP6C6L2DC^@43(0OFW?E]U.-4C)F,"\,?L=BP$Y+N[_>1[KAM
M@@W3X9)U%?-BSK&I<D+W9J"S7F(205 !Q3+A(\@C&*LOE%:>;F#P5 YC@FGM
M,G.:UXI!B,=-X'IV*';F6)Q3H!.7*BYC6)W$G\'?[OF9J"'F1VD<P0W</D2>
MZE263>1?90&D,#@RDPF.F?8_[&,Q1ML'F@/L7*D4O_,.K,X2D38JRR"(6TB"
M)-E/1*9_K%Z0^%ND,BT]D6OFL;&HK,4+@7+)O3">@_KX>0DX$3ZOZNUN6^UV
M4N'S7UP49_XSYKSX,I27UR\J!JS+23 LBW(_[D*Y@RM=%7%_8B<%<K-@'^L+
MV6LF+(#;-Z3"/W8\7Q& .AXOYS)?+*YM8*4Z+.%F<V\>CL6CXURNIF-,C3#5
M9@8O A/JZ;R,551@\NK\['UL4%%Y*LQ/"XI0@#K#VZ1:I@V(S_R9D\QOB66W
M #=-EQ9PWF-D\L14[*"T&[R'TT[D/TI9],P5*V'Q\ 5.Q+#)NA?U(&^1(G1M
MVTNL(2A42#B]^#F)SAQ8$!=3B+R-J3GXE#RI.:JNJNW!L)N,NHCR<L2DOL*4
M[J;BB/ET:I=WDS/Z8H< FC5?&3LX2_NW"VWUPGY31-^:IY1U*9O5?V07?/WK
MOJV R@PDAV75*&X,?1]+V/0MHL6C!6P9Y57 %QL3&Z:F;H/7:D#WAO5H/# >
M,?:%N<@$\&<64"$\R7S:M:.]>_[VO& \MU9\,CCA\!.IA-DO2\R7E1%GEUH\
MY$S;U.]4+R+<;"UA;!<C7B_.^F2,L(0_5MN**6G%[0UQ6XS;4NWJJN<VU$:B
M,R^%V]1"DJ;R<=NQ";J/2Q=.@-=:3YI-Q)&E<&3O\!PI/AD>/'SJ([ 5UBDO
MDBD+2;0X3@F('=BQY0.6<,96$J)"=#"GRWS^T'["W(N,/"^P\H35N=FPVYIR
MPOG?1M,/2.<M=H>)A6;.I!-:U ;AM8SPV[Q,DR*L^RR?P93%JFH'SUAUNS5'
M-2_BB5OE%R1_K,DVR*H82BD(FU(0AI2"0"D(E() *0B4@E"#%(1CBOE/%S:-
M4@#2=4-S:8E:*G(:=#;#=)$R[]SWIK=P/,.ZFWYR[(=/YF-0L.N$(D7^L<N=
M8_=*U$V+-I-')ED.?@*W,4PUKNOE8[S77=CE9R%- "5](8EE^]A/61+5#)>=
ME4IP?7^CZ+UV*PCS_!(?-;0J9.PGADHQFW&C 7O08=,@5_9^$+'>ICM>SK&P
MXIB_@-TB?2:"5GALG>&Z/-1:A$+R4J=!N=:Y\:S(#C]8IA0>@EASI7P-_A#-
MY? KXF(28'P$^\*K-_$>>)X(;95]O&2=3A[?[9I>U+OGI4E(T2"[%@&@8@M-
M45Z6ARY,\3)0AE2*^UF8;M"D;W)^)@LLBAE>*;=342DQN$H54;BQ2KDC)L\'
M*W$&?8+D:8FWW;!ZP^K:HH!W_"N*! W6=WX6+3!VGXMA<&PB(W;#HH;)#V'7
MK&B/L1\;%O[E#<\$?<GP>GFLL"F1R9C:7B"6V'/X[;@'ZB]^!._+X6'OEV&?
M)" ^TX'9B?OCE!SF!RW*+=I.?+-DG\4H?R8H=9L=! +LG0>04]'Y7YG'L.PC
MF-SOH_95LA[&\4<K_><^^!OLG0BAB&U??8$W.>5X)TQ.N6MC-;Q$L(;R.X:%
M2/9PY9#*ZHB) !!>C6XY0DIR1?EKV1 ,S,]MXII2%)V*/KVU 2'9-^/IA-2(
MVWV"[L2&G9_YQE/M4[3"](\@])HK!'P!"I]_K/JS+)H>BV=_ED%#081TF*\E
MZ)C+I2#[:\*FC+>^A6&5[.!\K,<K?8B!_)1R%K^#<A'&9T'2A=0ON.H0H;KH
M\/=R8M>5\H=<%!>88@7Q^:W-'C!XI\*PC+>,DAIA<FG OB(/3,PR7L5[;889
MKBT<8=W&B&AS9AM"JX"OK,:U!UO'&P@G$C_B,\(%Q)436?5>%(T/(N2QO+R,
M9<==#!_&0^4W'R.J(7&EQ X(2AZ)D.!!<W!^7)YLX0G+XU W"4+HZ\PSX1H]
M7B@Z:V?"GE.BOV:@Y8;-#IAELD>Q>H_%E<"YXV*?@!^,]R4#"$+%-]#WL#<!
M#_&[Q>Z>/Y RA!(9TJ;,6XBE309:I<?+PAN/AFEQ/R./F,5.6SQ_A3V(EN]@
M'HB&F;$VM9(5!<7(OJSLR?1$ZP=8-!\/*!M4/[208V3'F];^:Y6C^><%:;3P
M[\N%9=@V7XV/!/=@XC=%!*3(M(0GPJ;S[K&A(.4Z=+10I%#)GUYZPW_R5,T1
M=J(6T?!R,[GG+^L  Q01DT9N ^78"Y@==%8\^:AI E=H6XGIB$?RE%4T(GBK
MSD![EWT=5I[*]6 98XBQA08_",'/8C3X^%)&62:P6FH(3>(</X$[T6HD8?),
M11NCP*<RJS9Z?2V?P$ C)KC"P_:PJ&%%->ZP#T;&4_AH@?$4F"VHN&%G56&H
M",3RE ?L4AUT >FV$= X4<IYA(\/.74?"R.5*!'6W?I=S#8*+S\A!>V_=HLM
MYZYFW,#SL]"HC02S:0/P+.?U3@VZOK\Y/QM@(UA<A\(I08F1@A#'[TU/MA3G
M7<0MT54=("=F:,]C7VJ)_C*PG-@'N-_(0X^NZ<V0*Y2I"Z2(#<I1W3@_$R-P
MX1!^2Z@2Z#6"2<9'FYD V6#7H&3@0F.)HT9*TEPTDED8Z/,V%^A5C:?R2TLH
MWH%!?(.G[QF*,Q*L+C+P/6?I2@\3[S0==1R7O@FA3OFF=&1EO1$ZTD1CW6@J
MQ@A[<:?GR]7&ER;,E44$%-,6P18<XT-9+(5-PD=V%6YEU@%Y00[P6/K0N'PX
M/Q-N(<9]ESP%!F5^X,("19&75$8!A/F,6+; B.GTO)^VPJ\3$%6C1,D7CBI,
M$(L1E<BK; $)\>XNHAP)2E#3%U/>W/&2[J\WW5]CL!Q=8!_\)I8NL.D"FRZP
MZ0+[-"ZPR4X([(3M+OEK9DK<VJ"QPN>$LRA]W;?&O>?-N!-"NNY"SU)8YPN+
M=8!)S#5<O$9V3>]'X+\(O)3)DBRR!3OJK9;S,^D47+W51F5\##8Z*)$X<!U]
M'=>8]2I]NKC@8(<B1UUD)K1"_3ZRM&#+116&2]B?E/D4;"7O( <[&'A13'NQ
MA-,2E]S"D@@=26BJH9L;H//!%&[C+-OM30TW\Q.:4>=GZAOE_RX=="!RTP$8
M;VD+9QJ;O!9Q"]QS*4R36!D,+(#H>;SZ1=I$D7U,>5]83NOP6XPTA2T;[<_Y
M663$/IC2<<N+$J!1)P_D&:4OG[6BRD.I(Y'*?=7>*'<C>-"C\ :+O0TW+[1<
M)7&A=^W?XAB<U2UO*:,E^IE=U^'I02(&09J*PD1WDU^1KTX5SX1],%Q>3<SD
M+2BPH$[VD=1W*_4WRA^V$VVFW#,CJ$6!H3&P%-^']V!1MI/8!L"*T!.P2G=*
M%MEA3$46U<%$:DQVHH!=,@*$N]/'ZYH:H@<"Q,S">,:M@?F)IL_"O\%?"@HU
M\DXUT2UYU!I6^NIC&SI!9I9:<JRLCJR$P[4CCM0Q49\ZE"!$C'_3#6N81&5(
MY-5%\+I8H>4ENM:"J!"3"_>$#PZG8,I""GA-9(B2"2YW1OOR.@X=?"Q0];$3
M*U /#B"I2A0 4SX[=AB[LRI+05)OT)\NL6PEUVDB]2>3+V783]0].KY100DO
M%TNQ<)G#A2-.+G1!18Y "ZE81NHX8Q$B<7XV28< A:7T]HEW2->SQM:V[Q#X
M<+N EK@$O>/B^MJ>A/V.,;/F!.H/_?<^$3U\+R^Y% &NCVUG??WKZ\,BO&@Q
M2GPMLJ>\!)X7*\J&\A25OKXZN%*NT3/[TW G\FX>< _@9VP!D_&6NR*P"!&/
M805&@4I1;-'JC=6#:X1:33IT#Y_#4>D!(77".WQS&/8!HT!Z\\4@-AD8.N!$
M]W2)]>))8KC2HXP+"481;"E@,N.F+[%E? 2N=]ER6J(D&5[UH0!%AS:6(S6C
M.KZ\<*6Q,O7S,T]61A$HDRQI(\,J@HGR\!1 9A8^0H8BA&$GP-BNW"=^9XW7
MX)-8=*JHV,.OR\/(R8RMB44_H"*%54%YW32?I\OYHGVY]-WCE4,4>LK/[Y)_
M.CPZ83+P30IN((-.[?).LM;A$C$Z#/9Y50YYOC/^$3:$YWL@+B[8?&$YSPPG
MBD;4TO*-X(9K B<EXMY^ EW$DPZ1%M]9QOC'Y?UXYJ!^($:^1.V6T\S<F8!V
MGF*95JQ^I%3>)LP'J2HL*O2A*(-7-Z]+VNJ=$3P!6<@E455*2X1,\_N>B<FC
M.B9B__!SH(+&R[IB_ 6/60%=*_KT/L(UV7KN'\B)O#+M_0).$YX\R0Z7/:&+
M[$_[1!I&&WKI!3MZ?K8N@+2^,C>ZWA :I,0 +[K$E&75PS)^$BYO/=< 3KZU
M;>=1");KI3\3]M K_(!,6KB]O0ZJ4W-I'=UVMC"RQ/1%R4%G).*">-5X#E1R
M8B"=0$YSC92+1620$#NB:?)8)#$8Y[KX@/'/\]'X'2TR9BMZ3+#\Z+-XIPSS
MY1$_?('\^1LBA-<%G-!-ZSXWK2K=M-)-*]VTTDTKW;3236OM4X6'R?JA&+6-
MMW%?C%,*$_U]%^VZ<]7FM5K#/3L_ WVOOMKS9F3;&BR_+%UOR2,: =_NF= \
MU4Z@=H<[H\1=I,HGXV=+48<]77EU$7WIXG6+YQR$MGQ6ZQD><6EQWYC%KS)X
M_7GK.72FMT 1]E$11M<(#)!9GBM62%?M A7K:J<?E:CDC!"5WKJ;_BZ>\5X^
M LLMY6&&/.6T.AO*:0VN,FI*_I6GG8OK@&#]GF$!AF!*P83)$%)X=\1FAC45
M/C/3]I;B,$2G*GYO^0>8@QCWRZLS!:UB.-^'.2GR.'B>;! %8%B1971^QK,[
MDEE,/.23H<7S8+B3P%D"ZY0EH;R0,M!$$CU1XJ,'E=?1F2IL(+XPF:P<4,3*
M%*_.S[YAJA;Z)[C?@F=Z2=^L3&+G5I((D9WP,PP=FOBMJQC)2N?I7'[93US'
MP([_1S[2TM1!.U7]+7S*#3Y$W8J:=F^(K7:T%"VA_>HL/7XS!O_E7=2P/4Q?
MB&Q<E!HN2BUN46JZQW=L48ETM\VYX& R8](;&.G6\U5:U]K-O:6GRG'<./QV
M2,3"?#6]'S<\4@5_.V8Q^WFO_BSQ/1,]@6+Q/6_J*W=#G1\SBJ*(,.[L63A^
M&/,.9N*_@OZ#,80;)]:M))<M8H;$]3[VZN0#O71+7D?W?PF*B6B,(PRUS& !
M?%%<Z(NBA-%E/,_?BUJ)C S[AX?-%L(4R5@VIG37)4/^3'\9OXUR,-$BZS8C
MWHV'I^H'HR MH&&%DVS)0BNPB1:*=]-&V$N0@!2_7,A+_)*2T6/QAT@.R8"U
MFM'#RCW%(T/EP)E.+V4OO4MOQIB?9(Q5OI#Q<_S> B84==T**B%@@,A"WC'*
M5S!4002-!-^:L<F#*(#BNOCM/;K!J+JJ=>%__5ZJ&\PGS'QAO+YF0368ZM,A
M(X]8N-LG=$!L6WV)N01PBWNA>(6",/A&_OCF+( "!QVME1 FL8QG4Y0JBJB:
MQY7)*JTBWYXM1)N9K_R>W)E>+N&M5U_O_GB="/CEWTC4( @B?**;[:#K2Q1*
MF4AUD_$YT4VVR^:&R3.\Q?"A-1!>T4?E9*^4CXXLT;!8NEA=B"\Z I HHYW;
MC.%88?#BU'R2'2[#M/A8%*@/.R^O[\,U8%4CL+RB6BSR67_SQ,0\9>($-SMX
M.XK!&5AC"+TX(N J>3!+_(K)T\C'(N 4('Z$$9(_>7YP:L>R\P(S=QI$6+ L
MD8"?M>');4Z$9OSMQ5EQJID]+Q V131F<K*X*%X9!-,4N1T(3_O)[\WPK0"Q
M1=IIF'6_T0C155WKZ6J_KR:,]MMHHN^">8H.. (EUE71+J;T=3?+4$>RRK><
MCCK4]U[.JEWUPG(V&5;=J[2U^%=485^TF59()^)3C]=E"Y(!@A@.C-W HA<3
M7A5:UJ1@,1;GP;#BJM2%%QSD3>!IYF(6+U+S:N4&O#)E3\P=FYZ,@I+/NE+^
MB6/%F$&"#UZ^AB7AY%?#$'PG"+^//R2"E$!W$.%>+5D01OXE\X.#OW#'1,RE
M# Z;BH), L$D<!@/+@M2K>./1'<&LV0]%CYM/!+13W0!3"0K14AG1U0A1R*Z
M:#I[*?Z:QQJ'H2_(L<-K" PG?;""KX5O\F,5D64M:5)C3*F8<ROVH!!=95>]
M(/<[?J3Q#&)!#>CB$7KTD_#*Q!)%@F1GN='9!!;MFJRAASJTQ&#\)J<5$6<&
M0V-3=@%]#TN#!Q$QKOL%,;@8MX6E FV\6(\+VY3JG/@Q<I5?8M<065<5Z^\+
M5M6/_'K+>D4EUD^L!"WD(V;VR_HJ@:26M !*@LPA-\7M)Z_'Y%O/41RB/W.=
MY<,,$^23\CR0NQG%%3-(J*4LK*6'J&2B%2VCO83O3KRGO )F7WJO>7C=0D12
M**]D%/CK%;)MB:J"^* E #'&W/W)PA[>D:0T@^#>>$P'!V7TAHKXSFG U!%3
M) L>;0Y$C&DYITUK0%!AK2W<UU6R$QW3>9"FC&83I6]X:DFJN&,R])0K7R)1
M8J6.:_R;#TMS(NYX3!&5>[\<^5S-UGOM2[7=4H*"I_ ;]E)H)0N?\@@C5?U5
MN7OD\-1"M X5<A1SW/"$O4DP3U33DP<33!7/D>IMDBU6UI@(RD6G-A-1B=JK
M?[S.=FM2SX 2(H$V7.%3)!!% E$D$$4"420010(=/A)(3U7TO<%0<1 _W! [
MH6B@+_LU).<7<1:35Y3Q/3PI+S6_Q1$ &6T">CVR$MX"3P!//PN2Z5;C?Z00
MO8\)T2OE%I6Z<5 H51AJLF!N5)$,SB(J_<LL4[B9^/U>XH#6&?@[W_RGJC)^
M,%QT/7E?F,N3'D^(K?[O/M<\P;Z=GRTP@@@O1!$I>:YE+=E*M(9_!P;]^/R,
MR=DKZ<FCE0=2>(P)@V%:&K^I$)N"UBB:C ]LY8O 'TL_<*M?*>]-:XD?3CR*
M?Y"GKF",UR.:I>=GHC2 +*:*5BA^$WU>83#"2T]28@G6&%1SI0AY>X_>TG H
M^;T@.D&4; TO$<2[K:!<-;]F<;EGZ%GF^ 75ML-\'EX*A:?M2]<N!I'Q_0O<
MNVNX=!>V[:1BFS">X-J>X(\/411!5#VSU@R<5DL$<>;22W302VZ":!+^2VP#
M$@"99V-3>'@OTW+OIME;_ U5O@*NPU?,XI>Y]@53&?^6!G+<=)9-'\%,SFDS
MKVC?XO%;M8Q\\2N@B./)\$NKE[]>J&FVT?.X:H=N),+ %A*K!(,HVT+.OV$9
M4]AZT_..0:>0BVRWZ^I; :M(<S? A)@CSGT8O6JW%/S?ZU4+NB%GF7 H-).)
MCOU\5&*OQA[?'_?OXXVP11AZ4E$B/CNZ@]J;X:2SM-_;KF]XXLM;-BLO[+M;
M]CJOQ9QKLMX$J81LEW*HW]Q\^/#QX\4.M'2XFQ=9.E8!/ML:]@Y_OH>^?=L
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M'-DB]I38:.R0-_;U+5_#C9J]/&/^_E+N/8\6)4;Y<.'^;]\ 08'=+'W'B\8
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M[=X:8$LP"W]32%;V0.YTVG*KEY7M+@+4R]FKEV'J:AY0M=5.O]7MK0851O,
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MTWYVWX80!70)8)HZ]QO IPSB3;8SZ+0Z;;4S3*O[XRG3?9-]G61+E7A3@W_
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MQE';7H+=,LE../U($U/S=J#:5.Y*=:CVU_O??!?W%"X^\KVI[1C>@G[&O_P
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M\"OC6K<;^+6$(OEQ:QLZ.-@KUV#>%N_)'18'&0\_%8XW_6J]ZK_+3D[6 7-
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MN! /OFA<H&/*M\9PB9IA>0M,N%[7)S*&%D5#_U^^ZQF31>H"$F?(&$-1U@V
MF=6XP*D3"["Y)(8>Y/2X'CD^ET+2@3%BZOE4>V(2?N!;419ZO.K:)0>A;L/;
M\?>H,H\]6$KS:#UMAO>#4R_B"\!NXBL\&Z8IC2DYD=0+8P)D:'GF K[QII@X
M#RM9 %])4:49G'KJ-G%>56J*AA:B@S0'WCY>X&P,FITQ=GQL&\H[F-&6@3]I
MIF>@J]-AIN;AL>QUQX3_ 1N;S6V+\1.E+85FIH&0I/E\(X RYG$L<]]^JAOE
M=WZ.;YKCQ0>'NQ\,=VS:KN_L/7JC&C9?UM0@5;J6Q/DE! !<K"0FH'(4C0/D
MN -H\O/>Q$%'.S!*I=54![AV (K&!9+4,J3>5@X@"@TA AI'OHZQ!:3I^*X7
MTEQ;H%2%V^4=@7'LDRX);@'83=H=_5X<7KJ?,N;A8=?/Q,'MY)B)TP>*::G#
M?C_I^8H&XL3)\9O8;"$#<$*=(7LP8CW^9AUB%N)JS3G$Y#3'4M2WD$;;>C;$
M(>\R,>GE-(GHW.]'J<GK9*]OPW2,>C+*65[4#G'%/]S<?/QX>[M],/'H@<*/
ML[EI+Q@CTT_8]UD)TCM&\/9Q@^_CQ*ZB"WJ')FOI#L+BNH3)],G0'@S30-/T
MQG>P4B/+4D+[Z#??Q056>3[>+^+?C%X,]S<TTN(??B:ML9 <@L%P36W'OO[G
MXZ#<R:-K'GSLI5O [H"/2N7P4<T<FU H(NZBN%5(3(S(,:PG!,+AR73+MM('
M:!E= <(M0,[T4LT\Q7V?J'SIKIF"<FKBI<;Y7855JB_D-DA=/2'5SVKT49Z,
M.D-;9\]>AL=3#D]-H:W(>??5N8X#NB5VW)F_2+KM8_R*$K *3.U*+WUTQEZ$
M,I,JQ/W@LQ]VC"N?F#8S[*RI)SPU=:;&\KQHG,H9W J-JZ>_M+M9S73VQ]_X
M;:9$?&9N(:8%K$@W*B^1_:LEW;.YQW/)E&%6+AFCM"N]<6%8F(LEN5/,V)C[
MSGBJN4S2'AW&9IA31:DIL2?_[,+?KJ5;U-*80YC*),SWD0;O+SM7J6RKN%L\
MS)' OR!FLA?*$%G*H(BE@ C0MUH_O1N;3'/P2J9OMOI9H3&$93(<$QR+R\)<
M1@#QW]O&Q35'-[6S*IT_@#,'\U^GD5;-611M/V9O_8$3_[NY]LBN'QRF_7ZM
M3> P;S7S65NX;Z2?5R7D!(!XLR[A)?ERD?KRMI4WSR5VHTM$"6^O %LM][YO
MIFP&CS]$Q_PQ98XV9SY PI4^>7J3@BB8 ^GZ#ZZA&YICK,RGS9+?1P%;Q#*)
M8Z[7F8^$ IL-O!4#K0K%@!P)EK%^ ,#"D47?&I9FC0W-E'"^!/%OGB/KI5.+
MUZ-*C)OL>T\Q3C3E1R N%&A._.G6.V'P"Z:4]@2(+V(OB]W1M=)L=Z)[HHS!
MC&M%GK9T("&I0T$=^R,K*3@?<A\B+7=YSEI9:;G2)>I[?]:O4OG3@? ^@7J)
M!!3>[Y:S.VA3]FL,-">=M^O%[YC.$63<SP5*;$SAC3$9>R)%$QAS)?-F7=S&
M]%ZEI7;;K>ZPGYJMGIWA&[^M0K)\Z^3>*J3@8)N"6.((ULZ<9J+4:P=_M?,-
M3_-VZLSWL[R%:I/*66=\UIGOE;^?.O/]=*^OSGQ_C1?UJK)![C63_+-UYGL5
M@_B]1*WP"O]!<(4C2Q>_$.U4W%O'GL4=#?\TO&E\D4/-#Y$[K3,,WI\X?N9"
MP/[!$;",;HV*K':[=6[[>D& 8?;K!\TE/^N"G*>G2IN5H*\B^/\@%_GAS;W'
MB_LF[JTZ?+^7.8&SYOM5Y_O#@R%>.?R^WS\LOS]#R^";8T^8ZP+D,&K/G"=C
M?*R*IS.AO (D0K^5AS#C5Q?<7%5D0KLN>JT:7N9"/.6 B%?*/)K,J4^U!1#A
MP7?F,LW!22W8HI$],=.>HU2OJUPK0ZE%2! U#R$'N  F_8<($X197Q%1TCXC
MVZ+&]EWE4OL8Z%R&@,I$Y]IBJ2M;J[?GBIRWKFP]N9J_(A285$E@G%G?V*[G
M'D@!Z<I*)ZL=P8GJ(#6"YL7 [BX86(K.(+>5<NI)=YI,D5U.BM\$R_%?Y6A7
M/TCET7_4',NP'MUOS"''\_DVIV]+U[ %3\*I>!(<5Z+S2B//<XP'GR?Z>[;T
MU=$-2W,6_.LIK,"<<GO5YYI4L:J$XKWF&N/&A04'H[FN<S@8K^TU7)J4X&/E
MQ@,.DW@R="H$H3D.XN?:DV:8P='AYS,; 0G7+PZ.3^(#'*!,O]8 Q;5'6,&G
MZC)[(MD!P.BU;N/"]CW7TRQ\65/Z8)BT@PT;= T H>:8"]S' YXIZPGV,F;S
MV& +G5GV#%[NV0ZN9EACAU&HU;.QT)E*6?AYP]TB3#WN?5_:.%_VV?9-G4_<
M>&#,DF*'D8P)+38'?+(\(V.%J:;SIPS7Q8YF\!SL@S^UYL6PK6<&Q],15L83
MVP0U7,X%*L92OY6P2MV,W+C0^+-L,L'Y(/"+\"CF(GP[X.O8=ZB%$;Y,@^_#
MC56+ ++KG B;7>;1E&11R\[QC$])AF-SH)%#;C6@M27&D(1F0!\X\(:0 LYH
MZX#]<[A1+!+7BQIQ0#50;:6?YMU1#=0R%R>N@&8Y/UY="G7*=09E#W]:5]Z3
MT=3A5%)SZ_LM^7ZKG4)?7_^*RJ0\S2)J(J]O^71(_=R*,,K&E37M0$Z3"]0(
ML#4"O (&T:LB?J1ZB1UIXO!Z!+FSHD/_>O\A*OZ2 Q^,L)%IAJ<CY6FP\N87
M_HRN>5K)^N<91F$/CP/DD$#7VMN"9<791$I/XMD*18:/3$)?A(_O**D,KSK\
M5T1\.N7]A.ODD^XQH'.8V#0-QH:?X507N=<YHTRY&DWSXF%J;-8F/"PA0AWA
MH:+*G0,/&#I#Y:I.<3N!9VM%)J<\_1!%Q=^>N$"J<;SFV>'7HN'I-3VPU*TU
MFU#^N92U$FUY9?J*Y+N\^RE/&<",@EUS ^1TGD%M>IR Z4')%ZY(OU"ZJMII
MM0:M=G]9\0NP:\21ZPNAU->)R+F@/ SW:Y0^M)6)0D_'5<*[+[<;LA97GV77
MDZ2.0&DE99]#!=NJ.QC*ZB!+KZT-KC,BSO48J[0556EWU&%;[15/>ZO-LJ)H
M+Y5\FYJ$N2_=%7H&M=67.[V!W,N<I5/7^-;VX_'W7)'SGI5NO<93'FF\T89J
MU?=4I.NNJF]<^'8Z:B>E+D;N3BSRO8&E#<L',15-A/C&G+@HWDIE_/7^PV_P
M_&^EB>'4[-Y<YR$9?-#3M)J*FM76I5:!SXA(<U%A=]#MIB:/%D&%JQ7(TJEP
MM_.LI<)23M-JMGI'58@W5 >NG:\8O/D5S4OLUO,2ZWF)];S$>EYB/2^Q\'F)
M61,2CS$+\4A5X,<;C5A A6Q4M;PZ]L4KH!FOM.9S ">@BV65T.Y;.(LENXG*
M62DLG)5<PQH'HPA%Q?HL59B-=<G78<TRO1>K<;$,.-] PKREMYU^1TUY;J/2
MVU&L/OH^K)S^*.#'5=D0<NE*W;HJMR[HRN17=55N?;_[WF]@?56O-J=&B+I.
MM[[E4F_Y%(B_0H5Y)X$]=>5NC0"ODF74M;S[U'&"O(D.#L8[-_>KT03F^*UC
M*Y%2<A+/UBDTN;V1L>P]R9Y3^#+ACI[[SGBJN6S9!U>%-!EU_B)8:M$!^-3*
MQPZX%%&:.D@UKMW3)SB: 0EXFQV"O_DNOF[/M[U?9"\P>C%<\8:/L[EI+QB[
MQ\Z@7PF;/Y,5LU_&:;LK*T-%[G:RXNOGE=3RFD@J%\VD,KK+HIFEI)!3IQFU
M+[=:;5G-S$FI5(/J#7'"/,&7UK#35GHI]GKO/[CLWS[.&GG"$.Z^,915H<U\
MMB I!$MDDYO>CF(0\$AHA]_%M12!4^+P7&-@K@ 2!2/34$J')S-BFKN#[JO5
MN/B[9OFH/2EM"MNW*:2(M*M9"VEBF$R7G@W1!?C^XXVD20Y[-%R/IY3!440>
M@ 3_0,*3[J^5L*DOMG'6,!:)N22N9E)797^.^ML?-Y9;M16<[];M*\E9.O<:
M1@V)*_Q#,WT6E'O<4<OH.RLV,R<#G=LM16D+#K-$!C\6<Q;C/TO?IGA/O/E
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MC%!V)X+C]F O'<@C[I^+-7H Q?-[X)<<Q;K.CF*-B7$@K>W,;4<3/FS8)%B
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M"U8Z"W93;PL6S)5+8-/<HS/;'9*BN0&X:!_/>#*9I%1+R;2R5"8G4U(#/5P
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MS"WW?20FY9/K3,[83X@SR3_PFCU6 )<_L-B;V).@3^_S0(/_,H%(3R<K??\
M#^?;A?F@_ ]02P$"% ,4    " !2,%96.@7Z"0 4  !<W   $0
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M:6UG,#(N:G!G4$L! A0#%     @ 4C!65GV*G4H! P  Z@P  !
M     ( !S38! &5X:&EB:71?,C,M,2YH=&U02P$"% ,4    " !2,%96RN]2
MR%L3   >%   #@              @ '\.0$ :6UA9V4P,# P,RYJ<&=02P$"
M% ,4    " !2,%96N6P=\KNG @"VLQD #0              @ &#30$ >FLR
@,S(Y,C@Q+FAT;5!+!08     "@ * '@"  !I]0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
